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Hypoxic regions (areas of subnormal oxygen levels) are a common feature with solid 
tumours that have reached a size of 2-3 mm in diameter. Such regions have 
characteristically responded poorly to conventional anti-cancer treatments such as 
radiation or chemotherapeutics. It has been previously demonstrated that the specific 
targeting of these cells is possible with compounds of specific properties, such as 
tirapazamine. 
This thesis describes an exploration of using transition metal complexes of 
cobalt(III) and copper(II) as hypoxia-selective prodrugs for use in cancer 
chemotherapy. The aim has been to use both the lowered pH and lowered oxygen 
levels found within hypoxic regions to activate prodrugs into their cytotoxic active 
form. Through doing this, the coordination chemistry of medicinally active N-oxide 
ligands has been expanded upon, including the first transition metal complexes of 
tirapazamine and the development of a novel series of heteroleptic complexes 
featuring an N-oxide and 2,2’-dipyridylamine ligand. The solution properties of the 
prepared complexes and their uncoordinated ligands have been studied so that their 
behaviour in biological systems can be better understood. The cobalt(III) heteroleptic 
complexes are shown to have promise for the purpose of improving delivery of N-
oxide based drugs, improving their solubility and altering their delivery and release. 
The complex of a tirapazamine analogue [Co(tpz-CN)(dpHa)2]
2+
 was shown to 
release the cytotoxic N-oxide rapidly under hypoxic conditions, but promisingly, this 
dissociation appears to be hindered in the presence of oxygen. In vitro cytotoxicity 
studies on this complex showed it to have the same IC50 value as its N-oxide ligand, 
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Cancer is a term used to describe over two hundred diseases which affect various 
organs, systems and tissues throughout the body but share several characteristics 
which include uncontrolled cellular growth.
1
 Most forms of cancer involve the 
formation of neoplasms (new growths) more commonly known as tumours, with 
notable exceptions including leukaemias. Cancer is said to be a complex disease, in 
that there is a connection between genotype (characteristics arising from genetic 
coding) and phenotype (characteristics expressed by an organism) but the correlation 
was found to be weak. Cancer is a complex disease in that it is the result of a 
multitude of factors, ranging from genetic to environmental factors. Due to the large 
range of contributing factors, the occurrence of the disease is hard to predict. 
Statistically one in three people in the UK will be diagnosed with a form of cancer 
during their life. In 2009, one in four of all deaths involved cancer, accounting for 
around 156 000 deaths.
2
 Cancer, along with other non-communable (non-infectious) 
diseases such as cardiac disease, neurodegenerative disorders and diabetes are the 
major causes of death in the western world owing to its aging population (Figure 
1.1), hence why the amount of research devoted to finding new treatments for these 
conditions has grown over the past few decades.
3
 

























Figure 1.1: Age distribution of the incidence of cancer according to age group 








Developments into anticancer agents such as cisplatin, along with earlier diagnoses, 
which use increasingly sensitive techniques, have vastly improved the prognosis for 
many cancer patients. However, despite these advances, there still remain several 
types of cancers which are problematic to treat such as brain tumours and prostate 
cancer, providing the need to develop improved anticancer agents with improved 
properties.
2
 There is also the desire to develop agents which can selectively target 
cancer cells, with techniques such as targeting specific genes or enzymes specifically 
expressed within tumours. The need for this is driven by the unpleasant side effects 
that accompany many anticancer chemotherapy agents such as cell loss, nausea and 
diminished immunological strength, brought about by their lack of selectivity in 
targeting cancer cells.  
1.2. Hypoxia in tumours 
Cancerous cells are set apart from normal healthy cells by several characteristics.
4
 
These six hallmarks of sustained angiogenesis, unlimited replication potential, ability 
to metastasise, evasion of apoptosis, evasion of anti-growth and self-sufficiency in 
growth signals enable cancer cells to escape the normal cellular control mechanisms 
which act within healthy cells. Angiogenesis is an important factor in tumour growth 
as it allows the tumour to develop a new vascular network in the surrounding tissue 
from a pre-existing blood vessel. 
Cell growth within normal tissues is a carefully controlled process, being regulated 
by several ‘checkpoints’ which occur throughout the cell cycle (Figure 1.2). The 
eukaryotic cell cycle consists of two main stages; interphase where the cell prepares 
itself for replication and mitosis where the division of the cell’s nucleus occurs. The 
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Figure 1.2: Schematic representation of the cell cycle 
The G1 phase involves the preparation of the enzymes needed for the DNA 
replication which occurs during the synthesis phase. During the G2 phase, several 
proteins are synthesised including the production of microtubule structures essential 
to the cell division process of mitosis. The G0 phase (cell quiescence) is when the 
cell is dormant, making no preparations for replication.
6
 
In order for replication to take place, the cell must successfully pass through the 
various checkpoints. To pass the G1 restriction checkpoint, the cell must be in a 
favourable environment and suitable condition for cell division to begin. Passage 
through the G2 checkpoint requires the entire cellular DNA to have been successfully 
replicated so that a chain of reactions can then take place which signal for the mitosis 
process to begin. There is also a checkpoint to ensure all chromosomes are attached 




Deregulation of the cell cycle through loss of checkpoint control causes a decreased 
genetic stability and uncontrolled cellular growth, facilitating tumour progression. 
The overall result of these characteristics is that cancer cells grow in a rapid, 




1.2.1. Tumour vasculature 
The vascular network within solid tumours is remarkably different to that found 
within normal tissue. Two types of vasculature are found within tumours; one being 
the vessels which existed in the tissue before the cancer invaded and the other being 
the vessels which have grown as a result of the malignant tissue’s increased 
angiogenic capability.
7
 The latter are prone to structural abnormalities such as 
swollen capillaries and incomplete endothelial lining of the vessel walls which 
causes them to leak.
8
 Both types are suspect to the development of blockages and 
blind ends as a result of the tissue’s uncontrolled growth putting an increased 
pressure onto the vessel walls.
9, 10
 
The poorly defined structure of a tumour’s vascular network can lead to cells being 
remote from any fully functioning blood vessels. Oxygen can typically diffuse 150 
μm through tissue but cells located at a distance greater than this from a functioning 





functioning blood vessel hypoxic region
 
Figure 1.3: The occurrence of hypoxia as a result of increasing distance from 




Cells with lowered oxygen levels are said to be hypoxic, and regions of such 
conditions were first recognised to occur within solid tumours during the mid 
1950’s.9 The development of hypoxic regions has been found to occur in the early 




has reached over 2–3 mm in diameter.13 There are two general types of hypoxia 
which have been found to occur within solid tumours. Chronic hypoxia is brought 
about by the cells being too far from a functioning blood vessel whilst intermittent 
hypoxia occurs when the irregular blood flow through vessels leaves regions of the 
tumour under-perfused for a temporary period of time.
14
 
1.2.2. Cellular effects of tumour hypoxia 
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor continually produced in 
all cells. Under normally oxygenated conditions, HIF-1 is hydroxylated by a prolyl 
hydroxylase enzyme (PHD) in the presence of ascorbate, iron(II), oxygen and α-
ketoglutarate (Scheme 1.1).
13
 The hydroxylated HIF-1 is then recognised as a 














Under hypoxic conditions, the degradation of HIF-1 is inhibited, causing it to 
accumulate within the cell’s nucleus where it interacts with an aryl hydrocarbon 
receptor nuclear translocator (ARNT). This causes the ARNT to become 
transcriptionally active and results in either the initiation of the cells process to adapt 
to survival under the hypoxic conditions or cell death.
15 
 If the adaptation mechanism 
is activated, the cell increases its expression of glycolytic enzymes such as 
hexokinase, and protein pyruvate kinase-1.
15, 16
 It also codes for the over-expression 
of proteins to aid increased glycolysis, such as the glucose transporter GLUT1 which 
facilitates glucose uptake.
15, 16
 These combined alterations allow for an increased rate 




tumour tissue, to produce sufficient amounts of ATP to meet the cell’s energy 
requirements. As in normal tissue, the increased glycolytic rate results in the 
formation of acidic by-products. 
The activation of ARNT by HIF-1 gives rise to an increased expression of vascular 
endothelial growth factor (VEGF) which signals for increased angiogenesis. This 
results in the regions of hypoxia within tumours to be transient, as once an area 
becomes hypoxic the increased expression of VEGF is signalled for so that more 
blood vessels are formed to improve the oxygen supply, but as the tumour grows 
other hypoxic regions develop.
17, 18
 
The occurrence of hypoxia in tumours has been correlated with an increasingly 
aggressive phenotype due to the higher rate of mutations, with an increased 
occurrence of metastasis. The greater potential for metastasis is also believed to be 
due to the tumour cell having already adapted to a hostile environment, so the 




Another chemical difference which sets hypoxic regions apart from normoxic 
regions is pH. It was initially assumed that the intracellular pH of hypoxic cells was 
more acidic than normoxic tumour cells. This was chiefly based on measurements 
made with pH microelectrodes, but it was only later realised that these electrodes 
were only measuring the extracellular pH rather than that inside the cell.
20
 It was 
with the use of techniques such as 
31
P NMR spectroscopy which allowed the 
measurement of chemical shifts of the species within the cell against that of the 
equivalent compound at known pH values. 
Figure 1.4 shows that in a normally oxygenated cell, glucose is transported into the 
cell by glucose transporter proteins (GLUT) where it is converted to pyruvate. It is 
then transferred to the cell’s mitochondria where it is reacted with oxygen in the 
Kreb’s cycle to produce energy, forming CO2 as a waste product. The CO2 can leave 
the cell by diffusing through the cell membrane and into the blood stream or can be 





Figure 1.4: The adaptations made by hypoxic tumour cells to control their 
intracellular pH (right) compared with a normally oxygenated cell (left). Key: CA 
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 membrane transporter protein) help maintain the cellular pH by exporting protons 
out of the cell where they can diffuse into the blood and be removed. The limited 
blood supply of tumour cells causes several problems with this regulation of pH 
which the cell has to adapt to in order to survive. Firstly, the lack of oxygen supply 
means that the cell has to provide its energy through anaerobic rather than aerobic 
respiration, meaning that imported glucose is converted to lactic acid. The 
accumulation of lactic acid within the cell would cause a decrease in pH, so the cell 




can also neutralise the lactic acid with HCO3
-
 which it imports into the cell using 
protein transporters such as NBC (Scheme 1.2).  





Scheme 1.2: The hydration of carbon dioxide catalysed by carbonic anyhydrase 
enzymes 
The CO2 formed by this neutralisation can then diffuse out of the cell as with aerobic 
cells. Once outside the cell, the CO2 can be rehydrated to form bicarbonate, and be 
transported back into the cell again if needed. These mechanisms maintain the 
intracellular pH, but result in the exporting of species into the extracellular space. In 
a cell with an adequate blood supply, these ions can be removed by the vascular 
network. Within regions with poor blood supply, the acidic species accumulate 
outside the cell as they are unable to be carried away by the blood supply, resulting 
in a sub-normal extracellular pH (Table 1.1).
21-24
 




 Normally oxygenated cells Hypoxic cells 
pHi (intracellular) 7.2 7.2 
pHe (extracellular) 7.4 6.9-5.5 
 
1.2.3. The therapeutic resistance of hypoxic tumour cells 
Unfortunately, the occurrence of hypoxia in tumours is problematic in anticancer 
treatments, being strongly correlated with a poorer patient prognosis.
25
 Hypoxic 
tumour cells have an increased resistance to radiotherapy, chiefly owing to the 
cytotoxicity of this treatment relying on the radiation generated formation of 
dioxygen radicals (Scheme 1.3). In hypoxic cells, the DNA based radicals can be 




oxygen to react with, the DNA radical can abstract a hydrogen from a molecule such 













Scheme 1.3: The resistance of hypoxic tumour cells to radiotherapy.
10
 
Hypoxic tumour cells also exhibit an increased resistance to many chemotherapeutic 
treatments. One reason for this is limited drug delivery; the poor blood supply to the 
hypoxic regions of tumours means that any chemotherapeutic agent would have to be 
able to diffuse over a relatively long distance from the nearest functional blood 
vessel to reach the area. Another reason is that many anticancer chemotherapeutic 
agents take effect through anti-proliferative mechanisms, proving effective by the 
general assumption of malignant cells having a greater proliferative rate than healthy 
cells. The onset of hypoxia in tumours causes the rate of cell proliferation to 
decrease owing to the cells becoming stationary at the G1/S checkpoint because of 
the unfavourable environment the cell is within.
26, 27
 Anti-proliferative agents 
therefore often prove ineffective against hypoxic tumour cells whilst they are 
stationary in the cell cycle. A third reason is that several agents such as bleomycin 
rely on a mechanism similar to that of radiation in that oxygen is used to generate the 
cytotoxic species.
28
 There is also the potential for the more acidic extracellular 
environment of hypoxic tumour regions to change the protonated state of 




1.3. Hypoxia selective agents 
1.3.1. Cytotoxic agents 
There is much interest in the development of anticancer agents which are able to be 
cytotoxic only when in the environment of a hypoxic tumour region. The differing 
cellular conditions found within hypoxic tumour regions; namely low oxygen levels 
and lowered pH, provide an opportunity to selectively target tumours.
29
 There are 
three general classes of compounds which have been shown to have the capability of 
selectively targeting hypoxic cells; quinones, nitroaromatics and N-oxides.
30, 31
 The 
general strategy used to achieve hypoxic selectivity is for the compound to be a non-
toxic prodrug which can undergo selective reduction within hypoxic tumour cells. 
The reduced species ideally needs to be stable enough to enable it to be re-oxidised 
back to the prodrug species in the presence of oxygen (Scheme 1.4). Under hypoxic 





Scheme 1.4: Chemotherapeutic strategy for hypoxia-selective cytotoxic agents 
1.3.1.1. Quinones 
The naturally occurring quinone derivative Mitomycin C (Figure 1.5) became one of 


















Quinones themselves generally have low toxicity but their functionality can be used 
to selectively activate cytotoxic groups.
33
 Under hypoxic conditions, quinones can be 
reduced by a multi-step mechanism which proceeds via the formation of a semi-
quinone one-electron reduction product or hydroquinone which is the result of a two 
electron reduction. These species undergo further reductions which yield the 
cytotoxic DNA alkylating species which can cause the formation of guanine-guanine 


































































































Scheme 1.5: Proposed mechanism for the formation of DNA cross-links between 








The nitroaromatic nitracrine (Figure 1.6), an analogue of the widely-studied 
acridines, was found to be one of several nitroaromatic compounds to show some 







Figure 1.6: Structure of nitracrine (compound [2]).
39 
Acridines, a class of DNA chelating agents, have been long known for their 
medicinal properties, first finding use as anti-bacterial and anti-parasitic agents.
38
 
Initial in vitro experiments of nitracrine ([2]) showed a highly selectivity for AA8 
(Chinese hamster ovarian) cells under hypoxic conditions compared to under aerobic 
conditions although the active cytotoxic species is yet to be fully identified.
39-41
 
Nitracrine has two bio-reducible groups; a nitro group and an N-oxide, which both 
need to be reduced before the molecule is transformed into its active form.
42
  
Nitro reduction was investigated as a means of selectively activating a 
phosphoramidate mustard prodrug.
44
 One of the investigated compounds provided 
highly promising results with 1-methyl-2-nitro-1H-imidazol-5-yl)methyl N,N-bis-(2-




















[3] demonstrated a 300-fold increase in potency against H460 (human lung cancer) 
cells when under hypoxic conditions compared to aerobic conditions, and a 200-fold 
increase against HT29 (human colon adenocarcinoma) cells (Table 1.2).
43
  
Table 1.2: IC90 data for compound [3] against H460 and HT 29 cells.
44
  
Cell line IC90 (N2) / μM IC90 (air) / μM 
H460  0.1 30 
HT29  0.2 40 
 
The proposed mechanism for the selective activation of the compound under hypoxic 

























































F]FMISO) (Figure 1.8) is the most widely used 






 The selective retention of [4] within hypoxic cells is due to 
the nitro group undergoing reduction by nitroreductase enzymes, forming a reactive 













N-oxides represent a class of compounds which have undergone extensive research 
for use as hypoxia-selective agents, with one particular example having undergone 
phase II and phase III clinical trials.
46
 3-Amino-1,2,4-benzotraizine-N1,N4-oxide 
(Figure 1.9), commonly known as tirapazamine, has undergone clinical trials in 
combination with other anticancer treatments such as cisplatin and radiotherapy, 










Figure 1.9: Structure of tirapazamine (tpzH)  
In vitro studies have demonstrated that tirapazamine (tpzH) has a promising 100-200 
fold selective cytotoxicity toward hypoxic cells over normally oxygenated cells.
36
 
Table 1.3 shows the IC50 values against selected cell lines under both aerobic and 




observed in the IC50 values of tpzH when under hypoxia compared to aerobic 
conditions, with the greatest selectivity observed against the H226 (human lung 
squamous carcinoma) cell line. 




Cell line IC50 / μM after 3 hours exposure Differential toxicity 
 Aerobic Hypoxic  
A549 247.0 ± 44 7.4 ± 0.5 33.2 
H322 980 ± 24 54.3 ± 1.7 18.1 
H358 1231.0 ± 62 48.1 ± 5.6 25.6 
H460 110.0 ± 10 4.2 ± 2.0 26.2 
H522 141.0 ± 12 8.9 ± 0.6 15.8 
H647 135.0 ± 22 6.3 ± 2.0 21.4 
H226 941.0 ± 189 22.8 ± 4.6 41.3 
 
Despite extensive studies, the mechanism responsible for tpzH’s selective 
cytotoxicity is still a subject of great debate between two different mechanisms 
which propose the cytotoxic species to be either a hydroxyl radical or a tpzH-based 
radical species. However, there is general agreement on the tpzH undergoing a one 
electron enzymatic reduction to form a radical based active species.
50
 Although the 
identity of the responsible biological reducing agents remains elusive, many have 
reported evidence for the reduction being carried out by cytochrome P450 
reductase.
51, 52
 The one-electron reductive enzyme xanthine oxidase has also been 









Gates et al. proposed that the cytotoxicity of tpzH arises from the generation of 
hydroxyl radicals (Scheme 1.7). This proposal was based upon characterisation 
studies of the products arising from tpzH-mediated DNA damage found that the 
strand breakage was non-sequence specific and matched the strand damage formed 
by hydroxyl radicals.
54
 The mechanism involves the one electron reduction of tpzH 
followed by protonation of the N4-oxide oxygen. This then allows the elimination of 



































Anderson et al. reported spectral evidence which disfavoured the hydroxyl radical 
elimination or mechanism that involving the formation of a charged species. They 
proposed the formation of a benzotriazinyl radical (Scheme 1.8). The benzotriazinyl 
species is a nitrogen-centred radical which would be more oxidising in nature than a 
carbon-based radical species so would be more likely to cause the DNA damage 
caused by tpzH.
55
 They proposed that such a species could be generated via the 
elimination of water from the species from the one electron protonated product. This 
hypothesised mechanism was further supported by the results of spin-trapping 
experiments, where EPR spectroscopy indicated the formation of a carbon-centred 




results concluded that the nitrogen-centred radical had poor stability, and therefore a 
short life time, so went on to form the detected carbon-centred radical.
56
 Pulse 
radiolysis studies supported this hypothesis by demonstrating the occurrence of 





































Scheme 1.8: Proposed mechanism of activity for tpzH involving the elimination of 
water to form a benzotriazinyl radical.
49
 
Whilst highly effective in vitro, this success has not translated into immediate 
clinical success. This has been partly attributed to the distribution of tpzH outside the 
bloodstream being too poor, preventing it from penetrating deep into the tumour to 
the hypoxic regions where it would be most potent.
57
 It has also been suggested that 
tpzH is metabolised too quickly upon reaching the reducing environment of hypoxic 
reagents, preventing the drug from penetrating far enough within.
58
 Another problem 
has been the side effects which result from tpzH’s toxicity. Studies have found that 
the use of tpzH in clinical trials correlates with the increased occurrence of 
symptoms such as nausea, fever, low blood pressure and deafness.
59
 There is 
therefore a large amount of ongoing research into analogues of tpzH which optimise 




general toxicity. These include SN30000 ([5]) which is under clinical 
investigation,
60, 61
 SN2971 ([6]) and 7-chloro-2-thienylcarbonyl-3-


































1.4. Transition metal anticancer agents 
1.4.1. The platinum revolution 
During the late 1960’s experiments were being conducted into the effect of electrical 
current on cell growth in bacterial cultures. It was found that the Escherichia coli 
cells became abnormally elongated due to inhibition of cellular division.
64
 It was 
found that this cell elongation was caused by the platinum(IV) complex 
[NH4]2[PtCl6]. After the trialling of many platinum compounds against tumour cells, 
it was found that the anticancer activity required a neutral complex with two cis 
amine-type ligands. One of the compounds trialled was cis-
diamminedichloroplatinum(II), and it was this compound which gained approval for 











Figure 1.11: Structure of cisplatin 
The mechanism of action of cisplatin has been intensively studied. The chloride 
concentration found within blood plasma (100 mM) is high enough that exchange of 
the chloride ligands of cisplatin for water is disfavoured.
66
 Upon entering a cell (5-20 
mM), one of the chloride ligands is exchanged for an aqua ligand.
67
 This aquation 
process is vital to the complex’s activity owing to the aqua ligand being a more 
reactive ligand than chloride when complexed to platinum(II).
68
 The mono-aqua 
complex can then covalently bind to the cellular DNA, typically through the N7 

























































The binding of cisplatin to the DNA leads to the formation of a Pt-DNA adduct, 




Figure 1.12: Crystal structure of cisplatin having formed a 1,2- guanine intrastrand 
crosslink, causing structural distortion to the DNA (image taken from reference 69). 
Problems associated with cisplatin such as high renal toxicity are understood to be 
due to it reacting with proteins before reaching the cell.
70
 Another problem with 
cisplatin is that it is ineffective against some cancers, whilst others are able to 
develop a resistance to it. These problems have led into many avenues of research, 
including the development of effective but less toxic platinum complexes such as 
carboplatin and or oxaliplatin (Figure 1.13),
71-73
 or the use of alternative metals such 
as ruthenium.
30, 74
 The platinum complexes [9] and [10] show reduced toxicity and 
therefore cause milder side effects in patients, but have lower cytotoxicities towards 
cancer cells, owing to the lower reactivity of the bidentate ligands which have 



















Figure 1.13: Structures of the second generation cisplatin compounds carboplatin 




1.4.2. Other examples of transition metal-based anticancer agents 
The ability of a metal to alter the activity of a therapeutically active ligand has been 
demonstrated by examples including several relevant to anticancer treatments. 
Tamoxifen is a prodrug commonly used for the treatments of hormone dependant 
breast cancers and is converted within the body to its active hydroxytamoxifen form. 
Its activity derives from its ability to competitively bind to the estrogen ERα 
receptors but problems with this drug include its ineffectiveness against hormone-
independent breast cancers, and the tendency of resistance amongst tumour cells 
which can increase over long periods of treatment.
75
 There are numerous transition 
metal complexes reported in the literature which incorporate a hydroytamoxifen 
derivative as a ligand, stemming from the promising results with ferrocene 

































Figure 1.14: Structure of hydroxytamoxifen, the active form of the prodrug 







 and cyclopentadienyl rhenium tricarbonyl [14].
76, 79
 
Ferrocene derivatives of hydroxytamoxifen, such as [11] were found to not only 
exhibit anti-proliferative activity against the hormone-dependent breast cancer cell 




against which tamoxifen shows poor activity.
80
 It is believed that the activity against 
the hormone-dependent cell line is due to a similar mode of tamoxifen itself, in that 
it competitively binds to the estrogen receptors, demonstrated by several binding 
studies.
76, 80
 Structure-activity relationship and electrochemical studies have 
supported the hypothesis that the cytotoxic species formed is a quinine methide 
(Scheme 1.10), where it was found that the activity of various analogues of [11] was 
dependent on the presence of at least one para-phenol moiety.
81
 This mechanism is 
also supported by a study which involved a ruthenocene derivative, which showed 
similar activity against hormone-dependent MCF7 cells but no anti-proliferative 























Scheme 1.10: Proposed mechanism for the generation of a putative cytotoxic quinine 
methide species from [11].
83, 84
 
It was proposed that in preparing the oxaliplatin derivative [12], a system of 
selectively delivering platinum to breast tumours would result, but the results proved 
disappointing.
77
 Complex [13] was tested against hormone-dependent breast cancer 
cell line MCF7 and compared with estradiol which provides the standard estrogenic 




estrogenic effect and therefore has an anti-proliferative action. The results showed 
that rather than the anticipated increase in anti-proliferative activity brought about by 
the titanocene dichloride fragment, [13] increased cell proliferation almost to the 
extent of estradiol.
78
 Therefore [13] does not appear to be a promising anti-tumour 
candidate compound. Two of the tested rhenium complexes, [14], exhibited anti-
proliferative activity against MCF7 cells which was slightly higher than that 
obtained for the tamoxifen prodrug hydroxytamoxifen, suggesting this complex does 
show potential as an anticancer compound.
79
 
Another biologically active ligand which has been incorporated into metal 
complexes which show anticancer properties is acetylsalicylic acid, more commonly 
known as the prodrug form as aspirin (Figure 1.15). There have been numerous 
variations of both ligand modifications and metal, some of which will now be 
discussed. It was found that [15] displayed anti-proliferative properties against breast 
cancer with a significantly lower IC50 than aspirin.
85
 It was subsequently found that 
[15] showed equal inhibition of both COX-1 and COX-2 cyclooxygenase enzymes.
86
 
Aspirin, functions as an anti-inflammaory drug by inhibition of COX-1,
87
 so it was 
thought that the anti-proliferative activity of [15] might be attributed to the inhibition 

































Figure 1.15: Structures of acetylsalicylic acid (aspirin) and examples of its 





The cobalt carbonyl complex [15] proved to be the most active complex, followed by 
the ruthenium complex [16], but unlike with the hydroxytamoxifen complexes, the 
ferrocene complex [18] and also iron complex [17] showed poor activity, suggesting 
the alkyne ligand is needed for activity. 
The anti-proliferative activity of [16] against the cell lines has thrown doubt over the 
biological action of these complexes. COX inhibition studies of [16] showed it to be 
a poor inhibitor, but its anti-proliferative activity is almost equal to [15], suggesting 
it is either acting via a different biological target or COX inhibition is not the source 
of the anti-proliferative activity. 
















Compound IC50 / μM 
 MCF7 MDA-MB 231 HT-29 
Cisplatin [8] 2.0 ±0.3 3.3 ±0.5 2.4 ±0.4 
Aspirin >50 >50 >50 
[15] 1.4 ± 0.3 1.0 ±0.3 9.8 ±3.0 
[16] 1.4 ±0.2 2.4 ±0.0 2.2 ±0.0 
[17] >20 >20 >20 




1.4.3. The development of hypoxia selective transition metal complexes 




(Figure 1.16), has high selectivity for trapping 
64
Cu within hypoxic tumour cells for 














Figure 1.16: Structure of the PET imaging agent [Cu(ATSM)] (copper(II) diacetyl-
bis-(N-methylthiosemicarbazone)) 
[Cu(ATSM)] reached the latter stages of clinical trials, but progress into full clinical 
use has been hindered by high liver accumulation of 
64
Cu. Analogues similar to [19] 
(Figure 1.17) are retained within cells non-discriminatively, so these non-selective 
complexes and [Cu(ATSM)] have been widely studied to understand the hypoxia 






























Figure 1.17: Structures of [Cu(ATSM)] and some of its analogues show poorer 
hypoxia selectivity 
Various chemical properties of this type of complex have been studied and correlated 
with their hypoxia selectivity, including redox potentials and partition coefficients. 




the copper(II) complex, the greater the hypoxia selectivity and indicate that for a 
copper(II) complex to be hypoxia selective, it needs to have a reduction potential 
greater than -0.57 V vs. Ag/AgCl in DMSO, although it is important to note this is 
not the sole determining factor.
90, 91
 It is thought that the selectivity of [Cu(ATSM)] 
arises from the complex undergoing reduction only in hypoxic cells. Upon reduction, 
the ligand dissociates, and the copper(I) isotope is then bound by ‘copper-
scavenging’ proteins within the cell such as metallothionein (Scheme 1.10).92 
Experiments have shown that the copper(I) binding-proteins Ctr1 (a membrane 
copper transporter) and Atx1 (a copper chaperone protein) were not able to extract 
the copper(II) centre from [Cu(ATSM)]. Upon addition of a reducing agent, the 














1.4.3.2. Cobalt(III) complexes of nitrogen mustard ligands 
Nitrogen -mustards (Figure 1.18) are a group of potently cytotoxic compounds 


















Figure 1.18: General structure of a N-mustard (left) and the cobalt(III) N-mustard 
complex [20] (right) 
Denny et al. have explored how N-mustards might be developed into hypoxia 
selective agents by complexing mustard –type ligands to cobalt.95, 96 Cobalt is one of 
the most suitable metals to be used for the purpose of hypoxia-selective ligand 
dissociation owing to the general coordination chemistry of its +3 and +2 oxidation 
states. In its +3 oxidation state, cobalt forms octahedral complexes and has a d
6
 
electron configuration. Cobalt(III) complexes are typically low spin, and owing to 
the electron configuration are kinetically inert. Upon undergoing a one-electron 
reduction to cobalt(II), a change to a high spin electron configuration occurs and so 
the eg orbitals become partially filled (Figure 1.19). The eg orbitals point directly at 
the ligand orbitals rather than in-between them, resulting in a weakening of the 
metal-ligand bonding interaction when they become occupied which corresponds to 
a lengthening bond length. The lability of cobalt(II) complexes is also contributed to 
by Jahn-Teller distortion which occurs upon there being an uneven distribution of 
electrons amongst degenerate d orbitals. The difference in lability of these two 








Figure 1.19: The electron configurations of a general cobalt(III) and cobalt(II) 
complex with octahedral geometry  
With using cobalt(III) complexes as a prodrug, it is hoped that the complex will 
become selectively reduced in hypoxic cells to the equivalent but more reactive 
cobalt(II) complex. From the cobalt(II) complex, the ligands can easily dissociate 
and can then take effect on their biological targets. The reactivity of N-mustards is 
controlled by the electron density on the nitrogen atom, so by coordinating this to a 
metal centre reduces their reactivity. Complex [20] was found to show 
approximately 30-fold selective cytotoxicity towards EMT6 (mouse mammary 
tumour) cells under hypoxia compared to aerobic conditions.
98
 This selectivity was 
assumed to be due to the complex undergoing selective reduction within hypoxic 

































Scheme 1.12: Proposed mechanism of the selective release of the N-mustard ligand 
from the cobalt(III) complex [20].
99
 
Similar complexes were prepared which in addition to the bidentate amine N-
mustard contained carbonato or oxalato ligands. These complexes were found to 
reduce the toxicity of the N-mustard through being coordinated to the cobalt(III) 































[21] [22]   
Figure 1.20: Structures of the cobalt(III) N-mustard bis-carbonato and oxalate 




Table 1.5: IC50 values of the cobalt(III) N-mustard complexes [21] and [22] against 
AA8 and UV4 cells.
95
 
 1C50 / μM 
 AA8 UV4 
Uncoordinated mustard 2.4 0.04 
[21] 20 0.36 
[22] 3.1 0.04 
The difference in toxicity under hypoxic and aerobic conditions was also explored, 
with [21] found to be 20 times more potent under hypoxia and [22] over ten times 
more cytotoxic (Table 1.6).
95
  
Table 1.6: CT10 values of the cobalt(III) N-mustard complexes [21] and [22] (CT10 = 
concentration × time (h) to give 10% survival).
95
 
 CT10 / μM  
 air N2 
Uncoordinated mustard 0.18 3.0 
[21] 90 4.5 
[22] 32 2.7 
 
1.4.3.3. Cobalt(III) complexes of other ligands 
Hambley has developed a cobalt(III) prodrug of marimastat (Figure 1.21), a drug 
which inhibits matrix metalloproteinase (MMP) enzymes which are thought to be 

























The prodrug complex was designed with the aim of selectively delivering the 
inhibitor to tumour cells. The reduced ability of marimastat to inhibit matrix 




Table 1.7: IC50 values of marimastat and its cobalt(III) [23] determined by MMP 
inhibition assay under aerobic conditions 
 IC50 / μM 
Marimastat 7.0 ± 0.5 
[23] 900 ± 100 
It is widely reported that the fluorescence of certain fluorophores can be quenched 
upon coordination to a cobalt(III) centre.
102, 103 
This provides a useful tool for being 
able to monitor the occurrence of bio-reduction within cells, but also to be able to 
observe where in the cell it occurs using techniques such as confocal microscopy. 
Hambley and co-workers have prepared a series of cobalt(III) complexes (Figures 

















Figure 1.22: Structure of the cobalt(III) complex [24] containing a fluorescent ligand 
The ability of [24] to be reduced by biologically relevant agents such as ascorbate 
and cysteine were investigated using fluorescence. The increase in emission brought 
about by the dissociation of the ligand upon reduction of the cobalt(III) centre was 
monitored as a function of time. Complex [24] was observed to have a significantly 
increased cytotoxicity against A2780 (human ovarian carcinoma) cells and to be 
over 40 times greater than that of the fluorophores or [Co(Cl)2(cyclam)]Cl (Table 
1.8).
104
 Complex [24] was observed to be reduced at the same rate by ascorbic acid 
under both aerobic and anaerobic conditions.
104
 




Compound IC50 / μM 
[24] 4.8 +/- 0.3 
Ligand of [24] >200 
[Co(Cl)2(cyclam)]Cl >200 
 
Another study investigated the cytotoxicity of complexes [25] and [26] (Figure 1.22) 


































Figure 1.23: Structures of the cobalt(III) complexes [25] and [26].
105
 
The results of cytotoxicity assays against DLD-1 (human colon carcinoma) cells 
show that complexation of each of the two fluorophores to a cobalt(III) centre has 
dramatically increased their potency (Table 1.9).  
 




Compound IC50 under normoxia / μM IC50 under hypoxia / μM 
[25]  1.3 +/- 0.7 1.9 +/- 0.2 
Fluorophore of [25] 99 +/- 5 >200 
[26]  35.6 +/- 0.9 20.04 +/- 0.1 
Fluorophore of [26] >200 177 +/- 0.2  
[Co(Cl)2(cyclam)]
+
 >200 >200 
 
The cytotoxicity of [25] did not change between hypoxic and normoxic conditions, 
whilst [26] showed a slight increase in cytotoxicity under hypoxia. Imaging results 




into the spheroid than the ligand on its own. The deeper penetrating fluorescence 
observed with complex [26] showed that metal coordination was aiding the delivery 
of the ligand deeper into the mass but the ligand was then able to dissociate. The 
ligand of [25] was able to penetrate deeper into the tissue but complexation to 
cobalt(III) improved its delivery to the hypoxic regions. These findings from the 
spheroid experiments, however, do not explain the increased cytotoxicity values of 





1.4.3.4. Copper(II) complexes of nitrogen mustard ligands 
In addition to complexes of cobalt(III), N-mustard derivatives have been coordinated 






























Complex [27] was found to have the greatest aqueous stability out of the three 
complexes examined, and was shown to undergo a reversible one-electron reduction 
at -0.013 V. The other two complexes, [28] and [29], were shown to undergo 
reductions at more negative redox potentials, but showed no degree of reversibility 
(Table 1.10). The complexes were tested against K562 (human chronic myeloid 
leukaemia) cells under normoxic and hypoxic conditions, and compared to the 
cytotoxicity of their respective uncoordinated mustard ligands under normoxia 
(Table 1.10). Complexation of the ligand in [27] brought about the greatest 




change was observed upon complexation to [28] and [29]. The toxicity of [28] and 
[29] slightly decreased under hypoxia, whereas the cytotoxicity of [27] increased 




Table 1.10: IC50 values of the copper(II) complexes [27], [28] and [29] against K562 




Compound IC50(air) / μM IC50(hypoxia) / μM Ered / V vs Ag/AgCl 
[27] 53.4 ± 10 2.2 ±0.25 -0.212 
Ligand of [27] 22 --- --- 
[28] 10.1 ±1 51.3 ±10 -0.339 
Ligand of [28] 7.5 --- --- 
[29] 8.4 ±0.7 15.9 ±1 -0.439 
Ligand of [29] 10.5 --- --- 
 
 
From studies with [Cu(ATSM)] ([19]), it appeared that a more negative reduction 
potential for the copper(II) centre aided hypoxia selectivity. This was demonstrated 
with [19] possessing a reversible reduction potential of -0.57 V vs. Ag/AgCl in 
DMSO, whilst its analogues were found to show a correlation between poorer 
hypoxia selectivity and a less negative reduction potential.
107, 108 
On the basis of this, 
it would be expected that complex [29] would show the greatest hypoxia selectivity, 
owing to it having the most negative reduction potential of the complexes examined 
(0.439 V vs. Ag/AgCl in DMSO), but this complex showed no hypoxia selectivity. 
The selectivity of [27] demonstrates that the stability of the copper(II) complex and 
reversibility of the copper(II) reduction are important factors in obtaining hypoxia-










It has been established that owing to the nature of growth within tumours, regions of 
sub-normal oxygen levels occur. It has been found that in addition to the lack of 
oxygen in these hypoxic regions, which causes their environment to be more 
reducing, cellular adaptations cause the extracellular environment of these regions to 
become more acidic. It has been found that the occurrence of hypoxia renders many 
anticancer treatments less effective, but it also provides an opportunity for the 
development of prodrugs to selectively target these areas of tumours. One suitable 
area for the development of such prodrugs is transition metal chemistry where a 
metal can be used to deliver and control the activity of a cytotoxic ligand or 
contribute to the cytotoxicity itself. The requirements needed to achieve a hypoxia-
selective prodrug that is both selective and effective in vivo are not yet fully 
understood and the pursuit of developing such a prodrug remains a challenge to 
medicinal chemists. 
Metals can have a highly-varied role in medicinal chemistry; they can provide the 
cytotoxic activity, provide improved delivery of a therapeutically active ligand and 
can also modify a ligand’s biological behaviour. The examples discussed highlight 
the unpredictable nature that designing inorganic medicinal compounds can involve, 
such as stability and reactivity. The accidental discovery of cisplatin is yet to be 
matched in success with other complexes. Trying to combine the second generation 
analogue of oxaliplatin with hydroxytamoxifen produced a complex with ineffective 
activity but the ferrohydroxytamoxifen complex [11] showed promising activity. 
With another family of metal complexes incorporating derivatives of aspirin, the 
ferrocene derivative [18] showed poor anti-proliferative activity compared with the 
cobalt complex [15] and ruthenium complex [16]. Studies of cobalt(III) complexes 
[25] and [26] have demonstrated that complexation can improve a drug’s delivery 
throughout the tumour with the use of fluorescence studies. No cobalt(III) complexes 
have as yet emerged beyond laboratory use for as hypoxia-selective cytotoxic drugs, 
partly due to lack of cytotoxic selectivity. Complex [19] ([Cu(ATSM)] has failed to 
enter full clinical use over concerns of the isotopically-labelled copper accumulating 





1.6. Project Aims 
Although it has been demonstrated that hypoxia selectivity can be achieved, a 
hypoxia selective cytotoxic agent is yet to reach full clinical usage. This project aims 
to use ligand systems that are known to already demonstrate hypoxia selectivity, 
with the aim of improving their properties such as delivery, selectivity and stability. 
Ligands to be investigated in this way include those based upon 2,2’-dipyridylamine 
(dpHa) (Figure 1.25) which is a therapeutic fragment of several inhibitors designed 












Figure 1.25: Structure of dpHa (2,2’dipyridylamine) (left) and an example of a 
dpHa-based kinase inhibitor (right).
111
 
Another ligand to be explored is tpzH (Figure 1.26). Despite its highly potent and 
selective cytotoxicity against hypoxic tumour cells in vitro, full clinical use has not 









tpzH   
Figure 1.26: Structure of tpzH (tirapazamine) 
This project will focus on using copper(II) and cobalt(III) to form complexes that act 
as hypoxia-selective prodrug compounds. The aim is to develop compounds with a 




metal before the active species is formed within the hypoxic tumour cellular 









of ligand  
Scheme 1.13: Proposed ‘double trigger’ mechanism for the complexes to be 
prepared during this project 
This strategy aims to produce transition-metal based prodrugs with improved 
biological properties and provide a method of improving upon compounds which 
already show a degree of hypoxia selectivity. 
Most previous work on hypoxia selectivity has ignored the occurrence of sub-normal 
pH values within hypoxic regions of tumours. This project aims to study how this 
difference in pH may be used to aid the activation of hypoxia-selective prodrugs in 
conjunction with other properties such as reduction potentials. The use of more than 
one environmental factor to activate such prodrugs could result in improved hypoxia 
selectivity. 
The target metal complexes will be fully characterised, including full chemical 
structure determination where possible. The various solution properties of the metal 
complexes and their ligands will studied, including their pH-dependant behaviour 
and redox chemistry because the anaerobic environment and acidified pH of hypoxic 
tumour cells are two features which differentiate them from normal cells. The 
cytotoxicity of the complexes will also be evaluated, and analysed in the context of 
the results obtained from the solution studies. This will allow for obtaining a better 
understanding of how their properties relate to activity and how they might be 
improved upon.  
   Chapter Two 
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Chapter Two: Evaluation of 2, 2’-dipyridylamine complexes as kinase 
inhibitors 
2.1. Introduction to kinase inhibitors 
The majority of anti-cancer agents target cellular DNA, but there is an increase in the 
development of drugs that take effect on other biological targets. The human genome 
encodes for 518 known kinases and the past few decades have revealed the 
relationship between kinase gene mutations which alter their function, and many 
human diseases.
113, 114 
Kinases are a class of enzymes which catalyse the 
phosphorylation of specific amino acids on proteins such tyrosine or threonine. 
Through the transfer of the phosphate group from ATP to the substrate, the 
electronic character of that region of the protein is altered which can result in a 
conformational change, and thus alter its function (Scheme 2.1). This 
conformational change can enable the protein to be ‘switched’ on and off, allowing 
kinases to play an integral role in the control of cellular processes such as 





the kinase enzyme has 
two binding sites; one 
for ATP and one for the 
substrate molecule
Following binding at both 
sites, the phosphate is 
transferred from the ATP 
to the substrate
If the substrate is a 
protein, the 
phosphorylation may 
cause a conformational 
change
 
Scheme 2.1: Scheme showing the general biological activity of kinase enzymes 
Due to their importance in cell regulation, and implications in disease, it is not 
surprising that in 2002, it was estimated that out of the biological targets used by 
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drugs, over a quarter of the targets were protein kinases.
116, 117
 The specificity of 
kinases towards their particular substrate is usually due to altered structure and 
conformation about the active site. This feature can be exploited by medicinal 
chemists to develop inhibitors which can specifically target one particular kinase. An 
example of a kinase-selective inhibitor is Gefitinib which specifically inhibits 
epidermal growth factor receptors and thereby hinders cancer cell growth. However, 
broad spectrum inhibitors which act upon multiple pathways, such as Dasatinib 
which targets multiple tyrosine kinases, have also been proved clinically useful. In 
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Figure 2.1: Kinase inhibitors which entered clinical use for the treatment of cancer 
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It can be seen that they all consist of a flexible chain of aromatic rings with groups 
capable of forming complimentary hydrogen-bonding interactions with the residues 
about the active site. The aromatic rings can be positioned into the hydrophobic 
regions within the kinase active site (Figure 2.2). The larger the number of 
interactions with the active site, the stronger the affinity of the inhibitor and the more 





Figure 2.2: How the small molecule inhibitor dasatinib binds into the ATP cavity 
region of the active site of a protein kinase enzyme: Crystal structure (above) of 
dasatinib bound to Human p38 MAP Kinase (PDB code 3LFA),
120, 121
 and scheme of 
interactions within the active site (below) showing hydrogen-bonds between protein 
and inhibitor (dashed lines) and hydrophobic regions.
118
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It can be seen how it may be possible to coordinate inhibitors such as dasatinib to a 
metal centre (Figure 2.3) due to it containing two nitrogen heterocycles which can 














Figure 2.3: How the kinase inhibitor dasatinib could coordinate to a metal centre 
through its two pyridyl nitrogen atoms 
There are now inhibitors emerging that can also be potentially coordinated to metal 
centres which contain a 2,2’-dipyridylamine fragment such as KI1 and KI2. 122, 123 
These inhibitors feature phenyl or napthyl substituents on the pyridyl rings which are 
designed to fit within the hydrophobic pockets of the active site. The pyridyl 
nitrogen atoms can act as hydrogen-bond acceptors and the amine which can behave 














Figure 2.4: Structures of inhibitors containing the 2,2’-dipyridylamine fragment 
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Sentinel Oncology have developed a library of inhibitors based around the 2,2’-
dipyridylamine fragment appended to a Lewis base group to act as a further 

















Figure 2.5: Examples of inhibitors developed by Sentinel Oncology which 
incorporate 2,2’-dipyridylamine.111  
These inhibitors are designed so that they can bind to the kinase active site when in 
the anti conformation but is inactive when in the syn conformation (Figure 2.6). The 
aim of this study is to evaluate the therapeutic potential of coordinating a kinase 
inhibitor therapeutic fragment, 2,2’-dipyridyl amine (dpHa) to metals in order to 
provide a hypoxia selective kinase inhibitor. The pyridyl nitrogen atoms are well-
positioned to be both coordinated to a metal centre, thus enforcing the inactive syn 


















anti conformation syn conformation
 
Figure 2.6: The anti and syn conformations of dpHa and the syn conformation that 
can be enforced upon coordination to a metal centre 
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2.2. Complexes of 2,2’-dipyridylamine as kinase inhibitors 
This work starts off by preparing and studying complexes of 2,2’-dipyridylamine 
(dpHa). The coordination chemistry of dpHa has been widely reported including and 
includes various applications such as ruthenium complexes used for the reduction of 
aromatic ketones through transfer hydrogenation and lanthanide coordination 

























Figure 2.7: Examples of reported metal complexes of dpHa.
119, 120 




 and zinc(II) 
have previously been reported in the literature along with their structures, as has that 
for [Zn(dpHa)2]2BF4.
128, 129
 The structures of [Co(Cl)2(dpHa)] and [Zn(Cl)2(dpHa)] 
were both reported as having a tetrahedral geometry whilst the [Cu(Cl)2(dpHa)] and 
[Zn(dpHa)2](BF4)2 having distorted tetrahedral geometries. These complexes were 
all prepared and characterised, with diffraction quality crystals being obtained for 
[Co(Cl)2(dpHa)] and [Zn(Cl)2(dpHa)] by slow diffusion of Et2O into a DMF 
solution. As the space group obtained for these crystals matched those of the 
reported structures in the literature, the identity of the complexes was confirmed. 
2.2.1. Copper(II) and cobalt(II) bis-2,2’-dipyridylamine complexes 
[Cu(dpHa)2]Cl2 was prepared according to the reported method by reacting a 
solution of two equivalents dpHa in acetone with an ethanolic solution containing 
one equivalent of CuCl2.2H2O (Scheme 2.2).
130
  















Scheme 2.2: Preparation of [Cu(dpHa)2]Cl2 
The product formed as a green precipitate which could be isolated as a bright green 
powder in 87% yield. Filtering a methanolic suspension of the product removed any 
[Cu(Cl)2(dpHa)] which may have formed and which is insoluble in MeOH. The 
product could then be obtained by reducing the filtrate to dryness. Green diffraction 
quality crystals were obtained by slow evaporation from a solution of MeOH layered 
over 
n
BuOH over the duration of a week at room temperature. The structure shows 
the two dpHa ligands coordinated to the copper(II) centre, with the N(1) and N(4) 
nitrogen atoms of the two pyridyl ligands being trans to each other (Figure 2.8). One 
of the chloride ligands is coordinated to the metal centre in the axial position.  
 
Figure 2.8: ORTEP diagram (50% probability ellipsoids) of [Cu(Cl)(dpHa)2]Cl.
131
 
Hydrogen atoms (except H(2a), H(1b) and H(5)), omitted for clarity. Selected bond 
lengths / Å and angles / °: Cl(1)-Cu(1) 2.3013(8), Cu(1)-N(4) 1.989(2), Cu(1)-N(1) 
2.007(2), Cu(1)-N(6) 2.075(2), Cu(1)-N(3) 2.139(2), N(1)-Cu(1)-N(3) 88.49(8), 
N(4)-Cu(1)-N(6) 88.72(8) 
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For five-coordinate metal complexes, a value, τ, can be calculated to qualitatively 
determine if the structure is square pyramidal, trigonal bipyramidal or distorted i.e. 









Figure 2.9: Relevant parameters of a five coordinated complex needed to calculate 
the τ value (A is the axial ligand, β is the greatest angle between the basal ligands 
and α is the angle trans to β).132 
If a five coordinate complex such as that shown in Figure 2.9 is of perfect square 
pyramidal geometry, then the angles α and β both equal 180º. If the complex adopts 
a perfect triganol-bipyramidal geometry, β is equal to 180º whilst α equals 120º. The 
τ value can be calculated according to the following equation: 
τ  
 β  α 
  
 
When τ is equal to 0 then the structure can be considered to be of a perfect square 
pyramidal geometry and 1 for a complex of trigonal-bipyramidal geometry. The 




With cobalt(II), it is possible to form the bis-complex [Co(Cl)2(dpHa)2] by reacting 
two equivalents of dpHa with one equivalent CoCl2.6H2O in a methanolic 
solution.
133
 The reaction mixture was filtered and the solvent of the filtrate allowed 
to partially evaporate at room temperature, leading to a precipitate, to allow for 
isolation of the product in 63% yield. This complex was converted to the mono dpHa 
complex [Co(Cl)2(dpHa)] upon the application of heat or addition of other solvents 
such as Et2O, acetone or EtOH. Crystals of the bis-complex were obtained by slow 
evaporation from a concentrated methanolic solution. The x-ray structure (Figure 
2.10) shows the two dpHa ligands in a cis-arrangement about the cobalt(II) centre 
along with two chlorides. One of the chloride ligands, Cl(2), has a 50% occupancy 
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due to it being exchanged for a neutral aqua ligand. When the aqua ligand is present, 
the charge of the complex is balanced by a non-coordinating chloride, Cl(3). 
 
Figure 2.10: ORTEP diagram (50% probability ellipsoids) of [Co(Cl)2(dpHa)2].
131
 
Hydrogen atoms (except H(1a), H(1b), H(2a), H(2b) and H(5)), omitted for clarity. 
Selected bond lengths /Å and angles /º : Co(1)-Cl(1) 2.4209(5), Co(1)-Cl(2) 
2.5115(13), Co(1)-N(1) 2.1482(14), Co(1)-N(3) 2.1526(14), Co(1)-N(4) 2.1293(15) 
Co(1)-N(6) 2.1343(14), N(4)-Co(1)-N(6) 84.05(5), N(1)-Co(1)-N(3) 81.90(5). 
Hydrogen-bond distances / Å and angles /º: H(2b)···Cl(3) 2.34(5), O(2)···Cl(3) 
3.159(4), O(2)- H(2b)···Cl(3) 166(4) 
The chloride ligand with full occupancy forms a hydrogen-bond with the central 
amine of a pyridyl ligand of an adjacent complex. The presence of hydrogen-bonds 
can be determined crystallographically through the application of several criteria 
(Table 2.1). The traditional crystallographic method for hydrogen-bond 
determination is to compare the distance between the hydrogen-bond donor and 
acceptor atoms with the sum of their van der Waals radii. It is more reliable to use 
the distance between the donor and acceptor atoms rather than between the hydrogen 
and acceptor atoms owing to the position of hydrogen atoms not being as easily 
defined. The distance between Cl(1) and N(5) is 3.2295(16) Å which is less than the 
sum of their van der Waal radii of chlorine and nitrogen (1.75 and 1.55 Å 
respectively). 
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IUPAC have also recently stated a hydrogen-bond interaction needs to have a X–
H···Y angle near to 180º and no less than 110º.
135
 The measured angle of Cl(1)-
H(5)-N(5) is 178(2)º which again provides evidence for the presence of a hydrogen-
bonding interaction.  
The second chloride ligand, Cl(2) is hydrogen-bonded to the H(1B) hydrogen of the 
uncoordinated water. This water also shows a hydrogen-bonding interaction between 
its oxygen O(1) and the amine proton H(2a) of the pyridyl ligand of an adjacent 
complex. When the coordination site of the second chloride is occupied by 
coordinated MeOH, this forms a hydrogen-bond with its alcohol proton, H(2b) to the 
uncoordinated chloride Cl(3) which in turn also acts as the hydrogen-bond donor 
with the amine proton on the adjacent complex. These combined interactions form 
infinite sheet structures throughout the crystal (Figure 2.9). 
Parameter Criteria for hydrogen-bond definition 
dD···A  < rD + rA + 0.5 
dH···A  < rH + rA - 0.12 
ɸD-H···A  > 100º 




Figure 2.11: ORTEP representation of the infinite sheets formed by hydrogen-
bonding interactions (dotted lines) between the complex and solvent.
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 Complex 
only shown as [Co(Cl)2(dpHa)2].H2O for clarity. Hydrogen-bond distances / Å and 
angles /º: H(2b)···Cl(3) 2.34(5), O(2)···Cl(3) 3.159(4), H(1b)···Cl(2) 2.36(6), O(1) 
···Cl(2) 3.123(5), H(5)···Cl(1) 2.43(2), N(5)···Cl(1) 3.2295(16), H(2a)···Cl(3) 
2.39(2), N(2)···Cl(3) 3.265(2), H(2a)···O(1) 1.87(2), N(2)···O(1) 2.744(4), O(2)- 
H(2b)···Cl(3) 166(4), O(1)-H(1b)···Cl(2) 155(5), N(5)-H(5)···Cl(1) 178(2), N(2)-
H(2a)···O(1) 178(2) 
 
2.2.2. Cobalt(III) complex of 2,2’-dipyridylamine 
A cobalt(III) complex was initially prepared by addition of H2O2 and one equivalent 
of NH4PF6 to a methanolic solution of [Co(Cl)2(dpHa)2], with the resulting product 
expected to be [Co(Cl)2(dpHa)2]PF6. Crystals were obtained upon the reaction 
mixture being left to stand overnight. The structure revealed a cobalt(III) centre 
coordinated to two dipyridylamine ligands as expected with the PF6 counter-ion, but 
no chloride ligands. In their place was a four-atom triganol group, which was 
modelled as both nitrate and carbonate. It was found that modelling with a carbonate 
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ligand provided the best fit to the diffraction data. This was then confirmed 
experimentally by preparing the complex under nitrogen and in the presence of 
excess carbonate. Preparing the complex under inert conditions resulted in a reaction 
mixture that could not be characterised by NMR spectroscopy owing to the large 
proportion of cobalt(II) present. Carrying the reaction out with excess NaHCO3 led 
to a far higher yield (41%) of red crystals was produced upon leaving the reaction 
mixture standing overnight. As PF6 is not a biologically suitable anion, a more 
appropriate counter-ion was needed to be used in its place. The structure obtained for 
with the PF6 counter-ion showed no evidence for the presence of chlorides from the 
original cobalt(II) salt being present in the complex, coordinating or non-
coordinating. It was therefore decided to use nitrate, which could be provided by 
using a Co(NO3)2.6H2O in place off the chloride anion. 
The cobalt(III) complex was therefore prepared directly by reacting Co(NO3)2.6H2O 
with two equivalents of dpHa, NaHCO3 and H2O2 (Scheme 2.3) to form 





















Scheme 2.3: Preparation of [Co(CO3)(dpHa)2]NO3  
Diffraction quality crystals of the resulting complex again were formed by leaving 
the filtered reaction mixture to stand. The data were fitted with two models; a 
coordinated carbonate and uncoordinated nitrate, and vice versa, to confirm that the 
carbonate was present as a ligand and nitrate as a counter-ion. Modelling the 
complex as [Co(CO3)(dpHa)2]NO3 provided the best fit with the diffraction data 
(Figure 2.12).  









NO3 counter-ion and hydrogen atoms (except H(3a) and H(6a)) omitted for clarity. 
Selected bond lengths /Å and angles /º: Co(1)-O(1) 1.8981(10), Co(1)-O(2) 
1.9117(10), Co(1)-N(1) 1.9250(12), Co(1)-N(2) 1.9261(12), Co(1)-N(5) 1.9342(12), 
Co(1)-N(4) 1.9437(13), O(1)-Co(1)-O(2) 69.23(4), N(1)-Co(1)-N(2) 88.94(5), N(5)-
Co(1)-N(4) 89.57(5) 
The structure shows a near-octahedral metal centre which appears to be slightly 
distorted by the carbonate having a bite angle of 69.23(4)º. The cobalt-ligand bond 
lengths are all under 2 Å which is characteristic for a cobalt(III) complex. The 
crystal structure reveals two complexes within the lattice are linked via two 
hydrogen-bonds formed between the amine proton H(3a) and the carbonate oxygen 
O(3) of the adjacent complex (Figure 2.13). The other amide proton of the complex, 
H(6a) forms a hydrogen-bond with the uncoordinated nitrate anion. These 
interactions have formed dimeric units throughout the lattice, with each consisting of 
two complexes and two nitrate counter-ions.  




Figure 2.13: ORTEP representation of the hydrogen-bonding interactions evident 
within the crystal structure of [Co(CO3)(dpHa)2]NO3.
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 Hydrogen-bond distances / 
Å and angles /º: H(6a)···O(6) 2.05(2), N(6)···O(6) 2.8175(18), H(3a)···O(3) 2.02(2), 
N(3)···O(3) 2.8553(17), N(6)-H(6a)···O(6) 159(2), N(3)-H(3a)···O(3) 173(2) 
The 
1
H NMR spectrum of the complex in D2O (Figure 2.14) shows that there are 
eight signals for the sixteen aromatic protons, indicating that there are two equivalent 
sets of pyridyl rings. The NMR spectroscopic data fits with the two dpHa ligands 




H NMR (D2O, 400 MHz) of [Co(CO3)(dpHa)2]NO3. δ8.05 (td, 2H, J = 
8.0, 1.0 Hz, H
a
), δ7.99 (td, 2H, J = 8.0, 1.0 Hz, Hb), δ7.60 (dd, 1H, J = 6.0, 1.0 Hz, 
H
c), δ7.46 (dd, 1H, J = 6.0 Hz, 1.0 Hz, Hd), δ7.36 (d, 1H, J = 6.0 Hz, He), δ7.24 (d, 
1H, J = 8.5 Hz, H



















H COSY NMR spectrum (Appendix 1) shows correlation between H
a
 and 






 peak is shown to also be coupled to H
d
, indicating 
that these four signals correspond to protons on the same aromatic ring. Similar 








, indicating that these 
proton signals correspond to the second pyridyl ring environment. 
2.3. Complexes of 2,2’-dipyriylmethylamine 
To aid the solution studies which will be discussed in Chapter 5, which include pKa 
determinations, it was decided that methylation of the central amine of dpHa would 
help ascertain whether observed processes were due to changes in the protonation 
state or not. 
2.3.1. Preparation of N-methyl-2,2’-dipyriylamine 
There is precedence in the literature for the preparation of N-methyl-2,2’-
dipyridylamine (dpma) by methylation of dpaH after treatment with various bases. 
Boyer et al. used 
n
BuLi as the base with the eventual product being a yellow oil, 
whereas Krebs et al
 
 had used NaH to produce a red oil.
136, 137
 The latter paper 
described a series of dpHa derivatives where the central amine has been methylated, 
but for all other alkylations involving the addition of an ethyl or butyl group, 
hydroxide was used as the base instead. As no explanation was provided for the use 





Scheme 2.4: Preparation of the dpma ligand from dpHa 
The resulting product was isolated as a yellow oil and 
1
H NMR spectroscopic 
analysis (Figure 2.15) indicated the addition of the methyl to the dpHa and that the 
two pyridyl rings had remained chemically equivalent, whilst ESI-MS confirmed the 
addition of the methyl group with the molecular ion increasing by 15 to m/z 186. 




Figure 2.15: Assigned 
1
H NMR spectra (400 MHz, d6-DMSO) of dpHa (above) and 
dpma (below). 
1H NMR of dpHa: δ9.65 (br. s, 1H, NH), δ8.21 (ddd, 2H, J = 5.0, 2.0, 
1.0 Hz, H
a), δ7.73 (dt, 2H, J = 8.5, 1.0 Hz, Hd), δ7.64 (ddd, 2H, J = 8.5, 7.0, 2.0 Hz, 
H
c), δ6.86 (ddd, 2H, J = 7.0, 5.0, 1.0 Hz, Hd). 1H NMR of dpma: δ8.30 (ddd, 2H, J = 
5.0, 2.0, 0.8 Hz, H
a), δ7.65 (ddd, 2H, J = 8.5, 7.0, 2.0 Hz, Hc), δ7.22 (dt, 2H, J = 8.0, 
1.0 Hz, H
d), δ6.98 (dd, 2H, J = 7.0, 5.0, 1.0 Hz, Hb), δ3.51 (s, 3H, CH3). 
 
2.3.2. Preparation of metal(II) complexes of N-methyl-2,2’-
dipyriylamine 
The N-methyl-2,2’-dipyriylamine ligand (dpma) was complexed to metal(II) chloride 
salts in the same way as for dpHa. Complexation to copper(II) chloride was achieved 
by reacting equimolar amounts of the two together in methanolic solution where the 
product precipitated out as a green solid was then isolated by filtration in 69% yield. 
Diffraction quality crystals of the product were obtained through slow evaporation of 
the filtrate over a couple of days. The [Cu(Cl)2(dpma)] complex crystallises as a 
dimer with two μ2-chloride bridging ligands (Figure 2.16). The two copper centres 
are 3.6823(8) Å apart and are related by an inversion operation.  




Figure 2.16: ORTEP diagram (50% probability ellipsoids) of [{Cu(Cl)2(dpma)}2].
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Hydrogen atoms omitted for clarity. Selected bond lengths /Å and angles /º : Cl(1)-
Cu(1) 2.2911(9), Cl(2)-Cu(1) 2.2838(9), Cl(2)-Cu(1) 2.6874(9), Cu(1)-N(3) 
1.993(3), Cu(1)-N(1) 2.004(3), Cu(1)-Cl(2) 2.2838(9), N(3)-Cu(1)-N(1) 84.50(11) 
The near-square pyramidal geometry of the complex is reflected in its τ value of 
0.14.
127
 The reported structure of [Cu(Cl)2(dpHa)] shows the dpHa ligand to be 
almost planar with difference in angle between the planes of the two rings being 6.9º. 
In the [Cu(Cl)2(dpma)] complex, the corresponding value is 49.6º. Possibly as a 
result of this increased bend through the central amine, the bite angle (N-Cu-N) of 
the dpma complex is, at 84.5º, smaller than that of the dpHa complex which is 94.6º. 
The complex produced upon reacting equimolar amounts of dpma with ZnCl2 in 
MeOH forms as a white precipitate which can be isolated by filtration in 71% yield. 
Diffraction quality crystals were obtained by slow diffusion of Et2O into a solution 
of DMF. The resulting structure is analogous with that of the one previously reported 
for [Zn(Cl)2(dpHa)], so allows a more direct comparison between the dpHa and 
dpma complexes than was possible for the copper(II) complexes. The complex has 
tetrahedral geometry (Figure 2.17) with similar metal-ligand bond lengths to the 
[Zn(Cl)2(dpHa)].  




Figure 2.17: ORTEP diagram (50% probability ellipsoids) of [Zn(Cl)2(dpma)].
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Hydrogen atoms omitted for clarity. Selected bond lengths /Å and angles /º : Cl(1)-
Zn(1) 2.2100(4), Cl(2)-Zn(1) 2.2368(4), N(1)-Zn(1) 2.0275(13), N(3)-Zn(1) 
2.0205(12), N(3)-Zn(1)-N(1) 90.71(5) 
The differences arise in the bite angle for the dpRa ligand and the angle between the 
planes of the two pyridyl rings (Table 2.2 and Figure 2.18).  
Table 2.2: Comparison of dpRa bite angle in [Zn(Cl)2(dpHa)] and [Zn(Cl)2(dpma)] 
 N-Zn-N bite angle / º Angle between dpRa planes / º 
[Zn(Cl)2(dpHa)]
128
 93.1(1) 5.5 
[Zn(Cl)2(dpma)] 90.71(5) 30.1 
  
The comparison between these two structures suggests that the steric bulk of the 
forces the pyridyl ligand into a less planar conformation (Figure 2.18). 
 
Figure 2.18: Overlay of [Zn(Cl)2(dpHa)] (blue) and [Zn(Cl)2(dpma)] (red) showing 
the increased bend between the two pyridyl rings upon methylation.
128, 171 
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Diffraction quality crystals were obtained from the filtrate of the [Zn(Cl)2(dpma)] 
reaction mixture which produced an unexpected structure (Figure 2.19). It showed 
that one of the pyridyl nitrogen atoms had undergone methylation, leaving the 
central nitrogen as a secondary amine. The zinc(II) chloride then coordinated to the 
other pyridyl nitrogen, forming a tetrahedral tris-chloride species having obtained an 
additional chloride ion. 
 
Figure 2.19: ORTEP diagram (50% probability ellipsoids) of [Zn(Cl)3(Me-
dpHa)].
131
 Hydrogen atoms except H(2a) omitted for clarity. Selected bond lengths 
/Å: Cl(1)-Zn(1) 2.2416(4), Cl(2)-Zn(1) 2.2406(4),Cl(3)-Zn(1) 2.2857(4), N(1)-Zn(1) 
2.0883(12) 
It is most probable that this pyridyl methylated ligand was formed as a very minor 
product in the methylation reaction rather than being a process occurring in the 
presence of the zinc(II) ion, but it has not been observed in 
1
H NMR spectra or MS. 
Significantly, this structure shows the dpHa ligand in an anti-conformation when 
there is no interaction shared by the two pyridyl nitrogen atoms.  
Crystallisation of reaction mixtures from reacting the dpma ligand with cobalt(II) 
chloride resulted in some diffraction quality crystals which revealed a bis-complex 
(Figure 2.20). The structures shows a cobalt(II) centre coordinated to two dpma 
ligands in an octahedral cis-geometry. The cobalt centre is also coordinated to a 
water molecule and a chloride. However, the chloride ligand is also coordinated to 
another cobalt(II) centre which has an additional three chloride ligands. One of the 
chloride ligands of the second cobalt centre, Cl(4) shares an intramolecular 
hydrogen-bonding interaction with H(1a) of the water ligand. The aqua ligand has 
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been identified as being water rather than hydroxide by locating two protons using 
the electron difference map. The other hydrogen of the water ligand, H(1b), forms an 
intermolecular hydrogen-bond with one of the chloride ligands of the second cobalt 
centre, Cl(2), of an adjacent complex, forming hydrogen-bonded chains within the 
crystal lattice (Figure 2.21). 
 
Figure 2.20: ORTEP diagram (50% probability ellipsoids) of [Co(μ2-
Cl)(dpma)2(H2O)(CoCl3)].
131
 Hydrogen atoms (except H(1a) and H(1b)) omitted for 
clarity. Selected bond lengths /Å and angles /º: Cl(1)-Co(2) 2.3063(5), Cl(1)-Co(1) 
2.5291(5), Cl(2)-Co(2) 2.2871(5), Cl(2)-Co(2) 2.2871(5), Cl(3)-Co(2) 2.2600(5), 
Cl(4)-Co(2) 2.2730(5), Co(1)-N(1) 2.1061(15), Co(1)-N(3) 2.1076(14), Co(1)-O(1) 
2.1126(13), Co(1)-N(6) 2.1154(14), Co(1)-N(4) 2.1230(14), N(1)-Co(1)-N(3) 
82.66(5), N(6)-Co(1)N(4) 82.66(6). Hydrogen-bond distances / Å and angles /º: 
H(1a)···Cl(4) 0.81(3), O(1)···Cl(4) 3.1531(15), O(1)-H(1a)···Cl(4) 177(2) 
 




Figure 2.21: ORTEP representation of the supramolecular chains created through 
hydrogen-bonding interactions within the lattice of [Co(Cl)(dpma)2(H2O)(CoCl3)].
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Hydrogen-bond distances / Å and angles /º: H(1b)···Cl(2) 2.52(3), O(1)···Cl(2) 
3.1779(14), H(1a)···Cl(4) 2.35(3), O(1)···Cl(4) 3.1531(15), O(1)-H(1b)···Cl(2) 
174(3), O(1)- H(1a)···Cl(4) 177(2) 
 
2.3.3. Preparation of a cobalt(III) complex of N-methyl-2,2’-
dipyriylamine (dpma) 
To prepare and isolate the cobalt(III) complex, one equivalent cobalt(II) chloride was 
reacted with two equivalents of dpma in the presence of H2O2 and a triflate salt to 
provide a counter-ion which assisted the formation of diffraction-quality crystals. 
The reaction was originally carried out in the presence of excess NaHCO3 in case of 
the carbonate complex being more favourable than the bis-chloride as with the dpHa 
complex. The product was obtained as diffraction quality crystals in low yield (2%) 
upon slow evaporation of the filtrate from the methanolic reaction mixture. The 
structure shows the octahedral cobalt(III) centre coordinated to two dpma ligands in 
a cis-geometry with two chloride ligands (Figure 2.22). 
 




Figure 2.22: ORTEP diagram (50% probability ellipsoids) of 
[Co(Cl)2(dpma)2]OTf.
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 Hydrogen atoms and counter-ion omitted for clarity. 
Selected bond lengths /Å and angles /º : Cl(1)-Co(1) 2.2611(6), Cl(2)-Co(1) 
2.2421(6), Co(1)-N(3) 1.9468(16), Co(1)-N(1) 1.9481(16), Co(1)-N(6) 1.9556(16), 
Co(1)-N(4) 1.9623(16), N(3)-Co(1)-N(1) 87.73(7), N(6)-Co(1)-N(4) 87.40(7), Cl(2)-
Co(1)-Cl(1) 93.02(2) 
As with the 
1
H NMR spectrum of the cobalt(III) dpHa complex, each dpma ligand is 
split into two different ring environments but both the dpma ligands are equivalent 
(Figure 2.23). 
 






HNMR spectrum of [Co(Cl)2(dpma)2]OTf (400 MHz, d6-DMSO): 
δ8.16 (ddd, 2H, J = 8.5, 7.0, 1.5 Hz, Ha), δ8.12 (ddd, 2H, J = 8.5, 7.0, 1.5 Hz, Hb) 
δ7.68 (d, 2H, J = 8.5 Hz, Hc), δ 7.65 (dd, 2H, J = 6.0, 1.5 Hz, Hd), δ7.51 (d, 2H, J = 
8.5 Hz, H
e), δ7.44 (dd, 2H, J = 6.0, 1.5 Hz, Hf), δ7.24 (td, 2H, J = 6.5, 1.0 Hz, Hg), 
δ7.07 (td, 2H, J = 6.0, 1.0 Hz, Hh), δ3.82 (s, 6H, CH3)  
The greatest difference between the two molecular structures of the cobalt(III) 
complexes of dpHa and dpma is their altered preferences between a carbonate ligand 
or two chloride ligands. When the dpHa complex was first prepared from 
[Co(Cl)2(dpHa)2], the chloride ions did not coordinate and it was with this reaction 
that carbonate coordination was first observed, affording [Co(CO3)(dpHa)2]
+
. When 
preparing the equivalent dpma complex, the presence of a silver salt and excess 
carbonate did not bring about coordination of the latter, resulting in the formation of 
[Co(Cl)2(dpHa)2]
+
. It seems that this difference is due to steric crowding about the 
metal centre brought about by the different orientation of the pyridyl rings about the 
cobalt(III) centre (Figure 2.24). 
 
 




Figure 2.24: Ball and stick representation showing the different orientation about the 
cobalt(III) centres of dpHa and dpma (complexes shown perpendicular to the Co-
CO3 and Co-Cl2 plane).
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2.4. Complexes of N-ethyl-2,2’-dipyriylamine (dpea)  
In order to help ascertain whether differences between the dpHa and dpma 
complexes were predominantly steric or electronic, it was decided to use N-ethyl-
2,2’-dipyridylamine (dpea), which was prepared using the same method as for dpma. 
The dpea ligand was complexed to both zinc(II) and copper(II) chloride, providing 
similar structures to those obtained for the analogous dpma complexes. 
[Cu(Cl)2(dpea)] again crystallised as a dimer with one chloride ligand from each 
metal Cl(2) bridging the two square pyramidal copper centres (Figure 2.25). The 
complex’s square pyramidal geometry was confirmed by a τ value of 0.08.132 
 
  




Figure 2.25: ORTEP diagram (50% probability ellipsoids) of [{Cu(Cl)2(dpea)}2].
131
 
Hydrogen atoms omitted for clarity. Selected bond lengths /Å and angles /º : Cl(1)-
Cu(1) 2.2830(4), Cl(2)-Cu(1) 2.2739(4), Cu(1)-N(1) 2.0114(14), Cu(1)-N(3) 
2.0133(13), N(1)-Cu(1)-N(3) 85.74(5) 
Similar structural derivatives have been recently reported in the literature where the 
ligands used include N-cyclohexylmethyl-2,2’-dipyridylamine and N-benzylmethyl-
2,2’-dipyridylamine (Figure 2.26). Similar to the copper(II) complexes of dpma and 










Figure 2.26: Ligands used by Lindoy et al to coordinate to copper(II) chloride.
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Table 2.3: Comparison of the structural parameters of [{Cu(Cl)2(dpma)}2], 
[{Cu(Cl)2(dpea)}2] and the structures of [{Cu(Cl)2(dpPha)}2] and 
[{Cu(Cl)2(dpcya)}2] reported previously in the literature.
138
 
























N-Cu-N bond angle / ° 84.50(11) 85.74(5) 85.16(8) 84.19(16) 
Angle between rings / ° 127.42 128.75 129.07 127.95 
τ value 0.14 0.08 0.12 0.17 
Cu1-Cu1
i
 / Å 3.682 3.729 3.605 3.732 
 
These copper(II) complexes can all be considered to be of the form shown in Figure 
2.27 as the bulk of the atom directly attached to the amine nitrogen does not alter. 
The lack of significant change in the bond lengths and angles of these four structures 
suggests that the groups attached to the methylated central amine do not affect the 















R = H, CH3, Ph, cy  
Figure 2.27: General structure of copper(II) chloride complexes of dpRa ligands 
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In order to alter the coordination geometry from this, dpRa ligands where R is an 
isopropyl or phenyl group (Figure 2.28) would be worth investigating as these bring 









Figure 2.28: Potential dpRa ligands where there is increasing steric bulk closer to 
the central amine 
The zinc(II) complex was prepared by reacting equimolar amounts of dpea and 
ZnCl2 in methanolic solution. The product formed as a white precipitate which could 
then be isolated by filtration in 59% yield. Diffraction quality crystals were obtained 
by slow diffusion of Et2O into a DMF solution. The obtained structure shows a 
tetrahedral geometry similar to that of the analogous zinc dpRa complexes (Figure 
2.29).  
 
Figure 2.29: ORTEP diagram (50% probability ellipsoids) of [Zn(Cl)2(dpea)].
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Hydrogen atoms omitted for clarity. Selected bond lengths / Å and angles / °: Cl(1)-
Zn(1) 2.2274(7), Cl(2)-Zn(1) 2.2162(7), N(1)-Zn(1) 2.034(2), N(2)-Zn(1) 2.032(2), 
N(2)-Zn(1)-N(1) 89.95(8) 
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The complex shows similar metal-ligand bond lengths but a tighter bend between the 
two pyridyl rings of dpRa through the central amine (Table 2.4). The difference 
between the dpea and dpma zinc(II) complexes is less pronounced than between the 
dpma and dpHa complexes, suggesting that it is the steric bulk on the central amine 
which forces the dpRa ligand into a less planar conformation. 
Table 2.4: Comparison of the structural parameters of [Zn(Cl)2(dpHa)], 
[Zn(Cl)2(dpma)] and [Zn(Cl)2(dpea)] 
 [Zn(Cl)2(dpHa)] [Zn(Cl)2(dpma)] [Zn(Cl)2(dpea)] 












N-Zn-N bond angle / ° 93.08 90.71(5) 89.95(8) 
Angle between pyridyl 
rings / ° 
174.5 148.5 138.7 
 
As with the copper complexes, the similarity between the dpma and dpea complexes 
suggests that it is the steric bulk directly attached to the central amine which alters 
the coordination properties of the ligand. Therefore, to investigate how the 
coordination geometries of dpRa ligands might further be influenced by the central 
amine, ligands such as those shown in Figure 2.28 would be interesting to 
investigate. This work suggests that groups designed to increase the medicinal 
activity of dpRa type ligands could be attached to the central amine via a chain of 
one or more alkyl carbons, without compromising the ligand’s ability to coordinate 
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2.5. Complexations with a therapeutically active dpHa derivative 
2.5.1. Ligand synthesis 
Complexations with a therapeutically active kinase inhibitor, py-dpHa-CN, which 
contains the dpHa fragment were attempted. This derivative features a nitrile 
substituent on the 4-position on one pyridyl ring and a pyrrolidinylmethyl group in 
the same position on the other ring. These groups are designed to act as hydrogen-
bond acceptors in the kinase active site. This ligand was synthesised by preparing 2-
chloro-4-(1-pyrrolidinylmethyl)-pyridine from 2-chloro-4-pyridinecarboxaldehyde 
and coupling this with 2-amino-4-cyanopyridine through use of a Buchwald-Hartwig 























Scheme 2.5: Preparation of py-dpHa-CN. Reagents: i) 1.0 equiv. pyrrolidine, 2 mL 
acetic acid, 1.2 equiv. NaBH(OAc)3, ii) 1.4 equiv. Cs2CO3, 0.1 equiv. Pd(dba)3, 0.15 
equiv. Xantphos, 1 equiv. 2-amino-4-nitrilepyridine 
2.5.2. Attempt to prepare metal(II) complexes of py-dpHa-CN 
It was attempted to complex this ligand to M(II)Cl2 salts (where M is Co, Cu, Zn) in 
a manner similar to that used for the other dpRa ligands by reacting one equaivalent 

















Scheme 2.6: Initial complexation reaction with py-dpHa-CN, where M = cobalt(II), 
copper(II) and zinc(II) 
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Crystals were obtained from the methanolic reaction mixture for the zinc(II) and 
cobalt(II) reactions but the structures obtained from these showed that complexation 
did not take place (Figures 2.30 and 2.31). Instead, both structures show the pyridyl 
nitrogen, N(3), with the pyrrolidine substituent is protonated and is hydrogen-bonded 
to the other pyridyl nitrogen, N(1). This interaction enforces the two pyridyl rings to 
be in a syn-conformation. The pyrrolidine nitrogen (N5) is also protonated, resulting 
in the ligand having an overall double cationic charge. This charge is balanced in 
both cases by a non-coordinating tetrachloride metal(II) anion. 
 
 
Figure 2.30: ORTEP diagram (50% probability ellipsoids) of 
[dp(CN)(pyH)Ha][Zn(Cl)4].
131
 Hydrogen atoms (except H(2a), H(3) and H(5)), and 
solvent molecules omitted for clarity.  
 
 




Figure 2.31: ORTEP diagram (50% probability ellipsoids) of 
[dp(CN)(pyH)Ha][Co(Cl)4].
131
 Hydrogen atoms (except H(2a), H(3) and H(5)) and 
solvent molecules omitted for clarity. 
The product from the reaction with zinc(II) chloride has also been characterised by 
NMR (Figure 2.32). Analysis of the COSY spectra showed the H
a
 signal not to be 
coupled to any other signals, whilst H
b
 at δ9.94 was shown to be coupled to the 






, indicating it to be directly bonded to the 
pyrrolidine nitrogen. The peak corresponding to the protonated pyrrolidine was not 
observed in the spectrum of the free ligand (Figure 2.33).  
 
 






H NMR (d6-DMSO, 400 MHz) of [dp(CN)(pyH)Ha][Zn(Cl)4]. δ10.80 
(br. s, 1H, H
a), δ9.96 (br. s, 1H, Hb), δ8.52 (dd, 1H, J = 5.0, 1.0 Hz, Hc), δ8.41 (d, 
1H, J  = 5.5 Hz, H
d), δ8.04 (s, 1H, He), δ7.64 (s, 1H, Hf), δ7.38 (dd, 1H, J = 5.0, 1.0 
Hz, H
g), δ7.18 (dd, 1H, J = 6.0, 1.5 Hz, Hh), δ4.43 (d, 2H, J = 4.5 Hz, Hi), δ3.45 (m, 
2H, H
j), δ3.11, m, 2H, Hk) δ2.06 (m, 2H, Hl), δ1.86 (m, 2H, Hm) 
The complexation was attempted in the presence of Et3N which resulted in a 
different NMR spectrum (Figure 2.30), but the desired zinc complex was not 
successfully isolated or observed with MS. 
 
Figure 2.33: Overlay of 
1
H NMR spectra in d6-DMSO (400 MHz) of py-dpHa-CN 
(top), when reacted with ZnCl2, and with ZnCl2 and Et3N (bottom) 





H NMR spectrum of the product obtained by reacting py-dpHa-CN with ZnCl2 
in the presence of excess Et3N (Figure 2.34) shows an absence of signals 
corresponding to protons attached to the amine or pyrrolidine. The latter not being 
protonated is also supported by the alkyl protons of the pyrrolidine ring being split 
into two sets of signals rather than the eight observed when reacted with ZnCl2. 
Signals corresponding to the methylene linkage between the pyrrolidine and pyridyl 
ring have been tentatively assigned to the peak at δ3.55 which is partially obscured 
by a larger peak at δ3.66. 
 
Figure 2.34: Assignment of the product obtained from the reaction of 
[dp(CN)(pyH)Ha][Zn(Cl)4]with Et3N. δ8.43 (d, 1H, J = 5.0 Hz, H
a
), δ8.28 (m, 1H, 
H
b), δ8.20 (d, 1H, J = 5.0 Hz, Hc), δ7.44 (m, 1H, Hd), δ7.24 (dd, 1H, J = 5.0, 2.0 Hz, 
H
e), δ 6.92 (d, 1H, J = 5.0 Hz, Hf), δ3.56 (s, 2H, Hg), δ2.45 (m, 4H, Hh), δ1.70 (q, 
4H, J = 3.0 Hz, H
i
) 
2.5.3. Attempt to prepare a cobalt(III) complex of py-dpHa-CN 
It was thought that once the py-dpHa-CN ligand was coordinated to the cobalt(II) 
centre and then oxidised cobalt(III) then such a complex would be stable under 
physiological conditions until the metal centre underwent reduction at which point 
the therapeutically active ligand would rapidly dissociate. Several methods of 
achieving this were attempted without success, some of which are now described. 
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Firstly, it was tried using cobalt(II) chloride which was stirred with two equivalents 
of py-dpHa-CN in methanolic solution. After twenty minutes stirring, H2O2 was 
added to oxidise the cobalt (Scheme 2.7) which caused the reaction mixture to turn 
darker in colour. NaPF6 was added to provide a counter-ion.  After two hours stirring 
the reaction mixture was filtered and left to stand, leading to the gradual formation of 
a yellow-brown precipitate which gave rise to a mass spectrum which showed the 
peak corresponding to the free ligand, and a 
1
H NMR spectrum which showed broad 



















Scheme 2.7:Attempt to prepare a cobalt(III) py-dpHa-CN complex from cobalt(II) 
chloride using hydrogen peroxide 
It was then attempted to prepare the complex by reacting Co(NO3) 2.6H2O with two 
equivalents of py-dpHa-CN to remove the presence of chlorides from the reaction 
mixture, and to provide carbonate in case this was preferred as a ligand to nitrate as 
with [Co(CO3)(dpHa)2]NO3 (Scheme 2.8). 























Scheme 2.8: Attempt to prepare a cobalt(III) py-dpHa-CN complex from cobalt(II) 
nitrate using hydrogen peroxide in the presence of excess carbonate 
It was then tried to react two equivalents of py-dpHa-CN with Co(NO3)2.6H2O in the 
presence of Et3N to try and ensure that the pyrrolidine nitrogen was not protonated, 
thereby aiding its coordination to the metal centre (Scheme 2.9). Addition of the 
Et3N caused the reaction mixture to turn darker and after oxidation with H2O2, a fine 
brown precipitate was isolated which contained a paramagnetic mixture evident by 
1






















Scheme 2.9: Attempt to prepare a cobalt(III) py-dpHa-CN complex from cobalt(II) 
nitrate using Et3N and H2O2 
The results from this work suggest that ligands such as py-dpHa-CN are not suitable 
as ligands to coordinate to transition metal centres to create pro-drug complexes to 
act as kinase inhibitors. The previously described results suggest that the pyrrolidine 
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group is problematic due to its highly basic nature, resulting in it being protonated 
and therefore having a cationic charge. This decreases its ability to coordinate to a 
metal centre easily, even in the presence of bases intended to deprotonate the 
pyrrolidine nitrogen. 
The doubly protonated py-dpHa-CN ligand observed in the crystal structures are 
shown in the syn-conformation with a hydrogen-bond formed between the two 
pyridyl nitrogens. This is significant in that the hypothesis behind the design of this 
ligand was that the ligand remains in its anti-conformation when not in the kinase 
active site or not coordinated to a metal at physiological pH. 
2.6. Conclusions 
The coordination chemistry of dipyridylamine-type ligands has been further 
expanded upon including with derivatives where the central amine has been 
alkylated. It has been observed that changing from dpHa to dpma causes a more 
noticeable difference than between dpma and dpea. This suggests that it is the steric 
bulk of the group directly coordinated to the central amine which directly alters how 
the two pyridyl rings arrange in relation to each other, and thus alter the coordination 
environment of the complex. For metal(II) complexes of cobalt, copper and zinc, the 
observed geometries include octahedral, tetrahedral and square pyramidal whilst the 
two cobalt(III) complexes have displayed octahedral geometries. 
Structures of dpRa-type ligands have been obtained where the ligand is not 
coordinated through its two pyridyl nitrogen atoms. In one structure, the methyl 
group has added to the pyridyl nitrogen rather than the amide nitrogen and 
crystallised with a zinc trichloride species coordinated to the other pyridyl nitrogen 
atom. This structure showed the two pyridyl rings arranged in an anti-conformation 
where there are no hydrogen-bonds or coordinating metal species to hold the ligand 
into the syn-conformation. However, the structures obtained with py-dpHa-CN show 
that the presence of a hydrogen-bond between the two pyridyl nitrogen atoms can 
enforce the syn-conformation. The latter has highlighted that the presence of basic 
groups on dpHa ligand derivatives such as pyrrolidine can be problematic when 
trying to coordinate this type of a ligand to a metal centre. As the majority of the 
compounds in this library of kinase inhibitors feature a basic group designed to be 
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able to hydrogen-bond within the kinase active site, it would seem that this family of 

























Chapter Three: The synthesis of N1,N4-oxide ligands and the preparation of 
their complexes 
3.1. Introduction 
As described in Chapter 1, much has already been done in attempting to understand 
the basis of the hypoxia selectivity of tirapazamine (tpzH) and to develop derivatives 
with improved biological activity.
46-63
 In this context, derivatives of the structurally 
similar quinoxaline-N1,N4-oxides (Figure 3.1) have shown varied biological 
properties other than cancer cell cytotoxicity such as anti-parasitic activity against 
Trypanosoma cruzi and malarial parasites,
140-142
 and the treatment of hypertension 















Figure 3.1: Structures of tpzH (left) and quinoxaline-N1,N4-oxide (right) 
Both tpzH and quinoxaline-N1,N4-oxides have the potential to act as ligands in 
metal complexes. Gambino et al. have begun to exploit the coordination chemistry of 
N-oxide ligands to provide transition metal complexes with various biological 
properties.
140, 144-154
 Aromatic N-oxides exist as stable species with the nitrogen-
oxygen bond having dipolar character.
155
 The electron-rich character of the oxygen 
makes N-oxides well-suited to being used as hard to medium-hard electron donor 
ligands to coordinate to metal centres which are hard or borderline in character 
including high oxidation state f-block ions such as uranyl or late first row transition 
metals such as copper(II).
156-158
 
Coordination of pyridine-2-thiol-N-oxide to various metal centres has provided 
complexes with activity against Trypanosoma cruzi (Figure 3.2). This is the parasite 
responsible for diseases such as American trypanosomiasis (Chagas disease) which 
can lead to fatal cardiac damage, Leishmaniasis (a disease whose symptoms can 
range from skin ulcers to acute organ damage) and Human African trypanosomiasis 




leading to death. Coordination of pyridine-2-thiol-N-oxide to palladium(II) resulted 
in a three-fold increase in anti-parasitic activity compared to pyridine-2-thiol-N-
oxide whilst coordination to platinum(II) achieved higher selectivity towards the 
parasite than the free ligand.
149
 Coordination of pyridine-2-thiol-N-oxide to a gold(I) 




















Figure 3.2: Hypothesised structures of Gambino’s pyridine-2-thiol-N-oxide 
complexes which show activity against T. Cruzi.
149, 152 
The same research group have prepared and studied various transition metal 
complexes of quinoxaline-N1,N4-oxide ligands (Figure 3.3). Vanadyl complexes of 
this ligand were found to exhibit anti-parasitic activity against T. Cruzi,
146
 as well as 
activity as having insulin mimicking properties for the treatment of diabetes.
145
 
Palladium(II) complexes have also shown anti-T. cruzi properties, whilst iron(III) 
complexes of this ligand were shown to have some activity against M. 
tuberculosis.
148, 153, 154
 Several of these complexes have been examined for their anti-























































Figure 3.3: Examples quinoxaline-N1,N4-oxide complexes previously reported in 
the literature with biological applications.





Metal(II) complexes of palladium(II) and copper(II) were examined for their 
cytotoxic activity against V79 (Chinese hamster lung fibroblast) cancer cells under 









L2: R = Cl
L3: R = Br
L4: R = Me  
Figure 3.4: Ligands shown in Table 3.1 
Table 3.1: Reported cytotoxicity against V79 cells under normoxic and hypoxic 
conditions of quinoxaline-N1,N4-oxide ligands and their complexes.
140, 144, 147, 151
 
Compound Cell survival fraction with 20 μM compound / % 
normoxia hypoxia 
[Cu(L1)2]  18  1  
L2 100 0 
[Cu(L2)2]
 
 100 1 
[VO(L2)2] 57 0 
[Pd(L2)2] 92 0 




[VO(L3)2] 36  0 
L4 82 22  
[Cu(L4)2]  100 10 
[VO(L4)2] 60  0 
[Pd(L4)2]
 
 2 0 
 
Complexation of the chloro-analogue (L2) to copper(II) or palladium(II) resulted in 
no significant change in cytotoxicity by remaining cytotoxic to hypoxic cells and 
non-cytotoxic normoxia.
144, 151




survival fraction under normoxia from 100 to 57 whilst not reducing the potency 
under hypoxia.
147
 The copper(II) complex of the bromo-derivative L3 again showed 
no significance in activity compared to the free ligand whereas the vanadyl complex 
showed increased activity under normoxic conditions, decreasing the survival 
fraction from 90 to 36.
144, 147
 The copper(II) complex of the methylated-ligand L4 led 
to an increase in hypoxia cytotoxicity, increasing the survival fraction under 
normoxia from 82 to 100 and reducing the survival under hypoxia under hypoxia 
from 22 to 10.
144
 Incorporation of this ligand into vanadyl complex led to a decrease 
in the survival fraction under normoxia to 60 and hypoxia to 0 whereas coordination 
to palladium(II) resulted in no cell survival under either conditions.
147, 151
 
The solubility of these complexes was reported to be poor, with the palladium(II) 
complexes not being able to remain in DMSO solution long enough for 
13
C NMR 
experiments whilst many of the compounds were not soluble enough for obtaining of 
IC50 values.
151
 It was found that complexes of this type of ligand with a vanadyl 
centre led to complexes which not only showed higher potency and hypoxia selective 
cytotoxicity than tpzH, but showed improved solubility in solvents such as light 
alcohols than the ligands on their own.  
Despite the number of reports of the work on these complexes, they are yet to be 
characterised by NMR spectroscopic analysis (owing to most of the metals used 
being paramagntic) or single crystal diffraction.  
In this chapter, the work on N1,N4-oxide ligands is expanded upon using three 
ligands including the 3-aminoquinoxaline-2-carbonitrile-N1,N4-oxide (tpzH-CN) 
used by Gambino, but also 3-aminobenzo-1,2,4-triazine-N1,N4-oxide (tpzH) and 3-
aminoquinoxaline-2-amido-N1,N4-oxide (tpzH-CONH2) (Figure 3.5). The tpzH 
ligand is used for its hypoxia-selective cytotoxic properties whilst tpzH-CONH2 is 
also used because it was initially thought the amide might aid solubility, but also the 





















tpzH tpzH-CN tpzH-CONH2  
Figure 3.5: Structures of the N1,N4-oxide ligands used in this study 
 
3.2. Preparation of N1,N4-oxide ligands 
3.2.1. Preparation of 3-aminoquinoxaline-2-carbonitrile-N1,N4-oxide (tpzH-
CN) 
3-Aminoquinoxaline-2-carbonitrile-N1,N4-oxide (tpzH-CN) was prepared in a 
similar manner to that previously reported,
161
 through the use of a Beirut reaction.
162
 
This involves the reaction of benzofuroxan and propanedinitrile in DMF solution in 
the presence of Et3N (Scheme 3.1) to produce an orange precipitate which can then 
be isolated in vacuo (56% yield). The product was then washed with acetone, leaving 
a bright reddish orange fluorescent solid, which was then fully characterised by 
NMR and IR spectroscopy and MS spectrometry. After drying under vacuum, the 










NC CN,  Et3N
 
Scheme 3.1: Preparation of tpzH-CN using the Beirut reaction 
The NMR spectra of the tpzH-CN ligand could not be fully assigned owing to the 
lack of proton-proton coupling throughout the whole molecule. It can be determined 
how the aromatic protons are arranged in relation to one another through the use of 
COSY, HSQC and HMBC NMR experiments, but not where they are in relation to 








H NMR spectrum of tpzH-CN (400 MHz, d6-DMSO, ). δ8.29 (dd, 1H, J 
= 5.5, 1.0 Hz, H
a), δ8.27 (dd, 1H, J = 5.5, 1.0 Hz, Hb), δ8.08 (br. s, 2H,NH2), δ7.93 
(ddd, 1H, J = 8.5, 7.5, 1.0 Hz, H
c), δ7.66 (ddd, 1H, J = 8.5, 7.5, 1.0 Hz, Hd) 
 
3.2.2. Preparation of 3-aminoquinoxaline-2-amido-N1,N4-oxide (tpzH-
CONH2) 
The ligand 3-aminoquinoxaline-2-amido-N1,N4-oxide (tpzH-CONH2) was prepared 
by a method adapted from that reported in a patent.
163
 The tpzH-CONH2 was 
prepared by heating tpzH-CN in concentrated sulphuric acid which facilitates the 















Scheme 3.2: Preparation of tpzH-CONH2 
The reaction mixture was then cooled before being neutralised with concentrated 







H NMR spectrum of the crude product shows the presence of the ammonium 











H NMR assignment of crude tpzH-CONH2 (400 MHz, d6-DMSO) with 
peaks of NH4
+
 peaks at δ7.10 highlighted by *. δ9.41 (br. s, 2H), δ9.16 (br. s, 1H), 
δ8.67 (br. s, 1H), δ8.39 (d, 1H, J = 8.5 Hz, Ha), δ8.07 (d, 1H, J = 8.5 Hz, Hb), δ8.01 
(dd, 1H, J = 8.5, 7.0 Hz, H




Dissolving the crude product in acetone and filtering the resulting solution removes 
the ammonium salt and any unreacted tpzH-CN, allowing the pure product to be 
isolated in 16% yield. Close analysis of the 
1
H NMR spectrum of the pure product 
reveals that there are three broad singlets; one at δ9.85 and δ8.58 which both have an 
integration of one and a peak at δ8.19 which has an integration of two. It would be 
expected that there would be two broad singlets both with an integration of two 
which would correspond to the amide and amine NH2 groups but it is apparent that 
one of these is split into two signals. With the other N-oxide ligands discussed in this 
chapter, the amine protons appear at ca. δ8.1, so logically the amine of the tpzH-







H COSY NMR shows that the singlets at δ9.85 and δ8.58 are weakly coupled 







H COSY NMR spectrum of tpzH-CONH2 (400 MHz, d6-DMSO) 
highlighting the coupling between the singlets at δ9.85 and δ8.58. 
The fact that the two amide protons give two separate resonances suggests that they 
are not rotating fast enough for the two peaks to coalescence. Resonances of protons 
which form hydrogen-bonds typically move to a more downfield chemical shift, the 
extent of which depends on the interaction.
165
 The downfield chemical shift of the 
amide proton suggests that the acceptor atom of the hydrogen-bond is very electron 
rich character, such as an oxygen atom of an N-oxide group. The broad singlet with 
an integration of two at δ8.20 is at a chemical shift similar to the amine protons 







H NMR (400 MHz, d6-DMSO) spectrum of tpzH-CONH2 δ9.85 (br. s, 
1H, H
e), δ8.58 (br. s, 1H, Hf), δ8.41 (d, 1H, J = 8.0 Hz, Ha), δ8.31 (d, 1H, J = 8.0 Hz, 
H
b), δ8.19 (br. s, 2H, NH2), δ7.91 (ap. t, 1H, J = 8. 0 Hz, H








 implies there 
is a lack of rotation about the amide N-C bond, which is not uncommon for amides, 
owing to the distribution of electrons throughout the group (Scheme 3.3). The 
interaction between the C=O and N lone pairs results in a decrease of electron 
density on the C=O bond and increase on the C-N bond results in partial N=C 








Scheme 3.3: Resonance structures of a primary amide functional group 
Single red coloured crystals suitable for diffraction were obtained from a reaction of 
[Co(tpz-CN)2] with H2O2 in MeOH. The structure shows that the amide is arranged 
so N(4)-H(4b) is able to act as a hydrogen-bond donor to the N-oxide oxygen O(1). 
A hydrogen-bond is also evident between the carbonyl oxygen O(3) of the amide and 





Figure 3.10: ORTEP diagram (50 % probability ellipsoids) of tpzH-CONH2.
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Hydrogen atoms (except H(3a), H(3b), H(4a) and H(4b)) and solvent removed for 
clarity. Selected bond lengths /Å and angles /º: N(1)-O(1) 1.274(2), N(2)-O(2) 
1.327(2), C(7)-N(3) 1.326(2), C(9)-O(3) 1.228(2), C(9)-N(4) 1.329(2). Hydrogen-
bond distances / Å and angles /º: N(4)-O(1)···2.557(2), H(4B)···O(1) 1.90(3), 
N(3)···O(3) 2.622(2), H(3B)···O(3) 1.98(3), N(4)-H(4B)···O1 126(3), N(3)-
H(3B)···O3 (136(2),  
Analyses of the C-N bond lengths the C=O bond lengths within the amine do not 
indicate a reduction of C=O bond double bond character or any resulting change in 
the N-C bond (Table 3.2). 








Bond Bond length from structure / Å Standard literature value / Å 
C(9)-O(3) 1.228(2) 1.234 (for amide C=O) 




3.2.3. Preparation of 3-amino-1,2,4-benzotriazine-N1,N4-oxide (tpzH) 
3-amino-1,2,4-benzotriazine-N1,N4-oxide (tpzH) was prepared accordingly to a 



















3) NaOH H2O2, EtO2H
Scheme 3.4: Preparation of tpzH from 2-nitroaniline and cyanamide 
As 2-nitroaniline can be formed upon the reduction of benzofuroxan (Scheme 3.5), 
the preparation used for the synthesis of tpzH is not unrelated to that used to prepare 










Scheme 3.5: Preparation of benzofuroxan from 2-nitroaniline 
As the reduced form of the starting material is used, an additional oxidation step is 
needed to form the N1,N4-oxide product. This latter method has the advantage that if 
substituents are desired on the phenyl ring in the 5, 6, 7 or 8-positions then greater 










































Scheme 3.6: Possible isomers that can be produced from the two different methods 
of preparing tpzH-R type N1,N4-oxide ligands 
The product, once extracted with CHCl3, was recrystallised and then used without 
further purification. The intermediate and product were characterised, including by 





H NMR (400 MHz, d6-DMSO) spectrum of tpzH. δ8.21 (ddd, 1H, J = 
9.0, 1.5, 1.0 Hz, H
a), δ8.15 (dd, 1H, J = 9.0, 1.0 Hz, Hb), δ8.06 (br. s, 2H, NH2), 




Hay reported on the full NMR characterisation of tpzH, for which 
15
N NMR 


















Figure 3.12: Assignment of protons reported for the 
1





H NMR spectrum and assignment shown in Figure 3.10 agrees with that 









H chemical shift (splitting, J value / Hz) 
H
a
 8.14 (d, J =  8.7 Hz) 
H
b
 8.21 (d, J = 8.8 Hz) 
H
c
 7.95 (d, J = 8.8 Hz) 
H
d
 7.58 (ddd, J = 8.8, 7.1, 1.4 Hz) 
NH2 8.04 (br. s) 
 
Crystals suitable for study by x-ray diffraction were obtained through evaporation 





Figure 3.13: ORTEP diagram (50 % probability ellipsoids) of tpzH.
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 Hydrogen 
atoms (except H(3a) and H(3b)) and solvent removed for clarity. Selected bond 
lengths /Å: N(1)-O(1) 1.3330(15), N(2)-O(2) 1.2574(15).  
 
The crystal structure shows the O1 oxygen atom to form a hydrogen-bond with the 
proton H(3c) from the OH of a methanol molecule as well as to H(3b) of an adjacent 
tpzH molecule (Figure 3.14). 
 
Figure 3.14: ORTEP diagram of the hydrogen-bonding interactions evident in the 
crystal structure of tpzH.
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 Hydrogen-bond distances /Å and angles /º: H(3C) ··O(1) 
1.83(2), O(3)···O(1) 2.6962(16), H(3B)··· O(1) 2.04(2), N(3)···O(1) 2.8347(17), 
H(3A)···O(3) 1.89(2), N(3)···O(3) 2.8137(18), O(3)-H(3C)···O(1) 174(2), N(3)-





N1,N4-oxide ligands have been produced using two synthetic routes. These three 
ligands have been fully characterised, including assignment by NMR spectroscopic 












Figure 3.15: Proton environments used in Table 3.4 
Comparing the 
1
H NMR spectroscopic data of the three N-oxide ligands that the 
amine protons of tpzH-CONH2 are in the more deshielded environment with the 
amine protons having a chemical shift of δ8.91 whilst tpzH and tpzH-CN have their 
corresponding peaks appearing at δ8.05, and δ8.05 respectively. However, it should 
be noted that the more downfield shift of the amine of tpzH-CONH2 could be 
predominantly due to the hydrogen-bonds this group forms. 
Table 3.4: Summary of the 
1
H resonances of the prepared N1,N4-oxide ligands tpzH, 
tpzH-CN and tpzH-CONH2 (400 MHz, d6-DMSO) 
Ligand tpzH tpzH-CN tpzH-CONH2 
H
y
  δ8.20 (dd, 1H) 
δ8.14 (dd, 1H) 
δ8.29 (dd, 1H) 
δ8.27 (dd, 1H) 
δ8.41 (d, 1H) 
δ8.31 (d, 1H) 
H
z
 δ7.93 (ddd, 1H) 
δ7.57 (ddd, 1H) 
δ7.93(ddd, 1H) 
δ7.66(ddd, 1H) 
δ 7.91 (ap. t, 1H) 
δ7.67 (ap. t, 1H) 
NH2 δ8.05 (br. s, 2H) δ8.05 (br. s, 2H) δ8.91 (br. s, 2H) 
CONH2   δ9.85 (s, 1H) 
δ8.58 (s, 1H) 
 
It can be seen that the protons in the H
y
 environment on the different ligands all have 
similar chemical shifts, with one ranging from δ7.93 to 7.1, and the second from 
δ7.67 to 7.57, as these are too far away from the substituents in the 2-position to be 
affected. The chemical shifts of the protons in the H
y




more downfield value going from tpzH to tpzH-CN to tpzH-CONH2. This indicates 
that the different substituents on the ligands are most likely to affect the electronic 
nature of the N-oxide groups, as any electronic difference would have to go through 
the N-oxide nitrogen to affect the H
y
 protons. Therefore, the two groups through 
which the N1,N4-oxide ligands coordinate to metals are affected by altering the 
substituent in the 2-position, so a noticeable difference might be observed in their 
coordination chemistry such as the strength of bonding interaction to the metal 
centre. 
 
3.3. Preparation of metal(II) complexes 
The metal(II) complexes were prepared by a method adapted from that used by 
Gambino et al. where they typically used metal(II) sulfate salts reacting with two 
equivalents of tpzH-CN in the presence of Et3N to deprotonate the amine of the 
ligand The complexes reported here were prepared from metal(II) acetate salts as it 
was found that this removed the need to use Et3N. The cobalt(II), copper(II) and 
zinc(II) acetate salts were reacted with two equivalents of the N-oxide ligand in 























Scheme 3.7: Preparation of bis-N1,N4-oxide metal(II) complexes (R = N, C-CN and 
C-CO-NH2, M = Co, Cu, Zn) 
Characterisation of these in solution has been hindered by their lack of solubility in 
solvents other the DMSO and DMF. Therefore the only solution phase 




be done for the zinc(II) complexes owing to cobalt(II) and copper(II) being 
paramagnetic.  
 
3.3.1. Preparation of metal(II) complexes with 3-aminoquinoxaline-2-
carbonitrile-N1,N4-oxide 
As some previous complexes of tpzH-CN with various metals had been previously 
reported, it was decided to start with this ligand and prepare complexes of zinc(II), 
cobalt(II) and copper(II). Mixing two equivalents of tpzH-CN with M(OAc)2.xH2O 
(M = Co, Cu, Zn) in methanolic solution caused the formation of a dark red 
precipitate which was then isolated by filtration in yields greater than 75%. 
Formation of the zinc(II) complex could be confirmed by 
1
H NMR spectroscopy 
(Figure 3.16), where the peak corresponding to NH2 of the free ligand undergoes a 
downfield shift from δ8.05 to δ6.56, as well as integration change from two to one. 
The NMR spectrum indicates that the two tpz-CN ligands of the zinc(II) complex are 




H NMR ) (400 MHz, d6-DMSO) spectra of tpzH-CN (above) and 
[Zn(tpz-CN)2] (below δ8.16 (d, 1H, J = 8.0 Hz, H
a), δ8.14 (d, 1H, J = 7.5 Hz, Ha), 
δ7.87 (ddd, 1H, J = 8.5, 7.0, 1.0 Hz, Hb), δ7.42 (ddd, 1H, J = 8.5, 7.0, 1.0 Hz, Hb), 
δ6.55 (br. s, 1H, NH) 
For all of the metal(II) tpzH-CN complexes, complexation was easily confirmed 
through IR spectroscopic analysis (Figure 3.17). The amine NH stretch absorbance 
frequency changes from two bands at 3347 and 3310 cm
-1




ligand to one vibration at ca. 3380 cm
-1
 in the metal(II) complexes. Such a change is 
characteristic of the symmetry change in a primary amine occurring upon 
coordination to a metal centre. 
 
Figure 3.17: IR (KBr disc) of tpzH (above) and [Co(tpz-CN)2] (below). 
Obtaining crystals of these complexes proved challenging but small deep purple 
crystals of diffraction quality were obtained by slow diffusion of Et2O into a solution 
of DMF. One of the limitations in growing crystals of these complexes was their 
poor solubility, being only soluble in DMF and DMSO, and partially soluble in 
pyridine. It was attempted to carry out crystallisations in the presence of compounds 
such as indole, in the hope that by providing a hydrogen-bond donor to interact with 
the N-oxide groups, crystallinity might be encouraged but this was without success. 
Therefore, the complex of [Zn(tpz-CN)2] is currently the only structurally 
characterised metal(II) bis-N1,N4-oxide complex. 
The zinc(II) centre is coordinated to two tpz-CN ligands and a DMF solvent 
molecule (Figure 3.18). The five-coordinate metal centre has a distorted square-
pyramidal geometry (τ = 0.15).132 There was a high level of disordered solvent 
present in the unit cell so both the solved structure including the disorder and that 
using the SQUEEZE logarithm are presented in the appendix of crystallography data. 




owing to the whole unit cell having been modelled, providing a better model of the 
structure. 
 
Figure 3.18: ORTEP (50 % probability) of [Zn(tpz-CN)2(DMF)].
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 Hydrogen 
atoms (except H(3), H(7a) and H(19) and H(3b)) and solvent molecules removed for 
clarity. Selected bond lengths /Å and angles /º:N(1)-O(1) 1.340(3), N(2)-O(2) 
1.282(3), N(3)-Zn(1) 1.990(2), N(5)-O(3) 1.348(3), N(6)-O(4) 1.280(3), N(7)-Zn(1) 
1.989(2), O(1)-Zn(1) 2.0838(18), O(3)-Zn(1) 2.1196(19), O(5)-Zn(1) 2.078(2), N(3)-
Zn(1)-O(1) 79.60(8), N(7)-Zn(1)-O(3) 79.01(8)  
The effect of coordination of this type of ligand to a metal centre has upon the N-
oxide bond can be examined by comparing the N-O bond lengths of N1,N4-oxide 
ligands described previously with those from the [Zn(tpz-CN)2(DMF)] complex 
(Table 3.4).  
Table 3.5: N-O bond lengths of tpzH, tpzH-CONH2 and [Zn(tpz-CN)2(DMF)] 
 N-O bond distance /Å 
Structure 1-position 4-position 
tpzH 1.3330(15) 1.2574(15). 









The structures of tpzH and tpzH-CONH2 show that out of the two N-oxide moieties, 
the one adjacent to the amino group in the 1-position (1.333(5) and 1.327(2) Å 
respectively) is longer than the one in the 4-position (1.257(5) and 1.274(2) Å). 
Upon coordination to the zinc(II) centre, the N-O bond lengths, both N-O bond 
lengths appear to increase in length. The two coordinated ligands have bond lengths 
of 1.340(3) and 1.348(3) Å in the 1-position whilst those in the 4-position are 
1.282(3) and 1.280(3) Å. This concurs with the conclusions reported by Murthy and 
Patel who investigated the effect of coordinating N-oxide ligands to different metal 
centres using IR spectroscopy.
170
 They observed that the vibrational frequency of the 
N-O stretch decreased upon coordination which was attributed to the decreasing π 
character of the N-oxide bond. They also demonstrated that the stretch of the N-O 
bond when coordinated to a metal centre decreased going from a zirconyl complex 
(1222 cm
-1
), to thorium (1218 cm
-1
) then to a uranyl complex (1207 cm
-1
). This was 
correlated with a decrease in π-character of the N-oxide, resulting in a weakening of 
the N-O bond whilst the strength of the M-O bond increased. The lengthening of the 
N-oxide bonds observed in the complex can be attributed to the same effect, although 
it is interesting that the N-oxides in the 4-position have also lengthened even though 
they are not coordinated to the metal centre.
170
  
It can be seen from the crystal structure that the coordination of the two tpzH-CN 
ligands with the metal centre appear to be different, with one (ligand A) remaining 
linear whilst the other (ligand B) is distorted (Figure 3.19). However, it cannot be 
concluded that this difference results from different bonding interactions or is an 
effect of crystal packing. The zinc(II) centre lies within the plane of one of the tpz-






Figure 3.19: Mercury Stick representation of [Zn(tpz-CN)2(DMF)]to highlight the 
distortion in ligand B.
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The degree to which ligand B is bent can be represented by an interplanar angle, 
which measures the angle between the plane through which the metal coordinates to 
the ligand (plane one) and the plane that the ligand lies on (plane two) (Figure 3.18). 
The crystal structure of [Zn(tpz-CN)2(DMF)] shows an interplanar angle within 















Figure 3.20: Diagram to represent the interplanar angle between the metal-donor 
atoms and ligand 
This interplanar angle distortion could be a result of the decrease in π-character of 




π-density throughout the whole ligand and thus the effect is observed also in the 
uncoordinated N-oxide in the 4-position.  
From the structure, it is also evident that the two aromatic rings of the ligand, which 
would be expected to be planar, bend with respect to each other (Figure 3.21) which 
would further decrease the aromaticity of the system. For ligand A, this bend is 1.3° 








interplanar angle = 4.32
plane of the N-oxide ring
plane of the benzyl ring
 
Figure 3.21: Diagram to represent the bend between the two rings of coordinated 
tpzH-CN (ligand B) 
This structure contrasts with Torre’s reported EPR spectroscopic data which 
suggested that complexes of this nature exist as dimers in the solid state with the 


































Figure 3.22: Representation of the structure of copper bis-tpz-CN ligand complexes 






Several strategies were attempted in obtaining crystals, such as use of a solvent that 
was capable of π-stacking interactions which could facilitate crystal growth (e.g. 
pyridine), and adding an aromatic hydrogen-bond donor to the crystallisation such as 
indole. However, no further suitable crystals have yet been obtained for the zinc 
complex or any of diffraction quality for the cobalt(II) or copper(II) complexes of 
this ligand or for bis-complexes any of the other N1,N4-oxide ligands discussed in 
this chapter.  
3.3.2. Preparation of metal(II) complexes with an 3-aminoquinoxaline-2-
amido-N1,N4-oxide  
With tpzH-CONH2, there are three possible coordination sites through which it may 
coordinate to a metal centre. It can coordinate to a metal centre through the amine 
and adjacent N-oxide to form a 5-membered chelate ring as with tpzH-CN and tpzH, 
or through the amide. If coordination occurs through the amide, it would be most 
likely for the metal to bond to the carbonyl and N-oxide NH2 and its adjacent N-
























coordination mode A coordination mode B coordination mode C  
Figure 3.23: The possible two possible coordination sites of tpzH-CONH2; through 
the amine (A), through the amide NH and N-oxide (B) or through the amide carbonyl 
and N-oxide (C). 
Coordination through the amide nitrogen (B) is unlikely due to delocalisation of 
nitrogen atom’s electron density as described previously.155, 166 However, the rotation 
of the amide group so that coordination mode C can occur would have to overcome 
the hydrogen-bond between the carbonyl and N-oxide. Coordination through the N-




Upon the reaction of two equivalents of tpzH-CONH2 with copper(II) and zinc(II) 
acetate, a dark precipitate formed which could then be isolated in 88% and 78% 
yields, respectively. 
1
H NMR spectroscopic analysis of the zinc complex showed 
that some free ligand was present in the product. Comparison of the 
1
H NMR spectra 
of the free ligand and zinc(II) complex shows a general decrease in chemical shift of 
all the proton resonances shows that the protons have become more shielded. This 
indicates the ligand has become less electron rich upon coordination. There are still 




H COSY NMR 
(Figure 3.24). The coupling between these two singlets indicates that the two amide 
protons are in two different chemical environments, with the one at the higher 
chemical shift (δ9.52) remaining hydrogen-bonded to the highly electronegative N-






H COSY spectrum (400 MHz, d6-DMSO) of [Zn(tpz-CONH2)2] 
highlighting the coupling between the two amide proton peaks at δ9.52  and δ8.48 
(peaks corresponding to unreacted ligand denoted by *) 
With the zinc(II) complex, the signal for the amine remains at a relatively high 
chemical shift (δ7.87) compared with those from the complexes of tpzH-CN and 




tpzH-CONH2 ligand retaining the hydrogen-bond it forms with the amide carbonyl 




H NMR (400 MHz, d6-DMSO) of tpzH-CONH2 (above) and [Zn(tpz-
CONH2)2] (below). δ9.52 (br. s, 1H, H
d), δ8.48 (br. s, 1H, He), δ8.27 (d, 1H, J = 8.0 
Hz, H
a), δ8.14 (d, 1H, J = 8.0 Hz, Ha), δ7.87 (s, 1H, NH), δ7.81 (ap. t, 1H, J = 8.0 
Hz, H
b), δ7.40 (ap. t, J = 8.0 Hz, 1H, Hb) 
3.3.3. Preparation of metal(II) complexes with tpzH 
There are no previous reports describing the coordination of tpzH to metal centres 
but it was found that the ligand could be coordinated to metal(II) centres using the 
same method as for the previous two N-oxide ligands. The tpzH ligand is more 
readily soluble in solvents such as H2O, MeOH and EtOH than tpzH-CN and tpzH-
CONH2, but it was found that the prepared [M(tpz)2] complexes still had poor 
solubility. Metal(II) complexes of cobalt, copper and zinc were prepared and isolated 
in yields of around 60%. 
1
H NMR spectroscopic analysis of zinc(II) complex shows the similar upfield shift 
which occurs upon complexation of tpzH with the other ligands (Figure 3.26), 
indicating the decrease in electron density of the ligand. The amine signal of tpzH 




than that experienced by the amine of tpzH-CN (δ8.08 to δ6.55). This implies that 





H NMR (400 MHz, d6-DMSO) of tpzH (above) and [Zn(tpz)2] 
(below). δ8.10 (d, 1H, J = 8.0 Hz, Ha), δ7.93 (d, 1H, J = 8.0 Hz, Ha), δ7.87 (ap. t, 1H, 
J = 7.5 Hz, H
b), δ7.29 (ap. t, 1H, J = 7.5 Hz, Hb), δ7.03 (br. s, 1H, NH) 
3.4. Attempts to prepare cobalt(III) complexes 
Attempts to prepare cobalt(III) complexes of tpzH and tpzH-CN (Figure 3.27) 
proved unsuccessful. Some of the methods used to try to prepare these complexes are 






















Figure 3.27: The desired form of cobalt(III) N1,N4-oxide complexes 
It was first attempted to prepare a cobalt(III) tpz-R complex by reacting three 
equivalents of tpzH-R with Co(OAc)2.4H2O in MeOH with H2O2 (Scheme 3.8). 
Before the addition of the H2O2, the formation of a purple suspension indicated that 
the cobalt(II) bis-complex had been made, but upon addition of H2O2, the reaction 
mixture started to turn orange with a purple precipitate. The solid was isolated by 
filtration, and then shown by 
1
H NMR spectroscopy to be a paramagnetic species 
which was probably cobalt(II). This purple solid had the same IR spectrum as the 
[Co(tpz-R)2]. The solvent was dried off from the filtrate, and this was shown by 
1
H 































Scheme 3.8: Attempted preparation of a cobalt(III) tpzH-R complex using H2O2 
As it had previously been observed that the cobalt(II) complex dissociated in 
aqueous solution (discussed in Chapter 5), it was thought that the addition of H2O2 




complex forming. It was therefore decided to attempt the same reaction in the 
presence of an alternative oxidising agent, K2S2O8 (Scheme 3.9). Attempting this 
reaction at room temperature gave [Co(tpz-R)2] and free ligand. It seems that the 
cobalt(II) complex forming then precipitated out of solution, which was hindering 
the formation of the cobalt(III) complex, so the reaction mixture was heated at reflux 
for 24 hours in an attempt to keep the cobalt(II) complex in solution so it could be 
oxidised. It was from the attempts at this reaction which produced that diffraction 
































Scheme 3.9: Attempted preparation of a cobalt(III) tpzH-R complex using K2S2O8 
These reactions were also tried in solvents in which the [Co(tpz-R)2] complexes were 
more soluble; namely DMSO and DMF. Both of these failed to yield the desired 
cobalt(III) complex. It is likely that had the desired cobalt(III) complexes been 
successfully prepared, they would have suffered from the same poor solubility 
problems that the metal(II) complexes suffered by the metal(II) complexes, as they 
would also be electronically neutral  
3.5. Conclusions 
Three medicinally relevant N1,N4-oxide ligands have been prepared and fully 
characterised. It was observed that tpzH-CONH2 has an intramolecular bond 
between its amide NH and N-oxide which has been observed by both crystallography 
and 
1
H NMR spectroscopy. Metal(II) complexes (cobalt, copper, zinc) of tpzH, 




and zinc(II) complexes of these ligands have been prepared and it was observed, 
through NMR, that the intramolecular hydrogen-bond of tpzH-CONH2 remains upon 
coordination. The first crystal structure of a bis-quinoxaline-N1,N4-oxide complex 
has been successfully obtained, providing valuable information such as the decrease 























Chapter 4: Heteroleptic complexes of N1,N4-oxide ligands 
4.1. Introduction 
As described in Chapter 3, a significant limitation of the prepared complexes of 
N1,N4-oxide ligands tpzH, tpzH-CN and tpzH was their poor solubility. There was 
also the problem of not being able to prepare the desired cobalt(III) complexes. It 
was therefore attempted to incorporate the N-oxide ligands into metal complexes in a 
different manner to see if these limitations could be overcome. 
A strategy was found which enabled the preparation of a series of heteroleptic 





 row transition metals, heteroleptic complexes do not as regularly occur with 1
st
 
row metals. As an example, there is a reported series of heteroleptic complexes 
designed to act as antimycobacterial agents, featuring substituted tpzH-CN ligands 
















Figure 4.1: Structure of a previously reported heteroleptic copper(II) complex 
containing a N1,N4-oxide ligand.
172 
From the work described in Chapter 2, it was found that a cobalt(III) complex 
containing two dpHa ligands could be easily prepared in the presence of carbonate 
anion, a bidentate ligand with two hard negatively charged oxygen donor atoms 
(Figure 4.2). Comparably, the N1,N4-oxide ligands also coordinate via two hard 











Figure 4.2: The Lewis structures of the coordinating species of CO3
2-
 and tpz-R 
The first reaction was with one equivalent of tpzH-CN added to a stirred methanolic 
solution of Co(BF4)2.6H2O, in the presence of two equivalents of dpHa. This 
reaction was monitored with UV-vis spectroscopy which showed the λmax peak of the 
[Co(dpHa)2](BF4)2 reaction mixture at 482 nm decreases in intensity upon addition 
of tpzH-CN, with a new λmax peak emerging at 512 nm (Figure 4.3). 
 
Figure 4.3: UV-vis spectra overlay of the ethanolic reaction mixture of 
Co(BF4)2.6H2O with two equivalents dpHa before and after addition of one 
equivalent tpzH-CN 
This reaction caused the solution to turn gradually from orange to a dark purple, with 
the significant observation being that the dark purple product had remained in 
solution. As this was in stark contrast to the previous complexation reactions 
involving the 1 N1,N4-oxide ligands, the oxidising agent was not added in order to 
identify this cobalt(II) species. After being left to stir overnight, the solvent was 
dried off from the reaction mixture in vacuo and the resulting dark purple solid 
analysed by MS-ESI. The product produced a peak at m/z 601.1 which fitted for a 





























Scheme 4.1: Reaction which provided the first evidence for the formation of a 
heteroleptic complex containing dpHa and tpzH-CN 
This chapter presents the studies which have built upon this initial experimental 
observation. 
4.2. Preparation of heteroleptic metal(II) complexes 
4.2.1. Preparation of metal(II) complexes containing 2,2’-dipyridylamine and 
aminoquinoxaline-2-carbonitrile-N1,N4-oxide 
After it was found that cobalt heteroleptic complexes containing dpHa and tpzH-CN 
could be prepared, a synthetic strategy was needed that would allow complexes of 
other metals to be synthesised and isolated. This was first attempted by adding one 


























Scheme 4.2: Unsuccessful attempt to prepare [M(tpz-CN)(dpHa)]Cl (where M is 




It was found that no reaction occurred so Et3N was added to the reaction mixture, but 




























Scheme 4.3: Unsuccessful attempt to prepare [M(tpz-CN)(dpHa)]Cl (where M is 
copper or zinc) from [M(Cl)2(dpHa)] using Et3N 
It was then decided to switch to precursor complexes which were more readily 
soluble in light alcohols so that the reactants could be in solution to help facilitate the 
reaction. It was also decided to use precursor complexes which had weakly 
coordinating anions in place of coordinating ones, as the preliminary result of this 
study used BF4
¯
 as a counter-ion. There were already reported preparations in the 
literature for [Cu(dpHa)2]Cl2 and [Zn(dpHa)2](BF4)2 so it was decided to explore if 
these would be suitable precursor complexes. One equivalent of tpzH-CN was added 
to a green methanolic solution of [Cu(dpHa)2]Cl2, causing it to change colour to 
brown, and then dark red. This reaction was monitored with UV-vis spectroscopy, 
which indicated a new species had been formed as the absorbance of the mixture 
changed upon addition of the tpzH-CN (Figure 4.4). On comparing the UV-vis 
spectra it can be seen that the peaks at 433 and 695 nm present in the [Cu(dpHa)2]Cl2 
were replaced with a peak at 490 nm upon reaction with tpzH-CN. The reaction 
mixture was allowed to stir for an hour before being filtered to isolate the product as 
a dark red solid which was isolated in 68% yield. This was also confirmed with MS, 
which showed a peak at m/z 435.1 corresponding to a copper cation species 
coordinated to both dpHa and tpzH-CN moieties. Therefore, a synthetic route for 





Figure 4.4: UV-vis of [Cu(dpHa)2]Cl2 in MeOH before and after the addition of one 
equivalent tpzH-CN 
To confirm that [Cu(dpHa)2]Cl2 and tpzH-CN were reacting in a 1:1 ratio, 
[Cu(dpHa)2]Cl2 was titrated into a solution of tpzH-CN (Figure 4.5). The reaction 
was monitored at 478 nm, the λmax of uncoordinated tpzH-CN in methanolic 
solution. Upon sequential addition of [Cu(dpHa)2]Cl2, the absorbance of tpzH-CN at 
478 nm decreased until approximately one molar equivalent of [Cu(dpHa)2]Cl2 had 
been added, supporting a 1:1 reaction ratio. 
 
Figure 4.5: Absorbance at 478 nm during the titration of [Cu(dpHa)2]Cl2 into a 
methanolic solution of tpzH-CN 
Dark red diffraction quality crystals were obtained after several days of slow 
evaporation of the ethanolic filtrate under ambient conditions, and the resulting 






























Scheme 4.4: Successful preparation of [Cu(tpz-CN)(dpHa)]Cl from [Cu(dpHa)2]Cl2 
The structure showed a near square-pyramidal copper(II) centre (τ = 0.19) 





Figure 4.6: ORTEP diagram (50% probability) of [Cu(tpz-CN)(dpHa)(H2O)]Cl.
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Hydrogen atoms (except H(3), H(3a), H(3b) and H(6a)) and chloride counter-ion 
removed for clarity. Selected bond lengths / Å and angles /º: Cu(1)-O(1) 1.9614(13), 
Cu(1)-N(3) 1.9764(16), Cu(1)-N(7) 1.9828(15), Cu(1)-N(5) 1.9928(15), Cu(1)-O(3) 
2.3772(15), N(1)-O(1) 1.3508(18), N(2)-O(2) 1.2814(18), O(1)-Cu(1)-N(3) 81.21(6), 
N(7)-Cu(1)-N(5) 90.99(6) 
The N-O bond length of the N-oxide coordinated to the metal centre is 1.3508(18) Å 
and is therefore longer than the uncoordinated N-oxide bond which is 1.2814(18) Å. 
This agrees with the loss of π-character in the N-O bond that was said to occur upon 




stronger metal-oxygen bond. The lengthening of the uncoordinated N-oxide bond 
implies that the whole tpzH-CN ligand has decreased in π-character. 
Both hydrogen atoms of the aqua ligand were found using the electron difference 
map. The aqua ligand forms a hydrogen-bond from one of its protons, H(3a) to an 
uncoordinated chloride, which forms a hydrogen-bond with the H(6a) proton of the 
dpHa amine of an adjacent complex. The overall effect of this is the formation of 
linear chains throughout the crystal lattice (Figure 4.7). 
 
Figure 4.7: ORTEP diagram showing the intermolecular hydrogen-bonds present 
within the crystal structure of [Cu(tpz-CN)(dpHa)(H2O)]Cl.
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 Hydrogen-bond 
distances / Å and angles /º: H(3a)···Cl(1) 2.59(3), O(3) ··Cl(1) 3.3250(17), 
H(6a)···Cl(1) 2.39(3), N(6)···Cl(1) 3.1487(16)O(3)-H(3a)···Cl(1) 166(3), N(6)-
H(6a)···Cl(1) 172(2) 
The preparation of the analogous bis-dpHa zinc(II) chloride precursor complex, 
[Zn(dpHa)2]Cl2, was not available in the literature. Therefore the previously reported 
[Zn(dpHa)2](BF4)2 complex was used instead, as it seemed that any anions present 
needed to be weakly coordinating to allow the formation of these complexes. This 
complex was reacted with one equivalent of tpzH-CN in ethonolic solution to afford 
[Zn(tpz-CN)(dpHa)]BF4 as a crimson solid in 50% yield. The formation of this 
compound was first confirmed by MS which showed a peak at m/z 436.05, and then 
by NMR spectroscopy. Comparing the 
1
H NMR spectra of the crimson solid with 
that of tpzH-CN, dpHa, [Zn(dpHa)2](BF4)2 and [Zn(tpz-CN)2], which highlighted the 





Figure 4.8: Overlay of 
1
H NMR spectra (MeOD, 400 MHz) of dpHa, 
[Zn(dpHa)2](BF4)2, tpzH-CN and [Zn(tpz-CN)(dpHa)]BF4. Peaks of [Zn(tpz-
CN)(dpHa)]BF4 corresponding to tpzH-CN indicated by  and dpHa indicated by  
The comparison of the 
1
H NMR spectra shows that the resonances corresponding to 
tpzH-CN ligand have experienced an upfield shift upon incorporation into this 
heteroleptic complex, whilst the resonances corresponding to the dpHa ligand have 
experienced a general downfield shift. This indicates that effect of incorporating 
dpHa into this complex has caused its protons to become more deshielded with 
respect to the chemical shifts observed in the free ligand and other zinc(II) dpHa 








H NMR (MeOD, 400 MHz) of [Zn(tpz-CN)(dpHa)]BF4: δ8.50 (d, 2H, J 
= 5.0 Hz, H
a), δ8.32 (d, 1H, J = 8.5 Hz, Hb), δ8.27 (d, 1H, J = 8.5 Hz, Hc), δ7.99 
(ddd, 2H, J = 8.5, 7.0, 2.0 Hz, H
d), δ7.90 (ddd, 1H, J = 8.5, 7.5, 1.0 Hz, He), δ7.49 
(ddd, 1H, J = 8.5, 7.5, 1.0 Hz, H
f
), δ7.30 (d, 2H, J = 8.4 Hz, Hg), δ7.22 (ddd, 2H, J = 




The dpHa protons becoming more deshielded within the heteroleptic complex 
concurs with the donation of electron density from this ligand to the metal centre 
upon coordination. This is supported by the increase in shielding of the tpzH-CN 
ligand’s protons experience upon inclusion in the heteroleptic complex with respect 
to the free ligand, suggesting it has become more electron-rich upon coordination. 
Dark red diffraction-quality crystals of [Zn(tpz-CN)(dpHa)]BF4 were obtained by 
layering a methanolic solution over 
n
BuOH then allowing this to slowly evaporate 
over the course of a several days at room temperature. The structure shows the 
zinc(II) centre coordinated to one tpzH-CN and one dpHa ligand with one 
coordinated molecule of methanol (Figure 4.10). The metal centre has a near square 





Figure 4.10: ORTEP diagram (50% probability) of [Zn(tpzH-
CN)(dpHa)(MeOH)]BF4.
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 Hydrogen atoms except H(3), H(3a) and H(6a) and BF4
-
 
counter-ion removed for clarity. Selected bond lengths / Å and angles /º: N(1)-O(1) 
1.339(3), N(2)-O(2) 1.288(3), N(3)-Zn(1) 2.024(2), N(5)-Zn(1), 2.088(2), N(7)-
Zn(1) 2.080(2), O(1)-Zn(1) 2.0891(19), O(3)-Zn(1) 2.097(2), N(7)-Zn(1)-N(5) 
89.01(8), N(3)-Zn(1)-O(1) 78.32(8) 
The N-oxide bond coordinated to the metal centre has a N(1)-O(1) bond length of 
1.339(3), which is longer than that of the uncoordinated N-oxide which is 1.288(3). 
Table 4.1 compares some of the bond lengths found in [Zn(tpz-CN)(dpHa)]BF4 with 
those found for [Zn(tpz-CN)2(DMF)]. It can be seen the homoleptic complex has 
shorter bond lengths between the N-oxide amine and metal centre (1.990(2) and 
1.989(2) Å) as opposed to the heteroleptic complex where the equivalent bond length 









Table 4.1: Comparison of selected bond lengths of [Zn(tpz-CN)2(DMF)] and 
[Zn(tpz-CN)(dpHa)(MeOH)]BF4 / Å 














Table 4.2 lists the zinc(II)-pyridyl bond lengths of [Zn(tpz-CN)(dpHa)(MeOH)]BF4, 
[Zn(dpHa)2](BF4)2 and [Zn(Cl)2(dpHa)]. The data shows that the metal-pyridyl bond 
lengths are also longest in the heteroleptic complex. This, combined with the NMR 
data, implies that there may be exchange of electron density between the two ligands 
through the metal centre. 
Table 4.2: Comparison of zinc(II)-pyridyl bond lengths of [Zn(tpz-
CN)(dpHa)(MeOH)]BF4, [Zn(dpHa)2]2BF4 and [Zn(Cl)2(dpHa)] / Å.
128, 129 
 








The [Zn(tpz-CN)(dpHa)(MeOH)]BF4 complex forms two intermolecular hydrogen-
bonds using its tpzH-CN ligand; one from the amine proton H(3) to the nitrile N(4) 
of the adjacent complex, and the same interaction repeated vice versa (Figure 4.11). 






Figure 4.11: ORTEP diagram showing the hydrogen-bonds formed within the 
crystal of [Zn(tpz-CN)(dpHa)(MeOH)]BF4.
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Hydrogen-bond distances / Å and 
angles /º: H(3)···N(4) ··2.39(3), N(3) ··N(4) 3.182(3), N(3) H(3)···N(4) 169(3)] 
 
4.2.2. Preparation of metal(II) complexes containing 2,2’-dipyridylamine and 
aminoquinoxaline-2-amido-N1,N4-oxide 
[Cu(tpz-CONH2)(dpHa)]Cl was prepared by adding a methanolic solution of 
[Cu(dpHa)2](Cl)2 to an ethanolic solution of tpzH-CONH2. The dark red product was 
isolated as a dark red powder in 48% yield and was found to give a M
+
 peak at m/z 
453.1, corresponding to a copper species bound to one dpHa and one tpzH-CONH2 
ligand ([Cu(tpz-CONH2)(dpHa)]
+
). Diffraction-quality dark red crystals were 
obtained by allowing a methanolic solution layered over 
n
BuOH to slowly evaporate 





Figure 4.12: ORTEP diagram (50% probability) of [Cu(Cl)(tpz-CONH2)(dpHa)].
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Hydrogen atoms (except H3, H4a, H4b and H6a) and solvent molecules removed for 
clarity. Selected bond lengths / Å and angles / º: Cl(1)-Cu(1) 2.7263(6), Cu(1)-N(3) 
1.9334(19), Cu(1)-N(5) 1.9804(17), Cu(1)-N(7) 1.9839(18), Cu(1)-O(1) 1.9495(14), 
N(1)-O(1) 1.357(2), N(2)-O(2) 1.294(2), N(3)-Cu(1)-(O1) 81.88(7), N(5)-Cu(1)-
N(7) 89.75(7). Hydrogen-bond distances / Ǻ and angles /º: H(3)···O(3) 2.06(3), N(3) 
··O(3) 2.709(2), N(3)-H(3) ··O(3) 140(2), H(4a)···O(2) 1.85(3), N(4) ··O(2) 
2.580(3), N(4)-H(2) ··O(3) 140(3) 
The near square pyramidal copper(II) centre (τ = 0.08) is coordinated to one dpHa 
and one tpz-CONH2 ligand, with one axially coordinated chloride (Figure 4.12).
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The intramolecular hydrogen-bonds within the tpz-CONH2 ligand which occur 
between the amide NH and N-oxide oxygen, and amine NH with the carbonyl 
oxygen are still present upon coordination. Upon comparing the hydrogen-bond 
lengths of the free and coordinated ligand (Table 4.3), it can be seen that both of 
these intramolecular hydrogen-bonds have become longer upon coordination. It can 
also be seen that both of the N-oxide bonds become longer upon coordination, where 
















Figure 4.13: Atom numbering used in Table 4.2 
 
Table 4.3: Comparison of selected bond lengths / Å and angles / º of uncoordinated 
tpzH-CONH2 and [Cu(Cl)(tpz-CONH2)(dpHa)] 
Bond tpzH-CONH2 [Cu(Cl)(tpz-CONH2)(dpHa)] 
N(1)-O(1) 1.327(2) 1.357(2) 
N(2)-O(2) 1.274(2) 1.294(2) 
C(1)-N(3) 1.326(2) 1.308(3) 
H(3)···O(3) 1.98(3) 2.06(3) 
N(3) ··O(3) 2.622(2) 2.709(2) 
N(3)-H(3) ··O(3) 136(2) 140(2) 
H(4a) ··O(2) 1.90(3) 1.85(3) 
N(4) ··O(2) 2.557(2) 2.580(3) 
N(4)-H(2) ··O(2) 126(3) 140(3) 
 
In addition to the two intramolecular hydrogen-bonds, there is also an intermolecular 
hydrogen-bond network present within the crystal structure. A molecule of water 
present within the crystal structure forms two hydrogen-bonds with H(4c) and H(4d) 
to the axially coordinated chloride Cl(1) from two separate complexes. The O(3) 
oxygen of the water forms a hydrogen-bond to the N(6)-H(6a) amine of a third 
complex. The overall effect is the formation of ‘ladder’ type structures within the 





Figure 4.14: ORTEP diagram showing the hydrogen-bonds present in the structure 
of [Cu(Cl)(tpz-CONH2)(dpHa)].
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 Hydrogen-bond distances / Å and angles /º: 
H(3)···O(3) 2.06(3), N(3) ··O(3) 2.709(2), N(3)-H(3) ··O(3) 140(2), N(4)-H(4a) 
··O(2) 140(3), N(6)-H(6a) ··O(4) 173(3), H(4c)···Cl(1) 2.42(3), O(4) ··Cl(1) 3.154 
(2), H(4d)-Cl(1) 2.41 (3),O(4) ··Cl(1) 3.215 (2), O(4)-H(4c) ··Cl(1) 174 (3), O(4)-
H(4d) ··Cl(1) 172 (3) 
 
The [Zn(tpz-CONH2)(dpHa)]BF4 complex was prepared by adding a methanolic 
solution of [Zn(dpHa)2](BF4)2 to a stirred ethanolic orange suspension of tpzH-
CONH2, causing it to turn from orange to red. A reddish-pink precipitate was 
isolated by filtration which was found by 
1
H NMR spectroscopic analysis to contain 
the product in a 1:12 ratio with another species (Figure 4.15). This second 
compound does not have the same proton signals as any of the starting materials or 






Figure 4.15: Overlay of the 
1
H NMR spectra (MeOD, 400 MHz) of dpHa, 
[Zn(dpHa)2](BF4)2 and [Zn(tpz-CONH2)(dpHa)]BF4 (peaks of product denoted by 
). δ8.53 (m, 1H), δ8.44 (d, 2H, J = 8.5 Hz), δ8.32 (m, 1H), δ8.21 (m, 2H), δ8.16 
(ap. br. s, 20H), δ 7.95 (t, 20H, J = 7.5 Hz), δ7.83 (ap. t, 1H, J = 6.5 Hz), δ7.68 (m, 
1H), δ7.44 (t, 2H, J = 7.5 Hz), δ7.23 (d, 20H, J = 8.5 Hz), δ7.14 (t, 20H, J = 6.5 Hz) 
 
4.2.3. Preparation of metal(II) complexes containing 3-amino-1,2,4-
benzotriazine- N1,N4-oxide 
[Cu(tpz)(dpHa)]Cl was prepared by reacting one equivalent of [Cu(dpHa)2]Cl2 with 
an equimolar amount of tpzH in ethanolic solution and was isolated in 45% yield. 
The product has a MS peak at m/z 411.1, corresponding to a copper cation species 
containing one dpHa and one tpz ligand i.e. [Cu(tpz)(dpHa)]
+
. Diffraction-quality 
dark red crystals of the complex were obtained by allowing a concentrated 
methanolic solution to slowly evaporate over a few days at room temperature. The 
structure shows two independent complexes within the unit cell (Figure 4.16), each 
of which show a five-coordinate copper(II) centre bound to one tpzH and one dpHa 





Figure 4.16: ORTEP diagram showing the two [Cu(tpz)(dpHa)(MeOH)]Cl 




Figure 4.17: ORTEP diagram (50% probability) of (the Cu(1) complex) 
[Cu(tpz)(dpHa)(MeOH)]Cl.
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 Hydrogen atoms (except H3, H3a and H6a) and BF4
-
 
counter-ion removed for clarity. Selected bond lengths / Å and angles /º: Cu(1)-N(3) 
1.9429(18), Cu(1)-O(1) 1.9509(15), Cu(1)-N(7) 1.9714(18), Cu(1)-N(5) 1.9881(17), 
Cu(1)-O(3) 2.3323(19), N(1)-O(1) 1.355(2), N(2)-O(2) 1.261(2), N(3)-Cu(1)-O(1) 
83.02(7), N(7)-Cu(1)-N(5) 89.48(7) 
The complex containing the Cu(1) centre has near-square pyramidal geometry (τ = 




ligand forced to twist out of its non-planar conformation.
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 The plane of the C(1), 
N(1), N(3) and N(4) atoms is twisted by 7.8° away from the plane of the rest of the 
aromatic molecule (Figure 4.18). 
 
Figure 4.18: Diagram to illustrate the distortion within the tpzH ligand of the Cu(1) 
complex found in the crystal structure of [Cu(tpz)(dpHa)(MeOH)]Cl 
The second complex which contains the Cu(2) centre has a less distorted square 





Figure 4.19: ORTEP diagram (50% probability) of (the Cu(2) complex) 
[Cu(tpz)(dpHa)(MeOH)]Cl.
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 Hydrogen atoms (except H(3), H(3a) and H(6a)) and 
BF4
-
 counter-ion removed for clarity. Selected bond lengths / Å and angles /º: Cu(2)-
N(10) 1.9437(16), Cu(2)-N(12) 1.9736(16), Cu(2)-N(14) 1.9981(17), Cu(2)-O(4) 
2.0005(14), Cu(2)-O(6) 2.3215(15), N(8)-O(4) 1.3548(19), N(9)-O(5) 1.259(2), 




Table 4.4 shows that upon coordination the N(1)-O(1) bond lengthens, an effect 
which has been previously attributed to the loss of π-character in the N-O bond.170 
The data shows that the uncoordinated N(2)-O(2) bond lengthens, whereas the C(1)-











Figure 4.20: Atom assignments for used in Table 4.2 
Table 4.4: Comparison of selected bond lengths of uncoordinated and coordinated 
tpzH 
 tpzH [Cu(tpz)(dpHa)(MeOH)]Cl 
  Cu(1) centre Cu(2) centre 
N(1)-O(1) 1.3330(15) 1.355(2) 1.3548(19) 
N(2)-O(2) 1.2574(15) 1.261(2) 1.259(2) 
C(1)-N(3) 1.3241(19) 1.301(3) 1.305(2) 
 
The analogous zinc(II) complex was prepared by reacting equimolar amounts of 
[Zn(dpHa)2](BF4)2 and tpzH in methanol, and subsequently observed with MS (m/z 
412.2) and 
1





Figure 4.21: Overlay of the 
1
H NMR spectra (400 MHz, d6-DMSO) of 
[Zn(dpHa)2](BF4)2 (above), tpzH (middle) and [Zn(tpz)(dpHa)]BF4 (bottom). Data 
for [Zn(tpz)(dpHa)]BF4: δ8.32 (br. d, 2H, J = 3.0 Hz), δ8.14 (d, 1H, J = 8.5 Hz), 
δ7.97 (ap. d, 1H, J = 8.5 Hz), δ7.91 (t, 1H, 7.5 Hz), δ7.77 (t, 2H, J = 6.0 Hz), δ7.57 
(d, 2H, J = 6.0 Hz), δ7.33 (t, 1H, J = 7.5 Hz), δ7.16 (br. s, 1H), δ6.99 (t, 2H, J = 6.0 
Hz). In the spectrum of [Zn(tpz)(dpHa)]BF4, the coordinated tpz ligand is denoted by 
 and dpHa denoted by  
4.3. Preparation of heteroleptic cobalt(III) complexes 
[Co(tpz-CN)(dpHa)2](BF4)2 was prepared in 19% yield by adding one equivalent 
tpzH-CN to a stirred mixture of Co(BF4)2.6H2O and two equivalents dpHa. Upon 
addition of the tpzH-CN, the reaction mixture turned a dark red-purple colour, and 























































Scheme 4.5: Preparation of [Co(tpz-CN)(dpHa)2](BF4)2 
Formation of [Co(tpz-CN)(dpHa)2] was confirmed through MS where a peak at m/z 
601.13 and a +2 peak at m/z 301.07 corresponding to [Co(tpz-CN)(dpa)(dpHa)]
+
 and 
[Co(tpz-CN)(dpHa)2], respectively, were observed. 
1
H NMR spectroscopic analysis 
confirmed the formation of a new species containing several different aromatic rings. 
However, it was not possible to fully assign the NMR spectra owing to the similarity 
in chemical environment be of the different aromatic rings. From the combined 
results of 700 MHz COSY, HSCQ and HMBC NMR experiments, it was possible to 
assign the proton signals to one of five different ring environments, and to assign one 
as belonging to the tpzH-CN ligand (Figure 4.22). Even though four separate 
pyridyl rings had been identified, the lack of coupling through the central amine of 
dpHa and lack of any correlation between the different rings prevented the full 







H NMR (d6-DMSO, 700 MHz) of [Co(tpz-CN)(dpHa)2](BF4)2. δ8.16 
(t, 1H, J = 7.3 Hz, H
b), δ8.10 (m, 1H, Hc), δ8.07 (d, 1H, J = 4.8 Hz, Hd), δ7.99 (d, 
1H, J = 8.5, H
e), δ9.96 (d, 1H, J = 8.6 Hz, Hf), δ7.94 (s, 1H, Hg), δ7.90 (t, 1H, Hh), 
δ7.89 (t, 1H, Hi), δ 7.88 (t, 1H, Hj), δ7.73 (d, 1H, J = 5.7 Hz, Hk), δ7.61 (d, 1H, J = 
5.0 Hz, H
l), δ 7.58 (d, 1H, J = 5.0 Hz, Hm), δ 7.52 (d, 1H, J = 8.3 Hz, Hn), δ7.46 (d, 
1H, J = 8.0, H
m), δ7.42 (t, 1H, J = 7.7 Hz, Hn), δ7.24 (d, 1H, J = 7.8, Ho), δ7.18 (t, 
1H, J = 6.1, H
p), δ7.15 (d, 1H, J = 8.4 Hz, Hq), δ7.04 (t, 1H, Hr), δ7.03 (t, 1H. Hs), 
δ7.02 (t, 1H, Ht) 
 
Dark red diffraction-quality crystals were obtained through allowing an ethanolic 
solution to slowly evaporate at room temperature over the course of several days. 
The structure shows one tpzH-CN ligand and two dpHa ligands coordinated to an 















Hydrogen atoms (except H(3), H(3a) and H(6a)) and BF4
-
 counter-ions removed for 
clarity. Selected bond lengths / Å and angles /º: Co(1)-N(3) 1.9022(13), Co(1)-O(1) 
1.9059(11), Co(1)-N(5) 1.9337(13), Co(1)-N(8) 1.9422(14), Co(1)-N(7) 1.9484(14), 
Co(1)-N(10) 1.9484(13), N(1)-O(1) 1.3745(16), N(2)-O(2) 1.2645(18), N(3)-Co(1)-
O(1) 84.07(5), N(5)-Co(1)-N(7) 89.88(6), N(8)-Co(1)-N(10) 89.62(6) 
Within the crystal, the individual complexes are linked as dimeric units by two 
intermolecular hydrogen-bonds formed between the nitrile group from one complex 
and the amine of the tpz-CN of the other complex (Figure 4.24). 
 
Figure 4.24: ORTEP diagram showing the intermolecular hydrogen-bonding present 
within the crystal structure of [Co(tpz-CN)(dpHa)2](BF4)2.
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 Hydrogen-bond 





In order to be able to use the complex in biological assays, it was needed to be able 
to prepare the complex with an alternative counter-ion which is more biologically 
compatible. It was first tried to prepare [Co(tpz-CN)(dpHa)2]Cl2 by reacting one 
equivalent CoCl2.6H2O with two equivalents of dpHa in MeOH to form 
[Co(Cl)2(dpHa)2] in situ, then react this with one equivalent tpzH-CN. The resulting 
complex was then oxidised with K2S2O8 to form the cobalt(III) complex. It was 
necessary to discourage the formation of the bis-dpHa cobalt(III) complex so the 
reaction mixture was heated at reflux, as the stability of the bis-cobalt(II) octahedral 
complex becomes entropically less favourable upon heating compared with the 
tetrahedral [Co(Cl)2(dpHa)].
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 It was subsequently found that using cobalt(II) nitrate 
in place of cobalt(II) chloride resulted in [Co(tpz-CN)(dpHa)2]
2+
 being obtained in 






























Scheme 4.6: Preparation of [Co(tpz-CN)(dpHa)2](NO3)2 
With the tpzH-CONH2 ligand, it was initially thought that the bis-N-oxide cobalt(III) 
complex [Co(tpz-CONH2)2(dpHa)]
+
 complex was being formed. A peak at m/z 668.1 





spectroscopy indicated the presence of eight different proton environments and 
therefore two chemically different aromatic rings each containing four protons 
(Figure 4.25). The two separate ring environments only fits for the complex having 








H NMR (400 MHz, MeOD) of [Co(tpz-CONH2)2(dpHa)]
+
: δ8.30 (d, 
1H, J = 8.5 Hz), δ8.24 (dd, 1H, J = 6.5 , 1.5 Hz), δ7.87 (m, 4H), δ7.67 (ddd, 2H, J 
=7.5, 7.0, 1.0 Hz), δ7.36 (ddd, 2H, J = 8.5, 7.0, 1.0 Hz), δ7.16 (m, 4H) 
 
Figure 4.26: The three isomers of [Co(tpz-CONH2)2(dpHa)]
+
 (above) and the single 
isomer of [Co(tpz-CONH2) (dpHa)2]
2+
 with their chemically equivalent ring 







It was therefore attempted to prepare the complex using two equivalents of the tpzH-





1) dpHa                      



















Scheme 4.7: Attempt to prepare [Co(tpz-CONH2)2(dpHa)]NO3 from equimolar 
amounts of Co(NO3).6H2O and dpHa with two equivalents tpzH-CONH2 
Dark red diffraction quality-crystals from this reaction were obtained by allowing a 
methanolic solution layered over 
n
BuOH to slowly evaporate under ambient 
conditions over several days. The structure did not show the expected bis-N-oxide 
cobalt(III) structure, but that of [Co(tpz-CONH2)(dpHa)2](NO3)2. The structure 
shows an octahedral cobalt(III) centre coordinated to one tpzH-CONH2 ligand and 
two dpHa ligands (Figure 4.27), with two non-coordinating nitrate counter-ions. The 
structure shows that the two intramolecular hydrogen-bonds within tpzH-CONH2 










Hydrogen atoms (except H(3), H(3a) and H(6a)) and BF4
-
 counter-ion removed for 
clarity. Selected bond lengths / Å and angles /º: Co(1)-N(3) 1.882(3), Co(1)-N(5) 
1.941(3), Co(1)-N(7) 1.941(3), Co(1)-N(8) 1.948(3), Co(1)-N(10) 1.953(3), Co(1)-
O(1) 1.883(2), N(1)-O(1) 1.373(3), N(2)-O(2) 1.292(4), N(3)-Co(1)-O(1) 84.32(11), 
N(5)-Co(1)-N(7) 90.59(11), N(8)-Co(1)-N(10) 89.41(11). Hydrogen-bond distances / 
Å and angles /º: H(4a)···O(2) 1.79 (5), N(4)···O(2) 2.552(6), H(3a)···O(3) 2.13 (4), 
N(3)···O(3) 2.638(4), N(4)-H(4a)···O(2) 129(4), N(3)-H(3a)···O(3) 138(4) 
 
By comparing the bond lengths of the free and coordinated tpzH-CONH2 ligand, it 
can be seen that both of the N-oxide bonds lengthen upon coordination (Table 4.5) 

















Table 4.5: Comparison of selected bond lengths / Å and angles / º of tpzH-CONH2 
bond lengths in the free ligand and [Co(tpz-CONH2)(dpHa)2]2NO3 complex 
 tpzH-CONH2 [Co(tpz-CONH2)(dpHa)2]2NO3 
N(1)-O(1) 1.327(2) 1.373(3) 
N(2)-O(2) 1.274(2) 1.292(4) 
C(1)-N(3) 1.326(2) 1.307(4) 
H(3)···O(3) 1.98(3) 2.13 (4) 
N(3) ··O(3) 2.622(2) 2.638(4) 
N(3)-H(3) ··O(3) 136(2) 138(4) 
H(4a) ··O(2) 1.90(3) 1.79 (5) 
N(4) ··O(2) 2.557(2) 2.552(6) 
N(4)-H(2) ··O(2) 126(3) 129(4) 
 
Within the crystal, the central amine of one dpHa ligand, N(9)-H(9) forms a 
hydrogen-bond to the O(5) atom of a nitrate. The amide of the N-oxide ligand, N(4)- 
H(4b), forms a hydrogen-bond with O(8) of another nitrate. This same oxygen atom 
forms a hydrogen-bond with a second complex, to the N(6)-H(6) amine of a dpHa 
ligand. These interactions combine to form a hydrogen-bonded dimeric type 
structure comprising of two complexes and four non-coordinated nitrate anions, two 






Figure 4.29: ORTEP diagram showing the intermolecular hydrogen-bonding present 
within the crystal structure of [Co(tpz-CONH2)(dpHa)2]2NO3.
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 Hydrogen-bond 
distances / Å and angles /º: H(4b)···O(8) 2.413, N(4) ··O(8) 3.062, H(6) ··O(8) 1.97, 
N(6)···O(8) 2.784(4), H(9)···O(5) 2.08, N(9)···O(5) 2.872 (4), N(4)- H(4b)···O(8) 
161.56, N(6)- H(6)···O(8) 153.5, N(9)-H(9)···O(5) 149.8 
The presence of [Co(tpz-CONH2)(dpHa)2]
2+
 had not been observed with MS-ESI 
prior to the setting up of the crystallisations, despite complexes of this type being 
observed previously. It was therefore thought that the obtained crystals were of the 
minor product formed from the reaction, with the bulk product being [Co(tpz-
CONH2)2(dpHa)]
+
. It was subsequently tried to prepare the former as the main 
product. Reacting two equivalents of dpHa and one equivalent of tpzH-CONH2 
produced a 
1
H NMR spectra in D2O which resembled that of the [Co(tpz-
R)(dpHa)2]
2+
 complexes (Figure 4.30) with the number of different proton 
environments. MS peaks were observed at m/z 619.14 and 668.12, corresponding to 
[Co(tpz-CONH2)2(dpHa)2]
+
 and the [M-H]
+
 ion of [Co(tpz-CONH2)(dpHa)2]
2+
. 
Using the cobalt(II) chloride in place of the nitrate salt also yielded a mixture. It was 
found that the difference in aqueous solubility between the two complexes provides a 
means of separating them, as Co(tpz-CONH2)(dpHa)2]
2+
 is the more soluble in 
water. As the reaction is low yielding and the amount of Co(tpz-CONH2)(dpHa)2]
2+
 
isolated in this way is sufficient only for a 
1
H NMR spectrum, a more efficient 
means of preparing Co(tpz-CONH2)(dpHa)2]
2+









H NMR (400 MHz, D2O) of [Co(tpz-CONH2)(dpHa)2]
2+
: δ8.05 (m, 
2H), δ7.94 (m, 4H), δ7.75 (m, 3H), δ7.57 (d, 1H, J = 6.0 Hz), δ7.50 (m, 2H), δ7.45 
(d, 1H, J = 8.0 Hz), δ7.32 (d, br. d, 1H, J = 8.0 Hz), δ7.15 (d, 1H, J = 8.0 Hz), δ7.05 
(d, 1H, J = 8.0 Hz), δ6.98 (m, 3H), δ6.93 (t, 1H, J = 6.0 Hz) 
 
The cobalt(III) tpzH complex was similarly obtained to [Co(tpz-CN)(dpHa)2]
2+
, by 
reacting two equivalents of dpHa and one of tpzH with the appropriate cobalt salt, 
















1) 2 equiv. dpHa           
2) tpzH                  
3) K2S2O8
 
Scheme 4.8: Preparation of [Co(tpz)(dpHa)2]Cl2 





HNMR spectroscopic analysis showed a similar 
spectrum to that observed for the [Co(tpz-CN)(dpHa)2]
2+









H NMR (500 MHz, MeOD) of [Co(tpz)(dpHa)2]
2+
: δ8.16 (ddd, 1H, J = 
7.5, 7.0, 1.0 Hz), δ8.11 (ddd, 1H, J = 8.0, 7.0, 1.5 Hz), δ7.99 (d, 1H, J = 8.5 Hz), 
δ7.87 (m, 5H), δ7.82 (dd, 1H, J = 5.5, 1.0 Hz), δ7.67 (d, 2H, J = 6.5 Hz), δ7.57 (d, 
1H, J = 8.0 Hz), δ7.52 (d, 1H, J = 8.0 Hz), δ7.32 (ddd, 1H, J = 8.5, 5.5, 3 Hz), δ7.26 
(d, 1H, J = 8.0 Hz), δ7.17 (d, 1H, J = 8.5 Hz), δ7.10 (m, 4H) 
Crystals of [Co(tpz)(dpHa)2](BF4)2 were obtained by allowing a methanolic solution 
layered over 
n
BuOH to slowly evaporate over the course of a few days at room 
temperature. The structure is similar to that of the other two cobalt(III) structures, 
having an octahedral centre coordinated to one tpzH ligand and two dpHa ligands, 











 Hydrogen atoms 
(except H(3a), H(6a) and H(9a)) and BF4
¯
 counter-ions and solvent molecules 
removed for clarity. Selected bond lengths / Å and angles /º: Co(1)-O(1) 1.9059(12), 
Co(1)-N(3) 1.9077(14), Co(1)-N(8) 1.9314(14), Co(1)-N(7) 1.9361(14), Co(1)-
N(10) 1.9385(14), Co(1)-N(5) 1.9494(14), N(1)-O(1) 1.3650(17), N(2)-O(2) 
1.2668(18), O(1)-Co(1)-N(3) 84.49(5), N(7)-Co(1)-N(5) 89.37(6), N(8)-Co(1)-N(10) 
90.65(6) 
 
Comparing the bond lengths of the tpzH ligand when free and when coordinated to 
the cobalt(III) centre again shows that the N-oxide bond lengths lengthen upon 


















Table 4.6: Comparison of N-oxide bond lengths in tpzH and [Co(tpz)(dpHa)2](BF4)2 
 tpzH [Co(tpz)(dpHa)2]2BF4 
N(1)-O(1) 1.3330(15) 1.3650(17) 
N(2)-O(2) 1.2574(15) 1.2668(18) 
C(1)-N(3) 1.3241(19) 1.300(2) 
Within the crystal, dimer structures are formed by a two-fold hydrogen-bond 
between the uncoordinated N-oxide O(2) and the dpHa amine N(9)-H(9a) of the 
second complex (Figure 4.34). 
 
Figure 4.34: ORTEP diagram showing the intermolecular hydrogen-bonding present 
within the crystal structure of [Co(tpz)(dpHa)2](BF4)2.
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 Hydrogen-bond distances / 
























Upon comparing the bond lengths of the three cobalt(III) complexes (Table 4.7), it 
can be seen that the tpzH-CONH2 complex has the shortest metal-N-oxide bond 
lengths but longest metal-dpHa bond lengths. 
Table 4.7: Comparison of the crystallographically determined bond lengths of the 
cobalt(III) heteroleptic N-oxide complexes 
Bond tpzH-CN tpzH tpzH-CONH2 
Co(1)-O(1) 1.9059(11) 1.9059(12) 1.883(2) 
Co(1)-N(3) 1.9022(13) 1.9077(14) 1.882(3) 
Co(1)-N(5) 1.9337(13) 1.9314(14) 1.941(3) 
Co(1)-N(7) 1.9484(14) 1.9385(14) 1.941(3) 
Co(1)-N(8) 1.9422(14), 1.9361(14) 1.948(3) 
Co(1)-N(10) 1.9484(13) 1.9494(14) 1.953(3) 
N(1)-O(1) 1.3745(16) 1.3650(17) 1.373(3) 
N(2)-O(2) 1.2645(18), 1.2668(18) 1.292(4) 
 
A notable difference when preparing the heteroleptic cobalt(III) complexes was 
observed between using tpzH-CN and tpzH compared to tpzH-CONH2. With the 
former two ligands, the colour change from that of the precursor species to the 
purple colour of the heteroleptic complex was observed upon addition of the N-oxide 




addition of the oxidising agent, and took place a lot more gradually. This difference 
in the readiness of formation might help explain the difference in distribution of 
products obtained for the cobalt(III) complexes of tpzH-CN and tpzH compared to 
tpzH-CONH2. 
 
4.4. Extending the range of heteroleptic complexes 
The work described in Chapter 2 demonstrated that the methyl substituent of 2,2-
dipyridylmethylamine (dpma) affected the interplanar angle between the ligand’s 
two pyridyl rings. The copper(II) complex [Cu(tpz-CN)(dpma)]
+
 was prepared 
according to Scheme 4.9 and obtained in 68% yield as the crude product. A peak at 























Scheme 4.9: Preparation of [Cu(tpz-CN)(dpma)]Cl 
 
The cobalt(III) complex [Co(tpz-CN)(dpma)2]
2+
 was prepared according to Scheme 
4.10 in 23% yield.  
 
CoBF4.6H2O
1) 2 equiv. dpma              



























H NMR spectroscopic analysis showed that 
the complex was cobalt(III) owing to the peaks being sharp as opposed to broad 
which would be the case for cobalt(II). The spectrum (Figure 4.36) shows numerous 
peaks focused within the aromatic make proton region, making it difficult to assign 
but the presence of three signals rather than two in the region where the methyl 







H NMR (400 MHz, d6-DMSO) of the crude reaction mixture from the 
formation of [Co(tpz-CN)(dpma)2](BF4)2 
 
1,10-Phenanthroline (phen), like many other planar aromatic compounds, has been 
long accepted for its ability to chealte  DNA.
173
 It has been incorporated into 
cisplatin analogues such as [Pt(phen)(en)]Cl2 and lanthanide complexes such as 






























Phen is a planar has two nitrogen donor atoms which coordinate to a metal centre to 
form a 5-membered metallocycle. It was thought that this more structurally ligand 
would provide an interesting comparison to the more structurally flexible dpHa 
ligand, which forms 6-membererd metallocycles. The complex was prepared by 
reacting two equivalents of the phen ligand with Co(BF4)2.6H2O, and then adding 
one equivalent tpzH-CN. It was found to be necessary to add one equivalent Et3N to 
the reaction mixture prior to the addition of the K2S2O8 oxidising agent in order to 













1) 1,10-phenanthroline (2 equiv.)                      
2) tpzH-CN                                            
3) Et3N                                          
4) K2S2O8
 
Scheme 4.11: Preparation of [Co(tpz-CN)(phen)2](BF4)2 
Crystals were obtained by layering a DMF solution with Et2O, but these proved too 
small to provide sufficient X-ray diffraction. MS analysis of the product showed 





H NMR spectroscopic analysis showed a vast array of sharp signals 











H NMR (400 MHz, MeOD) overlay of tpzH-CN (above), phen and the 
crude [Co(tpz-CN)(phen)2]
2+
 product (bottom). Data for [Co(tpz-CN)(phen)2]
2+
: 
δ9.36 (d, 1H, J = 5.0 Hz), δ9.27 (d, 1H, J = 5.0 Hz), δ9.18 (dd, 2H, J = 8.0, 1.0 Hz), 
δ9.03 (m, 3H), δ8.90 (ap. t, 3H, J = 8.0 Hz), δ8.83 (d, 1H, J = 5.0 Hz), δ8.50 (m, 
4H), δ8. 4-8.3 (m, 14H), δ8.04 (dd, 2H, J = 8.0, 5.0 Hz), δ7.9 (m, 4H), δ7.8-7.6 (m, 
7H), δ7.50 (m, 3H) 
 
4.5. Conclusions 
A novel series of heteroleptic metal(II) and cobalt(III) complexes incorporating 2,2-
dipyridyl amine (dpHa) and one N1,N4-oxide ligand (tpzH, tpzH-CN or tpzH-
CONH2) has been prepared and characterised including several crystal structures. 
The metal(II) complexes were shown to contain a 1:1 ratio of dpHa to N-oxide 
through NMR, titrations and crystallography. The cobalt(III) complexes of tpzH and 
tpzH-CN form in a 1:2 ratio of N-oxide to dpHa. The cobalt(III) complex of tpzH-
CONH2 seems to be able to form in a 1:2 or 2:1 ratio, with the former structurally 





. These complexes display vastly improved solubility in solvents such 




The potential to extend this range of complexes has been demonstrated with the 
observation of complexes where the dpHa ligand has been substituted for other 
bidentate neutral nitrogen donor ligands. The inclusion of phenanthroline into these 























Chapter Five: Evaluation of solution phase properties 
As drug compounds take effect on their biological targets in solution, it is important 
to assess various solution properties such as aqueous stability. The objective of this 
part of the project was therefore was to examine the pH-dependent stability and 
redox chemistry of the complexes and ligands discussed in Chapters 2, 3 and 4. 
 
5.1. Examining the aqueous and pH-dependent solution stability 
5.1.1. Ligand stability and pKa determination 
Before considering the stability of the complexes, it is important to examine the 
ligands. It was found that the titrations of the ligands could be followed 
spectrophotometrically, focusing on wavelengths between 200 and 300 nm for the 
dpRa ligands, where electronic transitions of aromatic species typically occur.
165
 For 
the N-oxide ligands, changes in absorbance in the visible region between 400 and 
600 nm were monitored. 
 
5.1.1.1. pKa Determination of 2,2’-dipyridylamine type ligands 
The overlaid UV-vis spectra of dpHa at different pH values (Figure 5.1) show that 
as the pH increases, the absorbance at 319 nm decreases whilst the absorbance at 262 
and 308 nm increases. The absorbance at these wavelengths can be plotted as a 
function of pH. A sigmoidal curve can then be fitted to the data points which after 
fitting, allows for the calculation of the pKa value of that particular deprotonation 
process. The single curve fitted to the absorbance at 262 nm against pH for dpHa 
























































Inflection point = 6.9
 
Figure 5.1: UV-vis spectra at varying pH of dpHa (left) and a plot of absorbance of 
dpHa at 262 nm against pH (right) in water 
There are two possible deprotonation processes which could give rise to this pKa 
value; the deprotonation of a pyridinium ion or the deprotonation of the central 
amine (Scheme 5.1). Either of these processes feasibly could have a pKa of 6.9 given 
that pyridinium deprotonating to give pyridine has a pKa of 5.23 whilst the 


















Scheme 5.1: Possible processes that could occur in dpHa to give a pKa of 6.9; 
deprotonation of the pyridinium ion (above) or deprotonation of the central amine 
(below) 
The number of protons involved in this deprotonation process can be determined 






This equation can be expressed in the form of the gradient for a straight line where y 
is the y axis value, m is the slope of the line, x is the x axis value and c is the 
intercept of the y axis. 
 
In terms of the Henderson-Hasselbalch equation, this makes the y axis value equal to 
pH, the x axis value equal to log([A-]/[HA]), the y intercept equal to the pKa and the 
gradient equal to the number of protons exchanged. 
 The relative concentrations of [HA] (the species prior to deprotonation) and [A¯] 
(the species after deprotonation) were obtained using the absorbances at 262 and 319 
nm. These values were then used to plot log([A¯]/[HA]) against pH (Figure 5.2). 
















Gradient = -1.1 (0.0)
 
Figure 5.2: Plot of log([A¯]/[HA] against pH for dpHa  
The line fitted to the data has a gradient of -1.1, indicating that one proton per dpHa 
molecule is involved in the observed deprotonation process. In order to help 
elucidate whether the amine or pyridinium ion is being deprotonated during this 
process, a derivative of dpHa was employed where the central amine had been 
methylated. The methyl group on the central amine of 2,2’-dipyridylamine (dpma) 
rules out deprotonation of the central amine occurring, but should still allow 
formation of a pyridinium ion species. Addition of NaOH(aq) to an acidified solution 




253 and 321 nm to decrease. Plotting of the change in absorbance at 272 nm against 
the change in pH provides a pKa value of 5.3(0) (Figure 5.3). 
















































Inflection point = 5.3
 
Figure 5.3: UV-vis spectra at varying pH of dpma (left) and absorbance of dpma at 
272 nm against pH (right) in water 
 
This one-proton process can be attributed to the deprotonation of the pyridinium ion 
(Scheme 5.2). This pKa value is close to that reported in the literature for the 
analogous process in pyridine (5.23), suggesting that the pyridinium ion is no more 










Scheme 5.2: The process which gives rise to dpma’s pKa value of 5.3 
Analysis of the crystal structures of [Zn(Cl)2(dpHa)] and [Zn(Cl)2(dpma)] described 
in Chapter 2 provides one possible explanation as to why the dpma pyridinium 
species has a similar pKa value to that of pyridine, whilst the dpHa pyridinium ion 
has a pKa of 6.9. The crystal structure of the [Zn(Cl)2(dpHa)] complex shows that the 
ligand adopted an almost planar conformation with the interplanar angle between the 
two pyridyl rings being 174.5°. In the [Zn(Cl)2(dpma)] complex, the ligand is less 






Figure 5.4: Overlay of the crystal structures of [Zn(Cl)2(dpHa)] (blue) and 
[Zn(Cl)2(dpma)] (red) showing the increased bend between the two pyridyl rings 
brought about by methylation of the central amine. 
128, 171 
As the two rings in the dpHa complex are more planar with respect to one another, 
the protonated pyridyl nitrogen forming a N-H···N hydrogen bond to the other 
pyridyl nitrogen would be shorter and stronger than the hydrogen bond in dpma as 
the pyridinium N-H lies in same plane as its pyridyl ring so points towards the lone 











Figure 5.5: How the interplanar angle of dpHa favours and of dpma disfavours the 
formation of a N-H···N hydrogen bond 
To test this hypothesis, the dpea ligand where the central amine had been ethylated 
was employed. It was predicted that as the ethyl group would provide degree of 
steric bulk to the central amine 
With increasing pH, the absorbance increases at 276 and 308 nm and decreases at 
254 and 318 nm (Figure 5.5). Plotting the absorbance at 276 nm against pH 























































Inflection point = 5.3
 
Figure 5.6: UV-vis spectra at varying pH of dpea (left) and absorbance of dpea at 
276 nm as a function of pH (right) in water 
Both the dpea and dpma ligands were found to have a pKa value of 5.3, similar to 
that of free pyridine. This similarity indicates that there is no additional stabilisation 
of the protonated species contributed by the amine substituent or the second pyridyl 
ring. The methyl and ethyl substituents provide a similar amount of steric bulk 
adjacent to the central amine. The crystal structures of [Zn(Cl)2(dpea)] and 
[Zn(Cl)2(dpma)] discussed in Chapter 2 showed that these two ligands have similar 
interplanar angles between their two pyridyl rings, and this would seem to correlate 
with their pKa values (Table 5.1).  
 
Table 5.1: Experimentally found pKa values and interplanar angles for dpHa, dpma 
and dpea 
Ligand pka Interplanar angle in Zn complex / ° 
dpHa 6.9(0.0) 174.5 
dpma 5.3(0.0) 148.5 
dpea 5.3(0.0) 138.7 
 
With the py-dpHa-CN ligand, there are several sites which potentially can be 
protonated or deprotonated including the central amine, the two pyridyl nitrogen 





Figure 5.7: Sites of py-dpHa-CN that could be protonated or deprotonated  
Comparison of the UV-vis spectra at varied pH values show that at the pH increases 
from 3 to 6, the absorbance at 336 nm decreases whilst undergoing a bathochromic 
shift to 338 nm. Above pH 6, the absorbance at 338 nm continues to decrease and the 
λmax shifts to 342 nm whilst the absorbance at 295 nm increases (Figure 5.7).  




















































Figure 5.8: UV-vis spectra at varying pH of the py-dpHa-CN between pH 3 and 6 
(left) and pH 6.5 and 10.5 (right) in water 
Plotting the absorbance at 295 and 338 nm against pH shows that the pKa values for 
































Inflection point = 4.4
 


























Inflection point = 8.5
  
Figure 5.9: Sigmoidal fits for the py-dpHa-CN ligand for the absorbance at 336 nm 
between pH 3 and 6.5 (left) and absorbance at 295 nm between pH 6 and 10.5 (right) 
in water 
These two processes most likely to correspond to the deprotonation of the pyridyl 
nitrogens or central amine, as pyrrolidines are characteristically highly basic in 
nature (Scheme 5.3).
155
 Therefore the pKa of the pyrrolidinium appears to high to 
measure, which would go some way to explain the lack of success in the attempts to 




















5.1.1.2. pKa determination of 1,4-N-oxide ligands 
The 1,4-N-oxide ligands tpzH, tpzH-CN and tpzH-CONH2 all absorb strongly in the 
UV region and in the visible region between 430 and 475 nm due to a π- π* 
transition.
180
 This band in the visible region was used to monitor the titrations as its 




band between 500 and 560 nm increases. In the case of tpzH and tpzH-CN this 
corresponds to a colour change from yellow to purple (Figure 5.6). 
 
Figure 5.10: The colour change which occurs upon deprotonation of tpzH and tpzH-
CN (tpzH-CN shown) in water 
When titrating OH¯ into a solution of tpzH, no change is observed in the absorbance 
of the UV-vis spectrum until pH 10. Above this pH, the absorbance at 461 nm 
decreases whilst the absorbance at 535 nm increases (Figure 5.7). The absorbance at 
535 nm increases beyond the pH that can be measured accurately (pH 12), but the 
obtained data affords an approximate pKa value of 12.6(0). This pKa value is most 
likely to correspond to the deprotonation of the amine (Scheme 5.4). 





















































Figure 5.11: UV-vis spectra at varying pH of tpzH (left) and absorbance of tpzH at 




















Scheme 5.4: Deprotonation of tpzH 
The tpzH-CN ligand displays similar pH-dependent behaviour, showing no change 
in absorbance until above pH 9. Above this pH, the colour of the solution changes 
from orange to purple corresponding to a decrease in absorbance at 470 nm and an 
increase at 560 nm (Figure 5.8). Plotting the change in absorbance at 560 nm against 
pH gives a pKa value of 10.6(0). 

























































Inflection point = 10.6
 
Figure 5.12: UV-vis spectra at varying pH of tpzH-CN (left) and absorbance of 
tpzH-CN at 560 nm against pH (right) in water. 
Similarly, the absorbance of tpzH-CONH2 remained unaltered until ca. pH 10.5, 
when the absorbance at 430 nm decreases and increases at 490 nm (Figure 5.9). 
However, the change in absorbance is not as pronounced with this ligand as for tpzH 
and tpzH-CN, with the colour becoming slightly darker rather than turning purple. 
































    
























Inflection point = 11.9
 
Figure 5.13: UV-vis spectra at varying pH of tpzH-CONH2 (left) and its absorbance 
at 490 nm against pH (right) in water 
 
The pKa values of the N-oxide ligands are summarised in Table 5.2. 






5.1.2. Determining the pH stability of dipyridylamine complexes 
5.1.2.1. Cobalt(II) and zinc(II) complexes of dpHa 
With complexes of labile metal centres intended for use in biological systems, it is 
important to examine their stability in aqueous solution in addition to understanding 
the protonated state of the ligand. If a complex dissociates in aqueous solution to 
give an aqua species then it is not suitable to put into biological media where, in 
addition to water, there are many chelating agents. 
Upon addition of OH¯ to an acidified solution of [Co(Cl)2(dpHa)] the absorbance at 
250, 285 and 320 nm decreases whilst an increase occurs at 262 and 300 nm (Figure 
5.10). Plotting the change in absorbance at 262 nm against pH produces a single 
sigmoidal curve with a pKa value of 6.7, similar to that obtained for dpHa which 




























      





























Inflection point = 6.7
 
Figure 5.14: UV-vis spectra at varying pH of [Co(Cl)2(dpHa)] (left) and absorbance 
at 262 nm against pH overlaid with the absorbance of dpHa (right) in water 
The UV-vis spectra obtained during the titration of [Zn(Cl)2(dpHa)] show similar 
behaviour to the cobalt(II) complex (Figure 5.11). At pH 3, the solution absorbs at 
250, 285 and 320 nm. As the pH increases, the absorbance at these wavelengths 
decreases whilst the absorbance at 262 and 310 nm increases. Plotting the 
absorbance of the solution at 262 nm against pH affords a single sigmoidal curve 
which gives a pKa value of 6.7(0). 
























































Inflection point = 6.7
 
Figure 5.15: UV-vis spectra at varying pH of [Zn(Cl)2(dpHa)] (left) and absorbance 
at 262 nm against pH overlaid with the absorbance of dpHa (right) in water 
 
When titrating [Co(Cl)2(dpHa)] it was observed that above pH 8.5, a brown 
precipitate formed and when titrating [Zn(Cl)2(dpHa)] a white precipitate formed 
above pH 7.5. It was suspected that these precipitates were the result of the 
formation of metal hydroxo species so to try and confirm this, the respective metal 




The curves produced from the metal chloride salts have similar inflection points to 
those obtained from the second pKa process of the complexes, supporting the 
hypothesis that the deprotonation of aqua ligands is being observed. 
 










Inflection point = 8.8
Inflection point 
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Figure 5.16: Overlay of [Co(Cl)2(dpHa)] and CoCl2.6H2O (left) and overlay of 
[Zn(Cl)2(dpHa)] and ZnCl2 (right) in water 
5.1.2.2. Copper(II) complexes of dpHa 
The UV-vis spectra of [Cu(Cl)2(dpHa)] shows that as the pH is increased from 2.5 to 
6.3, there is an increase in absorbance at 300 nm and a decrease at 318 nm (Figure 
5.13). Above pH 6, the absorbance at 300 and 313 nm increases.  
 
Figure 5.17: UV-vis spectra at varying pH of [Cu(Cl)2(dpHa)] between pH 2.5 and 
pH 6.0 (left) and between pH 6.0 and pH 10.0 (right) in water 
Plotting the absorbance at 300 nm against pH for the first process between ca. pH 




(Figure 5.14). The absorbance between pH 5.5 and 10 gives a second sigmoidal 
curve with a pKa of 7.4(0). 
 

































Inflection point = 7.0























Inflection point = 4.0
 
Figure 5.18: Absorbance of [Cu(Cl)2(dpHa)] at 300 nm against pH between pH 2.5 
and 6 (left) and between pH 5.5 and 10 (right) in water 
As the second process, which occurs above pH 5.5, appears to have no isosbestic 
point, there was concern that the change in absorbance was due to a form of ligand 
exchange such as an alteration in the number of coordinated chlorides rather than a 
deprotonation. To rule out this possibility, [Cu(NO3)2(dpHa)] was titrated, using 
HNO3 as the acid to acidify the solution rather than HCl. In the absence of chloride, 
a similar change in absorbance is observed. As the pH is increased from pH 3, the 
absorbance at 317 nm decreases, whilst an increase is observed at 299 nm.  



















































Figure 5.19: UV-vis spectra at varying pH of [Cu(NO3)2(dpHa)] between pH 3 and 6 




The absorbance at 300 nm between pH 3 and 5 affords a sigmoidal curve which 
gives a pKa value of 3.7(0). 
























Inflection point = 6.9
 
Figure 5.20: Absorbance of [Cu(NO3)2(dpHa)] at 299 nm between pH 3 and 5 (left) 
and between pH 4 and 10 (right) in water 
Both of the copper(II) complexes display the increased absorbance above pH 6 
which corresponds to a process which has no isosbestic point. As this was found to 
occur in the absence of chloride ions, it is not a process which can be attributed to a 
change in the number of chlorides coordinated to the copper(II) centres. 
The similarity between the spectra of all three of the metal(II) complexes with that of 
dpHa at pH 3 suggests that at this pH, the dpHa ligand has dissociated (Figure 5.20). 
At pH 7 and 9, the complexes of cobalt(II) and zinc(II) still have UV-vis spectra 
which match that of the free ligand, which along with having similar pKa values to 
free dpHa implies that these metal(II) complexes dissociate in aqueous solution. 



























Figure 5.21: Overlay of the aqueous UV-vis spectra of dpHa, [Co(Cl)2(dpHa)], 
[Cu(Cl)2(dpHa)] and [Zn(Cl)2(dpHa)] at pH 3, 7 and 9 
As the two copper(II) complexes both have UV-vis spectra which, above pH 5, differ 
to that of the free ligand, it suggests that the dpHa remains coordinated in aqueous 
solution. This trend in stability of the copper(II) complexes over those of the cobalt 
(II) and zinc(II) is described by the Irving Williams series, which shows that the 




the first row of d-block with copper(II) having the greatest formation constant owing 
to additional stability arising from Jahn-Teller distortion.
181
  
5.1.2.3. Copper(II) complexes of dpRa 
The alkylated copper(II) complexes were titrated in order to help identify the 
protonation process observed with the copper(II) dpHa complexes, as the alkylation 
removes the possibility of deprotonation at the central amine. 
When the pH of a solution of [Cu(Cl)2(dpma) was increased from pH 3, it was 
observed that the absorbance at 310 nm blue-shifted to 302 nm at pH 5.5 (Figure 
5.25). Above pH 5, the absorbance at 302 nm increased in a manner similar to that 
observed for the copper(II) dpHa complexes. 



















































Figure 5.22: UV-vis spectra at varying pH of [Cu(Cl)2(dpma)] between pH 2.5 and 
pH 5.5 (left) and between pH 5 and pH 9 (right) in water 
Both of these processes can be fitted to a single sigmoidal curve to afford pKa values 
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Inflection point = 7.4
 
Figure 5.23: Absorbance of [Cu(Cl)2(dpma)] at 302 nm against pH between pH 2.5 
and 5.5 (left) and between pH 5.5 and 9 (right) in water 
As the pH of a solution of [Cu(Cl)2(dpea)] is increased from pH 3, the absorbance at 
316 nm decreases as the absorbance at 302 nm increases (Figure 5.27). Beyond pH 
5, the absorbance increases but no isosbestic point is found upon overlaying the 
spectra.  






















































Figure 5.24: Absorbance of [Cu(Cl)2(dpea)] between pH 3 and 5 (left) and pH 5 and 
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Inflection point = 5.9
 
Figure 5.25: Absorbance of [Cu(Cl)2(dpea)] at 302 nm against pH between n pH 2.5 
and 5 (left) and pH 5 and 9 (right) in water 
A sigmoidal curve can be fitted to a curve from both processes obtained by plotting 
the absorbance at 302 nm against pH, affording pKa values of 4.1(1) and 5.9(0) 
(Figure 5.28). 




Complex pKa (1) pKa (2) 
CuCl2.2H2O  7.0(1) 
[Cu(dpHa)(H2O)2]
2+
  6.74 
[Cu(Cl)2(dpHa)] 4.0(0.0) 7.4(0.0) 
[Cu(NO3)2(dpHa)] 3.7(0.0) 6.9(0.0) 
[Cu(Cl)2(dpma)] 3.5(0.0) 7.4(0.0) 
[Cu(Cl)2(dpea)] 4.1(1) 5.9(0.0) 
 
All the copper(II) dipyridylamine type complexes were observed to undergo two 
processes; one between pH 3 and 4 and the other between pH 6 and 7.5. The second 









to under a deprotonation process at 7.0(1) suggests that the complexes all undergo a 
certain degree of aquation when in aqueous solution. The similarity of the UV-vis 
spectra at lower pH values of the complexes when compared to their respective free 
ligand suggests that at this pH, the complex is dissociated.  
              
Figure 5.26: Overlay of the aqueous UV-vis spectra of the dpea (left) and dpma 
(right) with their copper(II) complexes at pH 3 (from top), pH 6 and pH 9 
5.1.2.4. Cobalt(III) complexes of dpRa ligands 
As complexes of cobalt(III) are considered to be kinetically inert, it was expected 




As the pH is increased from 2.5 to 5, the absorbance of [Co(CO3)(dpHa)2]
+
 at 300 
nm increases (Figure 5.29). Above pH 8, the solution becomes darker in colour as 
the absorbance at 300 nm decreases whilst the absorbance at 377 nm increases. 
























































Figure 5.27: pH dependence of the absorption spectra of [Co(CO3)(dpHa)2]
+
 
between pH 2.5 and pH 6.5 (left) and between pH 8 and pH 11 (right) in water 



























Inflection point = 2.6
 



























Inflection point = 10.3
 
Figure 5.28: Absorbance of [Co(CO3)(dpHa)2]
+
 against pH between pH 2.5 and pH 
6 (left) and between pH 7.5 and pH 12 (right) in water 
With the N-methylated complex [Co(Cl)2(dpma)2]
+
, no change in absorbance is 




































The cobalt(III) dpHa complex has, in addition to the two secondary amine ligands 
which can undergo deprotonation, a carbonato ligand which can be protonated to 
form bicarbonate. There are known examples of cobalt(III) bicarbonate complexes 
where the other ligands are pyridyl in character which were found to be kinetically 
stable under acidic conditions.
183, 184
 Although spectral evidence was not obtained to 
confirm the formation of a bicarbonate complex, the stability the complex showed in 
acidic solution as monitored by 
1
H NMR spectroscopy is similar to that of reported 
cobalt(III) bicarbonate complexes which have pyridyl ligands (Figure 5.30). It can 
be seen that after 48 hours, the peaks start to broaden, and by 72 hours, the sample 
contains a mixture of species. Although spectral evidence was not obtained to 
confirm the formation of a bicarbonate complex, the stability the complex showed in 
acidic solution as monitored by 
1
H NMR spectroscopy is similar to that of reported 
cobalt(III) bicarbonate complexes which have pyridyl ligands (Figure 5.30). It can 
be seen that after 48 hours, the peaks start to broaden, and by 72 hours, the sample 








H NMR (400 MHz, D2O) of [Co(CO3)(dpHa)2]
+
 before addition of 
HCl (spectrum a), then at time intervals after acidification; 24 hours (spectrum b), 48 
hours (spectrum c) and 72 hours (spectrum d). 
 
5.1.3. Titrations of metal(II) homoleptic N-oxide complexes 
The bis-N-oxide complexes were found to be insoluble in water. Due to the poor 
solubility of these complexes, it was not possible to have the solutions concentrated 
enough to enable accurate absorbance measurements of the band at ca. 520 nm of the 
coordinated ligand. The homoleptic complexes of all three N-oxide ligands had to be 
pre-dissolved in DMSO in-order to prepare their aqueous solutions. It was found that 
if starting at an acidic pH, only the free ligand was present but as the pH was 
increased, the bis-N-oxide complex formed and precipitated out of solution. The 
titrations of these complexes were subsequently carried out starting with a higher pH 
value titrating downwards to a more acidic pH. It was also found that the complexes 
of cobalt(II) and zinc(II) dissociated in aqueous solution of any pH value, evident by 
only the absorbance of the uncoordinated N-oxide ligand being observed. 




Addition of acid to a neutral solution of [Cu(tpz)2] causes the absorbance at 534 nm 
to decrease whilst the absorbance at 274, 354 and 460 nm increases (Figure 5.31). A 
single sigmoidal curve can be fitted to the absorbance at 460 nm when it is plotted 
against pH, providing a pKa value of 2.6(0). 















































Inflection point = 2.6
 
Figure 5.31: UV-vis spectra at varying pH of [Cu(tpz)2] (left) and absorbance at 460 
nm plotted against pH (right) in water 
When the pH of a solution of [Cu(tpz-CN)(dpHa)]Cl is decreased from pH 7, the 
absorbance at 275 and 470 increases whilst decreasing at 550 nm. A single sigmoidal 
curve can be fitted to the absorbance at 275 nm when it is plotted against pH, 
providing a pKa value of 2.4(0) (Figure 5.32). 




























   

























Inflection point = 2.4
 
Figure 5.32: UV-vis spectra at varying pH of [Cu(tpz-CN)2] (left) and absorbance at 
470 nm plotted against pH (right) in water 
[Cu(tpz-CONH2)2] shows similar behaviour to the other complexes when the pH of 
the solution is altered. As the pH is decreased, the absorbance at 296 and 530 nm 




sigmoidal curve can be fitted to the absorbance at 265 nm when it is plotted against 
pH, providing a pKa value of 2.2(1). 

















































Inflection point = 2.2
 
Figure 5.33: UV-vis spectra at varying pH of [Cu(tpz-CONH2)2] (left) and 
absorbance at 265 nm plotted against pH (right) in water 
It can be seen from Table 5.4, it can be seen that copper(II) bis-N-oxide complexes 
of this type dissociate when the pH is lowered to ca. 2.4. This dissociation is 
presumably caused by the amine of the N-oxide ligand becoming reprotonated, 
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5.1.4. Titrations of heteroleptic metal N-oxide complexes 
5.1.4.1. Titrations of heteroleptic metal(II) N-oxide complexes 
Out of the metal(II) heteroleptic complexes, only those of tpzH were found to be 
readily water soluble. However, these complexes were all found to be readily soluble 
in MeOH so were pre-dissolved in this solvent before being added to the aqueous 
solution, enabling their aqueous chemistry to be studied It was again found that only 
the copper(II) complexes remained associated in aqueous solution. It was found that 
the copper(II) complexes formed red coloured solutions until the required amount of 
acid was added for the complex to dissociate, where upon the solution turned yellow 
due to the absorbance of the free ligand (Figure 5.34).  
 
Figure 5.34: Aqueous solution of [Cu(tpz-CN)(dpHa)]Cl (left) and after addition of 
acid which causes the N-oxide ligand to dissociate (right). 
When the pH of a neutral aqueous solution of [Cu(tpz)(dpHa)]Cl is decreased, the 
absorbance at 463 nm increases whilst the absorbance at 520 nm decreases (Figure 
5.35). Plotting the absorbance at 463 nm against pH affords a pKa value of 5.4. 
























































Inflection point = 5.4
 
Figure 5.35: UV-vis spectra at varying pH of [Cu(tpz)(dpHa)]Cl (left) absorbance at 
463 nm plotted against pH (right) in water 
With [Cu(tpz-CN)(dpHa)]Cl, the absorbance at 470 nm increases and decreases at 
505 nm when the pH of a neutral solution is lowered (Figure 5.36). Fitting a 
sigmoidal curve to the absorbance at 470 nm plotted against pH affords a pKa value 
of 5.0(0). 


















































Inflection point = 5.0
 
Figure 5.36: UV-vis spectra at varying pH of [Cu(tpz-CN)(dpHa)]Cl (left) and 
absorbance at 470 nm against pH (right) in water 
At neutral pH, [Cu(tpz-CONH2)(dpHa)]Cl absorbs at 467 nm with a shoulder at 533 
nm. As the pH is decreased, the absorbance at these wavelengths decreases as the 
absorbance at 430 nm increases (Figure 5.37). Fitting a sigmoidal curve to the 






















































Inflection point = 5.8
 
Figure 5.37: UV-vis spectra at varying pH of [Cu(tpz-CONH2)(dpHa)]Cl (left) and 
absorbance at 430 nm plotted against pH (right) in water 
Table 5.5 shows that the N-oxide ligand dissociates from complexes of the type 
[Cu(tpzR)(dpHa)]
+
 between pH 5 and 6. Less acidic conditions are therefore required 
to facilitate dissociation of the N-oxide ligand from the heteroleptic complex than 
from the homoleptic complex which dissociated between pH 2 and 3.  
Table 5.5: pH values at which the [Cu(tpz-R)(dpHa)]Cl complexes dissociate 





5.1.4.2. Titrations heteroleptic cobalt(III) N-oxide complexes 
The cobalt(III) heteroleptic complexes would be expected to be kinetically stable 
against ligand dissociation upon acidification. No change in absorption was noticed 
with any of the three cobalt(III) complexes until above ca. pH 9.5. Above this pH, a 
shoulder on the band at ca. 500 nm would form at 600 nm (Figure 5.38). This 
process was found to be non-reversible as the addition of acid did not result in a 




















































Inflection point = 10.1
 
Figure 5.43: UV-vis spectra at varying pH of [Co(tpz)(dpHa)2]
2+
 (left) and 
absorbance at 600 nm plotted against pH (right) in water 
5.1.5. Conclusions 
In terms of solution stability, all of the cobalt(II) and zinc(II) complexes of both 
dpRa and tpzH-R ligands were found to dissociate in aqueous solution. All of the 
copper(II) complexes investigated were found not to dissociate in aqueous solution. 
This increase in stability agrees with the trend in stability of metal(II) complexes 
described by the Irving-Williams series, which shows a general increase in ligand 
affinity moving across M
2+
 first row d-block ions from left to right.
8
 The cobalt(III) 
complexes were found to be stable in aqueous solution due to the characteristic 
kinetic and thermodynamic stability of this ion’s +3 oxidation state.  
A deprotonation process was observed to occur in uncoordinated dpHa with a pKa of 
6.9, which was found to involve the loss of one proton. It is still unclear if this 
process corresponds to the deprotonation of the amine or the pyridinium ion. 
Alkylation of the central amine with a methyl or ethyl substituent resulted provided 
dpRa type ligands which were observed to undergo a deprotonation process with a 
pKa of 5.3.  With the dpRa type ligands, it was observed that altering the substituent 
on the central amine affected the pKa of the ligand’s pyridinium ion. It was found 
that the altered pKa might be attributed to the influence exerted by the steric bulk of 
the amine’s substituent on the interplanar angle between the two pyridyl rings. As 
the steric bulk of the substituent is increased, the planar angle between the two 
pyridyl rings is increased, resulting in poorer stabilisation of the pyridinium proton 




The amine groups of the N-oxide ligands were found to have pKa values above pH 
10. The deprotonation of tpzH and tpzH-CN resulted in dramatic changes to their 
UV-vis absorbance spectra correlating with a colour change from orange-yellow to 
deep purple. The purple coloured species was found to form an orange-yellow 
coloured species which had different UV-vis spectra to the original ligands. With the 
tpzH-CN ligand, the new species has a similar UV-vis spectrum to that of tpzH-
CONH2, indicating that the nitrile group may have undergone hydrolysis under the 
basic conditions. 
The copper(II) dpRa complexes were found to each undergo two proton-dependent 
processes; one at ca. pH 3.5 and the second between pH 6 and 7.5. 
[Cu(dpHa)(H2O)2]
2+
 has been previously reported to undergo a process with a pKa at 
6.7 which was attributed to the deprotonation an aqua ligand.
9
 As CuCl2 was 
observed to undergo a process with a pKa value of 7, the second process observed 
with these complexes seems likely to be the deprotonation of an aqua ligand 
coordinated to the copper(II) centre through the displacement of a chloride ligand.  
The homoleptic tpzH-R copper(II) complexes were found to be more stable towards 
acidic conditions than the heteroleptic complexes. The N-oxide ligands were 
observed to dissociate from the homoleptic complexes at ca. pH 2.5, whereas 
dissociation from the heteroleptic complexes occurred at ca. pH 5.5. The latter is a 
more biologically relevant pH, being near to that which can occur in the extracellular 
environment of hypoxic tumour cells. The difference between the acid stability of 
the homoleptic and heteroleptic complexes suggests that the interaction between the 
metal centre and N-oxide ligand differs upon incorporation of the dpHa ligand. 
5.2. Cyclic Voltammetry 
The technique of cyclic voltammetry allows for the measurement of reduction and 
oxidation potentials of a compound, but also a means of exploring their reversibility. 
The experiment uses a cell which contains three electrodes; a reference electrode 
which carries out the measurement, a working electrode to vary potential and an 
auxiliary electrode which completes the electrical circuit. The potential at the 
working electrode is swept from the starting potential, E0, at which no process takes 
place, to a second potential, E1, which is beyond the potential of the reaction 




starting potential. The current across the working electrode is measured as a function 
of the potential. There are several forms of electron transfer reactions which can take 
place at the electrode, which may be reversible, quasi-reversible or irreversible 




Figure 5.39: Representative cyclic voltammograms of a reversible process (black), a 
quasi-reversible process (red) and an irreversible process (green) 
 
For a reversible reaction, the electron transfer product is at the electrode on the 
reverse scan, so is able to undergo the reverse process and a change of current equal 
to that of the forward scan is observed. A true reversible system is rarely observed, 
and the current on the reverse wave is less than that on the forward scan so is said to 
be a quasi-reversible process. The two main factors which govern the reversibility of 
an electron transfer process are the kinetics of the transfer reaction and the rate of 
diffusion of the electroactive species between the bulk solution and the layer of 
solution surrounding the electrode. Reversible processes have a rate of electron 
transfer which is fast with respect to the scan rate. An irreversible process is when no 
corresponding peak is observed on the reverse scan. A process may be irreversible 
for several reasons. It may be that the product of the electron transfer is highly 
reactive so has all been consumed by another reaction before the reverse reaction 
may occur. The criteria used to assign electrode processes as reversible, irreversible 








Table 5.6: Criteria for reversible, irreversible and quasi-reversible electron transfer 
processes 
Parameter Reversible Quasi-reversible Irreversible 
Eox and Ered  Independant of v Varies with v Eox or Ered observed, varies 
with v 
Δ E  59/n 
Independant of v 
Increases with v No return wave 
Iox / Ired  Iox / Ired = 1 Iox / Ired ≠ 1 No return wave 
Plot of Iox vs. v
1/2
 linear Non-linear Linear 
 
All experiments were carried out under a N2 atmosphere, with the cell and electrodes 
being thoroughly cleaned with a suitable solvent and concentrated HNO3 between 
samples. Experiments in DMSO were carried out using 0.1 M 
n
Bu4NPF6 as the 
supporting electrolyte with the potentials measured between -1.75 0.75 V. Before 
analysis of each of the compounds, a blank sample was run and after analysis of the 
compound, the internal standard was added. For experiments in DMSO, the internal 
standard used was ferrocene (Figure 5.40). Using ferrocene not only acts as an 
internal standard, but provides a means of judging how effectively the cell is 
measuring the redox processes, as indicated by how close the peak separation of the 
Eox and Ered potentials are to the theoretical value of 0.059 V / n (where n is equal to 
the number of electrons transferred). Experimentally, a peak separation which is 























E = 0.077 V
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Figure 5.40: Cyclic voltammogram of ferrocene in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 supporting electrolyte) at 100 mV s
-1
 
Aqueous experiments were carried out using KCl as the supporting electrolyte and 
K3[Fe(CN)6] as the internal standard. The literature values for the internal standards 
used are provided in Table 5.7. 
Table 5.7: Literature electrode potentials for internal standards.
188
 
Redox process E1/2 / V 
Fc
+







Electrode potentials are reported vs. Ag/AgCl, but are converted to vs. NHE when 
required for the purposes of comparison with potentials reported in the literature 














Reference electrode E° vs NHE / V   E° vs SCE / V 
NHE 0 -0.2412 
SCE 0.2412 0 
Ag/AgCl 0.197 -0.0450 
 
 
5.2.1. Electrochemical properties of the ligands 
All the ligands were examined in DMSO solution. It was found that the dpRa ligands 
had no observable redox processes occurring in the potential range used. There has 
been much in the literature on the redox chemistry of tpzH and derivatives of its 
similar analogue tpzH-CN (Figure 5.41 and Table 5.9), with many studies 









Figure 5.41: Structures of tpzH-CN derivatives discussed in Table 5.9 
The cyclic voltammograms of these two ligands were obtained and found to be 












 Reduction potential / V vs NHE 
R Ered(1) Ered(2) Ered(2)-Ered(1) 
H -0.65 -0.785  
Cl -0.82 -0.97 0.15 
Br -0.76 -0.89 0.13 
Me -0.84 -0.97 0.13 
 
The tpzH ligand has peaks associated with reductive processes at -0.977, -1.181 and 
-1.300 V. On the return sweep, some poorly defined oxidative processes are 
observed at -1.427 and -1.109 with two more clearly defined processes at 0.326 and 
0.514 V (Figure 5.42). 
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Figure 5.42: Cyclic voltammogram of tpzH in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 supporting electrolyte at varied scan rates (from 20 to 800 mV s
-1
) 
For tpzH-CN, reductive processes are observed at -0.855 and -0.990 V, whilst 
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Figure 5.43: Cyclic voltammogram of tpzH-CN in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 supporting electrolyte at varied scan rates 
It has been hypothesised that the first reductive process is due to the reduction of one 
of the N-oxide groups at -0.855 V, quickly followed by it reacting with the DMSO 



























Scheme 5.6: Distribution of products upon reduction of tpzH-CN by NADPH 





Gates and co-workers reported that when reduced by NADPH cytochrome P450 
reductase, the most likely species to be formed has the radical at the 2 position 
(Scheme 5.6) rather than the 4-position.
189
 This is due to the nitrile group being 
better at stabilising the radical species than the amine because of the conjugation 













Scheme 5.7: Resonance stabilisation of the radical tpzH-CN species provided by the 
nitrile group 
The redox chemistry of tpzH-CONH2 is yet to be reported. The ligand undergoes 
reductive processes at -0.831 V, -0.977 V and -1.246 V. On the reverse scan, 
oxidation processes are observed at -0.907 V and 0.252 V. Running the potential 
sweep between -0.6 and -1.1 V does not provide evidence for the oxidation at -0.907 
V to be the reverse process for the reduction at -0.977 V. 
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Figure 5.44: CV of tpzH-CONH2 in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 




Like the tpzH-CN ligand, the N-oxide most likely to be reduced first is the one in 2-
position, adjacent to the amide group. Table 5.10 summarises the reduction potential 
of these ligands. It can be seen that tpzH-CN and tpzH-CONH2 were both found to 
undergo a reduction between -0.84 and -0.86 V with all three ligands undergoing a 
process at ca. -0.98 V. 
 
Table 5.10: Comparison of reduction potentials in dmso (values quoted as vs. 
Ag/AgCl at 100 mV s
-1
 with ferrocene as internal standard) 
 Ered (1) / V Ered (2) / V Ered(3) / V 
tpzH  -0.976 -1.177 
tpzH-CN -0.855 -0.988  
tpzH-CONH2 -0.835 -0.978  
 
 
5.2.2. Electrochemical properties of dpRa complexes 
As this project is concerned with investigating the use of transition metal complexes 
as bioreductive prodrugs, it is important to obtain an understanding of their reductive 
chemistry so that it can be hypothesised which reducing agents may act upon them in 
biological systems. It is also beneficial if their reductions are found to be reversible, 
as this is believed to aid selectivity for hypoxic cells if the reduced species can be 
oxidised back to the prodrug species in the presence of oxygen. [Cu(dpHa)2]Cl2 
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Figure 5.45: Cyclic voltammogram of [Cu(dpHa)2]2Cl in H2O (0.001M with 
0.1 M KCl supporting electrolyte) at varied scan rates 
By looking at the parameters of these electron transfer processes, it can be seen that 
the reduction is quasi-reversible, shown by Iox / Ired having a value of 1, and ΔE 
having a separation of 110 to 170 mV (see appendix 5.) This process is probably 
due to the reduction and subsequent oxidation of the copper centre, and the quasi-
reversible nature of the process indicates that the complex does not undergo 
immediate dissociation upon reduction. 
No clear cyclic voltammograms of the neutral copper(II) dpHa complexes could be 
obtained so these were studied in DMSO solution. [Cu(NO3)2(dpHa)] shows 
reductive processes at 0.010 and -0.226V, the former of which is not clearly defined 
and  becomes less distinct with increasing scan rate (Figure 5.46). An oxidative 
process is observed at 0.238 V and the shape of it implies a species which has 
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Figure 5.46: Cyclic voltammogram of [Cu(Cl)2(dpHa)] in DMSO (0.001M with 0.1 
M 
n
Bu4NPF6 supporting electrolyte) at varied scan rates.  
[Cu(Cl)2(dpma)] in DMSO undergoes reductive processes at -0.11 and -0.48 V and 
oxidative processes at -0.0754, 0.2034 and 0.4184 V (Figure 5.47). 
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Figure 5.47: Cyclic voltammogram of [Cu(Cl)2(dpma)] in DMSO (0.001M with 0.1 
M 
n
Bu4NPF6 supporting electrolyte at varied scan rates 
The [Co(CO3)(dpHa)2]
+
 complex undergoes a reduction at -0.185 V, with no 
oxidative processes observed on the return scan (Figure 5.48). This most likely 
corresponds to the one electron reduction of cobalt(III) to cobalt(II). Reasons for the 
lack of the reversibility of this reduction can be partially explained using the 
observations described in Chapter Two, where it was found that in solvents other 




concurs with the many reported cobalt(III) reductions in the literature being 
irreversible owing to the chemical changes which characteristically occur upon 
reduction to the more labile cobalt(II).
191
 













 50 mV s
-1
 100 mV s
-1
 150 mV s
-1
 200 mV s
-1
 250 mV s
-1
 300 mV s
-1
 350 mV s
-1
 400 mV s
-1
 450 mV s
-1
 500 mV s
-1
 550 mV s
-1













Figure 5.48: Cyclic voltammogram of [Co(CO3)(dpHa)2]
2+
 in DMSO (0.001M with 
0.1 M 
n
Bu4NPF6 supporting electrolyte) at 100 mV s
-1 
Table 5.11 summarises the reduction potentials obtained for the dpRa complexes. 
Copper(II) complexes of this ligand undergo a reduction at ca. -1.0 V. These values, 
when compared to those of the hypoxia selective complex [Cu(ATSM)] and its non-
selective analogue [Cu(PTSM)] (-0.59 and -0.51 V, respectively),
87
 would appear not 
to be negative enough in value to bring about hypoxia selective reduction. 
 
Table 5.11: Summary of dpRa complex reduction potentials 
Complex Solvent Ered / V vs. Ag / AgCl 
[Cu(dpHa)2]
2+
 H2O -0.08 V 
[Cu(NO3)2(dpHa)] DMSO 0.010 
[Cu(Cl)2(dpHa)] DMSO -0.11 
[Co(CO3)(dpHa)2]
2+




5.2.3. Electrochemical properties of N-oxide complexes 
5.2.3.1. Electrochemical properties of homoleptic N-oxide complexes 
All the copper(II) complexes analysed show several reductive processes, many of 
which can be attributed to the redox-rich chemistry of the ligands. [Cu(tpz)2] 
undergoes reductive processes at -0.75, -0.93 and -1.18 V and then several poorly 
defined oxidative peaks are ca. -1.0, 0.25 and 0.48 V (Figure 5.49). None of the 
reductive processes show any degree of reversibility. 
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Figure 5.49: Cyclic voltammogram of [Cu(tpz)2] in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 supporting electrolyte at varied scan rates 
The [Cu(tpz-CN)2] complex undergoes three irreversible reductions at -0.35, -0.69, -
0.85 and -1.06 V. On the reverse scan, it undergoes three oxidative processes at -
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Figure 5.50: CV of [Cu(tpz-CN)2] in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 
supporting electrolyte at varied scan rates 
The solubility of the [Cu(tpz-CONH2)2] complex was too poor to allow for CV 
experiments to be carried out. When pre-dissolved in DMSO, it precipitated out of 
the electrolyte solution over too short a time interval to allow measurements to be 
made. The two copper(II) complexes were observed to undergo a number of 












5.2.3.2. Electrochemical properties of heteroleptic N-oxide complexes 
The [Cu(tpz)(dpHa)]Cl complex undergoes four irreversible reductions at -0.40, -
0.79, -0.985 and -1.24 V, and then oxidative processes at -1.077, 0.194 and 0.517 V 
on the return sweep.  
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Figure 5.51: CV of [Cu(tpz)(dpHa)]Cl in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 
supporting electrolyte at varied scan rates 
Table 5.12 compares the reduction potentials found for tpzH, [Cu(tpz)2] and 
[Cu(tpz)(dpHa)]Cl. It can be seen that both the homo- and heteroleptic complexes 
undergo a reduction at ca. -0.77 V, but only the heteroleptic complex undergoes a 
reduction at a less negative potential than this at -0.4 V. Both complexes and the free 
ligand undergo reduction at ca. -0.95 and -1.2 V, implying these are both processes 
based on the ligand with little effect from the metal. 
Table 5.12: Reduction potentials of tpzH, [Cu(tpz)2] and [Cu(tpz)(dpHa)]Cl 
Compound Ered / V 
tpzH   -0.98 -1.18 
[Cu(tpz)2]  -0.75 -0.93 -1.18 




The cyclic voltammogram of [Cu(tpz-CN)(dpHa)]Cl shows reductive processes 
occurring at -0.31, -0.66, -0.84 V, -1.04 and-1.35 V and oxidations at -1.24, -0.99 
and 0.44 V on the reverse scan (Figure 5.52). 






100 Scan rate / mV s
-1
       20
       50
       75
       100
       150
       200
       250
       300
       400
       500
       600
       700












Figure 5.52: CV of [Cu(tpz-CN)(dpHa)]Cl in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 
supporting electrolyte at varied scan rates 
Table 5.13 shows the reduction potentials found for the tpzH-CN complexes and 
free ligand. The two complexes and free ligand again show similarity in their 
behaviour above -0.8V by undergoing two reductive processes at comparable 
potentials, implying these are ligand based processes. Both the homo- and 
heteroleptic complexes undergo reduction at ca. -0.33 and -0.67 V, suggesting that 
these are a result of coordination. 
Table 5.13: Reduction potentials of tpzH, [Cu(tpz-CN)2] and [Cu(tpz-CN)(dpHa)]Cl 
Compound Ered / V 
tpzH-CN   -0.86 -0.99 
[Cu(tpz-CN)2] -0.35 -0.69 -0.85 -1.06 





The [Cu(tpz-CONH2)(dpHa)]Cl complex undergoes reductions at -0.397, -0.781, -
0.959, -1.180 and, -1.154 V, with oxidations at -1.361, -0.174 V and 0.436 V on the 
reverse scan followed by a reduction at 0.107 V (Figure 5.53). 
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Figure 5.53: CV of [Cu(tpz-CONH2)(dpHa)]Cl in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 supporting electrolyte at varied scan rates  
The three heteroleptic copper(II) complexes all display similar redox behaviour in 
DMSO (Table 5.14), with three reductive processes centred around -0.35, -0.70 and 
-0.9 V. The latter two appear to be due to reductions occurring on the ligand, whilst 
the processes at ca. -0.35 V can tentatively be assigned as the reduction of the 
copper(II) centre. If this assignment is correct, then this is a reduction potential 
which is more suited to hypoxia selectivity than those found for the copper(II) dpHa 
complexes. 
Table 5.14: Summary of reduction potentials for [Cu(tpz-R)(dpHa)]Cl complexes in 
DMSO 
 Ered(1) / V Ered(2) / V Ered(3) / V 
[Cu(tpz)(dpHa)]Cl -0.404 -0.792 -0.985 
[Cu(tpz-CN)(dpHa)]Cl -0.314 -0.655 -0.828 





The three cobalt(III) heteroleptic complexes were all found to undergo irreversible 
reduction. [Co(tpz)(dpHa)2]Cl2 undergoes reduction at -0.056 and -0.946 V (Figure 
5.54). 
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Figure 5.54: CV of [Co(tpz)(dpHa)2]Cl2 in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 
supporting electrolyte at varied scan rates.  
[Co(tpz-CN)(dpHa)2]Cl2 undergoes reduction at -0.002 and -0.876 V, with a 
shoulder on the peak of the latter at -0.712 V (Figure 5.55). 
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Figure 5.55: CV of [Co(tpz-CN)(dpHa)]Cl2 in DMSO (0.001M with 0.1 M 
n




[Co(tpz-CONH2)(dpHa)2]Cl2 undergoes reduction at -0.447, -0.963 and -1.273 V 
(Figure 5.56). 
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Figure 5.56: CV of [Co(tpz-CONH2)(dpHa)]Cl2 in DMSO (0.001M with 0.1 M 
n
Bu4NPF6 supporting electrolyte at varied scan rates. 
All three of the cobalt(III) complexes share a reductive process centred around -0.9 
V which were found to be irreversible in nature. These reduction potentials are more 
negative than the range suggested by Reisner (-0.30 to -0.70 V vs. Ag/AgCl) for 
hypoxia-selective cobalt(III) complexes.
192
 A reduction potential that is too negative 
could place the complex beyond the capability of biological reagents within the cell 
whereas a complex has a reduction potential less negative than this range may 
undergo reduction too easily for any degree of hypoxia-selective cytotoxicity to be 
obtained.  
For copper(II) complexes, the results from [Cu(atsm)] studies have shown that its 
superior selectivity for hypoxic cells over its analogues is a result of its more 
reduction potential (-0.57 V vs. Ag/AgCl). [Cu(tpz)2] was observed to undergo its 
first reductive process at -0.75 V vs. Ag/AgCl whilst [Cu(tpz-CN)2] was found to 
undergo a reduction at -0.35 then a second process at -0.69 V vs Ag/AgCl. On the 
basis of these results, the homoleptic copper(II) tpzH complex should show the 




The heteroleptic copper(II) complexes all undergo a reductive process within the 
range of -0.314 to -0.404 V vs. Ag/AgCl, with [Cu(tpz)(dpHa)]Cl having the most 
negative reduction potential. This suggests that [Cu(tpz)(dpHa)]Cl should be the 
most resistant to reduction under normoxic conditions out of the three complexes. 
However, the study by Robins showed that a copper(II) N-mustard with a reversible 
reduction potential of -0.212 V vs. Ag/AgCl exhibited a degree of hypoxia selectivity 
whereas related copper(II) complexes with more negative but irreversible reduction 
potentials did not demonstrate any selectivity.
102
 
The copper(II) complex which appears most promising in terms of hypoxia 
selectivity, compared to Robins’ N-mustard complex is [Cu(dpHa)2]Cl2, which was 
found to have a quasi-reversible reduction at -0.08 V vs. Ag/AgCl in aqueous 
solution.
102
 Although its reduction potential is unlikely to be negative enough to 
prevent reduction outside of hypoxia, the reversible nature of this process indicates a 
desired stability in the reduced copper(I) complex. 
5.3. Effect of biological reducing agents 
Reductive enzymes hypothesised to have roles in bioreduction of drug molecules 
include cytochrome P450 and DT-diaphorase In addition to these, there are also 
several small molecule reducing agents present such as ascorbic acid, sulphur-
containing amino acids such as cysteine, and other species including glutathione and 
NADPH. From the work described thus far, it has been established that the 
cobalt(III) heteroleptic complexes are stable in aqueous solution, and the cobalt(II) 
complexes undergo ligand dissociation. It has also been demonstrated that the 
coordinated and uncoordinated N-oxide ligands can be distinguished using UV-vis 
spectroscopy. The work discussed presently utilises UV-vis spectroscopy to study 
the effect of biological small molecule reducing agents on [Co(tpz-CN)(dpHa)2]
2+
. 
A 10-fold excess of ascorbic acid was added into a UV-vis cuvette containing an 
aqueous solution of [Co(tpz-CN)(dpHa)2]
2+
. The subsequent series of recorded 
spectra show a decrease in absorbance at 525 nm, corresponding to the cobalt(III) 
complex, and an increase in absorbance at 471 nm, caused by the uncoordinated 



























Figure 5.57: UV-vis spectra monitoring the reaction of excess ascorbic acid with 
[Co(tpz-CN)(dpHa)2]
2+
 in aqueous solution 
By plotting the absorbance at 471 nm as a function of time, it can be seen that the 
ligand dissociation proceeds rapidly on the second time scale, but closer inspection 
of the start of the reaction shows that there is a delay before ligand dissociation 
occurs (Figure 5.58). 



















































Figure 5.58: Plot of absorbance at 471 nm against time following the reaction 
between [Co(tpz-CN)(dpHa)2]Cl2 and ascorbic acid to completion (left) and focusing 
on the start of the reaction (right) 
This induction period at the start of the reaction is attributed to the presence of 




with nitrogen before use. The rate of dissociation increases after ca. 600 s once the 
oxygen present in the solution has been consumed. To prove this hypothesis, the 
same reaction was carried out under nitrogen (Figure 5.59) where no induction 
period for the reaction is observed. 



















Figure 5.59: Plot of absorbance at 471 and 565nm against time following the 
reaction between [Co(tpz-CN)(dpHa)2]
2+
 and ascorbic acid under anaerobic 
conditions 
As hypoxic regions in tumours have a sub-normal extracellular pH, it was decided to 
investigate if the rate of reduction differed between neutral pH and that found in the 
extracellular hypoxic environment (pH 5.5). The reduction of [Co(tpz-CN)(dpHa)2]
2+
 
by ascorbate is noticeably faster at neutral pH than at pH 5.5 (Figure 5.60) but this is 






































Figure 5.60: Absorbance at 471 nm during the ascorabte mediated reduction of 
[Co(tpz-CN)(dpHa)2]
2+
 at pH 5.5 and pH 7 
Reduction by cysteine under anaerobic conditions is also observed to be more rapid 
at neutral pH than at pH 5.5 (Figure 5.61). When the reaction is carried out at pH 
5.5, the absorbance corresponding to free tpzH-CN starts to decrease after the 
reaction has gone to completion, indicating that the free ligand is being consumed by 
a further reaction. 


























Figure 5.61: Absorbance at 471 nm during the cysteine mediated reduction of 
[Co(tpz-CN)(dpHa)2]
2+




The UV-vis spectra obtained when this reduction is carried out at pH 7 are similar to 
those of obtained for when ascorbate is the reducing agent. When the reduction is 
carried out at pH 5.5, it can be seen that a species forms with a λmax value at ca. 420 
nm (Figure 5.62). 


















 (t = 0 s)
 
Figure 5.62: UV-vis spectra of the cysteine mediated reduction of  
[Co(tpz-CN)(dpHa)2]
2+
 at pH 5.5  
It has been reported that the reduction product of tpzH-CN can undergo hydrolysis 
(Scheme 5.8) in the presence of 2-sulfanylethan-1-ol.
189
 It is probable that a similar 
reaction is being observed in the presence of cysteine, supported by the newly 
formed species having an absorbance centred at 420 nm which is similar to that 













Scheme 5.8: Hydrolysis of the reduction product of tpzH-CN 


































Figure 5.63: Absorbance at 471 nm when [Co(tpz-CN)(dpHa)2]
2+
 is reduced by 
ascorbate, cysteine and glutathione at pH 5.5  
Comparison of the rate of reduction by the three reducing agents under anaerobic 
conditions show that reduction by glutathione and cysteine are similar, and are more 
rapid than the reduction by cysteine. This reflects the reduction potentials of the 
reducing agents (Table 5.15) and demonstrates that the reduction of the cobalt(III) 
complex occurs at a greater rate when in a more biologically reducing environment.   
Table 5.15: Reduction potentials of ascorbic acid, cysteine and glutathione 
Biological reducing agent E°’ / V 




The reduction by ascorbate can also be followed by monitoring the fluorescence of 
the uncoordinated tpzH-CN ligand (Figure 5.64) which provides the basis for 
possible future studies using confocal microspopy to see if the distribution of free 














































Figure 5.64: Emission spectra following the reduction of [Co(tpz-CN)(dpHa)2]
2+
 by 
ascorbate at pH 5.5 under anaerobic conditions (λexcitation = 470 nm) 
The cobalt(III) heteroleptic system has been shown to undergo reduction with 
biologically relevant reducing agents with the N-oxide ligand rapidly dissociating 
upon reduction to cobalt(II) in aqueous solution (Scheme 5.9). The fate of the dpHa 
ligand from the heteroleptic complexes has not been specifically investigated, but the 
results described in this chapter relating to their homoleptic complexes indicate that 











































Scheme 5.9: Reduction of [Co(tpz-R)(dpHa)2]
2+





The reduction was shown to be hindered in the presence of oxygen, taking place at a 
reduced rate, but the results suggest that in order to achieve selective reduction under 
hypoxic conditions, the reduction potential needs to be made more negative. 
 
5.4. Conclusions 
Studies on the pH-dependent properties of the complexes provided information on 
the solubility and stability of the complexes in aqueous solution. With both dpRa and 
tpzH-R ligands, complexes of cobalt(II) and zinc(II) were found to dissociate in 
aqueous solution. This order of stability is expected from that given by the Irving-
Williams series which shows an increase in ligand affinity going from left to right 




 The copper(II) complexes were found to 
be the most stable owing to the additional stabilisation of these complexes from 
Jahn-Teller distortion. The cobalt(III) complexes were all found to be stable in 
aqueous solution owing to the kinetic and thermodynamic stability of this element’s 
oxidation state which makes it ideal to be exploited in the development of hypoxic 
prodrugs. 
A method of altering the stability of dpRa-type complexes has been found by 
introducing steric bulk onto the central amine. Introduction of a methyl or ethyl 
group at this position resulted in the ligand’s dissociation from copper(II) at pH 5.3, 
a value near to that found within the extracelluar environment of hypoxic tumour 
cells. The homoleptic bis-tpzH-R copper(II) complexes were all found to be 
insoluble in water, and had to be dissolved in DMSO prior to aqueous studies. These 
complexes were found to dissociate between pH 2.2 and 2.6, a value much more 
acidic that that found in the extracellular hypoxic tumour environment.
21
 All of the 
copper(II) complexes were found to undergo irreversible reductions at various 
potentials, with [Cu(dpHa)2]Cl2 being the exception by having a quasi-reversible 
reduction. The copper(II) complexes containing tpzH were found to show the most 
negative reduction potentials compared to their analogous complexes. The cobalt(III) 
complexes were found to be stable apart from at extreme pH values, highlighting 
their characteristic stability. The heteroleptic complexes were all found to undergo 
an irreversible reduction at ca. at -0.9 V with [Co(tpz-CN)(dpHa)2]Cl2 at -0.002 V. It 




reducing agents such as ascorbate, cysteine and glutathione. Significantly for the 
purposes of hypoxia selectivity, it appears that this reduction proceeds at a slower 
rate in the presence of oxygen.  
The dissociation of tpzH-CN from its cobalt(III) complex was followed by using 
UV-vis and fluorescence techniques, which will provide a useful method for 






















Chapter Six: Biological studies, conclusions and future work 
This chapter discusses the results of biological studies and reviews them in the 
context of the conclusions from the previous chapters. 
6.1. Procedure for cell assays 
This chapter describes the results obtained from biological experiments using A549 
cells. A549 is a cell line originating from human lung adenocarcinoma. The cells 
were grown in DMEM. Upon reaching ca. 75% confluence, the medium was 
removed and the cells washed twice with 5 mL PBS. To remove the cells from the 
flask, they were then incubated with 1 mL 0.25% EDTA trypsin for 10 minutes at 37 
°C. 9 mL of medium was then added to the cells to form a single suspension. 0.5 and 
1.0 mL of the resulting supernatant were added to two new culture flasks, each 
containing 10 mL of fresh medium. 
Cell viability was measured using the MTT assay.
194
 MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) is a yellow compound which undergoes 
reduction catalysed by mitochondrial dehydrogenase enzymes within living cells to 
















Scheme 6.1: Mitochondrial reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide to MTT formazan 
Cells were plated in 100 μL medium at the seeding density of 1000 cells per well 
into 11 of the 12 columns of a 96-well microtitre plate. The first column was left to 
contain just media so to act as negative control. The plate was incubated for 20 hours 
to allow the cells to adhere to the plate. The compounds were dissolved in medium to 
form solutions of the required concentrations, which were sterilised before addition 




concentration per column of the plate. To one column, 100 μL medium was added 
which contained no drug, so as to provide the positive control. 
Following 3 days incubation, 50 μL of a solution containing 0.0125 g MTT in 6.25 
mL of PBS was added to each well then the plates incubated for two hours. The 
plates were centrifuged for 10 minutes then 220 μL of the supernatant removed from 
each well. DMSO (150 μL) was added to each well to solubilise the MTT formazan 
crystals, which become fully dissolved during 5 minutes agitation on a plate 
shaker.
195
 The absorbance at 540 nm of each well was measured using an automated 
plate reader. The absorbance at 540 nm for the positive and
negative controls was used to calculate the absorbance for 100% and 0% cell 
viability, and from this, the percentage cell viability for each of the drug 
concentrations was calculated. The percentage cell viability was plotted as a function 
of drug concentration, and to this a logistic sigmoidal curve was fitted. From the 
curve, a value for the IC50 (concentration at which 50% of the cells are no longer 
viable) could be obtained. 
 
6.2. Cytotoxicity studies of the uncoordinated ligands 
The dpHa ligand was not able to be tested owing to its insolubility in the biological 

















Concentration of tpzH / M
IC
50


















Concentration of tpzH-CN / M
IC
50
 = 135.8 M ± 5.9 
 
Fig 6.1: Example IC50 curves of tpzH (left) and tpzH-CN (right) against A549 cells 
The tpzH-CONH2 does not have high enough solubility to enable all the 


























 = 446 M ± 20 
 
Figure 6.2: Partial IC50 curve of tpzH-CONH2 against A549 cells 
The results from three separate plates were used to obtain a weighted average (aall), 





The error for the weighted average can then be calculated by:  
 
The weighted average IC50 values are presented in Table 6.1.  
Table 6.1: IC50 values (weighted mean) of tpzH, tpzH-CN and tpzH-CONH2 against 
A549 
Ligand IC50 / μMol Ered / V vs. Ag/AgCl 
tpzH 170.3 ± 6.2 -0.98 
tpzH-CN 143.0 ± 4.5 -0.86 





Comparing the reduction potentials of these two ligands with their IC50 values 
suggests that a lower reduction potential correlates with a lower IC50 value and 
therefore greater cytotoxicity under aerobic conditions. The reduction potential of 
tpzH-CONH2 is the least negative but the cytotoxic capability of this ligand under 
hypoxia is not yet known. Therefore, conclusions cannot yet be drawn as to if the 
lack of activity shown under normoxia is a result of tpzH-CONH2 good hypoxia 
selectivity or a lack of cytoxicity. 
The decreased activity of tpzH-CONH2 compared with tpzH and tpzH-CN may be a 
result of the chemical differences described in Chapter Five. When tpzH and tpzH-
CN underwent deprotonation, the UV-vis spectrum of the spectrum drastically 
altered as the solutions turned from orange to purple. When repeated with the tpzH-
CONH2 ligand, the solution was observed to become slightly darker rather than 
undergo a drastic colour change. There was also a noted difference in the reactivity 
of tpzH-CONH2 compared to the other two N-oxide ligands described in Chapter 
Four. Whilst tpzH and tpzH-CN were found to rapidly coordinate to the cobalt(II) 
centre of [Co(dpHa)2]
2+
 upon mixing, the tpzH-CONH2 ligand did not coordinate 
until the reaction mixture was heated at reflux with the oxidising agent. These 
observations suggest the tpzH-CONH2 ligand has greater kinetic stability than the 
other two N-oxide ligands, which may possibly arise from its intramolecular 
hydrogen bonds which were observed in both solution and the solid state. Future 
studies would need to examine the cytotoxicity of this ligand under hypoxic 
conditions to examine the potential of this ligand as a hypoxia selective agent.  
6.3. Cytotoxicity studies of copper(II) and cobalt(III) complexes 
The copper(II) and cobalt(III) complexes prepared in this thesis were tested but it 
was found that the solubility of some of the compounds prevented this. For those 
which would not dissolve directly into the biological medium, it was tried to pre-
dissolve them into a concentrated stock solution of water or DMSO from which to 
prepare the solution in medium. Unfortunately [Cu(Cl)2(dpHa)], [Cu(tpz-
CN)(dpHa)]Cl and [Cu(tpz-CONH2)(dpHa)]Cl precipitated out of solution when 

























 = 52.3 M ± 1.7 
The two copper(II) complexes assayed were [Cu(dpHa)2] Cl2 and [Cu(tpz)(dpHa)]Cl. 
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Figure 6.3: Example IC50 curves of [Cu(dpHa)2]Cl2 (left) and [Cu(tpz)(dpHa)]Cl 
(right) against A549 cells 
Table 6.2 summarises the mean weighted IC50 values for these complexes.  
Table 6.2: IC50 data for [Cu(dpHa)2]Cl2 and [Cu(tpz)(dpHa)]Cl against A549 cells 
Complex IC50 / μM 
[Cu(dpHa)2]Cl2 53.5 ± 0.8 
[Cu(tpz)(dpHa)]Cl 44.8 ± 2.1 
 
Firstly, it can be seen that the [Cu(tpz)(dpHa)]Cl complex is more potent than tpzH 
which was found to have an IC50 value of 170.3 ± 6.2 μM. This result is perhaps not 
surprising when compared to the IC50 value of [Cu(dpHa)2]Cl2 which is slightly less 
active. The cytotoxicity of these complexes is most likely to arise from rapid 
dissociation of the complex due to the copper centre undergoing substitution more 



























































 = 157.9 M ± 3.9
 
Figure 6.4: Example IC50 curves of [Co(tpz)(dpHa)2]2Cl (left) and [Co(tpz-
CN)(dpHa)2](NO3)2(right) against A549 cells 
It can be seen that there is a marked difference between the obtained IC50 values for 
the heteroleptic cobalt(III) complexes of tpzH and tpzH-CN (Figure 6.4 and Table 
6.3).  
Table 6.3: IC50 values (weighted mean) of tpzH, tpzH-CN, and the cobalt(III) 
complexes 
Compound IC50 / μM 
tpzH 170.3 ± 6.2 
tpzH-CN 143.0 ± 4.5 
[Co(tpz)(dpHa)2]Cl2 60.7 ± 2.1 
[Co(tpz-CN)(dpHa)2](NO3)2 158.3 ± 3.7 
[Co(CO3)(dpHa)2]NO3 > 466 
The Co(tpz-CN)(dpHa)2](NO3)2 complex has an IC50 value close to that of the 
uncoordinated tpzH-CN ligand, implying that no additional activity is brought about 
by the dpHa ligand or cobalt centre. This is further supported by the cytotoxic 
activity of [Co(CO3)(dpHa)2]NO3 being found to be beyond the tested range, being 
































 = 466 M ± 49
 
Figure 6.5: Example IC50 curve of [Co(CO3)(dpHa)2]NO3 against A549 cells 
The results obtained with [Co(tpz)(dpHa)2]Cl2 afford an IC50 value which is in 
juxtaposition to this, with the cobalt(III) complex having an almost three-fold greater 
activity than uncoordinated tpzH (Table 6.4). Significantly, this increase in activity 
brought about upon complexation is supported by the increased cytotoxic activity 
observed with the copper(II) heteroleptic complex.  
The results suggest that complexation of tpzH-CN to a cobalt(III) centre does 
increase its cytotoxic activity. One immediate advantage of the cobalt(III) complex 
over the free tpzH-CN ligand was its greater solubility; the complex was easily 
dissolved directly into the biological medium whereas the tpzH-CN ligand required 
being dissolved within a sonic bath. Complexation of tpzH to a metal centre would 
seem to bring about an increase in activity compared to the free ligand and future 
work would need to investigate this further. However, this dramatic increase in 
cytotoxicity compared to the active ligand and control complex not containing the 









A similar trend has been reported for the cobalt(III) complexes [21], [22] and [23] 
(Figure 6.6 and Tables 6.4 and 6.5), where the cytotoxicity of the cobalt(III) 
complex was greater than that of the uncoordinated ligand and the 








































Figure 6.6: Structures of the cobalt(III) complexes [24], [25] and [26].
104, 105 
Table 6.4: IC50 under aerobic conditions of complex [24] against A2780.
104
 
Compound IC50 against A2780 under / μM 
[24] 4.8 +/- 0.3 
Active ligand of [24] >200 
[Co(Cl)2(cyclam)]Cl >200 
 
Table 6.5: Activity of complexes [25] and [26] against DLD-1 cells.
105
 
Compound IC50 under normoxia/ μM  IC50 under hypoxia / μM  
[25]  1.3 +/- 0.7 1.9 +/- 0.2 
Active ligand of [25] 99 +/- 5 >200 
[26]  35.6 +/- 0.9 20.04 +/- 0.1 
Active ligand of [26] >200 177 +/- 0.2  
[Co(Cl)2(cyclam)]
+




6.4. Reduction in cells 
Owing to the similarity of the IC50 values of [Co(tpz-CN)(dpHa)2](NO3)2 and tpzH-
CN, it was thought that the N-oxide ligand was dissociating from the cobalt centre 
and taking effect upon the cell. To test this hypothesis, the complex was incubated 
with the cells at several concentrations, and its absorbance at 540 nm was monitored 
over 72 hours.  
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Figure 6.7: Absorbance at 540 nm of [Co(tpz-CN)(dpHa)2](NO3)2  during 
incubation with A549 cells 
 
Figure 6.7 clearly shows the gradual decrease in amount of the coordinated N-oxide 
















































Scheme 6.2: Dissociation of tpzH-CN from its cobalt(III) complex found to occur 
upon incubation with A549 cells 
The controls carried out with this experiment included monitoring the absorbance of 
the medium on its own, and the absorbance of medium containing cells but no 
complex. The absorbances of both controls were very similar and remained at a 
constant absorbance throughout, providing a measurement of no coordinated tpzH-
CN being present. The absorbance of the two controls at 540 nm is due to the strong 
colour of the DMEM medium. After 70 hours, the complex, when at 248 μM 
concentration, is observed to have almost undergone complete dissociation. This 
concentration is greater than the IC50 complex (158.3 ± 3.7 μM), which does not have 
a large enough absorbance at 540 nm to provide clear absorbance data for this 
experiment. If the tpzH-CN ligand was not dissociating, then this would have made 
[Co(tpz-CN)(dpHa)2](NO3)2 an unsuccessful candidate as a prodrug for tpzH-CN as 




release observed of the tpzH-CN ligand from the cobalt(III) centre needs further 
investigation so that the difference in cytotoxicty profiles between the complex and 
free ligand after different incubation times can be explored.  
To investigate if the reduction was due to cellular activity or the components of the 
medium, the experiment was repeated; one plate containing cells and one without. 
The absorbance of the equivalent concentrations between the plates remain the same 
over time (Figure 6.8), showing the reduction of the cobalt(III) complex is occurring 
independently of the cells.  
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Figure 6.8: Absorbance at 540 nm of [Co(tpz-CN)(dpHa)2](NO3)2  during 
incubation with A549 cells and incubation with DMEM medium 
The DMEM medium contains several compounds which can be reducing in nature 
(Table 6.6), including cysteine which was shown to be able to reduce [Co(tpz-
CN)(dpHa)2]
2+
 as described in Chapter Five. With or without the presence of cells, 
the reduction of the complex, and therefore dissociation of the tpzH-CN ligand, 
occurred over several days under aerobic conditions. This is significantly slower than 
the rate of reduction observed when the complex was mixed in solution with various 
reducing agents, suggesting the reduction of the complex dissociation of the tpzH-




rapid release of the tpzH-CN ligand in the hypoxic tumour environment than under 
normoxic conditions.  
 
6.5. Overall Conclusions 
The general aim of this project was to explore further the development of transition 
metal-based hypoxia prodrugs. It was observed that there were several organic 
compounds reported in the literature which had been shown to have high hypoxia-
selective cytotoxicity, but were failing to meet their full therapeutic potential in vivo 
owing to factors such as poor delivery or chemical instability. Therefore, it was 
decided to see if therapeutically active species could be improved upon through 
incorporation into a transition metal complex. The reasoning behind this was to add 
the reduction of the metal centre as an additional ‘barrier’ to the generation of the 
cytotoxic species of the drug, which should help improve selectivity.  
A series of complexes incorporating varied ligands have been prepared and 
characterised including a new class of heteroleptic complexes which incorporate two 
dpHa ligands and a therapeutically active 1, 4-N-oxide ligand such as tpzH. The 
metal centres used include copper(II) and cobalt(III) which are two of the most 
suitable metals to be used in the development of hypoxia-selective complexes. These 
complexes have been fully characterised and most have been structurally 
characterised using single crystal x-ray diffraction. One of the obtained structures 
was the first quinoxaline-1,4-N-oxide (tpz-H-R) transition metal complex (Figure 
6.9), despite there being many reports into the coordination chemistry of these 
quinoxaline di-N-oxide ligands.  
 





It became increasingly apparent that the poor solubility of this family of complexes 
would greatly hinder their biological applications but also their ease to study in 
solution. To overcome this, we were able to develop a novel range of heteroleptic 
complexes incorporating both a tpzH-R ligand and a dipyridylamine ligand (dpHa). 
Structural characterisation has shown that in metal(II) complexes of copper and zinc, 
these ligands are in a 1:1 ratio (Figure 6.10). 
 
Figure 6.10: Obtained structures of metal(II) heteroleptic complexes which 
incorporate a dipyridylamine and N-oxide ligand in a 1:1 ratio.
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 Clockwise from 
top left: [Cu(tpz-CN)(dpHa)]Cl, [Zn(tpz-CN)(dpHa)]Cl, [Cu(tpz)(dpHa)]Cl and 
[Cu(Cl)(tpz-CONH2)(dpHa)]. 
These heteroleptic complexes were immediately observed to have better solubility in 
various solvents which meant that their behaviour in solution could be studied. 2,2’-
dipyridylamine happened to be a ligand already studied in this project, allowing the 
chemistry of the heteroleptic complexes to be compared with the equivalent 





It was found that the difficulty of preparing cobalt(III) complexes of the tpzH-R 
ligands was overcome by using this heteroleptic system with the resulting products 
structurally characterised(Figure 6.11). 









One of the tpzH-R ligands successfully utilised was tirapazamine (tpzH), a 
compound which shows very high hypoxia selective toxicity in vivo. The successful 
synthesis of tpzH complexes provides a basis for one tactic of improving its 
biological properties. 
The solution properties of these complexes have been studied and compared to their 
homoleptic analogues where possible. For the copper(II) complexes, both the hetero- 
and homoleptic complexes of dpHa and the tpzH-R ligands were found to not 
undergo dissociation upon being in aqueous solution. The heteroleptic complexes 
were found to undergo dissociation at pH values similar to those believed to occur in 
the extracellular environments of solid tumours. They were found to undergo a 
reductive process using cyclic voltammetry in DMSO at potentials more negative 
that -0.3 V vs. Ag/AgCl which was shown to be irreversible. These reductions occur 
at a potential less negative than that found to be required for hypoxia selectivity in 
copper(II) complexes (-0.57 V vs. Ag/AgCl in DMSO) by studies of [Cu(ATSM)] 
analogues.
90, 91
 The heteroleptic copper(II) complex which had high enough 
solubility in biological medium for cytotoxicity assays against A549 cells was found 
to have an IC50 value of 44.8 ± 2.1 μM. This value is lower than that obtained for 
tpzH (170.3 ± 6.2 μM) and [Cu(dpHa)2]Cl2 (53.5 ± 0.8 μM), implying that the 
coordination of tpzH into this complex has not reduced the toxicity of tpzH under 
aerobic conditions. This agrees with the reduction potential not being negative 




The cobalt(III) heteroleptic complexes were found to contain one 1,4-N-oxide and 
two dpHa ligands. These were found to be stable in aqueous solution below pH 10. 
The reduction potential of cobalt(III) thought to be needed to facilitate hypoxia 
selectivity is of -0.305 to -0.705 V vs. Ag/AgCl.
193
 The heteroleptic cobalt(III) 
complexes of tpzH and tpzH-CN both showed a reduction process at -0.06 and 0.00 
V respectively.  
The [Co(tpz-CN)(dpHa)2](NO3)2 complex was found to have an IC50 value of 158.3 
± 3.7 μM against a549 cells under aerobic conditions, a value similar to that of 
uncoordinated tpzH-CN (143.0 ± 4.5 μM). This result along with the 
[Co(CO3)(dpHa)2](NO3)2 complex having an IC50 value greater than > 466 μM 
implies that the dpHa ligands and cobalt centre do not provide significant additional 
toxicity. The similarity of the IC50 values for the complex and tpzH-CN ligand 
indicates that the ligand is dissociating upon reduction of the metal centre. This was 
supported with spectroscopic studies monitoring absorbance of the complex 
incubated with A549 cells over several days. This, along with the reduction 
potentials for these complexes being less negative than that suggested to be needed 
for hypoxia selectivity by previous studies implies that the reduction potential of 
these cobalt(III) complexes needs to be made more negative. The monitoring of the 
reduction of [Co(tpz-CN)(dpHa)2](NO3)2 in cells was found to occur due to reducing 
agents within the biological medium, but encouragingly the reduction occurred over 
several days, implying that complexation of tpzH-CN to cobalt(III) brings about a 
decreased rate of release of the 1,4-N-oxide ligand, even under aerobic conditions. 
UV-vis spectroscopy experiments measuring the reduction by various biological 
reducing agents over time also support that the reduction of these cobalt(III) 
complexes is inhibited under aerobic conditions, so the ligands therefore dissociate at 
a slower rate.  
Cytotoxicity results of the [Co(tpz)(dpHa)2]Cl2 complex followed a trend observed 
with previously reported cobalt(III) complexes, in that the complex was more 
cytotoxic than its individual components. It is not clear how the complex affects the 
activity of the tpzH ligand, so studies are needed to confirm that the cytotoxic action 
of tpzH are inhibited upon complexation or if there is a cooperative mechanism 
between the different components. If the ligand is inactive when coordinated to the 




prodrug as long as its reduction potential can be tuned to a more negative value. If 
successful, this could result in a tpzH based hypoxia-selective prodrug with 
increased potency.  
6.6. Future Work 
Studies are needed to enable a fuller understanding of the results from the 
cytotoxicity assays. Time dependant IC50 studies would provide a useful indicator of 
how the activity of the 1,4-N-oxide ligands is altered through complexation. 
Confocal microscopy studies could provide beneficial information on if the 
distribution of the 1,4-N-oxide ligands within the cell differs when delivered as a 
complex or as an uncoordinated ligand. The cytotoxicity of these complexes under 
hypoxia needs to be investigated, including an investigation into whether the tpzH-
CONH2 ligand displays cytotoxicity in the absence of oxygen. 
The dpHa ligand for these complexes does not seem to induce significant 
cytotoxicity on its own, so perhaps provides an opportunity for this to be modified in 
an attempt to make the reduction potentials of the cobalt(III) complexes more 
negative. The potential to expand upon the library of these heteroleptic complexes 
has already been briefly illustrated with the incorporation of dpma and phen in place 
of the dpHa ligand. Exchanging the dpHa ligand for ones with three or four amine 
donors (Figure 6.12), to see what effect this has on the complex’s properties such as 




































Figure 6.12: Possible alternative ligands to use for the 1,4-N-oxide cobalt(III) 
heteroleptic complexes 
 




All experiments were carried out using chemicals obtained from Sigma Aldrich, 
Fluka, Lancaster Chemicals or Alfa Aesar and used without further purification. The 
compound CN-dpHa-py was provided by Sentinel Oncology, who also prepared its 
precursor 2-chloro-4-(1-pyrrolidin-1-ylmethyl)pyridine. Mass spectrometry and 
elemental analyses were performed by the mass spectrometry and microanalytical 




Elemental analyses were carried out on an Exeter Analytical Analyser calibrated 
against acetanilide and with S-Benzylthiuronium chloride as the internal standard. 
UV-vis spectra were collected on an Agilent 8453 instrument and IR data collected 
on an Avatar 370 FT-IR Thermo Nicolet Instrument. Fluorescence spectra were 
recorded on a Hitachi F-4500 fluorescence spectrophotometer. Mass spectrometry 
was carried out on a Bruker microTOF electrospray mass spectrometer. 
Measurements of pH were made with a standard glass electrode. 
 
X-ray diffraction data was collected on a single-crystal Bruker Smart Apex CCD 
diffractometer with a Mo-K(alpha) radiation source (λ = 0.71073 Å). Diffractometer 





 Data collection was carried out by the crystallography service at the 
University of York. Absorption corrections were applied by SADABS.
198
 Structures 
were solved by either Patterson or direct methods using SHELXS-97 and refined by 
full-matrix, least squares using SHELXL-97.
199, 200
 All non-hydrogen atoms and 
hydrogen atoms of heteroatoms were refined anisotropically. Hydrogen atoms were 
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7.2. Chapter Two proceedures 
7.2.1. Synthesis of dpRa ligands 





Five equivalents NaOH (0.24 g, 6.00 mmol) dissolved in 1 mL H2O was added to a 
stirred solution of dpHa (0.21 g, 1.24 mmol) in 6 mL DMSO, causing it to turn pale 
yellow. After 20 minutes stirring, two equivalents MeI (0.2 mL, 3.21 mmol) were 
added and the re action mixture was left to stir overnight. 20 mL H2O was added to 
the reaction mixture before the product was extracted with Et2O and dried over 
MgSO4. The product was obtained as yellow oil. 
Yield: 0.53 g, 0.0029 mmol, 66% 
1
H NMR (400 MHz, d6-DMSO): δ8.30 (ddd, 2H, J = 5.0, 2.0, 0.8 Hz, pyridyl-H), 
δ7.65 (ddd, 2H, J = 8.5, 7.0, 2.0 Hz, pyridyl-H), δ7.22 (dt, 2H, J = 8.0, 1.0 Hz, 




H} NMR (400 MHz, d6-DMSO): δ154.3, δ147.3, δ137.4, δ115.7, δ111.6 
MS ESI (+ve ion) / mz: 186.10 (M
+
)  
IR (NaCl cell) / cm
-1
: 3053, 3004.5, 2913, 1734, 1700, 1653, 1583, 1472, 1430, 
1355, 1326, 1278, 1139 
 





Five equivalents NaOH (0.15 g, 3.75 mmol) dissolved in 1 mL H2O was added to a 
stirred solution of dpHa (0.10 g, 0.58 mmol) in 6 mL DMSO, causing it to turn pale 
yellow. After 20 minutes stirring, two equivalents EtI (0.1 mL, 1.2 mmol) were 
added and the re action mixture was left to stir overnight. 20 mL H2O was added to 
the reaction mixture before the product was extracted with Et2O and dried over 
MgSO4. The product was obtained as a yellow oil. 
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Yield: 0.08 g, 0.40 mmol, 69% 




H NMR (400 MHz, d6-DMSO): δ8.29 (ddd, 2H, J = 5.0, 1.0, 0.5 Hz, pyridyl-H), 
δ7.60 (ddd, 2H, J = 7.5, 2.0, 1.0 Hz, pyridyl-H), δ7.12 (dt, 2H, J = 8.5, 1.0 Hz, 
pyridyl-H), δ6.92 (ddd, 2H, J = 7.4, 5.0, 1.0 Hz, pyridyl-H), δ4.15 (q, 2H, J = 7.0 Hz, 




H} NMR (400 MHz, d6-DMSO): δ156.4, δ148.0, δ137.4, δ117.0, δ114.4, δ42.2 
(CH2) , δ13.3 (CH3) 
IR (NaCl cell) / cm
-1
:2974, 2929, 1583, 1468, 1422, 1321, 1267, 1140, 1090, 985, 
772 
 





2-chloro-4-pyridinecarboxaldehyde (1.42 g, 10 mmol) was stirred with 1 equivalent 
pyrrolidine (0.8 mL, 10 mmol) in 50 mL DCM and 2 mL acetic acid was then added. 
To the stirred solution 1.2 equivalents NaBH(OAc)3 (2.54 g, 12.0 mmol )was added 
then the reaction mixture was left to stir overnight. The reaction mixture was then 
filtered through celite and washed with DCM. The filtrate was concentrated and 
purified by column chromatography to afford the product as a brown oil. 
Yield: 1.5 g, 7.63 mmol, 74% 
 








Pd2(dba)3 (0.09 g, 0.1 mmol), Xantphos ligand (0.09 g, 0.15 mmol), 2-amino-
isonicotinonitrile (0.12 g, 1.0 mmol) finely ground Cs2CO3 (0.46 g, 1.4 mmol), 2-
chloro-4-(1-pyrrolidin-1-ylmethyl)pyridine (0.20g, 1.0 mmol) in 4 mL toluene were 
placed in a re-sealable microwave tube. The tube was then sealed and underwent 
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three cycles of being placed under vacuum and then filled with N2. The mixture was 
heated at 100ºC overnight and then allowed to cool. The reaction mixture was 
diluted with THF and then filtered and concentrated. The product was purified on a 
SiO2 flash column using 0-100% gradient DCM then 10% saturated NH3 / MeOH in 
DCM to afford the product as an off-white powder. 
1
H NMR (400 MHz, d6-DMSO): δ10.51 (br. s, 1H, NH), δ8.48 (br. s, 1H, pyridyl-
H), δ8.39 (br. s, 1H, pyridyl-H), δ8.16 (br. s, 1H, pyridyl-H), δ7.70 (br. s, 1H, 
pyridyl-H), δ7.33 (br. s, 1H), δ7.22 (br. s, 1H), δ4.38 (br. s, 2H, alkyl-H), δ3.32 (br. 
s, 2H, py-H), δ3.08 (br. s, 2H, py-H), δ2.04 (br. s, 2H, py-H), δ1.88 (br. s, 2H, py-H) 
 
7.2.2. Preparation of dpRa complexes 
Preparation of [Co(Cl)2(dpHa)].
127, 133 
One equivalent dpHa (0.98 g, 5.6 mmol) was added to a stirred solution of 
CoCl2.6H2O (1.32 g, 5.5 mmol), causing the formation of a dark blue precipitate. 
After stirring for 10 minutes, the precipitate was isolated by filtration in vacuo as a 
royal blue powder and washed with EtOH then Et2O. Dark blue single crystals 
suitable for diffraction were obtained by slow diffusion of Et2O into a DMF solution. 
Yield: 1.39 g, 4.6 mmol, 84% 
CHN; found: %C 39.03, %H 2.84, %N 13.54; calculated (CoC10H9N3Cl2): %C 





Two equivalents dpHa (0.27 g, 1.6 mmol) were added to a stirred solution of 
CoCl2.6H2O (0.91 g, 0.8 mmol) in 10 mL MeOH. After 0.5 hours stirring, the 
solution was left to stand and over the course of a week, deep pink crystals suitable 
for diffraction formed. 
Yield: 0.24 g, 0.51 mmol, 64% 
 
Preparation of [Co(CO3)(dpHa)2]NO3 
One equivalent Co(NO3)2.6H2O (0.20 g, 0.69 mmol) was stirred in 10 mL MeOH 
and to this, two equivalents dpHa (0.24 g, 1.40 mmol) were added causing a colour 
change from pink to orange. After 0.5 hours, two equivalents NaHCO3 (0.1282 g, 
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1.53 mmol) were added followed by 5 mL H2O2 which caused the reaction mixture 
to turn dark red. After two hours stirring, the reaction mixture was filtered and then 
the filtrate left to stand. After a couple of days, red crystals had formed which were 
isolated by filtration and washed with Et2O. 
Yield: 0.14 g, 0.28 mmol, 41% 
1
H NMR (400 MHz, D2O): δ8.05 (td, 2H, J = 8.0, 1.0 Hz, pyridyl-H), δ7.99 (td, 2H, 
J = 8.0, 1.0 Hz, pyridyl-H), δ7.66 (dd, 2H, J = 6.0, 1.0 Hz, pyridyl-H), δ7.47 (ap. t, 
2H, J = 6.0 Hz, pyridyl-H), δ7.40 (dd, 2H, J = 6.0, 1.0 Hz, pyridyl-H), δ7.30 (br. d, 
2H, J = 8.5 Hz, pyridyl-H) δ7.15 (ap. td, 2H, J = 7.0, 1.0 Hz, pyridyl-H), δ6.98 (td, 




H} NMR (400 MHz, d6-DMSO): δ157.7, δ154.8, δ153.5, δ151.9, δ141.7, 
δ141.3, δ120.4, δ119.7, δ114.2, δ113.6 
IR (KBr disc) / cm-1: 3193, 3076, 2980, 1646, 1569, 1506, 1419, 1384, 1322, 776 
MS ESI (+ve) / m/z: 461.1 [Co(CO3)(dpHa)2]
+
 
CHN Analysis; found: %C 47.69, %H 3.48, %N 18.53; calculated (for 





Two equivalents dpHa (0.74 g, 4.34 mmol) dissolved in 20 mL acetone were added 
to 1 equivalent CuCl2.6H2O (0.37 g, 2.17 mmol) stirred in 30 mL EtOH, causing the 
formation of a bright green suspension. After 45 minutes stirring the product was 
isolated by filtration in vacuo and washed with acetone. Green diffraction quality 
single crystals were obtained by slow evaporation from a solution of MeOH layered 
over 
n
BuOH over the duration of a week at room temperature 
Yield = 0.90 g, 1.88 mmol, 87%  
MS ESI (+ve ion) / m/z: = 405.1 [Cu(dpHa)2]
2+
 
CHN Analysis; found: %C 48.78, %H 3.86, %N 17.00; calculated (for 





Two equivalents dpHa (0.88 g, 5.10 mmol) were added to a stirred solution of 
CuCl2.2H2O (0.87 g, 5.00 mmol) in 10 mL MeOH, resulting in the formation of a 
dark green precipitate. After 20 minutes stirring, the precipitate was collected in 
vacuo and washed with EtOH. 
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Yield: 1.43 g, 4.60 mmol, 90% 





One equivalent dpHa (0.27 g, 1.6 mmol) was added to Cu(NO3)2.3H2O (0.39 g, 1.6 
mmol) stirred in 10 mL EtOH, causing the formation of a green precipitate. After 15 
minutes stirring, the precipitate was isolated as a green solid by filtration in vacuo 
and washed with EtOH then Et2O. 
Yield: 0.39 g, 1.1 mmol, 69% 
CHN Analysis; found: %C 33.33, %H 2.54, %N 18.97; calculated (for 





One equivalent dpHa (1.13 g, 6.6 mmol) was added to a stirred solution of ZnCl2 
(0.90 g, 6.7 mmol) in 10 mL hot MeOH, causing the formation of a white 
precipitate. This was stirred for 10 minutes before the white precipitate was isolated 
by filtration in vacuo and washed with EtOH then Et2O. Colourless single crystals 
suitable for x-ray diffraction were obtained by slow diffusion of Et2O into a DMF 
solution. 
1
H NMR (400 MHz, d6-DMSO): δ10.01 (br. s, 1H, NH), δ8.25 (br. s, 2H, pyridyl-





H} NMR (400 MHz, d6-DMSO): δ153.8, δ146.7, δ140.8, δ117.8, δ114.3 
CHN Analysis; found: %C 39.03, %H 2.84, %N 13.54; calculated (for 





Two equivalents dpHa (0.71 g, 4.16 mmol) was added to solution of Zn(BF4)2 (0.49 
g, 2.05 mmol) in 30 mL MeOH which was heated at reflux. The reaction was left to 
heat at reflux overnight and allowed to cool before Et2O was added, causing the 
formation of a white precipitate. The white solid was isolated by filtration and 
washed with EtOH then Et2O. 
Yield: 0.47g, 0.81 mmol, 39% 




H NMR (400 MHz, MeOD): δ8.05 (br. d, 4H, J = 4.0 Hz, pyridyl-H), δ7.94 (ddd, 
4H, J = 8.0, 7.5, 1.5 Hz, pyridyl-H), δ7.20 (d, 4H, J = 8.0 Hz, pyridyl-H), δ7.10 (t, 
4H, J = 6.0 Hz, pyridyl-H) 
MS ESI (+ve ion) / mz: 406.1 
 
Preparation of [Co(Cl) 2(dpma)2]OTf  
CoCl2.6H2O (0.42 g, 1.77 mmol) was added to a stirred solution of two equivalents 
dpma (0.66 g, 3.57 mmol) in 10 mL EtOH. After 10 minutes stirring, one equivalent 
KOTf (0.34 g, 1.8 mmol) was added followed by 2 mL H2O2 which immediately 
caused the solution to turn dark red. This was stirred for one hour then the reaction 
mixture was filtered. Dark red single crystals suitable for diffraction were obtained 
upon leaving the filtrate to stand over the course of a week. 
Yield (of crystals): 0.03g, 0.04 mmol, 2% 
1
H NMR (400 MHz, d6-DMSO): δ8.16 (ddd, 2H, J = 8.5, 7.0, 1.5 Hz, pyridyl-H), 
δ8.12 (ddd, 2H, J = 8.5, 7.0, 1.5 Hz, pyridyl-H), δ7.68 (d, 2H, J = 8.5 Hz, pyridyl-H), 
δ 7.65 (dd, 2H,J = 6.0, 1.5 Hz, pyridyl-H), δ7.51 (d, 2H, J = 8.5 Hz, pyridyl-H), 
δ7.44 (dd, 2H, J = 6.0, 1.5 Hz, pyridyl-H), δ7.24 (td, 2H, J = 6.5, 1.0 Hz, pyridyl-H), 
δ7.07 (td, 2H, J = 6.0, 1.0 Hz, pyridyl-H), δ3.82 (s, 6H, CH3) 




Preparation of [Cu(Cl) 2(dpma)] 
One equivalent dpma (1.01 g, 5.5 mmol) was added to a stirred solution of 
CuCl2.2H2O (0.98 g, 5.7 mmol) in 10 mL MeOH, causing a green precipitate to 
form. After 20 minutes stirring, the product was isolated by filtration in vacuo as a 
green solid and washed with MeOH then Et2O. Green diffraction quality single 
crystals were obtained by leaving the filtrate to stand for two days at room 
temperature.  
Yield: 0.84 g, 2.6 mmol, 47% 
CHN Analysis; found: %C 41.00, %H 3.45, %N 12.89; calculated (for 
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Preparation of [Zn(Cl)2(dpma)] 
One equivalent dpma (0.34 g, 1.8 mmol) was added to a stirred solution of ZnCl2 
(0.26 g, 1.9 mmol) in 6 mL hot MeOH, causing the formation of a white precipitate. 
After 10 minutes stirring, the reaction mixture was filtered in vacuo to isolate the 
product as a white powder. The product was washed with MeOH then Et2O. 
Colourless single crystals suitable for x-ray diffraction were obtained by slowly 
diffusing Et2O into a DMF solution. 
Yield: 0.34 g, 1.1 mmol, 61% 
1
H NMR (400 MHz, d6-DMSO): δ8.25 (2H, ddd, J = 5.0, 2.0, 1.0 Hz, pyridyl-H), 
δ7.61 (ddd, 2H, J = 9.0, 7.0, 2.0 Hz, pyridyl-H), δ7.18 (dt, 2H, J = 9.0, 1.0 Hz, 




H} NMR (400 MHz, d6-DMSO): δ157.51, δ148.2, δ137.8, δ117.3, δ114.4, 
δ35.5 
 
Preparation of [Cu(Cl) 2(dpea)] 
One equivalent dpea (0.05 g, 0.26 mmol) was added to a solution of CuCl2.2H2O 
(0.05g, 0.27 mmol) in 5 mL MeOH, causing the formation of a green precipitate. 
After 10 minutes stirring, the green solid was isolated by filtration in vacuo and 
washed with MeOH then Et2O. Green single crystals of diffraction quality were 
obtained by allowing the filtrate from the reaction to stand for several days at room 
temperature. 
Yield: 0.02g, 0.06 mmol, 23%  
 
Preparation of [Zn(Cl)2(dpea)] 
One equivalent dpea (0.05 g, 0.25 mmol) was added to a stirred solution of ZnCl2 
(0.04 g, 0.29 mmol) in 5 mL MeOH, causing the formation of a white precipitate. 
After 10 minutes stirring, the white solid was isolated by filtration in vacuo and 
washed with MeOH then Et2O. Colourless single crystals of diffraction quality were 
obtained by allowing Et2O to slowly diffuse into a DMF solution.  
Yield: 0.04 g, 0.12 mmol, 49% 
1
H NMR (400 MHz, d6-DMSO): δ8.31 (br. d, 2H, J = 4.0 Hz, pyridyl-H), δ7.64 (ap. 
t, 2H, J = 7.5 Hz, pyridyl-H), δ7.14 (d, 2H, J = 8.0 Hz, pyridyl-H), δ6.98 (ap. t, 2H, J 
= 5.0 Hz, pyridyl-H), δ4.16 (q, 2H, J = 7.0 Hz, CH2), δ1.15 (t, 3H, J = 7.0 Hz, CH3)  
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7.3. Chapter Three procedures 









2-nitroaniline (2.40 g, 17.4 mmol) was stirred at 100ºC with cyanamide (1.29 g, 30.7 
mmol) until a molten red liquid formed. This was then allowed to cool to room 
temperature before the slow drop-wise addition of ice cold conc. HCl (37%). The 
mixture was then stirred at 100 ºC for 30 minutes and was then allowed to cool to 
room temperature. 4 mL 16 M NaOH(aq) was added drop-wise before the reaction 
was stirred at 100 ºC for 2 hours. 50 mL H2O was added to the reaction mixture after 
it had been allowed to cool. A bright yellow precipitate was isolated by filtration and 
washed with cold MeOH. 
Yield: 1.81 g, 11.2 mmol, 65% 
MS ESI (+ve ion): 163.06 
1
H NMR (400 MHz, d6-DMSO): δ8.12 (ddd, 1H, J = 8.0, 1.2, 1.0 Hz, phenyl-H), 
δ7.77 (ddd, 1H, J = 8.5, 8.0, 1.5 Hz, phenyl-H), δ5.52 (ddd, 1H, J = 8.5, 1.5, 1.0 Hz, 
phenyl-H), δ7.3 (m, 3H, phenyl-H and NH2) 
 









3-amino-1,2,4-benzotriazine-1-oxide (0.54 g, 3.33 mmol) was stirred  in a mixture of 
50 mL glacial acetic acid and 50 mL H2O2 at 70°C overnight. The bright orange 
reaction mixture was then slowly neutralised with NaHCO3 and filtered, before the 
product was extracted from the filtrated with CHCl3. The dark bright orange product 
was recrystallised from hot EtOH. 
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Yield: 0.12g, 0.65 mmol, 20% yield 
1
H NMR (400 MHz, MeOD): δ8.34 (dt, 1H, J = 8.0, 1.0 Hz, phenyl-H), δ8.21 (ddd, 
1H, J = 8.5, 1.0, 0.5 Hz, phenyl-H), δ8.02 (ddd, 1H, J = 8.5, 7.0, 1.5 Hz, phenyl-H), 
δ7.62 (ddd, J = 9.0, 7.0, 1.5 Hz, phenyl-H) 
1
H NMR (400 MHz, d6-DMSO): δ8.20 (d, 1H, J = 8.0 Hz, phenyl-H), δ8.13 (d, 1H, J 
= 8.0 Hz, phenyl-H), δ8,05 (br. s, 2H, NH2), δ7.94 (dt, 1H, J = 8.5, 7.0, 1.0 Hz, 




H} NMR (400 MHz, d6-DMSO): δ151.9, δ138.8, δ135.8, 131.0, 127.0, 121.4, 
117.3 
IR (KBr disc) / cm-1: 3411, 3290, 3095, 1646, 1592, 1490, 1422, 1364, 1173, 1101 
MS ESI (+ve ion) / mz: 179.06 (M+)  
CHN Analysis; found: %C 47.24, %H 3.50, %N 30.94; calculated (for C7H6N4O2): 
%C 47.19, %H 3.39, %N 31.45 
 
Synthesis of 3-aminoquinoxaline-2-carbonitrile-N1,N4-oxide (tpzH-CN).
161 
Benzofuroxan (3.06 g, 22.5 mmol) was stirred with two equivalents propanedinitrile 
(2.6 mL, 45.4 mmol) in 5 mL DMF and cooled with an ice bath. Upon addition of 
Et3N (0.05 mL, 0.36 mmol) the reaction mixture became more red in colour and was 
stirred at 0ºC for 2 hours. The reaction mixture was then filtered to isolate the 
product as a fluorescent orange suspension which was then washed with acetone 
until the washings were no longer brown. The product was then dried in vacuo. 
Yield: 2.56g, 12.7 mmol, 56% 
MS ESI (+ve ion) / mz: 203.01 (M+) 
1H NMR (400 MHz, MeOD): δ8.42 (ddd, 1H, J = 9.0, 1.5, 0.5 Hz), δ8.37 (ddd, 1H, J 
= 8.5, 1.2, 0.5 Hz), δ8.00 (td, 1H, J = 7.0, 1.5 Hz), δ7.10 (ddd, 1H, J = 9.0, 7.0, 1.2 
Hz) 
1
H NMR (400 MHz, d6-DMSO): δ8.29 (dd, 1H, J = 5.5, 1.0 Hz, phenyl-H), δ8.27 
(dd, 1H, J = 5.5, 1.0 Hz, phenyl-H), δ8.08 (br. s, 2H, NH2), δ7.93 (ddd, 1H, J = 8.5, 




H} NMR (400 MHz, d6-DMSO): δ146.4, 137.3, 134.6, 132.1, 127.9, 120.1, 
δ118.3, δ110.9, δ109.0 
IR (KBr) / cm
-1
: 3352 (NH2), 3259 (NH2), 2234 (CN), 1625, 1348, 1235, 1101, 857, 
767, 609 
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CHN Analysis; found: %C 53.26, %H 3.03, %N 27.43; calculated (for C9H6N4O2): 
%C 53.47, %H 2.99, %N 27.71 
 










3-aminoquinoxaline-2-carbonitrile-N1,N4-oxide (tpzH-CN) (0.99 g 4.9 mmol) was 
stirred in 100 mL >95% H2SO4 to afford a yellow solution. This was stirred 
overnight at 90ºC then allowed to cool to room temperature.  This was then poured 
onto ca. 800 cm
3
 crushed ice and stirred in an ice bath whilst the reaction mixture 
was neutralised with concentrated NH3, bringing about a colour change from yellow 
to a bright reddish orange. About 100 cm
3
 more crushed ice was added to the 
mixture which was left to stir for an hour, during which time a bright orange 
precipitate formed. This was collected by filtration in vacuo and the resulting orange 
solid dissolved in acetone. The orange solution was filtered and then the solvent 
dried off from the filtrate to afford the product as an orange solid. Single red 
coloured crystals suitable for diffraction were obtained from a reaction of [Co(tpz-
CN)2] with H2O2 in MeOH. 
Yield: 0.17g, 0.76 mmol, 6% 
MS ESI (+ve ion) / mz: 221.06 (M+1) 
IR (KBr disc) / cm
-1
: 3371 (NH), 3251 (NH2), 1671 (C=O), 1581, 1459, 1397, 1343, 
1283, 1277, 1101, 1039, 767, 657 
1
H NMR (d6-DMSO, 400 MHz): δ9.85 (br. s, 1H, amide NH), δ 8.58 (br. s, 1H, 
amide NH), δ8.41 (d, 1H, J = 8.5 Hz, phenyl-H), δ8.30 (d, 1H, J = 8.5 Hz, phenyl-
H), δ8.19 (br. s, 1H, NH2), δ7.91 (ap. t, 1H, J = 7.5 Hz, phenyl-H), δ7.67 (ap. t, 1H, J 




H} NMR d6-DMSO, 400 MHz): δ162.2, δ145.3, δ135.2, δ133.2, δ131.1, 
δ127.4, δ123.9, δ120.2, δ117.4.  
CHN Analysis; found: %C 48.79, %H 3.75, %N 24.90; calculated (for C9H8N4O3): 
%C 49.09, %H 3.66, %N 25.45 
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7.3.2. Preparation of homoleptic complexes of N1,N4-oxide ligands 
 
Preparation of [Cu(tpz)2]  
Two equivalents tpzH (0.05 g, 0.30 mmol) were added to a stirred solution of 
Cu(OAc)2.2H2O (0.03 g, 0.15 mmol) in 10 mL MeOH, causing the formation of a 
deep red precipitate. After 0.5 hours, the dark red solid was isolated by filtration in 
vacuo and washed with MeOH. 
Yield: 0.04 g, 0.09 mmol, 59% 
IR (KBr disc) / cm
-1
: 3360, 3310, 3110, 1570, 1500, 1410, 1360, 1260, 1210, 1160, 
1110, 1030 
 
Preparation of [Zn(tpz)2]  
Two equivalents tpzH (0.02 g, 0.09 mmol) were added to a stirred solution of 
Zn(OAc)2 (0.01 g, 0.05 mmol) in 10 mL MeOH, causing the formation of a deep red 
precipitate. After 0.5 hours, the dark red solid was isolated by filtration in vacuo and 
washed with MeOH. 
Yield: 0.02 g, 0.04 mmol, 84% 
1
H NMR (d6-DMSO, 400 MHz): 8.10 (d, 1H, J = 8.5 Hz, phenyl-H), 7.93 (d, 1H, J 
= 8.08 Hz, phenyl-H), 7.87 (t, 1H, J = 7.68 Hz, phenyl-H), 7.29 (t, 1H, J = 7.86 




H} NMR (d6-DMSO, 400 MHz): 149.5, 134.8, 129.2, 124.0, 119.6, 
116.0, 111.2 
IR (KBr disc) / cm
-1
: 3380, 3310, 1580, 1500, 1410, 1360, 1220, 1160, 1110, 1030 
 
Preparation of [Co(tpz-CN)2] 
Two equivalents tpzH-CN (0.08 g, 0.39 mmol) were added to a stirred solution of 
Co(OAc)2.4H2O (0.05 g, 0.20 mmol) in 10 mL MeOH, causing the formation of a 
dark purple precipitate. After 0.5 hours, the purple solid was isolated by filtration in 
vacuo and washed with MeOH. 
Yield: 0.08 g, 0.16 mmol, 83% 
IR (KBr disc) / cm
-1
: 3380 (N-H), 3090, 2980, 2230 (C≡N), 1560, 1490, 1400, 1360, 
1290, 1220, 1130, 1040 
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Preparation of [Cu(tpz-CN)2] 
Two equivalents tpzH-CN (0.16 g, 0.79 mmol) were added to a stirred solution of 
Cu(OAc)2.2H2O (0.07 g, 0.39 mmol) in 10 mL MeOH, causing the formation of a 
deep red precipitate. After 0.5 hours, the dark red solid was isolated by filtration in 
vacuo and washed with MeOH. 
Yield: 0.14 g, 0.30, 76% 
IR (KBr disc) / cm
-1
 3380 (N-H), 3350, 2990, 2230 (C≡N), 1640, 1560, 1470, 1380, 
1290, 1230, 1150, 1050 
 
Preparation of [Zn(tpz-CN)2] 
Two equivalents tpzH-CN (0.20 g, 0.99 mmol) were added to a stirred solution of 
Zn(OAc)2 (0.10 g, 0.54 mmol) in 10 mL MeOH, causing the formation of a deep red 
precipitate. After 0.5 hours, the dark red solid was isolated by filtration in vacuo and 
washed with MeOH. Small deep –purple coloured single crystals suitable for single 
x-ray diffraction were obtained upon slow diffusion of Et2O into a DMF solution.  
Yield: 0.14 g, 0.30 mmol, 56% 
1
H NMR (400 MHz, d6-DMSO): δ8.15 (br. s, 2H, phenyl-H), δ7.87 (br. s, 1H, 




H} NMR (400 MHz, d6-DMSO z): δ149.5, δ134.8, δ129.2, δ124.0, δ124.0, 
δ119.6, δ116.0, δ111.1 
IR (KBr disc) / cm
-1
: 3360 (N-H), 3100, 2230 (C≡N), 1580, 1490, 1360, 1220, 1130, 
1050  
 
Preparation of [Cu(tpz-CONH2)2] 
Cu(OAc)2.H2O (0.017 g, 0.08 mmol) was added to a stirred suspension of tpzH-
CONH2 (0.033 g, 0.15 mmol) in 20 mL MeOH, causing it to turn from orange to 
dark red / purple. The reaction mixture was stirred or 1 hour before the precipitate 
was isolated by filtration in vacuo as a dark red-purple solid which was then washed 
with methanol then acetone.   
Yield: 0.07 g, 0.13 mmol, 89% 
IR (KBr disc) / cm
-1
: 3330, 3290, 1675, 1539, 1400, 1240, 1196, 1134, 1039, 889, 
668, 588, 520 
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Preparation of [Zn(tpz-CONH2)2]  
Zn(OAc) 2.(0.01 g, 0.06 mmol) was dissolved in 5 mL MeOH and added to a stirred 
orange suspension of tpzH-CONH2 (0.02 g, 0.11 mmol) in 15 mL MeOH, causing 
the formation of a purple-red precipitate. This was stirred for 1 hour then the solid 
isolated by filtration in vacuo and washed with methanol then acetone. 
Yield: 0.0236 g, 0.047 mmol, 78% 
1
H NMR (d6-DMSO, 400 MHz): δ9.52 (br. s, 1H, CONH), δ8.48 (br. s, 1H, CONH), 
δ8.27 (d, 1H, J = 8.0 Hz, phenyl-H), δ8.14 (d, 1H, J = 8.0, phenyl-H), δ7.87 (s, 1H, 
NH), δ7.81 (ap. t, 1H, J = 8.0 Hz, phenyl-H), δ7.40 (ap. t, J = 8.0 Hz, 1H, phenyl-H)  
Solubility was too poor to allow for 
13
C NMR 
IR (KBr disc): 3283, 3268, 3101, 1679, 1560, 1500, 1439, 1403, 1322, 1274, 1202, 
1118, 1042, 1020, 768, 665, 598, 504, 450 
 
7.4. Chapter Four procedures 
7.4.1. Preparation of heteroleptic complexes containing tpzH 
Preparation of [Co(tpz)(dpHa)2](BF4)2 
Two equivalents dpHa (0.65 g, 3.80 mmol) and one equivalent Co(BF4)2.6H2O (0.65 
g, 1.90 mmol) were stirred together in 20 mL EtOH to afford an orange solution. 
One equivalent tpzH-CN (0.37 g, 1.82 mmol) was added, causing the reaction 
mixture to turn dark red. After 20 minutes stirring, one equivalent K2S2O8 (0.55 g, 
2.03 mmol) was added and this was stirred for 2 hours. The reaction mixture was 
filtered then Et2O added to the filtrate to cause the formation of a dark red-purple 
precipitate. The precipitate was isolated by filtration, washed with Et2O and dried in 
vacuo to afford the product as a dark red-purple solid. Dark red diffraction quality 
crystals were obtained by allowing a methanolic solution layered over 
n
BuOH to 
slowly evaporate at room temperature. 
Yield: 0.57 g, 0.76 mmol, 42% 





1H NMR (400 MHz, MeOD): δ8.15 (ddd, 1H, J = 8.5, 7.0, 1.5 Hz), δ8.09, 1H, (ddd, 
J = 8.5, 7.0, 1.5 Hz), δ8.00 (d, 1H, J = 8.5 Hz), δ7.90 (dd, 1H, J = 6.5, 1.0 Hz), δ7.89 
(m, 5H), δ7.80 (dd, 1H, J = 7.0, 1.0 Hz), δ7.68 (d, 2H, J = 6.5 Hz), δ7.54 (d, 1H, J = 
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8.5 Hz), δ7.47 (d,1H, J = 8.0 Hz), δ7.31 (ddd, 1H, J = 8.5, 5.0, 3.0 Hz), δ7.22 (d, 1H, 




H} NMR (400 MHz, MeOD): δ154.7, δ153.6, δ152.3, δ152.1, δ150.2, δ147.3, 
δ142.0, δ141.6, δ141.0, δ137.3, δ135.1, δ129.4, δ124.6, δ121.2, δ120.3, δ120.2, 
δ120.0, δ114.4, δ113.8, δ113.6, δ112.5 
IR (KBr disc) / cm
-1
:3427, 3323, 3183, 3043, 1658, 1561, 1471, 1391, 1379, 1301, 
1277, 1155, 1033, 1016, 821, 675 
 
Preparation of [Co(tpz)(dpHa)2]Cl2 
Two equivalents dpHa (0.16 g, 0.96 mmol) and one equivalent CoCl2.6H2O (0.11 g, 
0.47 mmol) were stirred together in 20 mL EtOH to afford a blue suspension. One 
equivalent tpzH (0.09 g, 0.48 mmol) was added, causing the reaction mixture to turn 
dark red. After 20 minutes stirring, one equivalent K2S2O8 (0.22 g, 0.81 mmol) was 
added and this was stirred for 2 hours. The reaction mixture was filtered then Et2O 
added to the filtrate to cause the formation of a dark red-purple precipitate. The 
precipitate was isolated by filtration, washed with Et2O and dried in vacuo to afford 
the product as a dark red-purple solid. Yield: 0.064 g, 0.098 mmol, 21% 





1H NMR (400 MHz, MeOD): δ8.14 (ddd, 1H, J = 8.5, 7.0, 1.5 Hz), δ8.09, 1H, (ddd, 
J = 8.5, 7.0, 1.5 Hz), δ8.00 (d, 1H, J = 8.5 Hz), δ7.90 (dd, 1H, J = 6.5, 1.0 Hz), δ 7.89 
(m, 5H), δ7.80 (dd, 1H, J = 7.0, 1.0 Hz), δ7.67 (d, 2H, J = 6.5 Hz), δ7.54 (d, 1H, J = 
8.0 Hz), δ7.47 (d,1H, J = 8.0 Hz), δ7.31 (ddd, 1H, J = 8.5, 5.0, 3.0 Hz), δ7.22 (d, 1H, 
J = 8.5 Hz), δ7.21 (d,1H, J = 8.5 Hz), δ7.15 (m, 4H) 
 
Preparation of [Cu(tpz)(dpHa)]Cl 
[Cu(dpHa)2]Cl2 (0.23g, 0.49 mmol) was added to a stirred suspension of one 
equivalent tpzH (0.09 g, 0.49 mmol) in 15 mL EtOH, causing the reaction mixture to 
gradually turn dark red. After 1 hour of stirring the reaction mixture was filtered, 
before the solvent was dried off from the filtrate to give the crude product as a dark 
red powder which was then recrystallised from hot EtOH.  
Yield: 0.09 g, 0.21 mmol, 46% 
MS ESI (+ve ion) / mz: 411.05 
CHN Analysis; found: %C 45.88, %H 4.86, %N 19.21; calculated (for 
CuC17H14N7O2Cl): %C 45.64, %H 3.15, %N 21.92 




7.4.2. Preparation of heteroleptic complexes containing tpzH-CN 
Preparation of [Co(tpz-CN)(dpHa)]Cl 
One equivalent tpzH-CN (0.038 g, 0.19 mmol) was added to a stirred suspension of 
[Co(Cl)2(dpHa)] (0.05 g, 0.17 mmol) in 10 mL EtOH, causing it to turn from blue to 
purple. After 1 hour of stirring, the solid was isolated by filtration and washed with 
EtOH then Et2O. The solid was dissolved in the minimum amount MeOH. The 
solvent was dried off from the filtrate to afford the product as a purple solid.  
Yield: 0.045g, 0.01 mmol, 57% 
MS ESI (+ve) / m/z: 431.05 
 
Preparation of [Co(tpz-CN)(dpHa)2]BF4 
Two equivalents dpHa (0.65 g, 3.80 mmol) was added to a stirred solution of 
Co(BF4)2.6H2O (0.65 g, 1.90 mmol) in 15 mL EtOH, causing the reaction mixture to 
turn orange. To this, one equivalent tpzH-CN (0.37 g, 1.83 mmol) was added, 
causing the solution to gradually turn dark red. This was stirred for 0.5 hours before 
K2S2O8 (0.55 g, 2.03 mmol) was added. The reaction mixture was heated at reflux 
overnight. The reaction mixture was allowed to cool then filtered. Et2O was added to 
the filtrate, and the resulting precipitate was isolated by filtration in vacuo. 
Yield: 0.57 g, 0.74 mmol, 40% 






H NMR (d6-DMSO, 700 MHz) of [Co(tpz-CN)(dpHa)2](BF4)2. δ8.16 (t, 1H, J = 7.3 
Hz), δ8.10 (m, 1H), δ8.07 (d, 1H, J = 4.8 Hz,), δ7.99 (d, 1H, J = 8.5), δ9.96 (d, 1H, J 
= 8.6 Hz), δ7.94 (s, 1H), δ7.90 (t, 1H), δ7.89 (t, 1H), δ 7.88 (t, 1H), δ7.73 (d, 1H, J = 
5.7 Hz), δ7.61 (d, 1H, J = 5.0 Hz), δ 7.58 (d, 1H, J = 5.0 Hz), δ 7.52 (d, 1H, J = 8.3 
Hz), δ7.46 (d, 1H, J = 8.0 Hz), δ7.42 (t, 1H, J = 7.7 Hz), δ7.24 (d, 1H, J = 7.8 Hz), 
δ7.18 (t, 1H, J = 6.1 Hz), δ7.15 (d, 1H, J = 8.4 Hz), δ7.04 (t, 1H), δ7.03 (t, 1H), 
δ7.02 (t, 1H) 
1
H (400 MHz, MeOD): δ8.12 (m, 2H), δ8.07 (dd, 1H, J = 8.5, 1.0 Hz), δ8.01 (dd, 
1H, J = 8.5, 1.0 Hz), δ7.88 (m, 5H), δ7.70 (dd, 1H, J = 6.0, 1.5 Hz), δ7.60 (dd, 3H, J 
= 7.5, 1.0 Hz), δ7.41 (ddd, 1H, J = 8.5, 7.5, 1.0 Hz), δ7.33 (dd, 1H, J = 7.5, 1.0 Hz), 
δ7.20 (dd, 1H, J = 8.0, 1.0 Hz), δ7.10 (m, 3H), δ7.03 (ddd, 1H, J = 7.0, 6.5, 1.0 Hz) 






H} NMR (400 MHz, d6-DMSO): δ155.48, δ154.27, δ152.81, δ151.78, δ151,32, 
δ149.72, δ147.67, δ142.09, δ141.55, δ136.13, δ133.15, δ130.74, δ125.75, δ120.78, 
δ120.74, δ120.06, δ116.02, δ114.79, δ114.35, δ113.92, δ112.13, δ110.82 
IR (KBr disc) / cm
-1
: 3351 (NH), 3257 (NH), 2241 (C≡N), 1641, 1588, 1576, 1532, 
1488 1389, 1375, 1230, 1159, 1109, 1046, 1018, 851, 775, 609, 5306 
CHN Analysis; found: %C 42.86, %H 3.20, %N 16.94; calculated (for 
CoC29H23N10O2B2F8): %C 44.88, %H 2.99, %N 18.05 
 
Preparation of [Co(tpz-CN)(dpma)2](BF4)2  
Co(BF4)2.6H2O (0.12 g, 0.36 mmol) was added to a stirred solution of two 
equivalents dpma (0.15 g, 0.81 mmol) in 10 mL EtOH, causing it to change from 
yellow to orange. After 10 minutes stirring, one equivalent tpzH-CN (0.08 g, 0.37 
mmol) was added and then, after an additional 0.5 hours stirring, two equivalents 
K2S2O8 (0.12g, 0.44 mmol) were added. The reaction mixture was heated at reflux 
overnight then allowed to cool. The reaction mixture was filtered then Et2O added to 
the dark purple filtrate to cause a purple solid to form. This was then isolated by 
filtration in vacuo then the solid dissolved in EtOH and filtered. The solvent was 
dried off from the filtrate to yield the product as a dark purple solid. 
Yield: 0.067 g, 0.083 mmol, 23% 






Preparation of [Cu(tpz-CN)(dpHa)]Cl 
[Cu(dpHa)2]Cl2 (0.29g, 0. 58 mmol) was added to a stirred suspension of one 
equivalent tpzH-CN (0.12 g, 0.59 mmol) in 10 mL EtOH, causing the reaction 
mixture to gradually turn dark red. After 2 hours of stirring the reaction mixture was 
filtered to isolate a dark red solid. This was then dissolved in MeOH and filtered. 
The solvent was dried off from filtrate to give the product as a dark red powder. 
Diffraction quality dark red crystals were obtained after several days of slow 
evaporation of the ethanolic filtrate under ambient conditions. 
Yield: 0.1853 g, 0.39 mmol, 68% 
MS ESI (+ve) / m/z: 435.05 
IR (KBr disc) / cm
-1
: 3353 (NH), 3256 (NH), 2237 (C≡N), 1636, 1588, 1526, 1476, 
1351, 1230, 1159, 1109, 1046, 1018, 851, 775, 609, 530 
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CHN Analysis; found: %C 46.58, %H 3.54, %N 19.48; calculated (for 
CuC19H14N7O2Cl): %C 48.41, %H 2.99, %N 20.80; calculated (for 
CuC19H16N7O3Cl): %C 46.63, %H 3.30, %N 20.04 
 
Preparation of [Zn(tpz-CN)(dpHa)]BF4 
Two equivalents dpHa (0.035 g, 0.16 mmol) were stirred in EtOH with 0.024 g 
Zn(BF4)2 (0.16 mmol) for 10 minutes. To this, 0.032 g tpzH-CN (0.16 mmol) was 
added, gradually forming a crimson precipitate during 30 minutes stirring. The 
precipitate was isolated by filtration and washed with EtOH and Et2O. Dark red 
crystals suitable for x-ray diffraction were obtained by slow evaporation from a 
solution of MeOH and 
n
BuOH.  
Yield: 0.028 g, 0.054 mmol, 85% 




H NMR (MeOD, 400 MHz): 8.43 (d, 2H, J = 4.3 Hz, pyridyl-H), 8.21 (d, 1H, J = 
8 Hz, phenyl-H), 8.17 (d, 1H, J = 8.8 Hz, phenyl-H), 7.88 (t, 2H, J = 7.8 Hz, 
pyridyl-H), 7.80 (t, 1H, J = 7.9 Hz, phenyl-H), 7.39 (t, 1H, J = 7.9 Hz, phenyl-H), 
7.20 (d, 2H, J = 7.13 Hz, pyridyl-H), 7.13 (t, 2H, J = 6 Hz, pyridyl-H)  
1
H NMR (d6-DMSO, 400 MHz):  10.24 (br. s, 1H, pyridyl-NH), 8.38 (d, 2H, J = 
4.0 Hz, pyridyl-H), 8.18 (ap. t, 2H, J = 9.5 Hz, phenyl-H), 7.91 (ddd, 1H, J = 8.0, 
7.0, 1.0 Hz, phenyl-H), 7.85 (ap. t, 2H, J = 7.0 Hz, pyridyl-H), 7.46 (m, 3H, 





H} NMR (d6-DMSO, 400 MHz): 152.25, 150.20, 147.37, 139.94, 135.56, 
135.47, 124.59, 119.97, 117.08, 116.22, 113.66, 111.82 
IR (KBr disc) / cm
-1
: 3525, 3337, 3086, 2238 (CN), 1641, 1590, 1564, 1530, 1479.3, 
1438, 1421, 1377, 1269, 1226, 1193, 1164, 1137, 1057, 1012, 770 
CHN Analysis; found: %C 43.76, %H 3.46, %N 16.97; calculated (for 
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7.4.3. Preparation of heteroleptic complexes containing tpzH-CONH2 
Preparation of [Co(tpz-CONH2)(dpHa)2]2NO3: 
Two equivalents tpzH-CONH2 (0.059 g, 0.27 mmol) were added to a stirred solution 
of Co(NO3)2.6H2O (0.051 g, 0.18 mmol) and dpHa (0.033 g, 0.19 mmol) in 10 mL 
EtOH. After two hours stirring, two equivalents K2S2O8 (0.11 g, 0.40 mmol) were 
added then the reaction mixture was left to heat at reflux overnight. 
Red-pink crystals suitable for diffraction were obtained through slow evaporation 
from a solution of MeOH layered over 
n
BuOH. 
Yield: 0.026 g, 0.035 mmol, 19% 




H NMR (400 MHz, D2O): δ8.05 (m, 2H), δ7.94 (m, 4H), δ7.75 (m, 3H), δ7.57 (d, 
1H, J = 6.0 Hz), δ7.50 (m, 2H), δ7.45 (d, 1H, J = 8.0 Hz), δ7.32 (d, br.d, 1H, J = 8.0 
Hz), δ7.15 (d, 1H, J = 8.0 Hz), δ7.05 (d, 1H, J = 8.0 Hz), δ6.98 (m, 3H), δ6.93 (t, 1H, 
J = 6.0 Hz) 
 
Preparation of [Cu(tpz-CONH2)(dpHa)]Cl 
One equivalent [Cu(dpHa)2]2Cl (0.05 g, 0.09 mmol) dissolved in 5 mL EtOH was 
added to a stirred suspension of tpzH-CONH2 (0.02 g, 0.10 mmol) in 10 mL EtOH, 
causing it to gradually change from orange to brown to red. After 2.5 hours stirring, 
the dark red solid was isolated by filtration in vacuo before being washed with cold 
EtOH then Et2O. Diffraction quality dark red crystals were obtained by allowing a 
methanolic solution layered over 
n
BuOH to slowly evaporate over the course of a 
few days at room temperature. 
Yield: 0.02 g, 0.05 mmol, 48% 
CHN Analysis; found: %C 46.28, %H 3.37, %N 19.47; calculated (for 
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7.5. Chapter Five Experimental Procedures 
Spectrophotometric pH titrations 
Titrations were carried out using 100 mL solution to minimise alterations in 
concentration and maintained at 0.1 M ionic strength with KNO3 with the analyte at 
an appropriate concentration for the monitoring of its absorbance. Solutions of the 
complexes were adjusted to a basic pH with NaOH(aq) and titrated with HCl(aq) and 
where needed, the complexes were dissolved in the minimum amount DMSO before 
being added to the aqueous solution. Solutions of the uncoordinated ligands were 
adjusted to an acidic pH with HCl(aq) and then titrated with NaOH(aq).  
 
Cyclic Voltammetry 
Electrochemical solutions were carried out either in DMSO or H2O. With DMSO, 
the solutions contained 0.1 M Bu4NPF6 as the supporting electrolyte and referenced 
against the ferrocene redox couple for this system (0.48 V). The potential was swept 
from 0 V to -1.75 V then to 0.6 V.  For aqueous measurements, 0.1 M KCl was used 





redox couple. The potential was swept from 0.4 V to -0.4 V then to 0.4 V.  The 
solutions were purged with N2 for 10 minutes prior to measurements being taken and 
samples were used at 1*10
-3
 M concentration. 
 
Experiments following reduction by biological agents 
All solutions were buffered using an appropriate buffer for the pH range (HEPES, 
MES, acetic acid). For anaerobic experiments the solutions were purged with N2 and 
injected into a quartz cuvette sealed with a suba-seal. 10-fold excesses of the 
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7.6. Chapter Six Experimental Procedures 
A549 (human lung adenocarcinoma epithelial) cells were kindly provided by the 
Department of Biology at the University of York. The cells were maintained in 
Dulbeco’s modified Eagle medium (DMEM) supplemented with 1% 2 mmol dm-3 L-
glutamine, 10% foetal bovine serum and 50 mmol dm
-3
 sodium pyruvate. The cells 
were kept in a humidified incubator maintained with 5% CO2 at 37°C. All 
manipulations were carried out in a class II laminar flow hood under a filtered 
laminar air flow. Upon reaching ca. 75% confluence, the medium was removed and 
the cells washed twice with 5 mL PBS. To remove the cells from the flask, they were 
then incubated with 1 mL 0.25% EDTA trypsin for 10 minutes at 37 °C. 9 mL 
medium added to the cells to form a single suspension. 0.5 and 1.0 mL of the 
resulting supernatant were added to two new culture flasks, each containing 10 mL 
of fresh medium. 
Cells were plated in 100 μL medium at the seeding density of 1000 cells per well 
into 11 of the 12 columns of a 96-well microtitre plate with the first column 
containing just media so to act as negative control. The plate was incubated for 20 
hours to allow them to adhere to the plate. The compounds were dissolved in 
medium to form solutions of the required concentrations, which were sterilised 
before addition to the plate.  
Following 3 days incubation, 100 μg MTT (150 μL of 2 mg mL-1) were added to 
each well then the plates incubated for two hours. The plates were centrifuged at 450 
g for 10 minutes then 220 μL of the supernatant removed from each well. 150 μL 
DMSO was added to each well to solubilise the MTT formazan crystals, which 
become fully dissolved during 5 minutes agitation on a plate shaker.
195
 The 
absorbance at 540 nm of each well was measured using an automated plate reader. 
The absorbance at 540 nm for positive and negative controls was used to calculate 
the absorbance for 100% and 0% cell viability, and from this, the percentage cell 
viability for each of the drug concentrations was calculated. The percentage cell 
viability was plotted as a function of drug concentration, and to this a logistic 
sigmoidal curve was fitted. From the curve, a value for the IC50 (concentration at 
which the cell viability has been halved) could be obtained graphically.  
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A2780 Human ovarian carcinoma cells 
A549 Human Caucasian lung carcinoma cells 
AA8 Chinese Hamster ovarian cells 
ARNT Aryl hydrocarbon receptor nuclear translocator 
ATP Adenosine triphosphate 
ap. apparent 
Atx Copper chaperone protein 
br. Broad 
Bu Butyl 
CA Carbonic anhydrase 
conc. Concentrated  
COSY  Correlation spectroscopy 
COX Cyclooxygenase enzyme 
Ctr1  Membrane copper transporter 
CV Cyclic voltammetry 
cyclam 1,4,8,11-tetraazacyclotetradecane 
d (NMR) Doublet 
DCM Dichloromethane 
DLD-1 Human colon adenocarcinoma cells 
δ Chemical shift  
ΔE Peak separation  
DMEM Dulbecco's modiﬁed Eagle's medium 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 





E1/2 Half wave potential 
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EDTA Ethylenediaminetetraacetic acid 
EMT6  Mouse mammary carcinoma cells 
EPR Electron paramagnetic spectroscopy 
Eox Oxidation potential 
equiv. Equivalents 
Ered Reduction potential 
ESI Electrospray ionisation 
Et Ethyl 
FBS Foetal bovine serum  
FMISO Fluoromisonidazole 
g Relative centrifugal force 
GLUT Glucose transporter protein 
GSH Glutathione 
HIF-1 Hypoxia inducible factor 1 
HMBC Heteronuclear Multiple Bond Correlation 
HSQC Heteronuclear Single Quantum Coherence 
H226  Human lung squamous carcinoma cells 
HT29 Human Caucasian colon adenocarcinoma cells  
H460 Human Non-small lung cancer cells 
i(prefix) Iso 
in vacuo Under reduced pressure 
Iox Oxidation current 
Iox Oxidation  current 
IR Infra red 
Ired Reduction current 
K562 Human Caucasian chronic myelogenous leukaemia cells 
λ Wavelength 
m Milli 
M  Metal 
m/z Mass to charge ratio 
MCF7 Human Caucasian breast adenocarcinoma cells  
MCT monocarboxylate transporter protein 
Me Methyl 
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MDA-MB 231 Human Caucasian breast adenocarcinoma cells  
μ Micro 
MMP Matrix metalloproteinase 
MS Mass spectrometry 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
mV Milli volts 





 co-transporter protein 





 membrane transporter protein 
NMR Nuclear magnetic resonance 
OAc Acetate 
ORTEP Oak Ridge Thermal Ellipsoid Programme 
OTf trifluoromethanesulfonate 
PBS Phosphate buffer solution 
PHD Prolyl hydroxylase enzyme  
phen 1,10-phenanthroline 
py Pyrrolidine 
q (NMR) Quintet 
s (NMR) Singlet 
t (NMR) Triplet 
tpzH 3-amino-1,2,4 –benzotriazine-N1,N4-oxide 
tpzH-CN 3-aminoquinoxaline-2-carbonitrile-N1,N4-oxide 
tpzH-CONH1 3-aminoquinoxaline-2-amido- N1,N4-oxide 
UV Ultraviolet 
UV4 Mutant Chinese Hamster ovarian cells 
V Volts 
VEGF Vascular endothelial growth factor 
vis Visible 
V79 Chinese Hamster lung fibroblast cells 
xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 
XRD X-ray diffraction 

































































































































Appendix 5: Electrochemical data for [Cu(dpHa)2]Cl2 at varied scan rates in H2O 
 
ν1/2 / mV s-1 Ered / V Ired / μA Eox / V Iox / μA ΔE / V Iox/Ired 
7.1 -0.074 -22.0 0.040 26.50 0.11 -1.2 
8.7 -0.080 -26.3 0.045 32.00 0.13 -1.2 
10.0 -0.077 -30.1 0.050 35.00 0.13 -1.2 
12.2 -0.091 -35.3 0.050 47.60 0.14 -1.4 
14.1 -0.092 -41.1 0.059 55.00 0.15 -1.3 
15.8 -0.109 -45.2 0.057 62.40 0.17 -1.4 
17.3 -0.107 -49.3 0.060 62.40 0.17 -1.3 
20.0 -0.086 -55.5 0.062 72.10 0.15 -1.3 

















Appendix 6: IC50 data for the compounds reported within this thesis 
IC50 data for tpzH and tpzH-CN against A549 cells 
 tpzH tpzH-CN 
plate 1 IC50 / μM 166.7198 165.5346 
plate 1 errors 9.28159 10.257 
plate 2 IC50 / μM 167.9529 135.766 
plate 2 errors 9.80719 5.89943 
plate 3 IC50 / μM 185.4239 142.48 
plate 3 errors 15.1865 9.6964 
Mean/ IC50 μM 170.285377 143.0166726 
error 6.2 4.5 
 
IC50 data for [Cu(dpHa)2]Cl2 and [Cu(tpz)(dpHa)]Cl against A549 cells 
 [Cu(dpHa)2]Cl2 [Cu(tpz)(dpHa)]Cl 
plate 1 IC50 / μM 52.3054 44.1623 
plate 1 errors 1.72019 4.71266 
plate 2 IC50 / μM 52.9496 45.137 
plate 2 errors 1.62683 3.48761 
plate 3 IC50 / μM 54.3705 44.8474 
plate 3 errors 1.17799 3.24293 
Mean/ IC50 μM 53.51087956 44.81574974 








































 [Co(tpz)(dpHa)2]Cl2 [Co(tpz-CN)(dpHa)2]Cl2 
plate 1 IC50 / μM 52.113 164.115 
plate 1 errors 5.5061 13.9674 
plate 2 IC50 / μM 61.09 157.852 
plate 2 errors 7.6159 3.88064 
plate 3 IC50 / μM 62.1932 138.9426 
plate 3 errors 2.35108 74.02022 
Mean/ IC50 μM 60.67240249 158.2515222 





Appendix 7: Crystallographic data 
Crystallographic data for [Cu(Cl)(dpHa)2]Cl    
Table 1.  Crystal data and structure refinement for phw1009m. 
Identification code  phw1009m 
Empirical formula  C20 H18 Cl2 Cu N6 
Formula weight  476.84 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.7191(19) Å = 90°. 
 b = 14.334(3) Å = 98.896(5)°. 
 c = 14.571(3) Å  = 90°. 
Volume 2005.4(7) Å3 
Z 4 
Density (calculated) 1.579 Mg/m3 
Absorption coefficient 1.375 mm-1 
F(000) 972 
Crystal size 0.36 x 0.24 x 0.16 mm3 
Theta range for data collection 2.00 to 28.34°. 
Index ranges -12<=h<=12, -19<=k<=19, -19<=l<=19 
Reflections collected 20466 
Independent reflections 4988 [R(int) = 0.0579] 
Completeness to theta = 28.34° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.803 and 0.575 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4988 / 0 / 270 
Goodness-of-fit on F2 1.037 
Final R indices [I>2sigma(I)] R1 = 0.0406, wR2 = 0.0909 
R indices (all data) R1 = 0.0591, wR2 = 0.0998 












 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw1009m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 9572(3) -465(2) 1665(2) 23(1) 
C(2) 10554(3) -760(2) 1144(2) 27(1) 
C(3) 11422(3) -94(2) 836(2) 28(1) 
C(4) 11269(3) 824(2) 1064(2) 24(1) 
C(5) 10247(3) 1078(2) 1604(2) 19(1) 
C(6) 8289(3) 2453(2) 3715(2) 19(1) 
C(7) 8802(3) 3301(2) 4037(2) 22(1) 
C(8) 9804(3) 3738(2) 3600(2) 22(1) 
C(9) 10259(3) 3296(2) 2861(2) 21(1) 
C(10) 9670(3) 2434(2) 2561(2) 17(1) 
C(11) 5215(3) 1877(2) 2472(2) 22(1) 
C(12) 3910(3) 2135(2) 2613(2) 24(1) 
C(13) 3212(3) 1561(2) 3160(2) 24(1) 
C(14) 3830(3) 759(2) 3528(2) 21(1) 
C(15) 5181(3) 539(2) 3354(2) 17(1) 
C(16) 9453(3) -405(2) 3802(2) 20(1) 
C(17) 9817(3) -1165(2) 4357(2) 22(1) 
C(18) 8764(3) -1681(2) 4661(2) 23(1) 
C(19) 7407(3) -1384(2) 4441(2) 20(1) 
C(20) 7119(3) -577(2) 3897(2) 16(1) 
Cl(1) 6590(1) 904(1) 890(1) 24(1) 
Cl(2) 1465(1) 3415(1) 536(1) 24(1) 
Cu(1) 7663(1) 779(1) 2407(1) 17(1) 
N(1) 9402(2) 440(2) 1899(1) 19(1) 
N(2) 10141(2) 2007(2) 1815(2) 19(1) 
N(3) 8689(2) 2020(1) 2969(1) 17(1) 
N(4) 5867(2) 1082(1) 2833(1) 18(1) 
N(5) 5764(2) -267(2) 3744(2) 18(1) 











 Table 3.   Bond lengths [Å] and angles [°] for  phw1009m. 
_____________________________________________________  
C(1)-N(1)  1.357(3) 
C(1)-C(2)  1.375(4) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.393(4) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.371(4) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.406(3) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.343(3) 
C(5)-N(2)  1.375(3) 
C(6)-N(3)  1.360(3) 
C(6)-C(7)  1.369(4) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.392(4) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.380(4) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.402(3) 
C(9)-H(9)  0.9500 
C(10)-N(3)  1.338(3) 
C(10)-N(2)  1.384(3) 
C(11)-C(12)  1.366(4) 
C(11)-N(4)  1.369(3) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.394(4) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.367(4) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.411(3) 
C(14)-H(14)  0.9500 
C(15)-N(4)  1.335(3) 
C(15)-N(5)  1.371(3) 
C(16)-N(6)  1.363(3) 
C(16)-C(17)  1.370(4) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.390(4) 





C(18)-C(19)  1.376(4) 
C(18)-H(18)  0.9500 
C(19)-C(20)  1.407(3) 
C(19)-H(19)  0.9500 
C(20)-N(6)  1.347(3) 
C(20)-N(5)  1.375(3) 
Cl(1)-Cu(1)  2.3013(8) 
Cu(1)-N(4)  1.989(2) 
Cu(1)-N(1)  2.007(2) 
Cu(1)-N(6)  2.075(2) 
Cu(1)-N(3)  2.139(2) 
N(2)-H(2A)  0.81(3) 



































































































Symmetry transformations used to generate equivalent atoms:  




Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw1009m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 29(2)  22(1) 18(1)  0(1) 3(1)  4(1) 
C(2) 34(2)  27(1) 21(1)  -1(1) 3(1)  11(1) 
C(3) 24(2)  42(2) 17(1)  -2(1) 5(1)  10(1) 
C(4) 22(1)  32(2) 17(1)  -1(1) 4(1)  1(1) 
C(5) 17(1)  27(1) 13(1)  0(1) 1(1)  3(1) 





C(7) 20(1)  25(1) 20(1)  -4(1) 1(1)  4(1) 
C(8) 23(2)  18(1) 24(1)  -1(1) -2(1)  2(1) 
C(9) 20(1)  21(1) 21(1)  5(1) 2(1)  1(1) 
C(10) 17(1)  19(1) 16(1)  6(1) 1(1)  5(1) 
C(11) 25(1)  20(1) 20(1)  -2(1) 0(1)  2(1) 
C(12) 22(1)  23(1) 25(1)  -1(1) -2(1)  8(1) 
C(13) 16(1)  31(2) 25(1)  -7(1) -1(1)  7(1) 
C(14) 15(1)  26(1) 21(1)  -3(1) 2(1)  1(1) 
C(15) 14(1)  21(1) 15(1)  -4(1) -1(1)  1(1) 
C(16) 14(1)  27(1) 19(1)  0(1) 2(1)  1(1) 
C(17) 17(1)  26(1) 22(1)  -1(1) 0(1)  6(1) 
C(18) 26(2)  20(1) 23(1)  1(1) 2(1)  5(1) 
C(19) 22(1)  17(1) 20(1)  1(1) 4(1)  -1(1) 
C(20) 15(1)  19(1) 14(1)  -4(1) 1(1)  2(1) 
Cl(1) 27(1)  26(1) 17(1)  0(1) 1(1)  5(1) 
Cl(2) 20(1)  27(1) 26(1)  5(1) 11(1)  4(1) 
Cu(1) 17(1)  18(1) 17(1)  1(1) 4(1)  2(1) 
N(1) 21(1)  19(1) 18(1)  0(1) 4(1)  2(1) 
N(2) 21(1)  20(1) 19(1)  2(1) 10(1)  -2(1) 
N(3) 17(1)  19(1) 16(1)  1(1) 4(1)  1(1) 
N(4) 19(1)  17(1) 17(1)  -1(1) 0(1)  1(1) 
N(5) 16(1)  19(1) 20(1)  2(1) 5(1)  -2(1) 




 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw1009m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 8978 -919 1872 28 
H(2) 10639 -1401 998 33 
H(3) 12110 -273 473 33 
H(4) 11851 1288 859 28 
H(6) 7622 2153 4027 23 
H(7) 8478 3587 4552 26 
H(8) 10168 4329 3807 27 





H(11) 5696 2271 2105 26 
H(12) 3491 2690 2344 29 
H(13) 2309 1726 3278 29 
H(14) 3359 358 3894 25 
H(16) 10177 -58 3591 24 
H(17) 10767 -1335 4529 27 
H(18) 8979 -2232 5017 28 
H(19) 6675 -1720 4654 23 
H(2A) 10600(30) 2370(20) 1550(20) 24(8) 



































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 7.  Hydrogen bonds for phw1009m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(5)-H(5)...Cl(2)#1 0.76(2) 2.42(3) 3.173(2) 171(2) 
 N(2)-H(2A)...Cl(2)#2 0.81(3) 2.35(3) 3.152(2) 168(3) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





Crystallographic data for [Co(Cl)2(dpHa)2] 
  Table 1.  Crystal data and structure refinement for phw0805m. 
Identification code  phw0805m 
Empirical formula  C20.50 H21 Cl2 Co N6 O 
Formula weight  497.26 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 7.8029(5) Å = 90°. 
 b = 16.0834(9) Å = 95.5590(10)°. 
 c = 16.7459(10) Å  = 90°. 
Volume 2091.7(2) Å3 
Z 4 
Density (calculated) 1.579 Mg/m3 
Absorption coefficient 1.102 mm-1 
F(000) 1020 
Crystal size 0.20 x 0.10 x 0.04 mm3 
Theta range for data collection 1.76 to 28.29°. 
Index ranges -10<=h<=10, -21<=k<=21, -22<=l<=22 
Reflections collected 21119 
Independent reflections 5195 [R(int) = 0.0319] 
Completeness to theta = 28.29° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.957 and 0.821 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5195 / 0 / 319 
Goodness-of-fit on F2 1.043 
Final R indices [I>2sigma(I)] R1 = 0.0306, wR2 = 0.0742 
R indices (all data) R1 = 0.0431, wR2 = 0.0790 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0805m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Co(1) 7965(1) 8302(1) 1441(1) 17(1) 
C(1) 11088(2) 9150(1) 2339(1) 20(1) 
C(2) 11982(2) 9762(1) 2770(1) 22(1) 
C(3) 11108(2) 10253(1) 3284(1) 20(1) 
C(4) 9393(2) 10093(1) 3357(1) 20(1) 
C(5) 8581(2) 9445(1) 2905(1) 16(1) 
C(6) 6096(2) 8497(1) 2974(1) 17(1) 
C(7) 4937(2) 8304(1) 3537(1) 21(1) 
C(8) 4240(3) 7524(1) 3536(1) 29(1) 
C(9) 4695(3) 6945(1) 2974(1) 35(1) 
C(10) 5794(3) 7186(1) 2430(1) 27(1) 
N(1) 9387(2) 8997(1) 2380(1) 18(1) 
N(2) 6875(2) 9276(1) 3017(1) 17(1) 
N(3) 6483(2) 7958(1) 2409(1) 19(1) 
C(11) 6736(2) 6987(1) 235(1) 23(1) 
C(12) 5652(3) 6404(1) -136(1) 27(1) 
C(13) 3885(3) 6516(1) -119(1) 28(1) 
C(14) 3283(2) 7222(1) 220(1) 24(1) 
C(15) 4481(2) 7805(1) 565(1) 18(1) 
C(16) 4644(2) 9302(1) 961(1) 16(1) 
C(17) 3595(2) 10011(1) 851(1) 21(1) 
C(18) 4347(2) 10781(1) 929(1) 24(1) 
C(19) 6135(2) 10843(1) 1099(1) 23(1) 
C(20) 7065(2) 10120(1) 1194(1) 19(1) 
N(4) 6187(2) 7670(1) 607(1) 19(1) 
N(5) 3845(2) 8530(1) 866(1) 20(1) 
N(6) 6351(2) 9352(1) 1153(1) 16(1) 
Cl(1) 9745(1) 8682(1) 392(1) 25(1) 
Cl(2) 9979(2) 7103(1) 1761(1) 24(1) 
O(1) 9444(6) 5366(3) 942(3) 32(1) 
C(21) 10575(7) 7012(3) 2283(3) 48(1) 
O(2) 9198(5) 7124(2) 1682(2) 28(1) 









Table 3.   Bond lengths [Å] and angles [°] for  phw0805m. 
_____________________________________________________  
Co(1)-N(4)  2.1293(15) 
Co(1)-N(6)  2.1343(14) 
Co(1)-O(2)  2.145(4) 
Co(1)-N(1)  2.1482(14) 
Co(1)-N(3)  2.1526(14) 
Co(1)-Cl(1)  2.4209(5) 
Co(1)-Cl(2)  2.5115(13) 
C(1)-N(1)  1.359(2) 
C(1)-C(2)  1.371(2) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.393(3) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.379(2) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.403(2) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.339(2) 
C(5)-N(2)  1.390(2) 
C(6)-N(3)  1.338(2) 
C(6)-N(2)  1.391(2) 
C(6)-C(7)  1.404(2) 
C(7)-C(8)  1.368(3) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.394(3) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.366(3) 
C(9)-H(9)  0.9500 
C(10)-N(3)  1.355(2) 
C(10)-H(10)  0.9500 
N(2)-H(2A)  0.88(2) 
C(11)-N(4)  1.353(2) 
C(11)-C(12)  1.370(3) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.393(3) 
C(12)-H(12)  0.9500 





C(13)-H(13)  0.9500 
C(14)-C(15)  1.408(2) 
C(14)-H(14)  0.9500 
C(15)-N(4)  1.343(2) 
C(15)-N(5)  1.382(2) 
C(16)-N(6)  1.342(2) 
C(16)-N(5)  1.391(2) 
C(16)-C(17)  1.406(2) 
C(17)-C(18)  1.371(3) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.400(2) 
C(18)-H(18)  0.9500 
C(19)-C(20)  1.372(2) 
C(19)-H(19)  0.9500 
C(20)-N(6)  1.354(2) 
C(20)-H(20)  0.9500 
N(5)-H(5)  0.80(2) 
Cl(2)-H(2B)  0.94(5) 
O(1)-H(1A)  0.86(5) 
O(1)-H(1B)  0.82(5) 
C(21)-O(2)  1.410(5) 
C(21)-H(21A)  0.9800 
C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
O(2)-H(2B)  0.83(5) 
Cl(3)-H(1A)  0.54(6) 






























































































































Symmetry transformations used to generate equivalent atoms:  
  
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0805m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Co(1) 18(1)  17(1) 18(1)  -2(1) 4(1)  -1(1) 
C(1) 16(1)  25(1) 20(1)  2(1) 2(1)  2(1) 
C(2) 14(1)  27(1) 23(1)  5(1) -1(1)  -2(1) 
C(3) 21(1)  19(1) 20(1)  2(1) -3(1)  -4(1) 
C(4) 21(1)  18(1) 20(1)  2(1) 0(1)  0(1) 
C(5) 15(1)  17(1) 17(1)  4(1) 0(1)  0(1) 
C(6) 14(1)  18(1) 18(1)  1(1) -1(1)  0(1) 
C(7) 20(1)  24(1) 19(1)  -3(1) 4(1)  -2(1) 
C(8) 34(1)  30(1) 26(1)  -2(1) 13(1)  -11(1) 
C(9) 52(1)  23(1) 32(1)  -4(1) 18(1)  -16(1) 
C(10) 39(1)  17(1) 27(1)  -4(1) 11(1)  -5(1) 
N(1) 14(1)  20(1) 18(1)  1(1) 2(1)  0(1) 





N(3) 21(1)  17(1) 18(1)  0(1) 4(1)  -2(1) 
C(11) 27(1)  22(1) 20(1)  -2(1) 8(1)  -1(1) 
C(12) 39(1)  22(1) 21(1)  -6(1) 3(1)  -1(1) 
C(13) 36(1)  24(1) 23(1)  -3(1) -4(1)  -10(1) 
C(14) 23(1)  27(1) 21(1)  0(1) -2(1)  -7(1) 
C(15) 21(1)  20(1) 15(1)  0(1) 4(1)  -4(1) 
C(16) 16(1)  20(1) 14(1)  -1(1) 3(1)  -1(1) 
C(17) 14(1)  28(1) 21(1)  2(1) 3(1)  3(1) 
C(18) 23(1)  22(1) 28(1)  2(1) 2(1)  6(1) 
C(19) 25(1)  19(1) 25(1)  2(1) 0(1)  -3(1) 
C(20) 18(1)  20(1) 19(1)  1(1) 0(1)  -2(1) 
N(4) 20(1)  19(1) 18(1)  -2(1) 6(1)  -3(1) 
N(5) 12(1)  25(1) 23(1)  -3(1) 4(1)  -3(1) 
N(6) 14(1)  18(1) 16(1)  -1(1) 2(1)  -1(1) 
Cl(1) 12(1)  42(1) 22(1)  -5(1) 3(1)  -3(1) 
Cl(2) 22(1)  22(1) 27(1)  -1(1) -1(1)  4(1) 
O(1) 45(2)  28(2) 27(2)  1(2) 18(2)  3(2) 
C(21) 63(3)  38(3) 37(3)  -2(2) -24(3)  20(2) 
O(2) 23(2)  31(2) 30(2)  -5(1) -3(2)  8(2) 
Cl(3) 21(1)  23(1) 23(1)  4(1) 6(1)  4(1) 
______________________________________________________________________________  
 
 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0805m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 11692 8814 1993 24 
H(2) 13170 9850 2720 26 
H(3) 11685 10691 3580 24 
H(4) 8774 10416 3707 24 
H(7) 4642 8709 3914 25 
H(8) 3456 7378 3913 35 
H(9) 4251 6395 2969 42 
H(10) 6092 6791 2045 33 
H(2A) 6480(30) 9625(13) 3357(12) 22(5) 
H(11) 7941 6906 231 27 
H(12) 6093 5937 -396 32 





H(14) 2081 7315 222 29 
H(17) 2386 9958 726 25 
H(18) 3661 11269 868 29 
H(19) 6687 11370 1148 28 
H(20) 8281 10160 1294 23 
H(5) 2830(30) 8561(14) 759(13) 30(6) 
H(1A) 9790(70) 5230(40) 490(30) 39 
H(1B) 9760(60) 5850(30) 1030(30) 39 
H(21A) 11645 7209 2085 72 
H(21B) 10685 6421 2420 72 
H(21C) 10351 7330 2761 72 






























































































































Symmetry transformations used to generate equivalent atoms:  
 
 Table 7.  Hydrogen bonds for phw0805m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(2)-H(2B)...Cl(3) 0.83(5) 2.34(5) 3.159(4) 166(4) 
 O(1)-H(1B)...Cl(2) 0.82(5) 2.36(6) 3.123(5) 155(5) 
 N(5)-H(5)...Cl(1)#1 0.80(2) 2.43(2) 3.2295(16) 178(2) 
 N(2)-H(2A)...Cl(3)#2 0.88(2) 2.39(2) 3.265(2) 175.9(18) 
 N(2)-H(2A)...O(1)#2 0.88(2) 1.87(2) 2.744(4) 178(2) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





   Crystallographic data for [Co(CO)3(dpHa)2]NO3  
  Table 1.  Crystal data and structure refinement for phw0906m. 
Identification code  phw0906m 
Empirical formula  C21 H18 Co N7 O6 
Formula weight  523.35 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 10.7832(7) Å = 90°. 
 b = 13.1835(9) Å = 93.4550(10)°. 
 c = 15.4280(10) Å  = 90°. 
Volume 2189.3(3) Å3 
Z 4 
Density (calculated) 1.588 Mg/m3 
Absorption coefficient 0.840 mm-1 
F(000) 1072 
Crystal size 0.35 x 0.10 x 0.07 mm3 
Theta range for data collection 2.03 to 28.31°. 
Index ranges -14<=h<=14, -17<=k<=17, -20<=l<=20 
Reflections collected 22341 
Independent reflections 5450 [R(int) = 0.0198] 
Completeness to theta = 28.31° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.944 and 0.826 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5450 / 0 / 324 
Goodness-of-fit on F2 1.055 
Final R indices [I>2sigma(I)] R1 = 0.0314, wR2 = 0.0788 
R indices (all data) R1 = 0.0347, wR2 = 0.0811 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0906m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 3835(1) 1868(1) 1575(1) 17(1) 
C(2) 4788(1) 1526(1) 2129(1) 19(1) 
C(3) 5799(1) 2168(1) 2324(1) 20(1) 
C(4) 5786(1) 3137(1) 1997(1) 19(1) 
C(5) 4731(1) 3469(1) 1496(1) 15(1) 
C(6) 1437(1) 5035(1) 711(1) 19(1) 
C(7) 1335(2) 6040(1) 929(1) 22(1) 
C(8) 2405(2) 6555(1) 1242(1) 24(1) 
C(9) 3510(2) 6040(1) 1340(1) 21(1) 
C(10) 3544(1) 5004(1) 1133(1) 16(1) 
C(11) 955(2) 2949(1) 1643(1) 19(1) 
C(12) -147(2) 2695(1) 1992(1) 25(1) 
C(13) -1016(2) 2121(1) 1494(1) 29(1) 
C(14) -746(2) 1806(1) 681(1) 23(1) 
C(15) 406(1) 2069(1) 369(1) 17(1) 
C(16) 4016(1) 1582(1) -471(1) 19(1) 
C(17) 4205(2) 786(1) -1024(1) 23(1) 
C(18) 3158(2) 319(1) -1438(1) 23(1) 
C(19) 1992(2) 629(1) -1243(1) 20(1) 
C(20) 1869(1) 1421(1) -647(1) 16(1) 
C(21) 2960(1) 3992(1) -1027(1) 17(1) 
Co(1) 2670(1) 3196(1) 287(1) 13(1) 
N(1) 3815(1) 2824(1) 1240(1) 15(1) 
N(2) 2527(1) 4520(1) 800(1) 15(1) 
N(3) 4637(1) 4480(1) 1288(1) 17(1) 
N(4) 1222(1) 2661(1) 825(1) 16(1) 
N(5) 2864(1) 1912(1) -295(1) 15(1) 
N(6) 697(1) 1698(1) -429(1) 17(1) 
O(1) 3851(1) 3761(1) -439(1) 17(1) 
O(2) 1872(1) 3701(1) -766(1) 17(1) 
O(3) 3137(1) 4413(1) -1725(1) 22(1) 
N(7) 8024(1) 503(1) 8506(1) 20(1) 
O(4) 7035(1) 418(1) 8062(1) 36(1) 
O(5) 8272(2) -56(1) 9139(1) 53(1) 









 Table 3.   Bond lengths [Å] and angles [°] for  phw0906m. 
_____________________________________________________  
C(1)-N(1)  1.3625(18) 
C(1)-C(2)  1.373(2) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.399(2) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.373(2) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.405(2) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.3451(19) 
C(5)-N(3)  1.3734(19) 
C(6)-N(2)  1.3572(19) 
C(6)-C(7)  1.373(2) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.399(2) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.372(2) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.405(2) 
C(9)-H(9)  0.9500 
C(10)-N(2)  1.3430(19) 
C(10)-N(3)  1.3745(19) 
C(11)-N(4)  1.3653(19) 
C(11)-C(12)  1.375(2) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.399(3) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.369(2) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.402(2) 
C(14)-H(14)  0.9500 
C(15)-N(4)  1.3437(19) 
C(15)-N(6)  1.379(2) 





C(16)-C(17)  1.375(2) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.406(2) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.373(2) 
C(18)-H(18)  0.9500 
C(19)-C(20)  1.403(2) 
C(19)-H(19)  0.9500 
C(20)-N(5)  1.3398(19) 
C(20)-N(6)  1.3758(19) 
C(21)-O(3)  1.2365(18) 
C(21)-O(1)  1.3169(18) 
C(21)-O(2)  1.3202(18) 
C(21)-Co(1)  2.3212(15) 
Co(1)-O(1)  1.8981(10) 
Co(1)-O(2)  1.9117(10) 
Co(1)-N(1)  1.9250(12) 
Co(1)-N(2)  1.9261(12) 
Co(1)-N(5)  1.9342(12) 
Co(1)-N(4)  1.9437(13) 
N(3)-H(3A)  0.84(2) 
N(6)-H(6A)  0.81(2) 
N(7)-O(4)  1.2379(18) 
N(7)-O(5)  1.2389(19) 


































































































































 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0906m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 18(1)  15(1) 17(1)  1(1) 2(1)  0(1) 
C(2) 22(1)  18(1) 17(1)  3(1) 2(1)  4(1) 
C(3) 19(1)  25(1) 17(1)  1(1) -1(1)  7(1) 
C(4) 16(1)  22(1) 18(1)  -3(1) -2(1)  0(1) 
C(5) 16(1)  17(1) 14(1)  -1(1) 1(1)  1(1) 
C(6) 18(1)  19(1) 19(1)  2(1) -1(1)  2(1) 
C(7) 23(1)  19(1) 23(1)  1(1) 2(1)  7(1) 
C(8) 30(1)  16(1) 27(1)  -2(1) 3(1)  2(1) 
C(9) 23(1)  16(1) 25(1)  -3(1) 1(1)  -3(1) 
C(10) 17(1)  16(1) 15(1)  1(1) 1(1)  -1(1) 
C(11) 22(1)  18(1) 18(1)  1(1) 2(1)  1(1) 
C(12) 28(1)  26(1) 22(1)  1(1) 9(1)  2(1) 





C(14) 18(1)  24(1) 28(1)  1(1) 2(1)  -5(1) 
C(15) 17(1)  15(1) 19(1)  3(1) 0(1)  0(1) 
C(16) 17(1)  20(1) 20(1)  1(1) 0(1)  0(1) 
C(17) 22(1)  22(1) 24(1)  -2(1) 2(1)  4(1) 
C(18) 29(1)  18(1) 21(1)  -4(1) 0(1)  4(1) 
C(19) 24(1)  15(1) 20(1)  -1(1) -4(1)  -2(1) 
C(20) 18(1)  13(1) 16(1)  3(1) -1(1)  -1(1) 
C(21) 20(1)  14(1) 17(1)  -2(1) -1(1)  -3(1) 
Co(1) 13(1)  12(1) 13(1)  0(1) -1(1)  -1(1) 
N(1) 15(1)  14(1) 15(1)  0(1) 0(1)  1(1) 
N(2) 17(1)  14(1) 15(1)  0(1) -1(1)  0(1) 
N(3) 15(1)  15(1) 20(1)  -1(1) -3(1)  -2(1) 
N(4) 16(1)  15(1) 17(1)  1(1) 0(1)  1(1) 
N(5) 16(1)  14(1) 14(1)  1(1) 0(1)  -1(1) 
N(6) 15(1)  17(1) 19(1)  -2(1) -2(1)  -3(1) 
O(1) 16(1)  18(1) 16(1)  1(1) 0(1)  -3(1) 
O(2) 17(1)  18(1) 16(1)  1(1) -2(1)  -2(1) 
O(3) 25(1)  23(1) 18(1)  4(1) -2(1)  -7(1) 
N(7) 23(1)  16(1) 21(1)  1(1) -1(1)  -1(1) 
O(4) 25(1)  36(1) 45(1)  12(1) -14(1)  -9(1) 
O(5) 71(1)  41(1) 43(1)  24(1) -27(1)  -23(1) 





 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0906m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 3166 1422 1420 20 
H(2) 4761 866 2375 23 
H(3) 6490 1936 2681 24 
H(4) 6477 3575 2107 23 
H(6) 716 4686 488 23 
H(7) 556 6377 869 26 
H(8) 2366 7255 1385 29 





H(11) 1548 3336 1981 23 
H(12) -314 2906 2562 30 
H(13) -1790 1951 1718 34 
H(14) -1328 1417 334 28 
H(16) 4719 1915 -202 23 
H(17) 5021 559 -1123 27 
H(18) 3256 -208 -1849 27 
H(19) 1276 310 -1508 24 
H(3A) 5260(20) 4814(16) 1458(14) 28(5) 













































































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 7.  Hydrogen bonds for phw0906m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(6)-H(6A)...O(6)#1 0.81(2) 2.05(2) 2.8175(18) 159(2) 
 N(3)-H(3A)...O(3)#2 0.84(2) 2.02(2) 2.8553(17) 173(2) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





   Crystallographic data for [{Cu(Cl)2(dpma)}2]  
  Table 1.  Crystal data and structure refinement for phw0814m. 
Identification code  phw0814m 
Empirical formula  C22 H22 Cl4 Cu2 N6 
Formula weight  639.34 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.0435(11) Å = 101.376(3)°. 
 b = 8.6428(13) Å = 105.068(3)°. 
 c = 11.4144(17) Å  = 107.467(3)°. 
Volume 610.78(16) Å3 
Z 1 
Density (calculated) 1.738 Mg/m3 
Absorption coefficient 2.203 mm-1 
F(000) 322 
Crystal size 0.18 x 0.13 x 0.04 mm3 
Theta range for data collection 1.94 to 28.32°. 
Index ranges -9<=h<=9, -11<=k<=11, -15<=l<=15 
Reflections collected 6294 
Independent reflections 3013 [R(int) = 0.0377] 
Completeness to theta = 28.32° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.916 and 0.666 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3013 / 0 / 155 
Goodness-of-fit on F2 1.036 
Final R indices [I>2sigma(I)] R1 = 0.0439, wR2 = 0.0992 
R indices (all data) R1 = 0.0594, wR2 = 0.1048 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0814m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 7085(5) 8692(4) 10261(3) 15(1) 
C(2) 8279(5) 10399(4) 10687(3) 16(1) 
C(3) 8201(5) 11340(4) 9848(4) 18(1) 
C(4) 6875(6) 10545(4) 8597(3) 18(1) 
C(5) 5707(5) 8810(4) 8216(3) 14(1) 
C(6) 2178(5) 6973(4) 6781(3) 15(1) 
C(7) 460(6) 7133(5) 5947(3) 22(1) 
C(8) -1565(6) 6213(5) 5872(3) 25(1) 
C(9) -1856(6) 5178(5) 6648(3) 23(1) 
C(10) -99(6) 5023(5) 7417(3) 19(1) 
C(11) 4631(6) 8815(5) 6000(3) 25(1) 
Cl(1) 2932(2) 2704(1) 7000(1) 22(1) 
Cl(2) 2889(1) 5109(1) 10389(1) 14(1) 
Cu(1) 4295(1) 5361(1) 8434(1) 12(1) 
N(1) 5841(4) 7886(3) 9036(3) 13(1) 
N(2) 4282(5) 7940(4) 6956(3) 17(1) 




 Table 3.   Bond lengths [Å] and angles [°] for  phw0814m. 
_____________________________________________________  
C(1)-N(1)  1.350(4) 
C(1)-C(2)  1.372(4) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.374(5) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.385(5) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.389(4) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.347(4) 
C(5)-N(2)  1.418(4) 
C(6)-N(3)  1.347(4) 





C(6)-N(2)  1.404(4) 
C(7)-C(8)  1.379(5) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.387(6) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.379(5) 
C(9)-H(9)  0.9500 
C(10)-N(3)  1.351(4) 
C(10)-H(10)  0.9500 
C(11)-N(2)  1.475(4) 
C(11)-H(11A)  0.9800 
C(11)-H(11B)  0.9800 
C(11)-H(11C)  0.9800 
Cl(1)-Cu(1)  2.2911(9) 
Cl(2)-Cu(1)#1  2.2838(9) 
Cl(2)-Cu(1)  2.6874(9) 
Cu(1)-N(3)  1.993(3) 
Cu(1)-N(1)  2.004(3) 































































Symmetry transformations used to generate equivalent atoms:  







 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0814m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 16(2)  12(2) 14(2)  3(1) 4(1)  4(1) 
C(2) 14(2)  13(2) 19(2)  0(1) 6(1)  4(1) 
C(3) 16(2)  8(2) 29(2)  2(1) 9(2)  4(1) 
C(4) 24(2)  13(2) 22(2)  9(1) 12(2)  8(1) 
C(5) 18(2)  14(2) 13(2)  4(1) 9(1)  8(1) 
C(6) 21(2)  17(2) 9(2)  1(1) 4(1)  11(1) 
C(7) 32(2)  23(2) 13(2)  5(1) 5(2)  17(2) 
C(8) 26(2)  33(2) 11(2)  -2(2) 1(2)  17(2) 
C(9) 17(2)  32(2) 15(2)  -1(2) 5(2)  8(2) 
C(10) 20(2)  21(2) 11(2)  0(1) 5(1)  5(2) 
C(11) 40(2)  21(2) 16(2)  11(2) 14(2)  9(2) 
Cl(1) 32(1)  16(1) 14(1)  1(1) 2(1)  8(1) 
Cl(2) 17(1)  13(1) 14(1)  6(1) 6(1)  6(1) 
Cu(1) 15(1)  9(1) 9(1)  2(1) 1(1)  2(1) 
N(1) 14(1)  10(1) 12(1)  2(1) 6(1)  2(1) 
N(2) 25(2)  17(2) 11(1)  8(1) 6(1)  7(1) 






 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0814m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 7136 8053 10849 17 
H(2) 9151 10927 11554 20 
H(3) 9045 12519 10122 22 
H(4) 6765 11177 8006 21 





H(8) -2752 6287 5293 29 
H(9) -3232 4591 6650 27 
H(10) -294 4279 7925 23 
H(11A) 3821 8019 5146 37 
H(11B) 6142 9230 6109 37 



























































Symmetry transformations used to generate equivalent atoms:  





 Crystallographic data for [Zn(Cl)2(dpma)]  
  Table 1.  Crystal data and structure refinement for phw0816m. 
Identification code  phw0816m 
Empirical formula  C11 H11 Cl2 N3 Zn 
Formula weight  321.50 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.5744(5) Å = 
98.9620(10)°. 
 b = 8.3068(6) Å = 98.0740(10)°. 
 c = 11.2830(8) Å  = 
114.5630(10)°. 
Volume 620.93(8) Å3 
Z 2 
Density (calculated) 1.720 Mg/m3 
Absorption coefficient 2.386 mm-1 
F(000) 324 
Crystal size 0.24 x 0.12 x 0.03 mm3 
Theta range for data collection 1.88 to 28.31°. 
Index ranges -10<=h<=10, -11<=k<=11, -15<=l<=15 
Reflections collected 6367 
Independent reflections 3047 [R(int) = 0.0125] 
Completeness to theta = 28.31° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.931 and 0.741 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3047 / 0 / 155 
Goodness-of-fit on F2 1.050 
Final R indices [I>2sigma(I)] R1 = 0.0206, wR2 = 0.0513 
R indices (all data) R1 = 0.0231, wR2 = 0.0527 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0816m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 7191(2) 8439(2) 9969(1) 22(1) 
C(2) 8096(2) 9674(2) 11090(1) 24(1) 
C(3) 8407(2) 11455(2) 11152(1) 24(1) 
C(4) 7837(2) 11937(2) 10100(1) 21(1) 
C(5) 7010(2) 10637(2) 8972(1) 17(1) 
C(6) 4902(2) 10176(2) 6907(1) 16(1) 
C(7) 4095(2) 11095(2) 6230(1) 19(1) 
C(8) 2431(2) 10100(2) 5282(1) 22(1) 
C(9) 1534(2) 8200(2) 5011(1) 21(1) 
C(10) 2416(2) 7392(2) 5699(1) 19(1) 
C(11) 7674(2) 13138(2) 7955(2) 24(1) 
Cl(1) 7381(1) 6362(1) 6340(1) 21(1) 
Cl(2) 2983(1) 4533(1) 7862(1) 23(1) 
N(1) 6681(2) 8901(2) 8920(1) 17(1) 
N(2) 6594(2) 11171(2) 7882(1) 18(1) 
N(3) 4076(2) 8340(2) 6614(1) 16(1) 




 Table 3.   Bond lengths [Å] and angles [°] for  phw0816m. 
_____________________________________________________  
C(1)-N(1)  1.3542(18) 
C(1)-C(2)  1.375(2) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.386(2) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.379(2) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.402(2) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.3471(18) 
C(5)-N(2)  1.4097(18) 
C(6)-N(3)  1.3486(18) 





C(6)-C(7)  1.4060(19) 
C(7)-C(8)  1.376(2) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.395(2) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.375(2) 
C(9)-H(9)  0.9500 
C(10)-N(3)  1.3513(19) 
C(10)-H(10)  0.9500 
C(11)-N(2)  1.4739(18) 
C(11)-H(11A)  0.9800 
C(11)-H(11B)  0.9800 
C(11)-H(11C)  0.9800 
Cl(1)-Zn(1)  2.2100(4) 
Cl(2)-Zn(1)  2.2368(4) 
N(1)-Zn(1)  2.0275(13) 



























































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0816m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  





C(2) 21(1)  34(1) 18(1)  9(1) 6(1)  12(1) 
C(3) 21(1)  30(1) 17(1)  0(1) 4(1)  9(1) 
C(4) 20(1)  19(1) 22(1)  2(1) 5(1)  8(1) 
C(5) 15(1)  18(1) 18(1)  4(1) 5(1)  8(1) 
C(6) 17(1)  17(1) 17(1)  5(1) 7(1)  9(1) 
C(7) 23(1)  18(1) 22(1)  8(1) 9(1)  12(1) 
C(8) 24(1)  27(1) 23(1)  13(1) 9(1)  17(1) 
C(9) 19(1)  27(1) 20(1)  7(1) 5(1)  11(1) 
C(10) 19(1)  18(1) 19(1)  4(1) 4(1)  7(1) 
C(11) 26(1)  14(1) 26(1)  6(1) 6(1)  5(1) 
Cl(1) 24(1)  22(1) 22(1)  7(1) 8(1)  14(1) 
Cl(2) 25(1)  16(1) 28(1)  8(1) 10(1)  8(1) 
N(1) 18(1)  17(1) 18(1)  6(1) 5(1)  9(1) 
N(2) 20(1)  13(1) 19(1)  4(1) 4(1)  6(1) 
N(3) 17(1)  14(1) 18(1)  5(1) 4(1)  8(1) 












 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0816m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 6911 7203 9928 26 
H(2) 8495 9318 11801 29 
H(3) 9010 12339 11915 29 
H(4) 8005 13144 10141 25 





H(8) 1892 10711 4811 26 
H(9) 362 7494 4376 25 
H(10) 1828 6099 5522 23 
H(11A) 7717 13333 7123 35 
H(11B) 9036 13616 8447 35 




























































Crystallographic data for [Zn(Cl)3(Me-dpHa)]  
  Table 1.  Crystal data and structure refinement for akd0802m. 
Identification code  akd0802m 
Empirical formula  C11 H12 Cl3 N3 Zn 
Formula weight  357.96 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 7.5645(5) Å = 90°. 
 b = 13.4638(9) Å = 90°. 
 c = 26.8958(17) Å  = 90°. 
Volume 2739.3(3) Å3 
Z 8 
Density (calculated) 1.736 Mg/m3 
Absorption coefficient 2.362 mm-1 
F(000) 1440 





Theta range for data collection 3.03 to 30.01°. 
Index ranges -10<=h<=10, -18<=k<=18, -37<=l<=37 
Reflections collected 28940 
Independent reflections 3986 [R(int) = 0.0290] 
Completeness to theta = 30.01° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.910 and 0.695 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3986 / 0 / 168 
Goodness-of-fit on F2 1.121 
Final R indices [I>2sigma(I)] R1 = 0.0254, wR2 = 0.0594 
R indices (all data) R1 = 0.0294, wR2 = 0.0607 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for akd0802m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 2997(2) 1327(1) 4860(1) 17(1) 
C(2) 3899(2) 1484(1) 5299(1) 19(1) 
C(3) 5722(2) 1388(1) 5299(1) 19(1) 
C(4) 6588(2) 1182(1) 4858(1) 18(1) 
C(5) 5590(2) 1066(1) 4426(1) 14(1) 
C(6) 6175(2) 1419(1) 3554(1) 14(1) 
C(7) 5272(2) 2325(1) 3552(1) 16(1) 
C(8) 5049(2) 2834(1) 3114(1) 20(1) 
C(9) 5740(2) 2454(1) 2672(1) 20(1) 
C(10) 6615(2) 1567(1) 2687(1) 18(1) 
C(11) 7715(2) 82(1) 3109(1) 19(1) 
Cl(1) 534(1) 2024(1) 3648(1) 19(1) 
Cl(2) 3192(1) -201(1) 3242(1) 18(1) 
Cl(3) 103(1) -366(1) 4278(1) 18(1) 
N(1) 3813(2) 1106(1) 4427(1) 15(1) 
N(2) 6451(2) 860(1) 3974(1) 16(1) 
N(3) 6819(2) 1057(1) 3120(1) 15(1) 













 Table 3.   Bond lengths [Å] and angles [°] for  akd0802m. 
_____________________________________________________  





C(1)-C(2)  1.379(2) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.385(2) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.383(2) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.394(2) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.3451(19) 
C(5)-N(2)  1.4065(19) 
C(6)-N(3)  1.3572(18) 
C(6)-N(2)  1.3732(19) 
C(6)-C(7)  1.398(2) 
C(7)-C(8)  1.374(2) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.396(2) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.366(2) 
C(9)-H(9)  0.9500 
C(10)-N(3)  1.360(2) 
C(10)-H(10)  0.9500 
C(11)-N(3)  1.478(2) 
C(11)-H(11A)  0.9800 
C(11)-H(11B)  0.9800 
C(11)-H(11C)  0.9800 
Cl(1)-Zn(1)  2.2416(4) 
Cl(2)-Zn(1)  2.2406(4) 
Cl(3)-Zn(1)  2.2857(4) 
N(1)-Zn(1)  2.0883(12) 


































































 Table 4.   Anisotropic displacement parameters  (Å2x 103) for akd0802m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 15(1)  19(1) 17(1)  -1(1) 1(1)  -1(1) 
C(2) 22(1)  21(1) 14(1)  -1(1) 2(1)  -1(1) 
C(3) 22(1)  21(1) 14(1)  -1(1) -5(1)  -1(1) 
C(4) 15(1)  20(1) 19(1)  -2(1) -3(1)  1(1) 
C(5) 14(1)  15(1) 15(1)  0(1) -1(1)  0(1) 
C(6) 10(1)  19(1) 15(1)  -1(1) 1(1)  -3(1) 
C(7) 15(1)  16(1) 18(1)  -3(1) 2(1)  -1(1) 
C(8) 18(1)  17(1) 24(1)  1(1) 1(1)  0(1) 
C(9) 20(1)  23(1) 18(1)  4(1) 0(1)  -1(1) 
C(10) 16(1)  23(1) 15(1)  -1(1) 1(1)  -1(1) 
C(11) 19(1)  21(1) 18(1)  -4(1) -1(1)  6(1) 
Cl(1) 19(1)  20(1) 19(1)  0(1) -2(1)  1(1) 
Cl(2) 18(1)  20(1) 17(1)  -3(1) 1(1)  -3(1) 
Cl(3) 13(1)  23(1) 17(1)  3(1) 0(1)  -2(1) 
N(1) 14(1)  18(1) 13(1)  0(1) -1(1)  -2(1) 
N(2) 12(1)  21(1) 15(1)  -1(1) 0(1)  3(1) 
N(3) 11(1)  18(1) 16(1)  -2(1) 0(1)  0(1) 





 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for akd0802m. 
________________________________________________________________________________  







H(1) 1745 1377 4863 21 
H(2) 3284 1653 5595 22 
H(3) 6371 1463 5599 23 
H(4) 7839 1121 4850 22 
H(7) 4813 2588 3853 20 
H(8) 4424 3446 3111 23 
H(9) 5605 2804 2368 24 
H(10) 7092 1300 2388 21 
H(11A) 8848 130 3283 29 
H(11B) 7921 -116 2763 29 
H(11C) 6968 -415 3273 29 












































Symmetry transformations used to generate equivalent atoms:  
  
 Table 7.  Hydrogen bonds for akd0802m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(2)-H(2A)...Cl(3)#1 0.79(3) 2.54(3) 3.3206(14) 168(2) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





   Crystallographic data for [Co(Cl)(dpma)2(H2O)(CoCl3)]  
  Table 1.  Crystal data and structure refinement for phw0905m. 
Identification code  phw0905m 
Empirical formula  C22 H24 Cl4 Co2 N6 O 
Formula weight  648.13 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 12.6688(7) Å = 90°. 
 b = 16.9011(10) Å = 
109.7950(10)°. 
 c = 12.7250(7) Å  = 90°. 
Volume 2563.6(3) Å3 
Z 4 
Density (calculated) 1.679 Mg/m3 
Absorption coefficient 1.740 mm-1 
F(000) 1312 
Crystal size 0.14 x 0.12 x 0.06 mm3 
Theta range for data collection 1.96 to 30.03°. 
Index ranges -17<=h<=17, -23<=k<=23, -17<=l<=17 
Reflections collected 28948 
Independent reflections 7437 [R(int) = 0.0279] 
Completeness to theta = 30.03° 99.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.901 and 0.797 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7437 / 0 / 324 
Goodness-of-fit on F2 1.026 
Final R indices [I>2sigma(I)] R1 = 0.0289, wR2 = 0.0710 
R indices (all data) R1 = 0.0388, wR2 = 0.0757 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0905m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 4414(2) 753(1) 3252(2) 24(1) 
C(2) 4639(2) 35(1) 2859(2) 29(1) 
C(3) 4123(2) -635(1) 3081(2) 32(1) 
C(4) 3420(2) -572(1) 3697(2) 28(1) 
C(5) 3217(1) 176(1) 4058(1) 20(1) 
C(6) 1627(2) -369(1) 4508(2) 26(1) 
C(7) 2737(1) 712(1) 5633(1) 17(1) 
C(8) 2499(2) 430(1) 6567(2) 23(1) 
C(9) 2768(2) 891(1) 7515(2) 25(1) 
C(10) 3288(2) 1618(1) 7539(2) 22(1) 
C(11) 3483(2) 1862(1) 6588(1) 20(1) 
C(12) 2982(2) 3742(1) 4474(2) 22(1) 
C(13) 2564(2) 4449(1) 4714(2) 26(1) 
C(14) 1595(2) 4426(1) 4992(2) 28(1) 
C(15) 1071(2) 3713(1) 5008(2) 26(1) 
C(16) 1528(2) 3022(1) 4727(1) 19(1) 
C(17) 351(2) 2187(1) 5469(2) 26(1) 
C(18) 723(1) 1793(1) 3771(1) 17(1) 
C(19) -320(2) 1406(1) 3376(2) 23(1) 
C(20) -553(2) 926(1) 2452(2) 25(1) 
C(21) 233(2) 838(1) 1922(2) 23(1) 
C(22) 1234(2) 1233(1) 2354(1) 20(1) 
Cl(1) 5199(1) 2392(1) 5176(1) 20(1) 
Cl(2) 7896(1) 3432(1) 5399(1) 22(1) 
Cl(3) 6825(1) 1821(1) 3308(1) 24(1) 
Cl(4) 5244(1) 3756(1) 3035(1) 25(1) 
Co(1) 3198(1) 1973(1) 4146(1) 15(1) 
Co(2) 6330(1) 2831(1) 4208(1) 18(1) 
N(1) 3693(1) 835(1) 3823(1) 19(1) 
N(2) 2481(1) 251(1) 4668(1) 19(1) 
N(3) 3190(1) 1432(1) 5635(1) 17(1) 
N(4) 2486(1) 3036(1) 4491(1) 19(1) 
N(5) 982(1) 2293(1) 4698(1) 20(1) 
N(6) 1499(1) 1688(1) 3278(1) 17(1) 







 Table 3.   Bond lengths [Å] and angles [°] for  phw0905m. 
_____________________________________________________  
C(1)-N(1)  1.352(2) 
C(1)-C(2)  1.379(3) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.383(3) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.375(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.400(2) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.347(2) 
C(5)-N(2)  1.405(2) 
C(6)-N(2)  1.470(2) 
C(6)-H(6A)  0.9800 
C(6)-H(6B)  0.9800 
C(6)-H(6C)  0.9800 
C(7)-N(3)  1.344(2) 
C(7)-N(2)  1.397(2) 
C(7)-C(8)  1.406(2) 
C(8)-C(9)  1.379(3) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.388(3) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.378(2) 
C(10)-H(10)  0.9500 
C(11)-N(3)  1.352(2) 
C(11)-H(11)  0.9500 
C(12)-N(4)  1.352(2) 
C(12)-C(13)  1.383(2) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.388(3) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.379(3) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.404(2) 
C(15)-H(15)  0.9500 





C(16)-N(5)  1.407(2) 
C(17)-N(5)  1.471(2) 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-N(6)  1.346(2) 
C(18)-N(5)  1.396(2) 
C(18)-C(19)  1.405(2) 
C(19)-C(20)  1.377(3) 
C(19)-H(19)  0.9500 
C(20)-C(21)  1.386(3) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.373(2) 
C(21)-H(21)  0.9500 
C(22)-N(6)  1.348(2) 
C(22)-H(22)  0.9500 
Cl(1)-Co(2)  2.3063(5) 
Cl(1)-Co(1)  2.5291(5) 
Cl(2)-Co(2)  2.2871(5) 
Cl(3)-Co(2)  2.2600(5) 
Cl(4)-Co(2)  2.2730(5) 
Co(1)-N(1)  2.1061(15) 
Co(1)-N(3)  2.1076(14) 
Co(1)-O(1)  2.1126(13) 
Co(1)-N(6)  2.1154(14) 
Co(1)-N(4)  2.1230(14) 
O(1)-H(1A)  0.81(3) 






































































































































 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0905m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 17(1)  32(1) 22(1)  -4(1) 6(1)  0(1) 
C(2) 22(1)  40(1) 23(1)  -6(1) 5(1)  10(1) 
C(3) 36(1)  27(1) 28(1)  -6(1) 5(1)  14(1) 
C(4) 34(1)  20(1) 26(1)  -1(1) 5(1)  7(1) 
C(5) 20(1)  20(1) 16(1)  0(1) 3(1)  3(1) 





C(7) 14(1)  18(1) 20(1)  2(1) 5(1)  2(1) 
C(8) 21(1)  23(1) 27(1)  6(1) 11(1)  1(1) 
C(9) 27(1)  30(1) 22(1)  6(1) 14(1)  8(1) 
C(10) 24(1)  27(1) 18(1)  -1(1) 9(1)  7(1) 
C(11) 21(1)  20(1) 20(1)  -1(1) 8(1)  2(1) 
C(12) 24(1)  17(1) 21(1)  1(1) 4(1)  -1(1) 
C(13) 30(1)  17(1) 26(1)  -2(1) 2(1)  1(1) 
C(14) 32(1)  22(1) 25(1)  -5(1) 2(1)  8(1) 
C(15) 25(1)  26(1) 24(1)  -5(1) 8(1)  7(1) 
C(16) 20(1)  19(1) 16(1)  -1(1) 4(1)  3(1) 
C(17) 26(1)  34(1) 24(1)  1(1) 16(1)  4(1) 
C(18) 16(1)  18(1) 18(1)  3(1) 6(1)  2(1) 
C(19) 17(1)  27(1) 25(1)  5(1) 8(1)  -1(1) 
C(20) 21(1)  29(1) 24(1)  3(1) 4(1)  -7(1) 
C(21) 26(1)  22(1) 17(1)  1(1) 2(1)  -4(1) 
C(22) 22(1)  21(1) 16(1)  1(1) 6(1)  1(1) 
Cl(1) 20(1)  21(1) 20(1)  0(1) 8(1)  -3(1) 
Cl(2) 20(1)  24(1) 21(1)  0(1) 7(1)  -1(1) 
Cl(3) 23(1)  21(1) 30(1)  0(1) 13(1)  1(1) 
Cl(4) 23(1)  22(1) 29(1)  9(1) 8(1)  3(1) 
Co(1) 16(1)  15(1) 15(1)  -1(1) 6(1)  -1(1) 
Co(2) 18(1)  18(1) 20(1)  2(1) 7(1)  1(1) 
N(1) 17(1)  22(1) 19(1)  -4(1) 5(1)  0(1) 
N(2) 21(1)  16(1) 20(1)  -1(1) 7(1)  -3(1) 
N(3) 17(1)  18(1) 17(1)  0(1) 6(1)  0(1) 
N(4) 20(1)  17(1) 18(1)  -1(1) 6(1)  1(1) 
N(5) 20(1)  21(1) 21(1)  -1(1) 11(1)  1(1) 
N(6) 16(1)  18(1) 17(1)  1(1) 5(1)  -1(1) 





 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0905m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  





H(2) 5136 1 2445 35 
H(3) 4254 -1136 2809 38 
H(4) 3078 -1030 3874 33 
H(6A) 1960 -826 4978 40 
H(6B) 1350 -532 3723 40 
H(6C) 1003 -163 4718 40 
H(8) 2156 -72 6545 27 
H(9) 2600 713 8148 30 
H(10) 3502 1937 8192 27 
H(11) 3842 2357 6602 24 
H(12) 3648 3753 4289 26 
H(13) 2928 4936 4689 31 
H(14) 1293 4902 5171 34 
H(15) 412 3691 5206 31 
H(17A) -411 2395 5124 39 
H(17B) 729 2474 6165 39 
H(17C) 315 1623 5631 39 
H(19) -855 1475 3742 27 
H(20) -1251 655 2177 30 
H(21) 83 513 1279 28 
H(22) 1767 1184 1982 23 
H(1A) 3800(20) 2821(15) 2750(20) 29 



























































































































 Table 7.  Hydrogen bonds for phw0905m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(1)-H(1B)...Cl(2)#1 0.66(3) 2.52(3) 3.1779(14) 174(3) 
 O(1)-H(1A)...Cl(4) 0.81(3) 2.35(3) 3.1531(15) 177(2) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





   Crystallographic data for [Co(Cl)2(dpma)2]OTf  
  Table 1.  Crystal data and structure refinement for phw0903m. 
Identification code  phw0903m 
Empirical formula  C23 H22 Cl2 Co F3 N6 O3 S 
Formula weight  649.36 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.5150(13) Å = 113.239(3)°. 
 b = 12.4156(19) Å = 91.134(3)°. 
 c = 13.291(2) Å  = 97.251(3)°. 
Volume 1277.0(3) Å3 
Z 2 
Density (calculated) 1.689 Mg/m3 
Absorption coefficient 1.025 mm-1 
F(000) 660 
Crystal size 0.17 x 0.11 x 0.08 mm3 
Theta range for data collection 1.67 to 28.29°. 
Index ranges -11<=h<=11, -16<=k<=16, -17<=l<=17 
Reflections collected 13211 
Independent reflections 6272 [R(int) = 0.0199] 
Completeness to theta = 28.29° 98.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.920 and 0.771 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6272 / 0 / 354 
Goodness-of-fit on F2 1.019 
Final R indices [I>2sigma(I)] R1 = 0.0339, wR2 = 0.0812 
R indices (all data) R1 = 0.0426, wR2 = 0.0861 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0903m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 7216(2) 7760(2) 5558(2) 20(1) 
C(2) 7214(2) 8210(2) 4767(2) 22(1) 
C(3) 5776(3) 8395(2) 4397(2) 24(1) 
C(4) 4402(2) 8132(2) 4838(2) 22(1) 
C(5) 4490(2) 7717(2) 5673(2) 17(1) 
C(6) 1789(2) 8148(2) 6114(2) 22(1) 
C(7) 2790(2) 6524(2) 6426(2) 16(1) 
C(8) 1223(2) 5970(2) 6349(2) 19(1) 
C(9) 946(2) 4987(2) 6593(2) 22(1) 
C(10) 2225(2) 4530(2) 6865(2) 21(1) 
C(11) 3729(2) 5116(2) 6931(2) 18(1) 
C(12) 5391(2) 9510(2) 8034(2) 18(1) 
C(13) 4504(2) 10411(2) 8432(2) 21(1) 
C(14) 3239(2) 10292(2) 9051(2) 23(1) 
C(15) 2948(2) 9291(2) 9266(2) 21(1) 
C(16) 3907(2) 8397(2) 8835(2) 17(1) 
C(17) 2171(2) 7111(2) 9489(2) 25(1) 
C(18) 4991(2) 6902(2) 9270(2) 18(1) 
C(19) 5073(3) 6616(2) 10190(2) 22(1) 
C(20) 6391(3) 6174(2) 10397(2) 25(1) 
C(21) 7599(3) 5998(2) 9688(2) 25(1) 
C(22) 7445(2) 6283(2) 8795(2) 22(1) 
Cl(1) 8452(1) 8254(1) 7952(1) 21(1) 
Cl(2) 7161(1) 5543(1) 6225(1) 21(1) 
Co(1) 6067(1) 7118(1) 7293(1) 15(1) 
N(1) 5886(2) 7547(1) 6039(1) 16(1) 
N(2) 3112(2) 7508(1) 6164(1) 17(1) 
N(3) 4007(2) 6134(1) 6771(1) 15(1) 
N(4) 5066(2) 8489(1) 8189(1) 15(1) 
N(5) 3684(2) 7388(1) 9064(1) 18(1) 
N(6) 6165(2) 6726(1) 8579(1) 17(1) 
C(23) 10025(3) 1357(2) 7622(2) 24(1) 
F(1) 11577(2) 1672(1) 7559(1) 32(1) 
F(2) 9886(2) 1225(1) 8569(1) 35(1) 





O(1) 9172(2) 2448(1) 6472(1) 25(1) 
O(2) 7258(2) 1993(2) 7639(1) 32(1) 
O(3) 9527(2) 3534(1) 8455(1) 31(1) 




 Table 3.   Bond lengths [Å] and angles [°] for  phw0903m. 
_____________________________________________________  
C(1)-N(1)  1.360(2) 
C(1)-C(2)  1.372(3) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.389(3) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.379(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.400(3) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.348(2) 
C(5)-N(2)  1.399(2) 
C(6)-N(2)  1.472(2) 
C(6)-H(6A)  0.9800 
C(6)-H(6B)  0.9800 
C(6)-H(6C)  0.9800 
C(7)-N(3)  1.342(2) 
C(7)-N(2)  1.394(2) 
C(7)-C(8)  1.405(3) 
C(8)-C(9)  1.376(3) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.392(3) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.374(3) 
C(10)-H(10)  0.9500 
C(11)-N(3)  1.355(2) 
C(11)-H(11)  0.9500 
C(12)-N(4)  1.358(2) 
C(12)-C(13)  1.365(3) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.397(3) 





C(14)-C(15)  1.375(3) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.405(3) 
C(15)-H(15)  0.9500 
C(16)-N(4)  1.345(2) 
C(16)-N(5)  1.392(2) 
C(17)-N(5)  1.473(2) 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-N(6)  1.350(2) 
C(18)-N(5)  1.402(2) 
C(18)-C(19)  1.405(3) 
C(19)-C(20)  1.378(3) 
C(19)-H(19)  0.9500 
C(20)-C(21)  1.387(3) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.374(3) 
C(21)-H(21)  0.9500 
C(22)-N(6)  1.356(2) 
C(22)-H(22)  0.9500 
Cl(1)-Co(1)  2.2611(6) 
Cl(2)-Co(1)  2.2421(6) 
Co(1)-N(3)  1.9468(16) 
Co(1)-N(1)  1.9481(16) 
Co(1)-N(6)  1.9556(16) 
Co(1)-N(4)  1.9623(16) 
C(23)-F(3)  1.326(3) 
C(23)-F(2)  1.338(2) 
C(23)-F(1)  1.344(2) 
C(23)-S(1)  1.831(2) 
O(1)-S(1)  1.4432(14) 
O(2)-S(1)  1.4435(15) 








































































































































 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0903m.  The anisotropic 






 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 15(1)  25(1) 19(1)  8(1) 4(1)  2(1) 
C(2) 20(1)  26(1) 22(1)  11(1) 8(1)  2(1) 
C(3) 28(1)  28(1) 21(1)  15(1) 5(1)  2(1) 
C(4) 18(1)  30(1) 21(1)  14(1) 2(1)  4(1) 
C(5) 15(1)  19(1) 15(1)  6(1) 2(1)  1(1) 
C(6) 17(1)  29(1) 25(1)  15(1) 4(1)  8(1) 
C(7) 14(1)  18(1) 15(1)  6(1) 3(1)  2(1) 
C(8) 12(1)  24(1) 22(1)  9(1) 2(1)  2(1) 
C(9) 15(1)  23(1) 26(1)  8(1) 3(1)  -1(1) 
C(10) 21(1)  18(1) 23(1)  9(1) 3(1)  0(1) 
C(11) 17(1)  18(1) 19(1)  7(1) 2(1)  4(1) 
C(12) 20(1)  19(1) 16(1)  8(1) 1(1)  -1(1) 
C(13) 27(1)  18(1) 19(1)  9(1) -1(1)  1(1) 
C(14) 24(1)  22(1) 20(1)  5(1) -1(1)  8(1) 
C(15) 19(1)  25(1) 18(1)  8(1) 3(1)  4(1) 
C(16) 16(1)  20(1) 15(1)  7(1) 0(1)  1(1) 
C(17) 22(1)  31(1) 26(1)  15(1) 10(1)  3(1) 
C(18) 21(1)  14(1) 19(1)  7(1) 1(1)  0(1) 
C(19) 31(1)  18(1) 17(1)  9(1) 2(1)  0(1) 
C(20) 37(1)  18(1) 22(1)  11(1) -8(1)  -3(1) 
C(21) 26(1)  22(1) 29(1)  12(1) -9(1)  0(1) 
C(22) 18(1)  23(1) 26(1)  11(1) -3(1)  1(1) 
Cl(1) 14(1)  26(1) 23(1)  12(1) 0(1)  -2(1) 
Cl(2) 16(1)  24(1) 23(1)  8(1) 4(1)  6(1) 
Co(1) 11(1)  18(1) 16(1)  8(1) 2(1)  2(1) 
N(1) 13(1)  19(1) 16(1)  7(1) 2(1)  2(1) 
N(2) 11(1)  22(1) 20(1)  12(1) 3(1)  3(1) 
N(3) 13(1)  17(1) 16(1)  6(1) 4(1)  2(1) 
N(4) 15(1)  17(1) 14(1)  7(1) 1(1)  0(1) 
N(5) 17(1)  21(1) 19(1)  10(1) 6(1)  2(1) 
N(6) 16(1)  17(1) 19(1)  8(1) -1(1)  0(1) 
C(23) 24(1)  26(1) 23(1)  12(1) 4(1)  3(1) 
F(1) 21(1)  48(1) 36(1)  23(1) 7(1)  10(1) 
F(2) 40(1)  46(1) 34(1)  30(1) 11(1)  15(1) 
F(3) 54(1)  23(1) 42(1)  6(1) -1(1)  5(1) 
O(1) 23(1)  38(1) 21(1)  18(1) 1(1)  0(1) 
O(2) 18(1)  53(1) 35(1)  28(1) 6(1)  3(1) 









 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0903m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 8190 7589 5779 24 
H(2) 8176 8392 4478 27 
H(3) 5740 8701 3846 29 
H(4) 3406 8232 4578 26 
H(6A) 1158 7719 5411 33 
H(6B) 2213 8946 6180 33 
H(6C) 1117 8203 6718 33 
H(8) 364 6270 6131 23 
H(9) -110 4622 6576 27 
H(10) 2061 3830 7001 25 
H(11) 4607 4795 7094 22 
H(12) 6272 9601 7632 22 
H(13) 4742 11104 8290 26 
H(14) 2587 10897 9322 27 
H(15) 2107 9206 9700 25 
H(17A) 2187 7622 10271 38 
H(17B) 2025 6279 9393 38 
H(17C) 1294 7247 9086 38 
H(19) 4231 6725 10663 26 
H(20) 6473 5989 11024 31 
H(21) 8511 5688 9817 30 































































































































 Crystallographic data for [{Cu(Cl)2(dpea)}2]  
  Table 1.  Crystal data and structure refinement for phw0916m. 
Identification code  phw0916m 
Empirical formula  C24 H26 Cl4 Cu2 N6 
Formula weight  667.39 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.2030(6) Å = 
110.9320(10)°. 
 b = 8.8918(8) Å = 91.609(2)°. 
 c = 11.7252(10) Å  = 
112.0740(10)°. 
Volume 638.46(10) Å3 
Z 1 
Density (calculated) 1.736 Mg/m3 
Absorption coefficient 2.112 mm-1 
F(000) 338 
Crystal size 0.27 x 0.22 x 0.08 mm3 
Theta range for data collection 1.89 to 28.28°. 
Index ranges -9<=h<=9, -11<=k<=11, -15<=l<=15 
Reflections collected 6527 
Independent reflections 3120 [R(int) = 0.0142] 
Completeness to theta = 28.28° 98.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.845 and 0.655 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3120 / 0 / 164 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0244, wR2 = 0.0667 
R indices (all data) R1 = 0.0259, wR2 = 0.0678 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0916m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 2437(3) 2326(2) 2643(2) 20(1) 
C(2) 1441(3) 3133(3) 3472(2) 23(1) 
C(3) 2455(3) 4943(3) 4187(2) 24(1) 
C(4) 4354(3) 5894(2) 4000(2) 20(1) 
C(5) 5238(3) 4993(2) 3107(2) 16(1) 
C(6) 6995(2) 3327(2) -372(2) 16(1) 
C(7) 7607(2) 4563(2) -891(2) 17(1) 
C(8) 8044(2) 6314(2) -148(2) 17(1) 
C(9) 7849(2) 6762(2) 1086(2) 17(1) 
C(10) 7277(2) 5452(2) 1556(1) 14(1) 
C(11) 8410(3) 7704(2) 3708(2) 20(1) 
C(12) 10656(3) 8174(2) 3660(2) 26(1) 
Cl(1) 5834(1) 770(1) 3021(1) 20(1) 
Cl(2) 7477(1) 292(1) 356(1) 17(1) 
Cu(1) 5894(1) 1897(1) 1545(1) 14(1) 
N(1) 4324(2) 3231(2) 2486(1) 15(1) 
N(2) 7115(2) 5872(2) 2826(1) 16(1) 






 Table 3.   Bond lengths [Å] and angles [°] for  phw0916m. 
_____________________________________________________  
C(1)-N(1)  1.352(2) 
C(1)-C(2)  1.379(2) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.395(3) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.384(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.402(2) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.342(2) 
C(5)-N(2)  1.401(2) 
C(6)-N(3)  1.349(2) 
C(6)-C(7)  1.379(2) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.390(2) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.382(2) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.393(2) 
C(9)-H(9)  0.9500 
C(10)-N(3)  1.345(2) 
C(10)-N(2)  1.420(2) 
C(11)-N(2)  1.481(2) 
C(11)-C(12)  1.520(3) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
Cl(1)-Cu(1)  2.2830(4) 
Cl(2)-Cu(1)  2.2739(4) 
Cu(1)-N(1)  2.0114(14) 




































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0916m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 19(1)  24(1) 20(1)  12(1) 6(1)  8(1) 
C(2) 19(1)  34(1) 23(1)  16(1) 8(1)  14(1) 
C(3) 26(1)  34(1) 22(1)  14(1) 11(1)  20(1) 
C(4) 25(1)  22(1) 20(1)  9(1) 7(1)  15(1) 
C(5) 19(1)  18(1) 15(1)  9(1) 5(1)  10(1) 
C(6) 16(1)  15(1) 16(1)  5(1) 3(1)  7(1) 
C(7) 17(1)  21(1) 16(1)  8(1) 4(1)  9(1) 
C(8) 17(1)  19(1) 21(1)  12(1) 4(1)  8(1) 
C(9) 16(1)  13(1) 21(1)  7(1) 4(1)  6(1) 
C(10) 13(1)  14(1) 15(1)  5(1) 3(1)  6(1) 
C(11) 26(1)  13(1) 16(1)  2(1) 3(1)  8(1) 
C(12) 25(1)  21(1) 24(1)  3(1) 1(1)  8(1) 
Cl(1) 23(1)  19(1) 20(1)  10(1) 4(1)  9(1) 
Cl(2) 17(1)  14(1) 21(1)  6(1) 6(1)  8(1) 
Cu(1) 17(1)  11(1) 16(1)  6(1) 6(1)  6(1) 
N(1) 16(1)  16(1) 16(1)  8(1) 5(1)  7(1) 
N(2) 19(1)  12(1) 14(1)  3(1) 5(1)  6(1) 








 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0916m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 1773 1089 2165 24 
H(2) 102 2474 3554 27 
H(3) 1844 5522 4803 28 
H(4) 5044 7133 4466 24 
H(6) 6651 2123 -888 19 
H(7) 7727 4223 -1742 21 
H(8) 8472 7192 -482 21 
H(9) 8100 7945 1604 20 
H(11A) 8195 7832 4562 24 
H(11B) 8000 8536 3503 24 
H(12A) 11021 7259 3747 38 
H(12B) 11481 9316 4339 38 





























































 Crystallographic data for [Zn(Cl)2(dpea)]  
  Table 1.  Crystal data and structure refinement for phw1002m. 
Identification code  phw1002m 
Empirical formula  C12 H13 Cl2 N3 Zn 
Formula weight  335.52 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.6933(17) Å = 91.554(4)°. 
 b = 8.1468(18) Å = 90.993(4)°. 
 c = 11.692(3) Å  = 108.414(4)°. 
Volume 694.8(3) Å3 
Z 2 
Density (calculated) 1.604 Mg/m3 
Absorption coefficient 2.136 mm-1 
F(000) 340 
Crystal size 0.33 x 0.17 x 0.12 mm3 
Theta range for data collection 1.74 to 28.35°. 
Index ranges -10<=h<=10, -10<=k<=10, -15<=l<=15 
Reflections collected 7094 
Independent reflections 3416 [R(int) = 0.0211] 
Completeness to theta = 28.35° 98.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.774 and 0.602 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3416 / 0 / 164 
Goodness-of-fit on F2 1.139 
Final R indices [I>2sigma(I)] R1 = 0.0291, wR2 = 0.0758 
R indices (all data) R1 = 0.0335, wR2 = 0.0815 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw1002m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 3623(3) -817(3) 8646(2) 17(1) 
C(2) 3049(3) 408(3) 9227(2) 20(1) 
C(3) 4096(3) 2141(3) 9135(2) 21(1) 
C(4) 5626(3) 2575(3) 8469(2) 19(1) 
C(5) 6130(3) 1268(3) 7910(2) 15(1) 
C(6) 6951(3) -1496(3) 4895(2) 21(1) 
C(7) 7675(3) -520(4) 3969(2) 25(1) 
C(8) 8376(4) 1276(4) 4124(2) 25(1) 
C(9) 8328(3) 2010(3) 5198(2) 23(1) 
C(10) 7647(3) 958(3) 6108(2) 17(1) 
C(11) 9192(3) 3289(3) 7512(2) 20(1) 
C(12) 9895(4) 3340(4) 8735(2) 26(1) 
Cl(1) 8449(1) -2562(1) 8357(1) 21(1) 
Cl(2) 3814(1) -4623(1) 6833(1) 25(1) 
N(1) 5152(3) -414(3) 8027(2) 16(1) 
N(2) 6968(3) -773(3) 5953(2) 18(1) 
N(3) 7693(3) 1656(3) 7231(2) 17(1) 






 Table 3.   Bond lengths [Å] and angles [°] for  phw1002m. 
_____________________________________________________  
C(1)-N(1)  1.347(3) 
C(1)-C(2)  1.379(3) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.395(4) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.379(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.395(3) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.351(3) 
C(5)-N(3)  1.408(3) 
C(6)-N(2)  1.354(3) 
C(6)-C(7)  1.380(4) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.396(4) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.382(4) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.389(3) 
C(9)-H(9)  0.9500 
C(10)-N(2)  1.346(3) 
C(10)-N(3)  1.411(3) 
C(11)-N(3)  1.484(3) 
C(11)-C(12)  1.515(4) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
Cl(1)-Zn(1)  2.2274(7) 
Cl(2)-Zn(1)  2.2162(7) 
N(1)-Zn(1)  2.034(2) 




































































Symmetry transformations used to generate equivalent atoms:  
 
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw1002m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 16(1)  16(1) 17(1)  2(1) -1(1)  3(1) 
C(2) 15(1)  27(1) 19(1)  0(1) 3(1)  7(1) 
C(3) 20(1)  26(1) 20(1)  -5(1) 1(1)  11(1) 
C(4) 17(1)  19(1) 20(1)  0(1) 0(1)  6(1) 
C(5) 14(1)  15(1) 15(1)  1(1) 0(1)  4(1) 
C(6) 23(1)  20(1) 20(1)  -2(1) -1(1)  9(1) 
C(7) 21(1)  38(2) 16(1)  -4(1) -1(1)  12(1) 
C(8) 21(1)  37(2) 18(1)  4(1) 3(1)  8(1) 
C(9) 21(1)  24(1) 22(1)  3(1) 2(1)  4(1) 
C(10) 12(1)  20(1) 18(1)  0(1) 3(1)  5(1) 
C(11) 16(1)  16(1) 25(1)  -1(1) 3(1)  1(1) 
C(12) 20(1)  27(1) 26(1)  -3(1) -1(1)  0(1) 
Cl(1) 20(1)  23(1) 21(1)  -1(1) 0(1)  8(1) 
Cl(2) 21(1)  17(1) 32(1)  -2(1) 0(1)  -1(1) 
N(1) 14(1)  18(1) 16(1)  1(1) 0(1)  4(1) 
N(2) 16(1)  20(1) 18(1)  -3(1) 1(1)  5(1) 
N(3) 14(1)  15(1) 18(1)  -2(1) 2(1)  2(1) 








 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw1002m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 2905 -2000 8684 20 
H(2) 1981 83 9673 24 
H(3) 3755 3020 9531 25 
H(4) 6331 3755 8392 23 
H(6) 6423 -2714 4787 25 
H(7) 7696 -1059 3241 30 
H(8) 8879 1982 3501 30 
H(9) 8760 3232 5312 27 
H(11A) 8738 4285 7402 24 
H(11B) 10212 3398 6984 24 
H(12A) 8959 3454 9261 39 
H(12B) 11012 4330 8855 39 































































 Crystallographic data for [dp(CN)(pyH)Ha][Zn(Cl)4]  
 
  Table 1.  Crystal data and structure refinement for phw0907m. 
Identification code  phw0907m 
Empirical formula  C19 H26 Cl4 N6 O Zn 
Formula weight  561.63 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.5322(3) Å = 
78.4510(10)°. 
 b = 9.9924(4) Å = 80.9670(10)°. 
 c = 15.6774(6) Å  = 
75.7830(10)°. 
Volume 1261.23(8) Å3 
Z 2 
Density (calculated) 1.479 Mg/m3 
Absorption coefficient 1.420 mm-1 
F(000) 576 
Crystal size 0.33 x 0.23 x 0.04 mm3 
Theta range for data collection 2.13 to 28.29°. 
Index ranges -11<=h<=11, -13<=k<=13, -20<=l<=20 
Reflections collected 13100 
Independent reflections 6215 [R(int) = 0.0117] 
Completeness to theta = 28.29° 99.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.945 and 0.751 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6215 / 4 / 336 
Goodness-of-fit on F2 1.052 
Final R indices [I>2sigma(I)] R1 = 0.0244, wR2 = 0.0656 
R indices (all data) R1 = 0.0277, wR2 = 0.0677 










 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0907m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 2474(2) 7241(2) 5332(1) 27(1) 
C(2) 3314(2) 7115(2) 6039(1) 28(1) 
C(3) 3983(2) 5761(2) 6446(1) 25(1) 
C(4) 3823(2) 4600(1) 6139(1) 22(1) 
C(5) 2966(2) 4856(1) 5411(1) 21(1) 
C(6) 2058(2) 3711(1) 4371(1) 19(1) 
C(7) 2157(2) 2442(1) 4085(1) 20(1) 
C(8) 1410(2) 2446(1) 3371(1) 20(1) 
C(9) 531(2) 3720(1) 2935(1) 23(1) 
C(10) 476(2) 4929(1) 3223(1) 23(1) 
C(11) 1512(2) 1080(1) 3077(1) 22(1) 
C(12) 3732(2) 1543(2) 1865(1) 29(1) 
C(13) 4366(2) 1019(2) 999(1) 38(1) 
C(14) 3524(2) -167(2) 999(1) 44(1) 
C(15) 2441(2) -305(2) 1865(1) 35(1) 
C(16) 4894(2) 5536(2) 7187(1) 29(1) 
N(1) 2291(1) 6136(1) 5018(1) 23(1) 
N(2) 2812(1) 3715(1) 5073(1) 21(1) 
N(3) 1232(1) 4909(1) 3930(1) 21(1) 
N(4) 5653(2) 5336(2) 7756(1) 38(1) 
N(5) 2139(1) 1108(1) 2130(1) 23(1) 
Cl(2) 5431(1) 9233(1) 3871(1) 28(1) 
Cl(3) 9785(1) 8216(1) 3672(1) 28(1) 
Cl(4) 7944(1) 11194(1) 2072(1) 30(1) 
Cl(5) 7505(1) 7599(1) 1956(1) 37(1) 
Zn(1) 7688(1) 9081(1) 2831(1) 23(1) 
C(17) 8073(4) 3539(4) -735(2) 62(1) 
C(18) 7503(3) 4598(3) 604(2) 52(1) 
C(19) 10085(3) 3057(2) 279(1) 31(1) 
N(6) 8636(3) 3688(4) 54(2) 33(1) 
O(1) 10669(13) 3190(30) 919(13) 34(2) 
C(17A) 6619(11) 4616(13) 84(7) 74(4) 
C(18A) 8975(16) 2811(16) -363(9) 101(6) 
C(19A) 9107(9) 3930(7) 814(4) 38(2) 









 Table 3.   Bond lengths [Å] and angles [°] for  phw0907m. 
_____________________________________________________  
C(1)-N(1)  1.3454(18) 
C(1)-C(2)  1.382(2) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.397(2) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.3853(19) 
C(3)-C(16)  1.448(2) 
C(4)-C(5)  1.3980(18) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.3352(17) 
C(5)-N(2)  1.3908(17) 
C(6)-N(3)  1.3481(17) 
C(6)-N(2)  1.3598(17) 
C(6)-C(7)  1.4071(18) 
C(7)-C(8)  1.3723(18) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.4121(18) 
C(8)-C(11)  1.5041(18) 
C(9)-C(10)  1.3598(19) 
C(9)-H(9)  0.9500 
C(10)-N(3)  1.3617(17) 
C(10)-H(10)  0.9500 
C(11)-N(5)  1.4939(17) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-N(5)  1.5001(18) 
C(12)-C(13)  1.525(2) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(13)-C(14)  1.529(3) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-C(15)  1.520(2) 





C(14)-H(14B)  0.9900 
C(15)-N(5)  1.5023(18) 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(16)-N(4)  1.141(2) 
N(2)-H(2A)  0.82(2) 
N(3)-H(3)  0.834(19) 
N(5)-H(5)  0.845(19) 
Cl(2)-Zn(1)  2.3151(4) 
Cl(3)-Zn(1)  2.2830(4) 
Cl(4)-Zn(1)  2.2502(4) 
Cl(5)-Zn(1)  2.2563(4) 
C(18)-N(6)  1.458(4) 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(17)-N(6)  1.442(3) 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(19)-O(1)  1.23(2) 
C(19)-N(6)  1.310(3) 
C(19)-H(19)  0.9500 
C(18A)-N(6A)  1.460(9) 
C(18A)-H(18D)  0.9800 
C(18A)-H(18E)  0.9800 
C(18A)-H(18F)  0.9800 
C(17A)-N(6A)  1.446(8) 
C(17A)-H(17D)  0.9800 
C(17A)-H(17E)  0.9800 
C(17A)-H(17F)  0.9800 
C(19A)-O(1A)  1.23(2) 
C(19A)-N(6A)  1.310(8) 























































































































Symmetry transformations used to generate equivalent atoms:  
  
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0907m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 30(1)  21(1) 31(1)  -5(1) -4(1)  -5(1) 
C(2) 29(1)  28(1) 31(1)  -10(1) -1(1)  -9(1) 
C(3) 21(1)  32(1) 23(1)  -7(1) -1(1)  -9(1) 
C(4) 21(1)  25(1) 21(1)  -2(1) -2(1)  -6(1) 
C(5) 20(1)  22(1) 20(1)  -5(1) 0(1)  -6(1) 
C(6) 17(1)  21(1) 18(1)  -2(1) -1(1)  -4(1) 
C(7) 19(1)  19(1) 20(1)  -2(1) -3(1)  -2(1) 
C(8) 17(1)  21(1) 21(1)  -5(1) 0(1)  -3(1) 
C(9) 21(1)  26(1) 21(1)  -4(1) -5(1)  -1(1) 
C(10) 22(1)  22(1) 21(1)  -1(1) -5(1)  1(1) 
C(11) 23(1)  22(1) 21(1)  -5(1) -2(1)  -5(1) 
C(12) 25(1)  38(1) 24(1)  -6(1) 0(1)  -10(1) 





C(14) 45(1)  52(1) 36(1)  -23(1) 3(1)  -7(1) 
C(15) 41(1)  31(1) 35(1)  -18(1) 2(1)  -8(1) 
C(16) 27(1)  35(1) 30(1)  -10(1) -2(1)  -11(1) 
N(1) 24(1)  21(1) 24(1)  -4(1) -3(1)  -4(1) 
N(2) 24(1)  17(1) 22(1)  -1(1) -7(1)  -2(1) 
N(3) 21(1)  18(1) 21(1)  -4(1) -3(1)  -2(1) 
N(4) 37(1)  46(1) 37(1)  -9(1) -11(1)  -12(1) 
N(5) 23(1)  25(1) 21(1)  -7(1) -4(1)  -3(1) 
Cl(2) 23(1)  26(1) 28(1)  1(1) -2(1)  2(1) 
Cl(3) 26(1)  21(1) 38(1)  2(1) -12(1)  -4(1) 
Cl(4) 30(1)  25(1) 34(1)  5(1) -8(1)  -8(1) 
Cl(5) 50(1)  32(1) 31(1)  -9(1) -8(1)  -10(1) 
Zn(1) 22(1)  20(1) 25(1)  -2(1) -4(1)  -3(1) 
C(17) 53(2)  95(2) 42(2)  -5(2) -28(1)  -16(2) 
C(18) 37(1)  52(2) 51(2)  0(1) 1(1)  7(1) 
C(19) 32(1)  34(1) 25(1)  -1(1) -7(1)  -6(1) 
N(6) 28(1)  40(2) 26(1)  1(1) -6(1)  -4(1) 
O(1) 38(4)  40(2) 25(2)  5(2) -10(4)  -14(4) 
C(17A) 44(5)  107(9) 54(6)  25(6) -18(4)  -6(5) 
C(18A) 83(9)  180(17) 73(8)  -65(10) -14(7)  -49(10) 
C(19A) 49(4)  32(3) 30(3)  4(3) -6(3)  -10(3) 
N(6A) 28(1)  40(2) 26(1)  1(1) -6(1)  -4(1) 




 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0907m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 2001 8154 5053 33 
H(2) 3433 7916 6241 34 
H(4) 4274 3675 6409 27 
H(7) 2738 1587 4385 24 
H(9) -13 3732 2448 27 
H(10) -96 5794 2928 27 
H(11A) 2239 321 3434 26 





H(12A) 4494 1105 2310 34 
H(12B) 3574 2574 1787 34 
H(13A) 5562 670 955 45 
H(13B) 4097 1782 499 45 
H(14A) 2866 61 501 52 
H(14B) 4339 -1052 949 52 
H(15A) 1408 -527 1789 42 
H(15B) 2996 -1047 2307 42 
H(2A) 3230(20) 2940(20) 5327(12) 32(5) 
H(3) 1220(20) 5650(20) 4097(12) 29(4) 
H(17A) 8930 2912 -1053 93 
H(17B) 7805 4459 -1106 93 
H(17C) 7101 3144 -583 93 
H(18A) 8041 4684 1092 77 
H(18B) 6552 4196 835 77 
H(18C) 7153 5526 255 77 
H(19) 10751 2440 -88 37 
H(17D) 6554 5101 -523 112 
H(17E) 6269 5302 482 112 
H(17F) 5909 3947 220 112 
H(18D) 9928 2173 -118 152 
H(18E) 9304 3265 -956 152 
H(18F) 8161 2281 -386 152 
H(19A) 8623 4623 1169 45 



















































Symmetry transformations used to generate equivalent atoms:  
 
 
 Table 7.  Hydrogen bonds for phw0907m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(2)-H(2A)...Cl(2)#1 0.82(2) 2.39(2) 3.2130(12) 175.3(17) 





 N(3)-H(3)...Cl(3)#2 0.834(19) 2.556(19) 3.1969(12) 134.5(15) 
 N(5)-H(5)...O(1)#2 0.845(19) 1.90(2) 2.716(12) 160.8(18) 
 N(5)-H(5)...O(1A)#2 0.845(19) 1.90(4) 2.73(3) 167(2) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





Crystallographic data for [dp(CN)(pyH)Ha][Co(Cl)4]  
  Table 1.  Crystal data and structure refinement for phw0909m. 
Identification code  phw0909m 
Empirical formula  C19 H26 Cl4 Co N6 O 
Formula weight  555.19 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.5434(10) Å = 78.621(2)°. 
 b = 9.9845(12) Å = 81.064(2)°. 
 c = 15.6817(19) Å  = 75.609(2)°. 
Volume 1262.2(3) Å3 
Z 2 
Density (calculated) 1.461 Mg/m3 
Absorption coefficient 1.126 mm-1 
F(000) 570 
Crystal size 0.45 x 0.04 x 0.03 mm3 
Theta range for data collection 2.14 to 27.11°. 
Index ranges -10<=h<=10, -12<=k<=12, -20<=l<=20 
Reflections collected 11967 
Independent reflections 5518 [R(int) = 0.0430] 
Completeness to theta = 27.11° 98.9 %  
Absorption correction None 
Max. and min. transmission 0.9670 and 0.6312 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5518 / 1 / 317 
Goodness-of-fit on F2 0.987 





R indices (all data) R1 = 0.0824, wR2 = 0.0975 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0909m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 2481(4) 7247(3) 5338(2) 28(1) 
C(2) 3311(4) 7122(3) 6040(2) 28(1) 
C(3) 3988(3) 5768(3) 6448(2) 24(1) 
C(4) 3821(3) 4610(3) 6140(2) 22(1) 
C(5) 2973(3) 4860(3) 5414(2) 21(1) 
C(6) 478(3) 4930(3) 3223(2) 24(1) 
C(7) 537(3) 3730(3) 2936(2) 23(1) 
C(8) 1408(3) 2452(3) 3368(2) 20(1) 
C(9) 2158(3) 2456(3) 4082(2) 20(1) 
C(10) 2065(3) 3715(3) 4369(2) 19(1) 
C(11) 4898(4) 5537(3) 7190(2) 31(1) 
C(12) 1509(4) 1088(3) 3075(2) 23(1) 
C(13) 3729(4) 1540(3) 1863(2) 30(1) 
C(14) 4353(4) 1007(4) 1003(2) 39(1) 
C(15) 3509(4) -170(4) 1004(2) 46(1) 
C(16) 2441(4) -313(3) 1862(2) 37(1) 
N(1) 2292(3) 6145(2) 5019(2) 23(1) 
N(2) 2811(3) 3722(3) 5072(2) 21(1) 
N(3) 1227(3) 4918(2) 3933(2) 20(1) 
N(4) 5659(3) 5334(3) 7760(2) 39(1) 
N(5) 2132(3) 1104(3) 2132(2) 25(1) 
C(17) -87(5) 6949(5) 9723(3) 37(1) 
C(18) 2490(7) 5399(6) 9408(4) 59(2) 
C(19) 1910(7) 6461(7) 10730(3) 67(2) 
N(6) 1440(4) 6270(3) 9915(2) 42(1) 
O(1) -675(17) 6810(19) 9087(14) 34(3) 
C(17A) 913(19) 6044(16) 9163(10) 37(1) 
C(18A) 1000(20) 7310(20) 10320(13) 59(2) 
C(19A) 3410(20) 5390(20) 9894(13) 72(7) 
N(6A) 1440(4) 6270(3) 9915(2) 42(1) 
O(1A) -390(60) 6820(70) 8970(50) 34(11) 
Cl(1) 7948(1) 11188(1) 2065(1) 32(1) 
Cl(2) 5422(1) 9229(1) 3874(1) 29(1) 
Cl(3) 9773(1) 8231(1) 3680(1) 30(1) 









 Table 3.   Bond lengths [Å] and angles [°] for  phw0909m. 
_____________________________________________________  
C(1)-N(1)  1.347(4) 
C(1)-C(2)  1.370(4) 
C(1)-H(1)  0.9500 
C(2)-C(3)  1.399(4) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.382(4) 
C(3)-C(11)  1.449(4) 
C(4)-C(5)  1.393(4) 
C(4)-H(4)  0.9500 
C(5)-N(1)  1.340(3) 
C(5)-N(2)  1.392(4) 
C(6)-C(7)  1.348(4) 
C(6)-N(3)  1.364(3) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.409(4) 
C(7)-H(7)  0.9500 
C(8)-C(9)  1.375(4) 
C(8)-C(12)  1.500(4) 
C(9)-C(10)  1.397(4) 
C(9)-H(9)  0.9500 
C(10)-N(3)  1.351(3) 
C(10)-N(2)  1.358(3) 
C(11)-N(4)  1.143(4) 
C(12)-N(5)  1.490(4) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(13)-N(5)  1.508(4) 
C(13)-C(14)  1.517(4) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-C(15)  1.523(5) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 





C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(16)-N(5)  1.506(4) 
C(16)-H(16A)  0.9900 
C(16)-H(16B)  0.9900 
N(2)-H(2A)  0.80(3) 
N(3)-H(3)  0.9736 
N(5)-H(5)  0.83(3) 
C(17)-O(1)  1.230(17) 
C(17)-N(6)  1.361(5) 
C(17)-H(17A)  0.9500 
C(18)-N(6)  1.363(6) 
C(18)-H(18D)  0.9800 
C(18)-H(18E)  0.9800 
C(18)-H(18F)  0.9800 
C(19)-N(6)  1.457(6) 
C(19)-H(19D)  0.9800 
C(19)-H(19E)  0.9800 
C(19)-H(19F)  0.9800 
C(17A)-O(1A)  1.230(18) 
C(17A)-H(17)  0.9500 
C(18A)-H(18A)  0.9800 
C(18A)-H(18B)  0.9800 
C(18A)-H(18C)  0.9800 
C(19A)-H(19A)  0.9800 
C(19A)-H(19B)  0.9800 
C(19A)-H(19C)  0.9800 
Cl(1)-Co(1)  2.2595(9) 
Cl(2)-Co(1)  2.3122(9) 
Cl(3)-Co(1)  2.2830(8) 












































































































Symmetry transformations used to generate equivalent atoms:  
 
 
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0909m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 28(2)  20(2) 34(2)  -5(1) -1(1)  -5(1) 
C(2) 31(2)  24(2) 32(2)  -10(1) -2(1)  -9(1) 
C(3) 21(2)  30(2) 25(2)  -7(1) 0(1)  -8(1) 
C(4) 20(2)  24(2) 22(2)  -2(1) -2(1)  -4(1) 
C(5) 20(2)  20(2) 20(2)  -4(1) 1(1)  -3(1) 
C(6) 25(2)  23(2) 20(2)  -2(1) -6(1)  2(1) 
C(7) 23(2)  25(2) 20(2)  -6(1) -4(1)  -1(1) 
C(8) 15(1)  20(2) 22(2)  -5(1) 3(1)  -4(1) 
C(9) 20(2)  16(1) 23(2)  -1(1) -4(1)  -2(1) 
C(10) 16(1)  20(2) 18(2)  -1(1) -1(1)  -2(1) 
C(11) 28(2)  37(2) 31(2)  -10(2) 0(2)  -12(1) 
C(12) 23(2)  25(2) 21(2)  -7(1) -1(1)  -4(1) 
C(13) 26(2)  38(2) 25(2)  -4(1) -2(1)  -9(1) 
C(14) 38(2)  49(2) 28(2)  -9(2) 2(2)  -11(2) 
C(15) 48(2)  55(2) 37(2)  -26(2) 3(2)  -5(2) 
C(16) 45(2)  32(2) 37(2)  -19(2) 2(2)  -8(2) 
N(1) 23(1)  20(1) 26(1)  -4(1) -4(1)  -2(1) 
N(2) 25(1)  16(1) 22(1)  -1(1) -7(1)  -1(1) 
N(3) 22(1)  16(1) 21(1)  -3(1) -3(1)  -1(1) 
N(4) 39(2)  47(2) 37(2)  -10(1) -11(1)  -13(1) 
N(5) 25(1)  26(1) 24(1)  -6(1) -4(1)  -2(1) 
C(17) 41(3)  33(2) 32(3)  1(2) -5(2)  -6(2) 
C(18) 51(3)  59(3) 58(3)  1(3) -7(3)  1(3) 
C(19) 64(4)  95(5) 45(3)  -4(3) -23(3)  -18(3) 
N(6) 48(2)  44(2) 35(2)  6(2) -18(2)  -11(2) 





C(17A) 41(3)  33(2) 32(3)  1(2) -5(2)  -6(2) 
C(18A) 51(3)  59(3) 58(3)  1(3) -7(3)  1(3) 
C(19A) 46(11)  105(18) 54(12)  35(12) -29(10)  -20(11) 
N(6A) 48(2)  44(2) 35(2)  6(2) -18(2)  -11(2) 
O(1A) 31(14)  31(11) 30(20)  13(9) -3(14)  -7(11) 
Cl(1) 34(1)  25(1) 36(1)  4(1) -9(1)  -9(1) 
Cl(2) 26(1)  25(1) 30(1)  0(1) -3(1)  3(1) 
Cl(3) 29(1)  21(1) 40(1)  2(1) -14(1)  -4(1) 
Cl(4) 54(1)  31(1) 33(1)  -10(1) -8(1)  -9(1) 






 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0909m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 2012 8162 5059 33 
H(2) 3424 7926 6243 34 
H(4) 4266 3684 6413 27 
H(6) -94 5796 2928 29 
H(7) -3 3746 2447 28 
H(9) 2740 1599 4382 24 
H(12A) 2234 328 3432 28 
H(12B) 415 880 3178 28 
H(13A) 4495 1106 2306 36 
H(13B) 3568 2572 1782 36 
H(14A) 5548 650 960 46 
H(14B) 4086 1768 503 46 
H(15A) 2846 63 508 55 
H(15B) 4322 -1057 951 55 
H(16A) 3001 -1057 2301 44 
H(16B) 1410 -536 1785 44 
H(2A) 3220(40) 2960(30) 5300(20) 33(10) 
H(3) 1255 5809 4087 24 
H(5) 1470(40) 1640(40) 1810(20) 47(11) 
H(17A) -732 7562 10101 44 
H(18D) 1908 5205 8971 89 
H(18E) 2948 4518 9777 89 
H(18F) 3370 5849 9110 89 
H(19D) 2855 6887 10601 100 
H(19E) 2188 5549 11108 100 
H(19F) 1003 7076 11028 100 
H(17) 1512 5345 8831 44 
H(18A) -19 7907 10122 89 
H(18B) 1844 7848 10201 89 
H(18C) 828 6970 10951 89 
H(19A) 3602 4660 9532 108 
H(19B) 3648 4963 10491 108 






















































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 7.  Hydrogen bonds for phw0909m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(5)-H(5)...O(1A)#1 0.83(3) 1.90(6) 2.71(4) 164(4) 
 N(5)-H(5)...O(1)#1 0.83(3) 1.94(4) 2.724(13) 157(4) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





   Crystallographic data for tpzH-CONH2  
  Table 8.  Crystal data and structure refinement for phw0904m. 
Identification code  phw0904m 
Empirical formula  C9 H10 N4 O4 
Formula weight  238.21 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 10.1467(8) Å = 90°. 
 b = 4.9859(4) Å = 99.619(2)°. 
 c = 19.8568(16) Å  = 90°. 
Volume 990.44(14) Å3 
Z 4 
Density (calculated) 1.598 Mg/m3 
Absorption coefficient 0.128 mm-1 
F(000) 496 
Crystal size 0.31 x 0.09 x 0.04 mm3 
Theta range for data collection 2.04 to 28.28°. 
Index ranges -13<=h<=13, -6<=k<=6, -26<=l<=26 
Reflections collected 9705 
Independent reflections 2467 [R(int) = 0.0212] 
Completeness to theta = 28.28° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.874 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2467 / 0 / 184 
Goodness-of-fit on F2 1.053 
Final R indices [I>2sigma(I)] R1 = 0.0530, wR2 = 0.1561 
R indices (all data) R1 = 0.0624, wR2 = 0.1657 





 Table 9.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0904m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 3356(2) 8612(3) 1029(1) 24(1) 
C(2) 4429(2) 10439(3) 1094(1) 29(1) 
C(3) 4597(2) 12208(4) 1636(1) 35(1) 
C(4) 3712(2) 12204(4) 2108(1) 34(1) 
C(5) 2661(2) 10431(3) 2049(1) 30(1) 
C(6) 2479(2) 8590(3) 1502(1) 23(1) 
C(7) 1262(2) 4967(3) 907(1) 21(1) 
C(8) 2160(2) 5010(3) 420(1) 21(1) 
C(9) 1979(2) 2985(3) -156(1) 23(1) 
N(1) 3163(1) 6796(3) 483(1) 23(1) 
N(2) 1444(1) 6774(3) 1427(1) 22(1) 
N(3) 255(1) 3266(3) 898(1) 24(1) 
N(4) 2790(2) 3082(4) -616(1) 36(1) 
O(1) 4004(2) 6944(3) 74(1) 46(1) 
O(2) 615(1) 6688(3) 1878(1) 30(1) 
O(3) 1084(1) 1309(3) -184(1) 35(1) 




 Table 10.   Bond lengths [Å] and angles [°] for  phw0904m. 
_____________________________________________________  
C(1)-C(6)  1.398(2) 
C(1)-N(1)  1.401(2) 
C(1)-C(2)  1.409(2) 
C(2)-C(3)  1.380(3) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.401(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.375(3) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.410(2) 
C(5)-H(5)  0.9500 
C(6)-N(2)  1.376(2) 





C(7)-N(2)  1.359(2) 
C(7)-C(8)  1.436(2) 
C(8)-N(1)  1.342(2) 
C(8)-C(9)  1.513(2) 
C(9)-O(3)  1.228(2) 
C(9)-N(4)  1.329(2) 
N(1)-O(1)  1.274(2) 
N(2)-O(2)  1.3271(18) 
N(3)-H(3A)  0.82(2) 
N(3)-H(3B)  0.81(3) 
N(4)-H(4A)  1.03(4) 
N(4)-H(4B)  0.92(3) 
O(4)-H(4C)  0.94(6) 
O(4)-H(4D)  0.96(5) 
O(4)-H(4E)  0.88(8) 


























































 Table 11.   Anisotropic displacement parameters  (Å2x 103) for phw0904m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 25(1)  16(1) 28(1)  2(1) -5(1)  2(1) 
C(2) 28(1)  21(1) 36(1)  6(1) -5(1)  -1(1) 
C(3) 36(1)  19(1) 42(1)  5(1) -16(1)  -6(1) 
C(4) 46(1)  18(1) 31(1)  -2(1) -15(1)  0(1) 
C(5) 41(1)  20(1) 24(1)  -1(1) -6(1)  4(1) 
C(6) 28(1)  15(1) 24(1)  2(1) -5(1)  3(1) 
C(7) 24(1)  16(1) 23(1)  1(1) -3(1)  3(1) 
C(8) 23(1)  16(1) 23(1)  0(1) -2(1)  2(1) 
C(9) 24(1)  19(1) 26(1)  -1(1) -2(1)  4(1) 
N(1) 23(1)  19(1) 28(1)  1(1) 2(1)  1(1) 
N(2) 26(1)  18(1) 21(1)  0(1) 1(1)  2(1) 
N(3) 25(1)  21(1) 25(1)  -2(1) 3(1)  -2(1) 
N(4) 33(1)  37(1) 39(1)  -11(1) 10(1)  -3(1) 
O(1) 44(1)  43(1) 55(1)  -6(1) 17(1)  -5(1) 
O(2) 36(1)  30(1) 25(1)  -2(1) 7(1)  1(1) 
O(3) 43(1)  28(1) 32(1)  -7(1) 4(1)  -9(1) 




 Table 12.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0904m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 5024 10453 772 35 
H(3) 5320 13443 1690 42 
H(4) 3841 13449 2475 41 
H(5) 2067 10446 2372 36 
H(3A) -170(20) 3340(40) 1212(11) 22(5) 
H(3B) 170(20) 2140(60) 600(14) 41(7) 
H(4A) 2740(40) 1730(80) -1010(20) 102(13) 
H(4B) 3540(30) 4150(70) -574(16) 65(9) 





H(4D) 9230(50) -900(100) 1730(20) 49 
H(4E) 8290(70) 1910(150) 1870(40) 49 














































Symmetry transformations used to generate equivalent atoms:  
 
 
 Table 14.  Hydrogen bonds for phw0904m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(4)-H(4D)...O(2)#1 0.96(5) 1.84(5) 2.776(2) 166(4) 
 O(4)-H(4C)...O(2)#2 0.94(6) 1.86(6) 2.772(2) 163(5) 
 N(4)-H(4B)...O(1)#3 0.92(3) 2.58(3) 3.251(3) 130(3) 
 N(4)-H(4B)...O(1) 0.92(3) 1.90(3) 2.557(2) 126(3) 
 N(4)-H(4A)...O(4)#4 1.03(4) 2.06(4) 2.963(2) 146(3) 
 N(3)-H(3B)...O(3)#5 0.81(3) 2.22(3) 2.901(2) 142(2) 
 N(3)-H(3B)...O(3) 0.81(3) 1.98(3) 2.622(2) 136(2) 
 N(3)-H(3A)...O(4)#6 0.82(2) 2.43(2) 3.079(2) 136.8(19) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y-1,z    #2 -x+1,y-1/2,-z+1/2    #3 -x+1,-y+1,-z       





   Crystallographic data for tpzH  
  Table 1.  Crystal data and structure refinement for phw0915m. 
Identification code  phw0915m 
Empirical formula  C8 H10 N4 O3 
Formula weight  210.20 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 7.0011(9) Å = 90°. 
 b = 18.680(3) Å = 91.747(3)°. 
 c = 7.2449(10) Å  = 90°. 
Volume 947.0(2) Å3 
Z 4 
Density (calculated) 1.474 Mg/m3 
Absorption coefficient 0.116 mm-1 
F(000) 440 
Crystal size 0.23 x 0.13 x 0.06 mm3 
Theta range for data collection 2.18 to 28.28°. 
Index ranges -9<=h<=9, -24<=k<=24, -9<=l<=9 
Reflections collected 9677 
Independent reflections 2350 [R(int) = 0.0384] 
Completeness to theta = 28.28° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.993 and 0.773 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2350 / 0 / 160 
Goodness-of-fit on F2 1.056 
Final R indices [I>2sigma(I)] R1 = 0.0446, wR2 = 0.1067 
R indices (all data) R1 = 0.0592, wR2 = 0.1169 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0915m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 6331(2) 6203(1) 3480(2) 19(1) 
C(2) 5113(2) 7571(1) 3840(2) 18(1) 
C(3) 4549(2) 8286(1) 4033(2) 21(1) 
C(4) 2807(2) 8425(1) 4778(2) 24(1) 
C(5) 1614(2) 7860(1) 5314(2) 23(1) 
C(6) 2158(2) 7159(1) 5133(2) 21(1) 
C(7) 3956(2) 7008(1) 4409(2) 17(1) 
N(1) 4614(2) 6319(1) 4232(2) 18(1) 
N(2) 6857(2) 7403(1) 3030(2) 19(1) 
N(3) 6947(2) 5538(1) 3278(2) 24(1) 
N(4) 7458(2) 6741(1) 2858(2) 20(1) 
O(1) 3588(2) 5762(1) 4788(2) 24(1) 
O(2) 7867(2) 7897(1) 2400(2) 25(1) 
C(8A) 1190(20) 4578(9) 2150(20) 34(2) 
C(8B) 1590(30) 4635(14) 1920(30) 42(4) 




 Table 3.   Bond lengths [Å] and angles [°] for  phw0915m. 
_____________________________________________________  
C(1)-N(3)  1.3241(19) 
C(1)-N(1)  1.3527(19) 
C(1)-N(4)  1.3624(18) 
C(2)-C(7)  1.397(2) 
C(2)-C(3)  1.402(2) 
C(2)-N(2)  1.4061(18) 
C(3)-C(4)  1.374(2) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.408(2) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.372(2) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.408(2) 





C(7)-N(1)  1.3740(18) 
N(1)-O(1)  1.3330(15) 
N(2)-O(2)  1.2574(15) 
N(2)-N(4)  1.3130(17) 
N(3)-H(3A)  0.93(2) 
N(3)-H(3B)  0.89(2) 
C(8A)-O(3)  1.409(18) 
C(8A)-H(8A1)  0.9800 
C(8A)-H(8A2)  0.9800 
C(8A)-H(8A3)  0.9800 
C(8B)-O(3)  1.43(3) 
C(8B)-H(8B1)  0.9800 
C(8B)-H(8B2)  0.9800 
C(8B)-H(8B3)  0.9800 


















































Symmetry transformations used to generate equivalent atoms:  
  
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0915m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 19(1)  20(1) 18(1)  1(1) 0(1)  0(1) 
C(2) 17(1)  19(1) 17(1)  0(1) 1(1)  0(1) 
C(3) 22(1)  19(1) 23(1)  -1(1) 0(1)  -1(1) 
C(4) 26(1)  22(1) 24(1)  -3(1) 0(1)  4(1) 
C(5) 19(1)  31(1) 19(1)  -2(1) 2(1)  4(1) 
C(6) 17(1)  27(1) 19(1)  0(1) 1(1)  -2(1) 
C(7) 17(1)  19(1) 16(1)  1(1) -2(1)  -1(1) 
N(1) 17(1)  18(1) 21(1)  2(1) 2(1)  -3(1) 
N(2) 16(1)  18(1) 21(1)  1(1) 3(1)  -1(1) 
N(3) 22(1)  19(1) 32(1)  3(1) 7(1)  1(1) 
N(4) 19(1)  19(1) 22(1)  1(1) 4(1)  1(1) 
O(1) 21(1)  19(1) 31(1)  5(1) 3(1)  -6(1) 





C(8A) 33(5)  28(3) 42(3)  -8(2) -7(3)  9(3) 
C(8B) 31(7)  35(6) 59(10)  -25(6) -18(5)  10(5) 




 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0915m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(3) 5352 8665 3657 26 
H(4) 2403 8907 4932 29 
H(5) 407 7967 5813 27 
H(6) 1336 6782 5491 25 
H(3A) 8200(30) 5478(10) 2930(30) 34(5) 
H(3B) 6300(30) 5186(11) 3810(30) 40(5) 
H(8A1) 1101 4469 827 51 
H(8A2) 267 4286 2805 51 
H(8A3) 2486 4471 2625 51 
H(8B1) 1619 4315 2996 63 
H(8B2) 2895 4707 1503 63 
H(8B3) 807 4421 925 63 










































 Table 7.  Hydrogen bonds for phw0915m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(3)-H(3C)...O(1) 0.87(2) 1.83(2) 2.6962(16) 174(2) 
 N(3)-H(3B)...O(1)#1 0.89(2) 2.04(2) 2.8347(17) 147.5(19) 
 N(3)-H(3A)...O(3)#2 0.93(2) 1.89(2) 2.8137(18) 174.5(17) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





   Crystallographic data for [Zn(tpz-CN)2(DMF)]  
  Table 1.  Crystal data and structure refinement for phw0901m. 
Identification code  phw0901m 
Empirical formula  C22.83 H21.50 N9.17 O5.50 Zn 
Formula weight  577.72 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.8016(12) Å = 90°. 
 b = 19.346(2) Å = 94.274(2)°. 
 c = 12.6985(16) Å  = 90°. 
Volume 2401.3(5) Å3 
Z 4 
Density (calculated) 1.598 Mg/m3 
Absorption coefficient 1.082 mm-1 
F(000) 1186.7 
Crystal size 0.28 x 0.07 x 0.04 mm3 
Theta range for data collection 1.92 to 28.30°. 
Index ranges -13<=h<=13, -25<=k<=25, -16<=l<=16 
Reflections collected 24425 
Independent reflections 5949 [R(int) = 0.0286] 
Completeness to theta = 28.30° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.958 and 0.847 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5949 / 16 / 380 
Goodness-of-fit on F2 1.121 
Final R indices [I>2sigma(I)] R1 = 0.0471, wR2 = 0.1103 
R indices (all data) R1 = 0.0581, wR2 = 0.1154 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0901m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 8161(3) 1597(1) 4312(2) 23(1) 
C(2) 8972(3) 2214(1) 4297(2) 25(1) 
C(3) 7021(3) 2929(1) 4356(2) 26(1) 
C(4) 6435(3) 3590(1) 4359(2) 33(1) 
C(5) 5045(3) 3649(2) 4377(2) 35(1) 
C(6) 4213(3) 3057(1) 4374(2) 30(1) 
C(7) 4772(3) 2405(1) 4361(2) 25(1) 
C(8) 6196(3) 2333(1) 4360(2) 22(1) 
C(9) 10414(3) 2149(2) 4247(2) 30(1) 
C(10) 6143(2) -1007(1) 3497(2) 23(1) 
C(11) 5306(2) -1610(1) 3299(2) 22(1) 
C(12) 7241(2) -2338(1) 3251(2) 22(1) 
C(13) 7797(3) -3003(1) 3192(2) 26(1) 
C(14) 9188(3) -3076(1) 3192(2) 27(1) 
C(15) 10035(3) -2488(1) 3231(2) 25(1) 
C(16) 9505(2) -1835(1) 3308(2) 22(1) 
C(17) 8084(2) -1750(1) 3344(2) 20(1) 
C(18) 3854(3) -1539(1) 3182(2) 26(1) 
C(19) 8287(3) -108(1) 6461(2) 27(1) 
C(20) 7408(3) -980(2) 7607(3) 35(1) 
C(21) 9690(3) -447(2) 8028(2) 34(1) 
N(1) 6780(2) 1687(1) 4337(2) 22(1) 
N(2) 8438(2) 2854(1) 4311(2) 28(1) 
N(3) 8615(2) 962(1) 4291(2) 28(1) 
N(4) 11557(3) 2036(2) 4229(2) 41(1) 
N(5) 7529(2) -1109(1) 3489(2) 22(1) 
N(6) 5814(2) -2250(1) 3205(2) 21(1) 
N(7) 5711(2) -383(1) 3668(2) 29(1) 
N(8) 2699(2) -1441(1) 3071(2) 37(1) 
N(9) 8452(2) -495(1) 7314(2) 28(1) 
O(1) 5976(2) 1127(1) 4322(2) 26(1) 
O(2) 9204(2) 3390(1) 4284(2) 40(1) 
O(3) 8357(2) -558(1) 3666(2) 29(1) 
O(4) 5028(2) -2776(1) 3070(2) 28(1) 





Zn(1) 7173(1) 238(1) 4295(1) 25(1) 
C(22) 2796(7) 4586(5) 5263(8) 40(2) 
C(23) 1644(11) 4864(12) 5857(8) 125(8) 
O(6) 453(7) 4940(4) 5159(6) 41(3) 
C(24) -615(11) 5221(10) 5742(10) 100(6) 
C(25) -1886(15) 5320(20) 5011(18) 202(16) 
C(26) 783(12) 4896(7) 5361(10) 11(3) 
C(27) -480(20) 4906(14) 3657(11) 77(12) 
C(28) -1492(13) 5370(9) 5350(13) 30(4) 
N(10) -407(15) 5060(11) 4780(10) 130(20) 




 Table 3.   Bond lengths [Å] and angles [°] for  phw0901m. 
_____________________________________________________  
C(1)-N(3)  1.308(3) 
C(1)-N(1)  1.368(3) 
C(1)-C(2)  1.434(3) 
C(2)-N(2)  1.345(4) 
C(2)-C(9)  1.425(4) 
C(3)-C(4)  1.401(4) 
C(3)-N(2)  1.402(4) 
C(3)-C(8)  1.409(4) 
C(4)-C(5)  1.369(4) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.405(4) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.377(4) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.403(4) 
C(7)-H(7)  0.9500 
C(8)-N(1)  1.374(3) 
C(9)-N(4)  1.144(4) 
C(10)-N(7)  1.303(3) 
C(10)-N(5)  1.373(3) 
C(10)-C(11)  1.437(3) 
C(11)-N(6)  1.344(3) 
C(11)-C(18)  1.427(3) 





C(12)-N(6)  1.405(3) 
C(12)-C(17)  1.406(3) 
C(13)-C(14)  1.370(4) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.407(4) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.373(4) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.406(3) 
C(16)-H(16)  0.9500 
C(17)-N(5)  1.372(3) 
C(18)-N(8)  1.146(3) 
C(19)-O(5)  1.250(3) 
C(19)-N(9)  1.317(4) 
C(19)-H(19)  0.9500 
C(20)-N(9)  1.457(4) 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
C(21)-N(9)  1.463(4) 
C(21)-H(21A)  0.9800 
C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
N(1)-O(1)  1.340(3) 
N(2)-O(2)  1.282(3) 
N(3)-Zn(1)  1.990(2) 
N(3)-H(3)  0.82(4) 
N(5)-O(3)  1.348(3) 
N(6)-O(4)  1.280(3) 
N(7)-Zn(1)  1.989(2) 
N(7)-H(7A)  0.84(4) 
O(1)-Zn(1)  2.0838(18) 
O(3)-Zn(1)  2.1196(19) 
O(5)-Zn(1)  2.078(2) 
C(22)-C(23)  1.503(5) 
C(22)-H(22A)  0.9800 
C(22)-H(22B)  0.9800 
C(22)-H(22C)  0.9800 
C(23)-O(6)  1.419(5) 





C(23)-H(23B)  0.9900 
O(6)-C(24)  1.435(5) 
C(24)-C(25)  1.510(5) 
C(24)-H(24A)  0.9900 
C(24)-H(24B)  0.9900 
C(25)-H(25A)  0.9800 
C(25)-H(25B)  0.9800 
C(25)-H(25C)  0.9800 
C(26)-O(7)  1.235(5) 
C(26)-N(10)  1.371(5) 
C(26)-H(26)  0.9500 
C(27)-N(10)  1.453(5) 
C(27)-H(27A)  0.9800 
C(27)-H(27B)  0.9800 
C(27)-H(27C)  0.9800 
C(28)-N(10)  1.459(5) 
C(28)-H(28A)  0.9800 
C(28)-H(28B)  0.9800 

















































































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0901m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  





C(2) 25(1)  29(1) 22(1)  0(1) 0(1)  -6(1) 
C(3) 34(1)  24(1) 21(1)  1(1) 2(1)  -4(1) 
C(4) 48(2)  22(1) 29(2)  -1(1) 4(1)  -6(1) 
C(5) 53(2)  23(1) 31(2)  0(1) 9(1)  8(1) 
C(6) 37(2)  28(1) 25(1)  1(1) 7(1)  7(1) 
C(7) 29(1)  24(1) 23(1)  2(1) 3(1)  1(1) 
C(8) 28(1)  21(1) 18(1)  0(1) 2(1)  -2(1) 
C(9) 30(1)  36(2) 23(1)  0(1) 0(1)  -12(1) 
C(10) 19(1)  25(1) 26(1)  0(1) 0(1)  -2(1) 
C(11) 20(1)  26(1) 22(1)  0(1) 0(1)  -4(1) 
C(12) 22(1)  24(1) 20(1)  0(1) 1(1)  -2(1) 
C(13) 30(1)  22(1) 25(1)  0(1) 4(1)  -3(1) 
C(14) 29(1)  25(1) 27(1)  0(1) 1(1)  4(1) 
C(15) 22(1)  31(1) 23(1)  -2(1) 2(1)  4(1) 
C(16) 20(1)  27(1) 20(1)  -1(1) 1(1)  -2(1) 
C(17) 20(1)  22(1) 19(1)  0(1) 0(1)  -2(1) 
C(18) 23(1)  28(1) 29(1)  -5(1) 2(1)  -5(1) 
C(19) 23(1)  21(1) 38(2)  1(1) 7(1)  2(1) 
C(20) 33(2)  35(2) 39(2)  4(1) 9(1)  -5(1) 
C(21) 33(2)  31(1) 37(2)  4(1) -3(1)  1(1) 
N(1) 22(1)  21(1) 24(1)  1(1) 1(1)  -3(1) 
N(2) 35(1)  25(1) 25(1)  0(1) -1(1)  -10(1) 
N(3) 20(1)  26(1) 37(1)  -3(1) 2(1)  -2(1) 
N(4) 29(1)  61(2) 31(1)  -2(1) 2(1)  -11(1) 
N(5) 18(1)  22(1) 27(1)  -2(1) 2(1)  -3(1) 
N(6) 21(1)  24(1) 19(1)  -2(1) 2(1)  -5(1) 
N(7) 18(1)  25(1) 44(1)  -5(1) 1(1)  1(1) 
N(8) 23(1)  42(1) 47(2)  -13(1) 1(1)  -3(1) 
N(9) 25(1)  25(1) 33(1)  3(1) 4(1)  -1(1) 
O(1) 21(1)  18(1) 39(1)  0(1) 0(1)  -4(1) 
O(2) 43(1)  29(1) 46(1)  0(1) 2(1)  -20(1) 
O(3) 20(1)  21(1) 46(1)  -6(1) 4(1)  -6(1) 
O(4) 26(1)  26(1) 33(1)  -4(1) 3(1)  -11(1) 
O(5) 24(1)  33(1) 38(1)  3(1) 1(1)  0(1) 
Zn(1) 21(1)  20(1) 35(1)  -1(1) 0(1)  -1(1) 
______________________________________________________________________________  
 







 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(4) 6994 3990 4350 40 
H(5) 4638 4094 4390 42 
H(6) 3250 3108 4382 36 
H(7) 4199 2008 4353 30 
H(13) 7219 -3397 3153 31 
H(14) 9580 -3524 3166 33 
H(15) 10994 -2544 3204 30 
H(16) 10092 -1443 3337 27 
H(19) 9010 194 6306 32 
H(20A) 6609 -949 7097 53 
H(20B) 7136 -866 8314 53 
H(20C) 7776 -1451 7608 53 
H(21A) 10339 -129 7731 51 
H(21B) 10109 -906 8115 51 
H(21C) 9452 -275 8716 51 
H(3) 9450(40) 940(19) 4270(30) 47(11) 
H(7A) 4880(40) -337(17) 3750(30) 38(9) 
H(22A) 2487 4535 4515 60 
H(22B) 3080 4135 5554 60 
H(22C) 3570 4907 5333 60 
H(23A) 1454 4543 6436 150 
H(23B) 1906 5317 6172 150 
H(24A) -320 5671 6055 120 
H(24B) -812 4904 6323 120 
H(25A) -1625 5437 4303 303 
H(25B) -2439 5695 5276 303 
H(25C) -2421 4891 4978 303 
H(26) 1531 4687 5048 13 
H(27A) -1195 4563 3489 115 
H(27B) 405 4721 3472 115 
H(27C) -686 5330 3254 115 
H(28A) -1240 5845 5549 45 
H(28B) -1618 5099 5988 45 




















































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 7.  Hydrogen bonds for phw0901m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(7)-H(7A)...O(5)#1 0.84(4) 2.34(4) 3.148(3) 163(3) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





   Crystallographic data for [Cu(tpz-CN)(dpHa)(H2O)]Cl  
  Table 1.  Crystal data and structure refinement for phw0911ma. 
Identification code  phw0911ma 
Empirical formula  C19 H16 Cl Cu N7 O3 
Formula weight  489.38 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 13.7739(5) Å = 90°. 
 b = 15.9937(6) Å = 92.4990(10)°. 
 c = 8.6766(3) Å  = 90°. 
Volume 1909.60(12) Å3 
Z 4 
Density (calculated) 1.702 Mg/m3 
Absorption coefficient 1.324 mm-1 
F(000) 996 
Crystal size 0.33 x 0.06 x 0.03 mm3 
Theta range for data collection 1.48 to 28.30°. 
Index ranges -18<=h<=18, -21<=k<=21, -11<=l<=11 
Reflections collected 25950 
Independent reflections 4749 [R(int) = 0.0344] 
Completeness to theta = 28.30° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4749 / 0 / 296 
Goodness-of-fit on F2 1.040 
Final R indices [I>2sigma(I)] R1 = 0.0312, wR2 = 0.0798 
R indices (all data) R1 = 0.0375, wR2 = 0.0835 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0911ma.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 3726(1) 1638(1) 1787(2) 16(1) 
C(2) 4476(1) 1898(1) 793(2) 17(1) 
C(3) 4140(1) 3333(1) 1235(2) 17(1) 
C(4) 4366(1) 4176(1) 1010(2) 21(1) 
C(5) 3886(1) 4774(1) 1821(2) 23(1) 
C(6) 3170(1) 4539(1) 2848(2) 21(1) 
C(7) 2924(1) 3713(1) 3053(2) 18(1) 
C(8) 3420(1) 3094(1) 2242(2) 16(1) 
C(9) 5086(1) 1296(1) 99(2) 19(1) 
C(10) 2719(1) -912(1) 2753(2) 19(1) 
C(11) 2916(1) -1738(1) 3065(2) 21(1) 
C(12) 2610(1) -2073(1) 4451(2) 21(1) 
C(13) 2120(1) -1571(1) 5439(2) 19(1) 
C(14) 1936(1) -732(1) 5036(2) 16(1) 
C(15) 737(1) 1771(1) 4607(2) 21(1) 
C(16) 102(1) 2047(1) 5661(2) 22(1) 
C(17) -91(1) 1528(1) 6908(2) 20(1) 
C(18) 343(1) 759(1) 7016(2) 19(1) 
C(19) 989(1) 514(1) 5880(2) 16(1) 
Cu(1) 2282(1) 829(1) 3313(1) 17(1) 
N(1) 3218(1) 2261(1) 2438(2) 17(1) 
N(2) 4647(1) 2707(1) 462(2) 17(1) 
N(3) 3471(1) 871(1) 2119(2) 18(1) 
N(4) 5570(1) 789(1) -389(2) 26(1) 
N(5) 2254(1) -396(1) 3734(2) 17(1) 
N(6) 1398(1) -269(1) 6024(2) 18(1) 
N(7) 1202(1) 1018(1) 4709(2) 18(1) 
O(1) 2515(1) 2038(1) 3395(2) 21(1) 
O(2) 5267(1) 2908(1) -533(2) 21(1) 
O(3) 1259(1) 799(1) 1036(2) 22(1) 






 Table 3.   Bond lengths [Å] and angles [°] for  phw0911ma. 
_____________________________________________________  
C(1)-N(3)  1.311(2) 
C(1)-N(1)  1.355(2) 
C(1)-C(2)  1.436(2) 
C(2)-N(2)  1.349(2) 
C(2)-C(9)  1.428(2) 
C(3)-C(4)  1.400(2) 
C(3)-C(8)  1.402(2) 
C(3)-N(2)  1.407(2) 
C(4)-C(5)  1.375(3) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.409(3) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.377(3) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.409(2) 
C(7)-H(7)  0.9500 
C(8)-N(1)  1.373(2) 
C(9)-N(4)  1.142(2) 
C(10)-N(5)  1.365(2) 
C(10)-C(11)  1.373(3) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.398(3) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.373(3) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.408(2) 
C(13)-H(13)  0.9500 
C(14)-N(5)  1.343(2) 
C(14)-N(6)  1.373(2) 
C(15)-N(7)  1.365(2) 
C(15)-C(16)  1.366(3) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.398(3) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.370(3) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.411(2) 





C(19)-N(7)  1.339(2) 
C(19)-N(6)  1.377(2) 
Cu(1)-O(1)  1.9614(13) 
Cu(1)-N(3)  1.9764(16) 
Cu(1)-N(7)  1.9828(15) 
Cu(1)-N(5)  1.9928(15) 
Cu(1)-O(3)  2.3772(15) 
N(1)-O(1)  1.3508(18) 
N(2)-O(2)  1.2814(18) 
N(3)-H(3)  0.79(3) 
N(6)-H(6A)  0.76(3) 
O(3)-H(3A)  0.72(3) 








































































































 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0911ma.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 16(1)  18(1) 15(1)  1(1) 2(1)  -1(1) 
C(2) 17(1)  17(1) 16(1)  0(1) 4(1)  0(1) 
C(3) 18(1)  17(1) 16(1)  0(1) 2(1)  -1(1) 
C(4) 23(1)  18(1) 22(1)  4(1) 3(1)  -3(1) 
C(5) 26(1)  15(1) 26(1)  2(1) 2(1)  -2(1) 
C(6) 22(1)  19(1) 21(1)  -2(1) -1(1)  3(1) 
C(7) 18(1)  19(1) 18(1)  -1(1) 2(1)  2(1) 
C(8) 17(1)  16(1) 16(1)  1(1) 1(1)  -1(1) 
C(9) 18(1)  20(1) 19(1)  2(1) 4(1)  -2(1) 
C(10) 21(1)  20(1) 17(1)  -1(1) 5(1)  -1(1) 
C(11) 21(1)  21(1) 21(1)  -4(1) 3(1)  1(1) 
C(12) 21(1)  17(1) 25(1)  0(1) -1(1)  2(1) 
C(13) 20(1)  18(1) 19(1)  3(1) 2(1)  -1(1) 
C(14) 15(1)  17(1) 17(1)  1(1) 1(1)  -1(1) 
C(15) 22(1)  18(1) 25(1)  6(1) 7(1)  0(1) 
C(16) 20(1)  16(1) 29(1)  1(1) 5(1)  0(1) 
C(17) 18(1)  22(1) 21(1)  -4(1) 4(1)  0(1) 
C(18) 19(1)  21(1) 17(1)  1(1) 4(1)  -2(1) 
C(19) 15(1)  16(1) 17(1)  0(1) 1(1)  -2(1) 
Cu(1) 19(1)  15(1) 17(1)  2(1) 6(1)  -1(1) 
N(1) 17(1)  17(1) 17(1)  1(1) 6(1)  -2(1) 
N(2) 16(1)  19(1) 15(1)  2(1) 3(1)  -2(1) 
N(3) 21(1)  15(1) 19(1)  0(1) 7(1)  0(1) 
N(4) 25(1)  25(1) 28(1)  2(1) 10(1)  3(1) 
N(5) 18(1)  16(1) 17(1)  0(1) 3(1)  -1(1) 
N(6) 21(1)  16(1) 15(1)  4(1) 6(1)  0(1) 
N(7) 18(1)  17(1) 18(1)  2(1) 4(1)  -1(1) 
O(1) 22(1)  18(1) 23(1)  0(1) 13(1)  -3(1) 
O(2) 19(1)  24(1) 20(1)  2(1) 9(1)  -3(1) 
O(3) 23(1)  22(1) 23(1)  -3(1) 1(1)  0(1) 






 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0911ma. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(4) 4844 4332 308 25 
H(5) 4038 5349 1689 27 
H(6) 2850 4959 3411 25 
H(7) 2429 3564 3730 22 
H(10) 2918 -687 1804 23 
H(11) 3251 -2073 2357 25 
H(12) 2741 -2641 4706 25 
H(13) 1908 -1789 6386 23 
H(15) 863 2123 3757 26 
H(16) -203 2578 5548 26 
H(17) -517 1708 7673 24 
H(18) 211 394 7845 22 
H(3) 3760(20) 511(18) 1720(30) 38(7) 
H(6A) 1298(18) -477(16) 6790(30) 25(6) 
H(3A) 1280(20) 390(20) 690(30) 43(9) 




































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 7.  Hydrogen bonds for phw0911ma  [Å and °]. 
____________________________________________________________________________  






 O(3)-H(3B)...Cl(1)#1 0.75(3) 2.59(3) 3.3250(17) 166(3) 
 O(3)-H(3A)...Cl(1)#2 0.72(3) 2.48(3) 3.1942(17) 172(3) 
 N(6)-H(6A)...Cl(1)#3 0.76(3) 2.39(3) 3.1487(16) 172(2) 
 N(3)-H(3)...N(4)#2 0.79(3) 2.57(3) 3.350(2) 171(3) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





    
Crystallographic data for [Zn(tpzH-CN)(dpHa)(MeOH)]BF4  
  Table 1.  Crystal data and structure refinement for phw1010m. 
Identification code  phw1010m 
Empirical formula  C20 H18 B F4 N7 O3 Zn 
Formula weight  556.59 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 7.5622(8) Å = 90°. 
 b = 16.4939(18) Å = 99.859(2)°. 
 c = 17.7364(19) Å  = 90°. 
Volume 2179.6(4) Å3 
Z 4 
Density (calculated) 1.696 Mg/m3 
Absorption coefficient 1.202 mm-1 
F(000) 1128 
Crystal size 0.28 x 0.06 x 0.04 mm3 
Theta range for data collection 1.70 to 28.35°. 
Index ranges -10<=h<=10, -21<=k<=22, -23<=l<=23 
Reflections collected 22248 
Independent reflections 5420 [R(int) = 0.0559] 
Completeness to theta = 28.35° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.953 and 0.724 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5420 / 0 / 338 
Goodness-of-fit on F2 1.019 
Final R indices [I>2sigma(I)] R1 = 0.0436, wR2 = 0.0896 
R indices (all data) R1 = 0.0697, wR2 = 0.1009 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw1010m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
B(1A) 2556(4) 339(2) 1812(2) 24(1) 
C(1) 1306(3) 4547(2) 845(1) 18(1) 
C(2) 1594(3) 5399(2) 757(1) 18(1) 
C(3) -917(3) 5743(2) 1325(2) 20(1) 
C(4) -2046(4) 6329(2) 1561(2) 23(1) 
C(5) -3485(4) 6084(2) 1878(2) 26(1) 
C(6) -3816(4) 5250(2) 1971(2) 27(1) 
C(7) -2722(4) 4671(2) 1745(2) 25(1) 
C(8) -1240(4) 4911(2) 1418(1) 20(1) 
C(9) 3019(4) 5667(2) 387(2) 21(1) 
C(10) 4171(4) 2450(2) -113(2) 22(1) 
C(11) 5053(4) 2202(2) -689(2) 24(1) 
C(12) 4209(4) 1640(2) -1215(2) 26(1) 
C(13) 2550(4) 1342(2) -1136(2) 24(1) 
C(14) 1743(3) 1619(2) -526(2) 20(1) 
C(15) -1760(4) 1909(2) 1188(2) 24(1) 
C(16) -3051(4) 1336(2) 1227(2) 24(1) 
C(17) -3262(4) 714(2) 685(2) 24(1) 
C(18) -2194(4) 702(2) 134(2) 22(1) 
C(19) -910(3) 1316(2) 129(2) 19(1) 
C(20) 3172(5) 2921(2) 2422(2) 46(1) 
F(1) 2755(3) 751(1) 1162(1) 38(1) 
F(2) 1104(3) -165(1) 1669(1) 56(1) 
F(3) 4085(3) -146(1) 2024(1) 69(1) 
F(4) 2419(2) 885(1) 2388(1) 33(1) 
N(1) -128(3) 4341(1) 1180(1) 20(1) 
N(2) 535(3) 5977(1) 984(1) 20(1) 
N(3) 2233(3) 3952(1) 613(1) 20(1) 
N(4) 4177(3) 5821(1) 73(1) 28(1) 
N(5) 2516(3) 2184(1) -32(1) 19(1) 
N(6) 99(3) 1289(1) -453(1) 22(1) 
N(7) -692(3) 1915(1) 647(1) 20(1) 
O(1) -491(3) 3553(1) 1249(1) 25(1) 
O(2) 823(3) 6733(1) 868(1) 26(1) 









 Table 3.   Bond lengths [Å] and angles [°] for  phw1010m. 
_____________________________________________________  
B(1A)-F(2)  1.365(4) 
B(1A)-F(1)  1.369(4) 
B(1A)-F(4)  1.380(3) 
B(1A)-F(3)  1.403(4) 
C(1)-N(3)  1.313(3) 
C(1)-N(1)  1.365(3) 
C(1)-C(2)  1.434(3) 
C(2)-N(2)  1.351(3) 
C(2)-C(9)  1.425(4) 
C(3)-N(2)  1.396(3) 
C(3)-C(4)  1.400(4) 
C(3)-C(8)  1.409(4) 
C(4)-C(5)  1.368(4) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.411(4) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.368(4) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.403(4) 
C(7)-H(7)  0.9500 
C(8)-N(1)  1.375(3) 
C(9)-N(4)  1.144(3) 
C(10)-N(5)  1.357(3) 
C(10)-C(11)  1.375(4) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.390(4) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.376(4) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.407(4) 
C(13)-H(13)  0.9500 
C(14)-N(5)  1.342(3) 
C(14)-N(6)  1.384(3) 





C(15)-C(16)  1.370(4) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.395(4) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.371(4) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.405(4) 
C(18)-H(18)  0.9500 
C(19)-N(7)  1.339(3) 
C(19)-N(6)  1.386(3) 
C(20)-O(3)  1.427(4) 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
N(1)-O(1)  1.339(3) 
N(2)-O(2)  1.288(3) 
N(3)-Zn(1)  2.024(2) 
N(3)-H(3)  0.81(3) 
N(5)-Zn(1)  2.088(2) 
N(6)-H(6A)  0.81(3) 
N(7)-Zn(1)  2.080(2) 
O(1)-Zn(1)  2.0891(19) 
O(3)-Zn(1)  2.097(2) 


















































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw1010m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
B(1A) 28(2)  19(1) 24(2)  -3(1) 6(1)  -6(1) 
C(1) 19(1)  16(1) 17(1)  -1(1) 2(1)  -2(1) 
C(2) 18(1)  15(1) 20(1)  -2(1) 4(1)  -1(1) 
C(3) 19(1)  23(1) 18(1)  1(1) 2(1)  3(1) 
C(4) 26(1)  20(1) 23(1)  -1(1) 3(1)  5(1) 
C(5) 27(2)  29(2) 23(1)  -1(1) 6(1)  9(1) 
C(6) 27(2)  33(2) 24(1)  2(1) 10(1)  5(1) 
C(7) 25(2)  24(1) 26(1)  3(1) 9(1)  3(1) 
C(8) 22(1)  21(1) 17(1)  0(1) 4(1)  1(1) 
C(9) 24(1)  12(1) 25(1)  -2(1) 0(1)  -1(1) 
C(10) 23(1)  15(1) 29(1)  4(1) 4(1)  1(1) 
C(11) 20(1)  20(1) 33(2)  6(1) 9(1)  4(1) 
C(12) 29(2)  22(1) 30(2)  3(1) 14(1)  6(1) 
C(13) 31(2)  18(1) 25(1)  -2(1) 8(1)  2(1) 
C(14) 20(1)  15(1) 25(1)  4(1) 4(1)  1(1) 
C(15) 26(2)  24(1) 22(1)  -1(1) 6(1)  -3(1) 
C(16) 21(1)  26(1) 25(1)  3(1) 6(1)  -5(1) 
C(17) 21(1)  20(1) 31(2)  4(1) 4(1)  -3(1) 
C(18) 22(1)  17(1) 25(1)  -2(1) 1(1)  -2(1) 
C(19) 19(1)  17(1) 23(1)  2(1) 3(1)  3(1) 
C(20) 61(2)  45(2) 30(2)  -6(2) -2(2)  5(2) 
F(1) 50(1)  31(1) 36(1)  2(1) 16(1)  -5(1) 
F(2) 69(1)  61(1) 46(1)  -29(1) 34(1)  -44(1) 
F(3) 79(2)  57(1) 60(2)  -12(1) -19(1)  35(1) 
F(4) 36(1)  32(1) 33(1)  -12(1) 9(1)  -9(1) 
N(1) 22(1)  16(1) 23(1)  1(1) 7(1)  0(1) 





N(3) 19(1)  18(1) 25(1)  -2(1) 9(1)  -3(1) 
N(4) 29(1)  19(1) 37(1)  -1(1) 9(1)  -4(1) 
N(5) 21(1)  14(1) 23(1)  4(1) 4(1)  0(1) 
N(6) 26(1)  18(1) 23(1)  -6(1) 6(1)  -5(1) 
N(7) 21(1)  19(1) 21(1)  0(1) 4(1)  -2(1) 
O(1) 29(1)  14(1) 36(1)  2(1) 14(1)  -1(1) 
O(2) 30(1)  13(1) 34(1)  0(1) 7(1)  -1(1) 
O(3) 38(1)  16(1) 30(1)  0(1) 0(1)  -1(1) 






 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw1010m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(4) -1816 6889 1502 28 
H(5) -4265 6476 2036 31 
H(6) -4816 5089 2194 33 
H(7) -2963 4112 1808 29 
H(10) 4754 2829 250 27 
H(11) 6207 2409 -727 29 
H(12) 4773 1463 -1625 31 
H(13) 1959 955 -1489 29 
H(15) -1603 2328 1562 28 
H(16) -3781 1360 1612 29 
H(17) -4138 304 698 29 
H(18) -2320 283 -239 26 
H(20A) 4357 3175 2465 70 
H(20B) 3142 2574 2868 70 
H(20C) 2252 3343 2399 70 
H(3) 3080(40) 4070(16) 414(15) 12(7) 
H(6A) -230(40) 953(19) -780(17) 24(8) 















































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 7.  Hydrogen bonds for phw1010m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(3)-H(3A)...F(1) 0.76(4) 2.37(4) 2.970(3) 137(3) 
 O(3)-H(3A)...F(4) 0.76(4) 2.12(4) 2.851(3) 163(4) 
 N(6)-H(6A)...F(2)#1 0.81(3) 2.06(3) 2.872(3) 176(3) 
 N(3)-H(3)...N(4)#2 0.81(3) 2.39(3) 3.182(3) 169(3) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





   Crystallographic data for [Cu(Cl)(tpz-CONH2)(dpHa)]  
Crystal Submitted by: 
Emma Dux 
Crystal Submitted on: 
21/06/11 
Data Collected on: 
27/06/11 





Table 1: Crystal data and structure refinement for phw1110  
Identification code  phw1110  
Empirical formula  C19H18ClCuN7O4  
Formula weight  507.39  
Temperature / K  110.0  
Crystal system  triclinic  
Space group  P-1  
a / Å, b / Å, c / Å  
8.5102(6), 9.2014(5), 
13.9166(10)  
α/°, β/°, γ/°  71.147(5), 89.498(6), 72.581(5)  
Volume / Å3  979.31(11)  
Z  2  
ρcalc / mg mm
-3
  1.721  
μ / mm-1  1.298  
F(000)  518  
Crystal size / mm3  0.2143 × 0.0672 × 0.038  
2Θ range for data collection  6.18 to 55.92°  
Index ranges  
-10 ≤ h ≤ 10, -12 ≤ k ≤ 12, -18 
≤ l ≤ 18  





Independent reflections  4127[R(int) = 0.0326]  
Data/restraints/parameters  4127/0/313  
Goodness-of-fit on F
2
  1.061  
Final R indexes [I>2σ (I)]  R1 = 0.0309, wR2 = 0.0676  
Final R indexes [all data]  R1 = 0.0371, wR2 = 0.0707  
Largest diff. peak/hole / e Å-3  0.419/-0.420  
Table 2 Fractional Atomic Coordinates (×10
4





) for phw1110. Ueq is defined as 1/3 of of the trace of the orthogonalised 
UIJ tensor. 
Atom x y z U(eq) 
C1 3062(3) 4575(2) 587.2(16) 10.6(4) 
C2 2388(3) 4812(3) -427.5(16) 12.1(4) 
C3 4679(3) 2573(3) -497.7(16) 12.7(4) 
C4 5469(3) 1543(3) -1025.7(17) 17.0(5) 
C5 6979(3) 399(3) -618.8(17) 18.4(5) 
C6 7703(3) 266(3) 315.1(18) 19.5(5) 
C7 6932(3) 1254(3) 849.0(17) 15.4(5) 
C8 5388(3) 2425(3) 443.2(16) 12.6(4) 
C9 808(3) 6167(3) -889.2(17) 14.2(5) 
C10 607(3) 6738(3) 2786.5(16) 13.3(4) 
C11 -513(3) 8098(3) 2863.1(16) 15.5(5) 
C12 86(3) 9206(3) 3109.2(17) 16.6(5) 
C13 1762(3) 8854(3) 3319.7(16) 14.5(5) 
C14 2832(3) 7385(3) 3279.7(15) 11.4(4) 
C15 5745(3) 5531(3) 3793.3(15) 11.7(4) 
C16 7235(3) 5368(3) 4306.0(16) 14.6(5) 
C17 8519(3) 3958(3) 4508.0(16) 15.8(5) 
C18 8293(3) 2693(3) 4238.7(16) 15.0(5) 





Cl1 2630.2(6) 2316.0(6) 3751.8(4) 16.68(12) 
Cu1 3729.0(3) 4684.8(3) 2487.90(19) 11.71(8) 
N1 4562(2) 3426(2) 950.1(13) 11.6(4) 
N2 3164(2) 3792(2) -916.7(13) 13.3(4) 
N3 2415(2) 5361(2) 1202.2(14) 13.7(4) 
N4 407(3) 6556(3) -1885.2(15) 18.9(4) 
N5 2272(2) 6380(2) 2968.8(13) 11.5(4) 
N6 4491(2) 6988(2) 3572.1(14) 12.4(4) 
N7 5537(2) 4334(2) 3508.8(13) 11.6(4) 
O1 5252.8(18) 3282.6(18) 1864.6(11) 14.6(3) 
O2 2599(2) 3869.1(19) -1797.8(11) 18.6(3) 
O3 -18.6(18) 6888.2(19) -357.4(12) 18.0(4) 
O4 5746(2) 9306(2) 3922.7(15) 21.1(4) 




) for phw1110. The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
C1 11.1(10) 7.9(10) 13.1(10) -1.9(8) 0.9(8) -5.0(8) 
C2 11.2(10) 12.4(10) 13.6(10) -2.9(9) 0.6(8) -6.4(9) 
C3 14.4(10) 13.5(11) 11.3(10) -2.5(9) 1.6(9) -7.6(9) 
C4 24.9(12) 18.1(11) 12.1(10) -6.2(9) 5.7(9) -11.4(10) 
C5 23.2(12) 14.4(11) 17.9(11) -6.4(10) 9(1) -5.7(10) 
C6 17.6(12) 14.8(11) 23.2(12) -5.4(10) 3.9(10) -2.3(9) 
C7 14.9(11) 14.9(11) 15.9(11) -3.8(9) 0.7(9) -5.2(9) 
C8 14.4(10) 12.6(10) 14.2(11) -5.6(9) 3.0(9) -7.7(9) 
C9 12.4(10) 13.6(11) 17.0(11) -2.6(9) 0.0(9) -7.5(9) 
C10 13.6(10) 15.0(11) 13(1) -4.9(9) 0.9(9) -6.7(9) 
C11 13.4(10) 17.3(11) 13.6(11) -3.2(9) -1.3(9) -3.4(9) 





C13 19.7(11) 12.7(11) 12.7(10) -5.7(9) 1.0(9) -6.0(9) 
C14 14.4(10) 12.9(10) 8(1) -2.9(8) 1.0(8) -6.2(9) 
C15 14.1(10) 13.1(11) 8.3(10) -2.5(8) 3.0(8) -6.2(9) 
C16 16.9(11) 17.7(11) 11.6(10) -5.5(9) 0.6(9) -8.1(9) 
C17 14.9(11) 20.7(12) 11.8(10) -3.8(9) -0.9(9) -7.2(9) 
C18 15.1(11) 15.1(11) 12.7(10) -4.9(9) 0.2(9) -1.3(9) 
C19 18.5(11) 12(1) 13.2(11) -5.1(9) 3.1(9) -5.2(9) 
Cl1 15.6(3) 12.3(3) 20.8(3) -4.5(2) -1.7(2) -3.5(2) 
Cu1 11.48(14) 12.26(14) 12.89(14) -7.12(11) -0.52(10) -2.65(10) 
N1 13.0(9) 13.0(9) 9.8(8) -5.1(7) -0.7(7) -3.9(7) 
N2 16.7(9) 16.2(9) 9.7(9) -3.7(8) 1.8(7) -9.7(8) 
N3 11.3(9) 12.0(9) 15.6(10) -4.6(8) -1.6(8) -0.2(8) 
N4 15.3(10) 20.9(11) 15.9(10) -2.8(9) -2.2(9) -2.8(9) 
N5 12.9(9) 12.1(9) 10.5(9) -4.2(7) 1.0(7) -4.8(7) 
N6 15.0(9) 10.4(9) 14.8(9) -6.3(8) 0.3(7) -5.9(8) 
N7 12.5(9) 12.9(9) 11.1(9) -5.9(7) 1.6(7) -4.3(7) 
O1 14.6(8) 18.5(8) 11.0(7) -8.4(7) -3.6(6) -1.9(6) 
O2 22.6(8) 24.0(9) 10.9(7) -7.8(7) -3.6(6) -7.6(7) 
O3 15.3(8) 17.8(8) 18.0(8) -5.9(7) -1.1(7) -1.3(7) 
O4 21.8(9) 14.8(9) 25.8(10) -9.3(8) -4.1(8) -1.4(8) 
Table 4 Bond Lengths for phw1110. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C2 1.453(3)   C12 C13 1.376(3) 
C1 N1 1.364(3)   C13 C14 1.404(3) 
C1 N3 1.308(3)   C14 N5 1.340(3) 
C2 C9 1.507(3)   C14 N6 1.378(3) 
C2 N2 1.347(3)   C15 C16 1.405(3) 
C3 C4 1.396(3)   C15 N6 1.383(3) 





C3 N2 1.409(3)   C16 C17 1.370(3) 
C4 C5 1.377(3)   C17 C18 1.396(3) 
C5 C6 1.397(3)   C18 C19 1.367(3) 
C6 C7 1.371(3)   C19 N7 1.358(3) 
C7 C8 1.407(3)   Cl1 Cu1 2.7263(6) 
C8 N1 1.365(3)   Cu1 N3 1.9334(19) 
C9 N4 1.334(3)   Cu1 N5 1.9804(17) 
C9 O3 1.229(3)   Cu1 N7 1.9839(18) 
C10 C11 1.362(3)   Cu1 O1 1.9495(14) 
C10 N5 1.361(3)   N1 O1 1.357(2) 
C11 C12 1.399(3)   N2 O2 1.294(2) 
Table 5 Bond Angles for phw1110. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
N1 C1 C2 117.36(18)   C17 C16 C15 119.1(2) 
N3 C1 C2 127.72(19)   C16 C17 C18 119.3(2) 
N3 C1 N1 114.91(19)   C19 C18 C17 118.5(2) 
C1 C2 C9 118.77(18)   N7 C19 C18 123.1(2) 
N2 C2 C1 119.32(18)   N3 Cu1 Cl1 104.18(6) 
N2 C2 C9 121.88(19)   N3 Cu1 N5 95.21(7) 
C4 C3 N2 120.30(19)   N3 Cu1 N7 161.38(8) 
C8 C3 C4 120.6(2)   N3 Cu1 O1 81.88(7) 
C8 C3 N2 119.14(18)   N5 Cu1 Cl1 93.19(5) 
C5 C4 C3 119.3(2)   N5 Cu1 N7 89.75(7) 
C4 C5 C6 120.3(2)   N7 Cu1 Cl1 93.42(5) 
C7 C6 C5 121.1(2)   O1 Cu1 Cl1 95.47(5) 
C6 C7 C8 119.2(2)   O1 Cu1 N5 171.30(7) 
C3 C8 C7 119.57(19)   O1 Cu1 N7 90.56(6) 
N1 C8 C3 119.01(19)   C1 N1 C8 123.44(18) 





N4 C9 C2 116.89(19)   O1 N1 C8 118.98(16) 
O3 C9 C2 119.92(19)   C2 N2 C3 121.40(18) 
O3 C9 N4 123.2(2)   O2 N2 C2 123.11(18) 
N5 C10 C11 123.4(2)   O2 N2 C3 115.49(17) 
C10 C11 C12 118.1(2)   C1 N3 Cu1 114.68(15) 
C13 C12 C11 119.6(2)   C10 N5 Cu1 117.75(14) 
C12 C13 C14 118.9(2)   C14 N5 C10 118.23(18) 
N5 C14 C13 121.49(19)   C14 N5 Cu1 122.75(14) 
N5 C14 N6 120.20(18)   C14 N6 C15 130.31(19) 
N6 C14 C13 118.31(19)   C15 N7 C19 118.05(18) 
N6 C15 C16 117.70(19)   C15 N7 Cu1 122.78(14) 
N7 C15 C16 121.73(19)   C19 N7 Cu1 117.65(14) 
N7 C15 N6 120.56(19)   N1 O1 Cu1 110.66(11) 
Table 6 Hydrogen Bonds for phw1110.  
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
N3 H3 O3 0.78(3) 2.06(3) 2.709(2) 140(2) 
N4 H4A O2 0.87(3) 1.85(3) 2.580(3) 140(3) 
N6 H6A O4 0.80(3) 2.03(3) 2.823(3) 173(3) 
Table 7 Torsion Angles for phw1110. 
A B C D Angle/˚ 
C1 C2 C9 N4 166.8(2) 
C1 C2 C9 O3 -11.1(3) 
C1 C2 N2 C3 -4.7(3) 
C1 C2 N2 O2 176.37(18) 
C1 N1 O1 Cu1 5.8(2) 
C2 C1 N1 C8 -4.9(3) 
C2 C1 N1 O1 175.26(17) 
C2 C1 N3 Cu1 -179.36(17) 





C3 C8 N1 C1 0.2(3) 
C3 C8 N1 O1 -179.93(18) 
C4 C3 C8 C7 1.7(3) 
C4 C3 C8 N1 -178.4(2) 
C4 C3 N2 C2 -179.2(2) 
C4 C3 N2 O2 -0.2(3) 
C4 C5 C6 C7 0.4(4) 
C5 C6 C7 C8 -0.3(3) 
C6 C7 C8 C3 -0.8(3) 
C6 C7 C8 N1 179.3(2) 
C7 C8 N1 C1 -179.9(2) 
C7 C8 N1 O1 0.0(3) 
C8 C3 C4 C5 -1.5(3) 
C8 C3 N2 C2 -0.1(3) 
C8 C3 N2 O2 178.95(19) 
C8 N1 O1 Cu1 -174.03(15) 
C9 C2 N2 C3 177.17(19) 
C9 C2 N2 O2 -1.8(3) 
C10 C11 C12 C13 -3.5(3) 
C11 C10 N5 C14 2.8(3) 
C11 C10 N5 Cu1 -164.62(17) 
C11 C12 C13 C14 0.1(3) 
C12 C13 C14 N5 5.1(3) 
C12 C13 C14 N6 -174.8(2) 
C13 C14 N5 C10 -6.4(3) 
C13 C14 N5 Cu1 160.33(16) 
C13 C14 N6 C15 166.1(2) 
C15 C16 C17 C18 -2.7(3) 





C16 C15 N7 C19 2.0(3) 
C16 C15 N7 Cu1 -163.55(16) 
C16 C17 C18 C19 1.4(3) 
C17 C18 C19 N7 1.7(3) 
C18 C19 N7 C15 -3.4(3) 
C18 C19 N7 Cu1 162.94(17) 
Cl1 Cu1 N3 C1 -90.53(16) 
Cl1 Cu1 N5 C10 -64.04(15) 
Cl1 Cu1 N5 C14 129.12(16) 
Cl1 Cu1 N7 C15 -126.54(16) 
Cl1 Cu1 N7 C19 67.82(15) 
Cl1 Cu1 O1 N1 98.91(12) 
N1 C1 C2 C9 -174.72(18) 
N1 C1 C2 N2 7.1(3) 
N1 C1 N3 Cu1 -0.8(2) 
N2 C2 C9 N4 -15.0(3) 
N2 C2 C9 O3 167.1(2) 
N2 C3 C4 C5 177.6(2) 
N2 C3 C8 C7 -177.47(19) 
N2 C3 C8 N1 2.4(3) 
N3 C1 C2 C9 3.8(3) 
N3 C1 C2 N2 -174.4(2) 
N3 C1 N1 C8 176.4(2) 
N3 C1 N1 O1 -3.5(3) 
N3 Cu1 N5 C10 40.52(17) 
N3 Cu1 N5 C14 -126.32(17) 
N3 Cu1 N7 C15 72.4(3) 
N3 Cu1 N7 C19 -93.3(3) 





N5 C10 C11 C12 2.2(3) 
N5 C14 N6 C15 -13.7(3) 
N5 Cu1 N3 C1 174.84(16) 
N5 Cu1 N7 C15 -33.36(17) 
N5 Cu1 N7 C19 161.00(16) 
N6 C14 N5 C10 173.41(19) 
N6 C14 N5 Cu1 -19.8(3) 
N6 C15 C16 C17 -177.98(19) 
N6 C15 N7 C19 -179.06(19) 
N6 C15 N7 Cu1 15.3(3) 
N7 C15 C16 C17 1.0(3) 
N7 C15 N6 C14 16.1(3) 
N7 Cu1 N3 C1 70.0(3) 
N7 Cu1 N5 C10 -157.46(16) 
N7 Cu1 N5 C14 35.71(17) 
N7 Cu1 O1 N1 -167.60(13) 
O1 Cu1 N3 C1 3.09(16) 
O1 Cu1 N7 C15 137.95(16) 
O1 Cu1 N7 C19 -27.69(16) 
Table 8 Hydrogen Atom Coordinates (Å×10
4





) for phw1110.  
Atom x y z U(eq) 
H4 4970 1631 -1659 20 
H5 7529 -302 -975 22 
H6 8749 -523 585 23 
H7 7435 1150 1485 18 
H10 205 6002 2596 16 
H11 -1668 8288 2752 19 





H13 2188 9594 3489 17 
H16 7351 6224 4510 18 
H17 9551 3843 4828 19 
H18 9158 1696 4385 18 
H19 6638 2050 3593 17 
H3 1570.0(3) 6020.0(3) 957(19) 16(7) 
H4A 1030.0(4) 5900.0(4) -2160.0(2) 34(8) 
H4B -500.0(3) 7180.0(3) -2120.0(2) 19(7) 
H6A 4780.0(3) 7660.0(3) 3704(19) 19(7) 
H4C 5060.0(4) 10050.0(4) 3870.0(2) 41(10) 
H4D 6110.0(4) 8980.0(4) 4510.0(3) 33(9) 
 
 
[RSC Journal Format]  
Experimental  
Single crystals of C19H18ClCuN7O4 [phw1110] were recrystallised from [solvents] 
mounted in inert oil and transferred to the cold gas stream of the diffractometer.  
Crystal structure determination of [phw1110]  
Crystal Data. C19H18ClCuN7O4, M =507.39, triclinic, a = 8.5102(6) Å, b = 
9.2014(5) Å, c = 13.9166(10) Å, α = 71.147(5)°, β = 89.498(6)°, γ = 72.581(5)°, U = 
979.31(11) Å
3
, T = 110.0, space group P-1 (no. 2), Z = 2, μ(Mo Kα) = 1.298, 13185 
reflections measured, 4127 unique (Rint = 0.0326) which were used in all 
calculations. The final wR(F2) was 0.0707 (all data).  
This report has been created with Olex2, compiled on 2011.02.15 svn.r1672. Please let us know if there are any errors or if you would 














Crystallographic data for [Cu(tpz)(dpHa)(MeOH)]Cl  
  Table 1.  Crystal data and structure refinement for phw0914m. 
Identification code  phw0914m 
Empirical formula  C18.60 H20.42 Cl Cu N7 O3.60 
Formula weight  498.75 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.2226(5) Å = 
91.4310(10)°. 
 b = 14.8803(8) Å = 92.7400(10)°. 
 c = 15.4862(9) Å  = 
98.8030(10)°. 
Volume 2096.7(2) Å3 
Z 4 
Density (calculated) 1.580 Mg/m3 
Absorption coefficient 1.209 mm-1 
F(000) 1023.3 
Crystal size 0.44 x 0.13 x 0.03 mm3 
Theta range for data collection 1.39 to 28.31°. 
Index ranges -12<=h<=12, -19<=k<=19, -20<=l<=20 
Reflections collected 21456 
Independent reflections 10332 [R(int) = 0.0223] 
Completeness to theta = 28.31° 98.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.965 and 0.70 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10332 / 0 / 610 
Goodness-of-fit on F2 1.028 
Final R indices [I>2sigma(I)] R1 = 0.0360, wR2 = 0.0881 
R indices (all data) R1 = 0.0470, wR2 = 0.0937 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0914m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 8438(2) 2505(1) 7946(1) 18(1) 
C(2) 9929(2) 4098(1) 8662(1) 20(1) 
C(3) 10647(2) 4903(1) 9063(1) 22(1) 
C(4) 10613(2) 5709(1) 8652(2) 25(1) 
C(5) 9888(3) 5712(2) 7834(2) 28(1) 
C(6) 9196(3) 4918(2) 7422(2) 28(1) 
C(7) 9210(2) 4098(1) 7851(1) 22(1) 
C(8) 5634(2) 111(1) 6615(1) 21(1) 
C(9) 4553(2) -635(1) 6604(1) 24(1) 
C(10) 3248(2) -609(1) 6114(1) 25(1) 
C(11) 3098(2) 151(1) 5655(1) 23(1) 
C(12) 4238(2) 895(1) 5709(1) 19(1) 
C(13) 7529(3) 2962(2) 4845(1) 27(1) 
C(14) 7234(3) 3416(2) 4115(2) 29(1) 
C(15) 5788(3) 3316(2) 3784(2) 29(1) 
C(16) 4715(3) 2748(2) 4173(1) 26(1) 
C(17) 5109(2) 2277(1) 4899(1) 20(1) 
C(18) 9877(3) 854(2) 6471(2) 45(1) 
Cu(1) 6991(1) 1982(1) 6404(1) 20(1) 
N(1) 8534(2) 3283(1) 7496(1) 23(1) 
N(2) 9926(2) 3253(1) 9058(1) 19(1) 
N(3) 7620(2) 1789(1) 7591(1) 19(1) 
N(4) 9201(2) 2488(1) 8728(1) 18(1) 
N(5) 5482(2) 883(1) 6190(1) 19(1) 
N(6) 4048(2) 1658(1) 5253(1) 22(1) 
N(7) 6484(2) 2405(1) 5247(1) 22(1) 
O(1) 7871(2) 3237(1) 6692(1) 31(1) 
O(2) 10637(2) 3235(1) 9771(1) 23(1) 
O(3) 8985(2) 1341(2) 5938(1) 48(1) 
C(19) 5877(2) 5564(1) 9188(1) 16(1) 
C(20) 4976(2) 3913(1) 8376(1) 18(1) 
C(21) 4557(2) 3056(1) 7965(1) 24(1) 
C(22) 3405(3) 2943(2) 7363(2) 30(1) 
C(23) 2662(3) 3676(2) 7162(2) 29(1) 





C(25) 4259(2) 4652(1) 8171(1) 17(1) 
C(26) 2701(2) 7777(1) 8113(1) 19(1) 
C(27) 1442(2) 8113(1) 7873(1) 21(1) 
C(28) 823(2) 8620(1) 8488(2) 24(1) 
C(29) 1502(2) 8790(1) 9291(1) 21(1) 
C(30) 2836(2) 8462(1) 9480(1) 17(1) 
C(31) 7292(2) 8296(1) 10335(1) 20(1) 
C(32) 7924(2) 8818(1) 11036(1) 22(1) 
C(33) 7026(2) 9299(1) 11514(1) 23(1) 
C(34) 5580(2) 9266(1) 11251(1) 20(1) 
C(35) 5012(2) 8721(1) 10521(1) 17(1) 
C(36) 7442(2) 7405(2) 7814(1) 25(1) 
Cu(2) 5007(1) 7250(1) 9207(1) 15(1) 
N(8) 4736(2) 5465(1) 8589(1) 16(1) 
N(9) 6125(2) 4053(1) 9017(1) 18(1) 
N(10) 6241(2) 6365(1) 9569(1) 18(1) 
N(11) 6582(2) 4843(1) 9404(1) 19(1) 
N(12) 3389(2) 7932(1) 8907(1) 17(1) 
N(13) 3561(2) 8716(1) 10261(1) 18(1) 
N(14) 5846(2) 8220(1) 10085(1) 17(1) 
O(4) 4095(2) 6207(1) 8422(1) 20(1) 
O(5) 6738(2) 3390(1) 9245(1) 25(1) 
O(6) 6334(2) 7902(1) 8084(1) 22(1) 
Cl(1) 9175(1) 8323(1) 5657(1) 32(1) 
Cl(2) 2139(1) 127(1) 1420(1) 21(1) 
O(7) 8941(3) 6239(2) 5870(2) 58(1) 
C(37) 8347(6) 5794(3) 5136(3) 91(2) 
O(8) 6251(9) 5308(6) 6662(6) 36(3) 






 Table 3.   Bond lengths [Å] and angles [°] for  phw0914m. 
_____________________________________________________  
C(1)-N(3)  1.301(3) 
C(1)-N(1)  1.359(2) 
C(1)-N(4)  1.374(3) 
C(2)-C(7)  1.392(3) 
C(2)-C(3)  1.393(3) 
C(2)-N(2)  1.411(2) 
C(3)-C(4)  1.375(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.405(3) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.379(3) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.406(3) 
C(6)-H(6)  0.9500 
C(7)-N(1)  1.365(3) 
C(8)-N(5)  1.360(3) 
C(8)-C(9)  1.372(3) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.398(3) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.373(3) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.402(3) 
C(11)-H(11)  0.9500 
C(12)-N(5)  1.341(3) 
C(12)-N(6)  1.382(3) 
C(13)-N(7)  1.358(3) 
C(13)-C(14)  1.368(3) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.391(3) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.372(3) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.402(3) 
C(16)-H(16)  0.9500 
C(17)-N(7)  1.338(3) 
C(17)-N(6)  1.382(3) 





C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
Cu(1)-N(3)  1.9429(18) 
Cu(1)-O(1)  1.9509(15) 
Cu(1)-N(7)  1.9714(18) 
Cu(1)-N(5)  1.9881(17) 
Cu(1)-O(3)  2.3323(19) 
N(1)-O(1)  1.355(2) 
N(2)-O(2)  1.261(2) 
N(2)-N(4)  1.307(2) 
N(3)-H(3A)  0.80(3) 
N(6)-H(6A)  0.76(3) 
O(3)-H(3B)  0.78(4) 
C(19)-N(10)  1.305(2) 
C(19)-N(8)  1.357(2) 
C(19)-N(11)  1.377(2) 
C(20)-C(21)  1.402(3) 
C(20)-C(25)  1.404(3) 
C(20)-N(9)  1.404(3) 
C(21)-C(22)  1.367(3) 
C(21)-H(21)  0.9500 
C(22)-C(23)  1.408(3) 
C(22)-H(22)  0.9500 
C(23)-C(24)  1.372(3) 
C(23)-H(23)  0.9500 
C(24)-C(25)  1.407(3) 
C(24)-H(24)  0.9500 
C(25)-N(8)  1.359(2) 
C(26)-N(12)  1.355(3) 
C(26)-C(27)  1.371(3) 
C(26)-H(26)  0.9500 
C(27)-C(28)  1.396(3) 
C(27)-H(27)  0.9500 
C(28)-C(29)  1.365(3) 
C(28)-H(28)  0.9500 
C(29)-C(30)  1.413(3) 
C(29)-H(29)  0.9500 
C(30)-N(12)  1.341(3) 





C(31)-N(14)  1.358(3) 
C(31)-C(32)  1.371(3) 
C(31)-H(31)  0.9500 
C(32)-C(33)  1.400(3) 
C(32)-H(32)  0.9500 
C(33)-C(34)  1.369(3) 
C(33)-H(33)  0.9500 
C(34)-C(35)  1.407(3) 
C(34)-H(34)  0.9500 
C(35)-N(14)  1.342(2) 
C(35)-N(13)  1.378(3) 
C(36)-O(6)  1.423(3) 
C(36)-H(36A)  0.9800 
C(36)-H(36B)  0.9800 
C(36)-H(36C)  0.9800 
Cu(2)-N(10)  1.9437(16) 
Cu(2)-N(12)  1.9736(16) 
Cu(2)-N(14)  1.9981(17) 
Cu(2)-O(4)  2.0005(14) 
Cu(2)-O(6)  2.3215(15) 
N(8)-O(4)  1.3548(19) 
N(9)-O(5)  1.259(2) 
N(9)-N(11)  1.307(2) 
N(10)-H(10A)  0.83(2) 
N(13)-H(13A)  0.74(3) 
O(6)-H(6B)  0.72(3) 
O(7)-C(37)  1.350(4) 
O(7)-H(7)  0.91(4) 
C(37)-H(37A)  0.9800 
C(37)-H(37B)  0.9800 
C(37)-H(37C)  0.9800 
O(8)-C(38)  1.389(14) 
O(8)-H(8A)  0.8400 
C(38)-H(38A)  0.9800 
C(38)-H(38B)  0.9800 

























































































































































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0914m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  






C(1) 17(1)  17(1) 19(1)  3(1) 1(1)  3(1) 
C(2) 18(1)  17(1) 23(1)  3(1) 1(1)  2(1) 
C(3) 18(1)  23(1) 24(1)  -1(1) 1(1)  0(1) 
C(4) 23(1)  19(1) 30(1)  0(1) 3(1)  -2(1) 
C(5) 31(1)  18(1) 34(1)  7(1) 1(1)  -1(1) 
C(6) 35(1)  22(1) 25(1)  7(1) -6(1)  -3(1) 
C(7) 22(1)  17(1) 25(1)  2(1) -2(1)  -1(1) 
C(8) 25(1)  19(1) 20(1)  2(1) -1(1)  4(1) 
C(9) 30(1)  17(1) 24(1)  1(1) 3(1)  3(1) 
C(10) 27(1)  20(1) 26(1)  -2(1) 3(1)  -4(1) 
C(11) 21(1)  24(1) 22(1)  -1(1) -1(1)  0(1) 
C(12) 22(1)  20(1) 17(1)  0(1) 4(1)  5(1) 
C(13) 30(1)  25(1) 24(1)  4(1) 1(1)  -2(1) 
C(14) 37(1)  25(1) 23(1)  6(1) 5(1)  -1(1) 
C(15) 40(1)  25(1) 22(1)  6(1) 0(1)  6(1) 
C(16) 30(1)  27(1) 22(1)  4(1) -1(1)  7(1) 
C(17) 25(1)  18(1) 19(1)  -1(1) 1(1)  6(1) 
C(18) 38(2)  59(2) 42(2)  5(1) 7(1)  21(1) 
Cu(1) 23(1)  17(1) 19(1)  3(1) -2(1)  -1(1) 
N(1) 30(1)  18(1) 20(1)  5(1) -6(1)  -2(1) 
N(2) 16(1)  20(1) 20(1)  1(1) 0(1)  5(1) 
N(3) 23(1)  14(1) 20(1)  2(1) 0(1)  1(1) 
N(4) 19(1)  16(1) 19(1)  1(1) 0(1)  4(1) 
N(5) 22(1)  17(1) 18(1)  0(1) 1(1)  3(1) 
N(6) 18(1)  25(1) 23(1)  4(1) -1(1)  3(1) 
N(7) 24(1)  19(1) 21(1)  1(1) 1(1)  0(1) 
O(1) 45(1)  21(1) 23(1)  7(1) -13(1)  -6(1) 
O(2) 21(1)  26(1) 23(1)  2(1) -6(1)  5(1) 
O(3) 36(1)  85(2) 30(1)  14(1) 11(1)  29(1) 
C(19) 14(1)  18(1) 17(1)  3(1) 3(1)  4(1) 
C(20) 20(1)  16(1) 19(1)  2(1) 4(1)  4(1) 
C(21) 31(1)  14(1) 27(1)  0(1) 6(1)  4(1) 
C(22) 40(1)  18(1) 29(1)  -3(1) 0(1)  1(1) 
C(23) 36(1)  23(1) 26(1)  -4(1) -8(1)  2(1) 
C(24) 27(1)  20(1) 22(1)  -1(1) -4(1)  5(1) 
C(25) 20(1)  15(1) 17(1)  2(1) 3(1)  3(1) 
C(26) 19(1)  15(1) 22(1)  3(1) 2(1)  3(1) 
C(27) 19(1)  18(1) 25(1)  4(1) -3(1)  1(1) 
C(28) 15(1)  16(1) 41(1)  4(1) -2(1)  3(1) 





C(30) 16(1)  12(1) 24(1)  4(1) 3(1)  2(1) 
C(31) 19(1)  16(1) 26(1)  2(1) 1(1)  4(1) 
C(32) 20(1)  19(1) 27(1)  2(1) -3(1)  2(1) 
C(33) 26(1)  18(1) 23(1)  -1(1) -1(1)  0(1) 
C(34) 25(1)  14(1) 22(1)  -1(1) 5(1)  3(1) 
C(35) 19(1)  13(1) 20(1)  2(1) 3(1)  2(1) 
C(36) 22(1)  28(1) 24(1)  -1(1) 4(1)  4(1) 
Cu(2) 15(1)  12(1) 19(1)  0(1) 0(1)  5(1) 
N(8) 18(1)  12(1) 19(1)  1(1) 0(1)  5(1) 
N(9) 19(1)  14(1) 24(1)  3(1) 4(1)  4(1) 
N(10) 17(1)  16(1) 21(1)  0(1) -2(1)  5(1) 
N(11) 17(1)  14(1) 26(1)  4(1) 2(1)  5(1) 
N(12) 16(1)  13(1) 21(1)  2(1) 2(1)  4(1) 
N(13) 19(1)  17(1) 22(1)  -3(1) 5(1)  7(1) 
N(14) 17(1)  13(1) 21(1)  1(1) 3(1)  3(1) 
O(4) 21(1)  13(1) 26(1)  1(1) -5(1)  9(1) 
O(5) 24(1)  14(1) 39(1)  6(1) 0(1)  10(1) 
O(6) 20(1)  18(1) 27(1)  0(1) 5(1)  2(1) 
Cl(1) 23(1)  41(1) 33(1)  12(1) 3(1)  7(1) 
Cl(2) 24(1)  16(1) 25(1)  1(1) 3(1)  8(1) 
O(7) 78(2)  39(1) 55(1)  18(1) -12(1)  4(1) 
C(37) 137(4)  65(3) 65(3)  -3(2) -28(3)  11(3) 
O(8) 27(4)  39(5) 45(5)  -4(4) 8(4)  11(4) 




 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw0914m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(3) 11152 4896 9612 27 
H(4) 11081 6265 8922 29 
H(5) 9874 6274 7557 34 
H(6) 8724 4926 6864 34 
H(8) 6532 86 6934 26 
H(9) 4689 -1156 6922 28 





H(11) 2232 174 5303 27 
H(13) 8512 3040 5081 32 
H(14) 7997 3789 3842 34 
H(15) 5544 3640 3290 35 
H(16) 3722 2676 3954 31 
H(18A) 10870 1200 6548 67 
H(18B) 9924 260 6195 67 
H(18C) 9451 767 7036 67 
H(3A) 7630(30) 1340(20) 7856(19) 37(8) 
H(6A) 3290(30) 1640(20) 5033(19) 38(8) 
H(3B) 9390(40) 1500(20) 5520(20) 57 
H(21) 5064 2564 8101 29 
H(22) 3103 2366 7079 36 
H(23) 1859 3584 6745 35 
H(24) 2560 5008 7409 28 
H(26) 3111 7418 7701 22 
H(27) 1004 8004 7305 25 
H(28) -66 8845 8349 28 
H(29) 1082 9126 9717 25 
H(31) 7898 7971 10007 24 
H(32) 8940 8852 11193 26 
H(33) 7418 9646 12018 28 
H(34) 4968 9607 11558 24 
H(36A) 8118 7338 8308 37 
H(36B) 7988 7732 7360 37 
H(36C) 6985 6801 7589 37 
H(10A) 6990(30) 6420(15) 9896(15) 14(5) 
H(13A) 3190(30) 9023(17) 10528(16) 18(6) 
H(6B) 6670(30) 8370(20) 8150(19) 38(9) 
H(7) 9040(50) 6840(30) 5720(30) 90(14) 
H(37A) 7564 6104 4894 136 
H(37B) 7939 5168 5266 136 
H(37C) 9108 5788 4716 136 
H(8A) 6845 5710 6438 54 
H(38A) 6500 4273 5918 54 
H(38B) 5399 4905 5516 54 
H(38C) 4887 4228 6268 54 
________________________________________________________________________________  
 






























































































































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 7.  Hydrogen bonds for phw0914m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(8)-H(8A)...O(7) 0.84 2.21 2.984(9) 154 
 O(7)-H(7)...Cl(1) 0.91(4) 2.20(4) 3.102(2) 168(4) 
 O(6)-H(6B)...Cl(2)#1 0.72(3) 2.40(3) 3.1135(17) 172(3) 
 N(13)-H(13A)...Cl(2)#2 0.74(3) 2.46(3) 3.1980(18) 175(2) 
 N(10)-H(10A)...O(2)#3 0.83(2) 2.21(2) 2.975(2) 155(2) 
 O(3)-H(3B)...Cl(1)#4 0.78(4) 2.30(4) 3.071(2) 167(3) 
 N(6)-H(6A)...Cl(1)#1 0.76(3) 2.48(3) 3.232(2) 177(3) 
 N(3)-H(3A)...Cl(2)#5 0.80(3) 2.51(3) 3.3028(18) 174(3) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y+1,-z+1    #2 x,y+1,z+1    #3 -x+2,-y+1,-z+2       





   Crystallographic data for [Co(tpz-CN)(dpHa)2](BF4)2  
  Table 1.  Crystal data and structure refinement for phw0913m. 
Identification code  phw0913m 
Empirical formula  C29 H23 B2 Co F8 N10 O2 
Formula weight  776.12 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 11.9399(10) Å = 90.789(2)°. 
 b = 12.6855(11) Å = 107.803(2)°. 
 c = 14.2855(12) Å  = 107.775(2)°. 
Volume 1948.0(3) Å3 
Z 2 
Density (calculated) 1.323 Mg/m3 
Absorption coefficient 0.518 mm-1 
F(000) 784 
Crystal size 0.41 x 0.33 x 0.20 mm3 
Theta range for data collection 1.51 to 28.31°. 
Index ranges -15<=h<=15, -16<=k<=16, -19<=l<=19 
Reflections collected 20042 
Independent reflections 9561 [R(int) = 0.0159] 
Completeness to theta = 28.31° 98.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.904 and 0.764 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9561 / 56 / 573 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0389, wR2 = 0.1065 
R indices (all data) R1 = 0.0428, wR2 = 0.1097 





 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw0913m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 6347(1) 4928(1) 2409(1) 25(1) 
C(2) 5087(1) 4199(1) 2067(1) 28(1) 
C(3) 5152(2) 3883(1) 3718(1) 30(1) 
C(4) 4548(2) 3388(2) 4379(1) 36(1) 
C(5) 5191(2) 3626(2) 5381(1) 39(1) 
C(6) 6417(2) 4352(2) 5727(1) 37(1) 
C(7) 7022(2) 4835(1) 5080(1) 33(1) 
C(8) 6386(2) 4597(1) 4062(1) 28(1) 
C(9) 4425(1) 3987(1) 1036(1) 30(1) 
C(10) 9294(2) 8197(1) 1484(1) 36(1) 
C(11) 9331(2) 8675(2) 635(1) 48(1) 
C(12) 9037(2) 7987(2) -237(1) 47(1) 
C(13) 8788(2) 6865(2) -209(1) 37(1) 
C(14) 8804(1) 6428(1) 689(1) 30(1) 
C(15) 9714(2) 4728(1) 3219(1) 37(1) 
C(16) 9972(2) 3758(2) 3100(2) 45(1) 
C(17) 9718(2) 3268(2) 2144(2) 49(1) 
C(18) 9245(2) 3779(2) 1349(2) 43(1) 
C(19) 9036(2) 4784(1) 1518(1) 33(1) 
C(20) 11269(2) 7354(1) 3426(1) 36(1) 
C(21) 12407(2) 7805(2) 4149(2) 46(1) 
C(22) 12443(2) 8241(2) 5066(2) 52(1) 
C(23) 11373(2) 8294(2) 5195(1) 43(1) 
C(24) 10251(2) 7873(1) 4409(1) 33(1) 
C(25) 6889(2) 7686(1) 2143(1) 31(1) 
C(26) 6172(2) 8280(2) 2313(1) 38(1) 
C(27) 6450(2) 8765(2) 3277(2) 43(1) 
C(28) 7452(2) 8668(2) 4010(1) 39(1) 
C(29) 8171(2) 8065(1) 3784(1) 31(1) 
Co(1) 8595(1) 6430(1) 2640(1) 25(1) 
N(1) 6944(1) 5077(1) 3390(1) 26(1) 
N(2) 4503(1) 3680(1) 2687(1) 31(1) 
N(3) 6990(1) 5469(1) 1868(1) 26(1) 
N(4) 3989(1) 3866(1) 191(1) 39(1) 





N(6) 8598(1) 5303(1) 715(1) 33(1) 
N(7) 9238(1) 5238(1) 2436(1) 30(1) 
N(8) 10189(1) 7344(1) 3559(1) 29(1) 
N(9) 9203(2) 8016(1) 4517(1) 35(1) 
N(10) 7864(1) 7548(1) 2869(1) 27(1) 
O(1) 8163(1) 5758(1) 3721(1) 30(1) 
O(2) 3393(1) 3028(1) 2362(1) 43(1) 
B(1A) 2889(6) 6372(6) 1568(4) 36(2) 
F(1A) 3554(5) 5679(4) 1899(3) 68(1) 
F(2A) 1635(3) 5832(2) 1143(2) 55(1) 
F(3A) 3156(12) 7182(8) 2300(6) 58(2) 
F(4A) 3115(8) 6840(5) 762(4) 119(2) 
B(1B) 2858(13) 6482(12) 1566(10) 71(7) 
F(1B) 3112(18) 5503(10) 1648(11) 186(6) 
F(2B) 1615(7) 6032(11) 1471(9) 213(7) 
F(3B) 3347(16) 7151(11) 2426(9) 44(2) 
F(4B) 3335(5) 6911(8) 828(5) 80(3) 
B(2A) 9031(6) 9132(6) 6808(6) 37(1) 
F(5A) 8560(9) 8088(7) 6354(8) 46(2) 
F(6A) 9866(2) 9797(2) 6395(2) 56(1) 
F(7A) 8002(3) 9492(2) 6607(2) 71(1) 
F(8A) 9665(14) 9194(9) 7817(6) 47(2) 
B(2B) 9453(9) 9198(9) 6872(9) 35(2) 
F(5B) 8781(15) 8138(10) 6342(13) 47(3) 
F(6B) 10531(5) 9267(5) 6672(5) 92(2) 
F(7B) 9096(5) 10084(3) 6499(2) 60(2) 






 Table 3.   Bond lengths [Å] and angles [°] for  phw0913m. 
_____________________________________________________  
C(1)-N(3)  1.3094(19) 
C(1)-N(1)  1.3446(19) 
C(1)-C(2)  1.430(2) 
C(2)-N(2)  1.3483(19) 
C(2)-C(9)  1.419(2) 
C(3)-C(8)  1.400(2) 
C(3)-C(4)  1.402(2) 
C(3)-N(2)  1.416(2) 
C(4)-C(5)  1.380(3) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.399(3) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.380(2) 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.399(2) 
C(7)-H(7)  0.9500 
C(8)-N(1)  1.3769(19) 
C(9)-N(4)  1.146(2) 
C(10)-N(5)  1.363(2) 
C(10)-C(11)  1.370(2) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.397(3) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.366(3) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.401(2) 
C(13)-H(13)  0.9500 
C(14)-N(5)  1.346(2) 
C(14)-N(6)  1.375(2) 
C(15)-N(7)  1.359(2) 
C(15)-C(16)  1.376(3) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.397(3) 
C(16)-H(16)  0.9500 
C(17)-C(18)  1.371(3) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.404(2) 





C(19)-N(7)  1.346(2) 
C(19)-N(6)  1.374(2) 
C(20)-N(8)  1.356(2) 
C(20)-C(21)  1.375(3) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.398(3) 
C(21)-H(21)  0.9500 
C(22)-C(23)  1.366(3) 
C(22)-H(22)  0.9500 
C(23)-C(24)  1.403(2) 
C(23)-H(23)  0.9500 
C(24)-N(8)  1.350(2) 
C(24)-N(9)  1.371(2) 
C(25)-N(10)  1.361(2) 
C(25)-C(26)  1.370(2) 
C(25)-H(25)  0.9500 
C(26)-C(27)  1.400(3) 
C(26)-H(26)  0.9500 
C(27)-C(28)  1.367(3) 
C(27)-H(27)  0.9500 
C(28)-C(29)  1.410(2) 
C(28)-H(28)  0.9500 
C(29)-N(10)  1.344(2) 
C(29)-N(9)  1.371(2) 
Co(1)-N(3)  1.9022(13) 
Co(1)-O(1)  1.9059(11) 
Co(1)-N(5)  1.9337(13) 
Co(1)-N(8)  1.9422(14) 
Co(1)-N(7)  1.9484(14) 
Co(1)-N(10)  1.9484(13) 
N(1)-O(1)  1.3745(16) 
N(2)-O(2)  1.2645(18) 
N(3)-H(3)  0.87(2) 
N(6)-H(6A)  0.79(3) 
N(9)-H(9)  0.79(3) 
B(1A)-F(3A)  1.348(8) 
B(1A)-F(1A)  1.354(7) 
B(1A)-F(4A)  1.365(7) 
B(1A)-F(2A)  1.373(6) 





B(1B)-F(1B)  1.364(13) 
B(1B)-F(2B)  1.380(12) 
B(1B)-F(4B)  1.388(11) 
B(2A)-F(5A)  1.339(8) 
B(2A)-F(6A)  1.384(6) 
B(2A)-F(7A)  1.390(6) 
B(2A)-F(8A)  1.396(9) 
B(2B)-F(7B)  1.378(10) 
B(2B)-F(6B)  1.380(9) 
B(2B)-F(8B)  1.384(12) 











































































































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw0913m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 28(1)  22(1) 25(1)  6(1) 10(1)  9(1) 
C(2) 29(1)  26(1) 26(1)  7(1) 10(1)  7(1) 
C(3) 33(1)  30(1) 28(1)  10(1) 13(1)  9(1) 
C(4) 36(1)  37(1) 37(1)  14(1) 18(1)  9(1) 
C(5) 45(1)  42(1) 35(1)  19(1) 21(1)  15(1) 
C(6) 44(1)  43(1) 29(1)  16(1) 15(1)  16(1) 
C(7) 36(1)  34(1) 27(1)  12(1) 10(1)  10(1) 
C(8) 33(1)  27(1) 27(1)  11(1) 13(1)  11(1) 
C(9) 27(1)  29(1) 31(1)  7(1) 11(1)  4(1) 
C(10) 46(1)  28(1) 27(1)  3(1) 18(1)  -1(1) 
C(11) 68(1)  34(1) 32(1)  6(1) 24(1)  -5(1) 
C(12) 59(1)  45(1) 29(1)  7(1) 24(1)  -3(1) 
C(13) 37(1)  45(1) 27(1)  -2(1) 17(1)  1(1) 
C(14) 26(1)  34(1) 28(1)  0(1) 12(1)  5(1) 
C(15) 34(1)  31(1) 37(1)  1(1) 2(1)  9(1) 
C(16) 41(1)  34(1) 51(1)  3(1) -2(1)  14(1) 
C(17) 46(1)  36(1) 59(1)  -6(1) 3(1)  19(1) 
C(18) 40(1)  37(1) 46(1)  -8(1) 5(1)  16(1) 
C(19) 28(1)  32(1) 35(1)  -3(1) 7(1)  9(1) 
C(20) 33(1)  34(1) 36(1)  3(1) 9(1)  6(1) 
C(21) 33(1)  44(1) 49(1)  2(1) 5(1)  7(1) 
C(22) 46(1)  51(1) 37(1)  2(1) -5(1)  6(1) 
C(23) 50(1)  41(1) 26(1)  3(1) 5(1)  4(1) 
C(24) 42(1)  27(1) 24(1)  7(1) 10(1)  3(1) 
C(25) 40(1)  29(1) 27(1)  7(1) 14(1)  11(1) 
C(26) 45(1)  36(1) 38(1)  8(1) 16(1)  16(1) 





C(28) 56(1)  34(1) 30(1)  3(1) 23(1)  12(1) 
C(29) 42(1)  26(1) 25(1)  7(1) 17(1)  6(1) 
Co(1) 28(1)  22(1) 22(1)  4(1) 9(1)  5(1) 
N(1) 27(1)  25(1) 25(1)  7(1) 9(1)  5(1) 
N(2) 30(1)  31(1) 30(1)  8(1) 11(1)  5(1) 
N(3) 28(1)  25(1) 23(1)  6(1) 8(1)  6(1) 
N(4) 35(1)  45(1) 30(1)  7(1) 10(1)  5(1) 
N(5) 29(1)  27(1) 24(1)  2(1) 13(1)  3(1) 
N(6) 35(1)  35(1) 28(1)  -5(1) 8(1)  11(1) 
N(7) 28(1)  27(1) 31(1)  2(1) 5(1)  7(1) 
N(8) 32(1)  25(1) 26(1)  5(1) 10(1)  4(1) 
N(9) 47(1)  35(1) 20(1)  3(1) 15(1)  7(1) 
N(10) 36(1)  25(1) 22(1)  6(1) 14(1)  7(1) 
O(1) 28(1)  29(1) 25(1)  9(1) 7(1)  1(1) 
O(2) 29(1)  50(1) 37(1)  11(1) 10(1)  -3(1) 
B(1A) 51(4)  27(3) 21(3)  -4(2) 4(3)  7(3) 
F(1A) 102(3)  77(2) 60(2)  23(2) 38(2)  65(2) 
F(2A) 51(1)  60(2) 39(1)  -16(1) 21(1)  -8(1) 
F(3A) 65(4)  51(2) 51(4)  -18(3) 18(3)  9(2) 
F(4A) 213(6)  97(4) 39(2)  21(2) 30(3)  51(4) 
B(1B) 87(13)  59(10) 58(11)  7(7) 30(9)  6(8) 
F(1B) 267(16)  110(6) 163(10)  -64(7) 30(9)  80(8) 
F(2B) 57(4)  334(15) 163(8)  -175(10) 12(4)  -21(5) 
F(3B) 54(4)  44(3) 23(2)  5(2) 10(2)  3(2) 
F(4B) 30(2)  142(6) 36(3)  15(3) 20(2)  -28(2) 
B(2A) 56(4)  34(2) 26(2)  10(2) 21(3)  16(2) 
F(5A) 44(2)  48(2) 33(3)  5(2) 10(1)  1(1) 
F(6A) 70(2)  51(1) 46(1)  20(1) 32(1)  4(1) 
F(7A) 88(2)  88(2) 70(2)  26(1) 41(1)  58(2) 
F(8A) 80(5)  36(2) 28(2)  11(2) 21(2)  20(3) 
B(2B) 58(7)  25(3) 25(3)  3(2) 19(4)  11(4) 
F(5B) 88(9)  34(4) 29(4)  3(3) 26(5)  24(4) 
F(6B) 70(3)  101(4) 125(5)  22(3) 63(3)  26(3) 
F(7B) 104(4)  33(2) 36(2)  10(1) 7(2)  30(2) 











 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(4) 3714 2898 4143 43 
H(5) 4797 3293 5840 46 
H(6) 6840 4515 6420 45 
H(7) 7857 5322 5323 39 
H(10) 9491 8666 2075 43 
H(11) 9552 9462 639 57 
H(12) 9012 8296 -842 56 
H(13) 8605 6387 -791 45 
H(15) 9874 5052 3869 44 
H(16) 10317 3426 3661 54 
H(17) 9872 2590 2046 59 
H(18) 9061 3456 693 51 
H(20) 11238 7037 2809 43 
H(21) 13151 7819 4028 55 
H(22) 13208 8500 5596 62 
H(23) 11389 8610 5807 52 
H(25) 6698 7355 1488 37 
H(26) 5500 8362 1787 46 
H(27) 5949 9157 3422 52 
H(28) 7662 9003 4666 46 
H(3) 6580(20) 5455(18) 1248(17) 37(5) 
H(6A) 8470(20) 4970(20) 195(19) 48(6) 


































































































































































Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 7.  Hydrogen bonds for phw0913m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(3)-H(3)...N(4)#1 0.87(2) 2.23(2) 3.048(2) 156.8(19) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  





   Crystallographic data for [Co(tpz-CONH2)(dpHa)2]2NO3  
Crystal Submitted by: 
Emma Dux 
Crystal Submitted on: 
7/6/11 
Data Collected on: 
9/6/11 





Table 1: Crystal data and structure refinement for phw1109  
Identification code  phw1109  
Empirical formula  C33H35CoN12O10  
Formula weight  818.66  
Temperature / K  110.0  
Crystal system  triclinic  
Space group  P-1  
a / Å, b / Å, c / Å  10.371(2), 12.715(3), 14.053(3)  
α/°, β/°, γ/°  
74.64(2), 76.945(18), 
81.408(19)  
Volume / Å3  1732.9(6)  
Z  2  
ρcalc / mg mm
-3
  1.569  
μ / mm-1  0.574  
F(000)  848  
Crystal size / mm3  0.32 × 0.1834 × 0.0798  
2Θ range for data collection  6.28 to 57.62°  
Index ranges  
-13 ≤ h ≤ 7, -17 ≤ k ≤ 16, -18 ≤ l 
≤ 17  





Independent reflections  7448[R(int) = 0.0280]  
Data/restraints/parameters  7448/38/542  
Goodness-of-fit on F
2
  1.049  
Final R indexes [I>2σ (I)]  R1 = 0.0595, wR2 = 0.1406  
Final R indexes [all data]  R1 = 0.0817, wR2 = 0.1558  
Largest diff. peak/hole / e Å-3  1.018/-0.444  
Table 2 Fractional Atomic Coordinates (×10
4





) for phw1109. Ueq is defined as 1/3 of of the trace 
of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
C1 5979(3) 445(3) 1626(2) 23.3(7) 
C2 7091(3) 856(3) 1786(3) 32.5(8) 
C3 8325(4) 345(4) 1506(3) 40.0(9) 
C4 8500(4) -542(4) 1132(3) 42.4(10) 
C5 7395(4) -969(3) 953(3) 38.8(9) 
C6 6137(3) -460(3) 1215(2) 26.5(7) 
C7 3788(3) -366(3) 1315(2) 24.9(7) 
C8 3634(3) 583(2) 1722(2) 17.1(6) 
C9 2588(4) -792(3) 1194(3) 29.9(8) 
C10 4228(3) 3560(3) 645(3) 26.2(7) 
C11 4562(4) 4012(3) -363(3) 30.6(8) 
C12 3625(4) 4127(3) -956(3) 33.7(8) 
C13 2399(3) 3785(3) -517(3) 27.8(7) 
C14 2126(3) 3315(3) 515(2) 23.9(7) 
C15 194(3) 2967(3) 1887(3) 24.4(7) 
C16 -1196(3) 3118(3) 2044(3) 31.2(8) 
C17 -1901(4) 3188(3) 2974(3) 36.1(9) 
C18 -1236(4) 3139(3) 3741(3) 35.6(9) 





C20 2740(3) 4577(3) 2562(2) 24.8(7) 
C21 3125(4) 5449(3) 2797(3) 30.0(8) 
C22 3939(4) 5243(3) 3501(3) 30.1(8) 
C23 4284(4) 4186(3) 3964(3) 27.1(7) 
C24 3815(3) 3326(3) 3721(2) 21.8(7) 
C25 3333(3) 1405(3) 4446(2) 21.9(7) 
C26 3429(3) 557(3) 5304(3) 27.2(7) 
C27 2657(4) -294(3) 5529(3) 30.1(8) 
C28 1776(3) -292(3) 4920(3) 28.9(8) 
C29 1739(3) 556(3) 4092(3) 25.5(7) 
Co1 2720.7(4) 2344.4(3) 2479.7(3) 19.42(13) 
N1 4718(3) 933(2) 1864.3(19) 20.6(6) 
N2 5019(3) -846(2) 1064(2) 28.9(7) 
N3 2515(3) 1158(2) 1979(2) 21.6(6) 
N4 2773(5) -1694(3) 829(3) 41.0(9) 
N5 3021(3) 3199(2) 1096(2) 21.1(6) 
N6 887(3) 2956(2) 941(2) 26.3(6) 
N7 839(3) 2843(2) 2643(2) 22.7(6) 
N8 3102(3) 3517(2) 2998.2(19) 20.0(6) 
N9 4091(3) 2274(2) 4254(2) 22.2(6) 
N10 2520(3) 1393(2) 3836(2) 21.0(6) 
O1 4531(2) 1810.3(18) 2293.8(17) 23.0(5) 
O2 5272(3) -1679(2) 665(2) 45.3(7) 
O3 1512(3) -328(2) 1432(2) 43.2(7) 
C30 167(8) 2071(9) 6450(7) 85(3) 
C30A -180.0(3) 2430.0(2) 6700.0(2) 85(3) 
C31 1398(8) 2630(8) 6356(7) 82(2) 
C31A 670.0(3) 3330.0(2) 6180(19) 82(2) 





C32A 0.0(3) 4430.0(2) 5738(17) 104(3) 
C33 2649(9) 3835(8) 6790(6) 89(3) 
C33A 1020.0(2) 4580.0(3) 4858(16) 89(3) 
O10 -728(6) 2836(8) 5898(4) 110(3) 
O10A -330.0(2) 1720.0(2) 6090.0(2) 111(8) 
N11 3947(3) -1916(2) 3792(2) 27.3(6) 
O4 4688(3) -1172(2) 3433(2) 45.4(7) 
O5 3984(3) -2513(2) 4653.4(19) 34.4(6) 
O6 3160(3) -2072(2) 3306(2) 43.2(7) 
N12 1203(3) 6213(3) 640(2) 34.2(7) 
O7 549(3) 5424(2) 1092(3) 49.1(8) 
O8 618(3) 7168(2) 427(2) 40.8(7) 
O9 2412(3) 6069(3) 388(2) 51.7(8) 




) for phw1109. The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+...+2hka×b×U12] 
Atom U11 U22 U33 U23 U13 U12 
C1 18.2(16) 28.1(17) 20.8(16) -2.4(13) -2.9(12) -0.8(14) 
C2 18.3(18) 42(2) 31.5(19) 1.8(16) -4.8(14) -5.5(16) 
C3 21.3(19) 52(3) 46(2) -6(2) -8.3(16) -6.5(18) 
C4 18.8(19) 48(2) 61(3) -16(2) -6.7(17) 1.1(17) 
C5 38(2) 33(2) 40(2) -10.4(17) -2.3(17) 8.8(18) 
C6 26.1(18) 27.7(18) 23.3(17) -4.2(14) -5.0(13) 2.0(15) 
C7 29.4(18) 23.4(17) 24.1(17) -3.2(14) -8.9(14) -8.6(14) 
C8 18.9(15) 18.6(15) 15.3(14) -2.4(12) -5.3(11) -6.2(12) 
C9 28(2) 33.3(19) 31.4(19) -6.4(16) -10.3(15) -7.7(16) 
C10 17.9(17) 29.8(18) 30.5(18) -7.5(15) -2.9(13) -4.1(14) 
C11 25.2(18) 36(2) 29.0(18) -6.6(16) 0.5(14) -8.6(16) 





C13 26.9(18) 31.5(19) 26.6(17) -7.0(15) -9.6(14) -1.5(15) 
C14 18.5(16) 25.0(17) 28.8(17) -8.9(14) -3.4(13) -1.5(14) 
C15 21.0(17) 18.1(15) 32.7(18) -3.1(14) -4.2(13) -4.3(13) 
C16 21.4(18) 26.3(18) 46(2) -4.5(16) -8.9(15) -5.0(15) 
C17 17.6(18) 28.8(19) 56(3) -4.8(18) -0.3(16) -3.4(15) 
C18 30(2) 29.0(19) 41(2) -7.3(17) 3.0(16) -2.2(16) 
C19 25.0(18) 23.6(17) 31.6(19) -4.5(14) 0.5(14) -1.9(14) 
C20 24.5(18) 24.0(17) 22.8(16) -3.4(13) -2.1(13) -0.2(14) 
C21 39(2) 20.1(17) 29.8(18) -4.7(14) -6.1(15) -2.5(15) 
C22 40(2) 22.8(17) 31.1(19) -9.2(15) -7.2(15) -7.3(16) 
C23 31.9(19) 26.6(17) 25.1(17) -7.9(14) -6.5(14) -5.4(15) 
C24 19.4(16) 22.6(16) 23.3(16) -9.2(13) 1.3(12) -3.0(13) 
C25 19.0(16) 19.9(16) 25.6(16) -6.7(13) -1.1(13) -0.9(13) 
C26 27.0(18) 26.3(17) 29.1(18) -5.2(14) -8.6(14) -2.9(15) 
C27 32(2) 25.5(18) 29.0(18) 0.9(15) -5.7(15) -3.5(15) 
C28 25.0(18) 25.1(18) 34.4(19) -4.5(15) -1.1(14) -7.2(15) 
C29 21.9(17) 25.9(17) 28.6(18) -4.5(14) -4.7(13) -5.5(14) 
Co1 16.2(2) 20.1(2) 22.0(2) -5.13(17) -3.28(16) -2.41(17) 
N1 18.6(14) 21.8(14) 23.1(14) -6.8(11) -5.4(11) -2.0(11) 
N2 37.3(18) 25.0(15) 26.3(15) -10.2(12) -6.0(13) -1.3(13) 
N3 15.1(15) 26.0(15) 27.2(15) -7.1(12) -7.8(12) -6.0(12) 
N4 55(2) 39(2) 39(2) -5.3(15) -21.9(18) -23.5(19) 
N5 18.2(14) 22.8(14) 22.7(14) -6.6(11) -3(1) -3.0(11) 
N6 21.4(15) 29.0(15) 30.7(16) -5.5(12) -9.0(12) -5.8(12) 
N7 17.0(14) 21.2(14) 27.6(15) -3.8(11) -1.6(11) -2.1(11) 
N8 20.4(14) 19.7(13) 19.2(13) -5.9(11) -1.2(10) -1.7(11) 
N9 23.9(15) 19.6(13) 23.9(14) -3.3(11) -7.6(11) -3.2(11) 
N10 18.6(14) 20.5(13) 24.3(14) -6.7(11) -3.2(11) -2.3(11) 





O2 51.2(18) 38.4(16) 54.1(18) -27.5(14) -11.2(14) 2.0(14) 
O3 34.0(16) 43.8(17) 59.7(19) -20.8(15) -13.5(13) -6.2(13) 
C30 44(5) 139(9) 73(6) -48(6) 5(4) -1(5) 
C30A 44(5) 139(9) 73(6) -48(6) 5(4) -1(5) 
C31 70(6) 96(7) 78(5) -35(5) 4(4) -6(4) 
C31A 70(6) 96(7) 78(5) -35(5) 4(4) -6(4) 
C32 148(9) 103(7) 65(5) -36(5) 7(5) -42(6) 
C32A 148(9) 103(7) 65(5) -36(5) 7(5) -42(6) 
C33 98(6) 138(8) 55(4) -38(5) -16(4) -54(6) 
C33A 98(6) 138(8) 55(4) -38(5) -16(4) -54(6) 
O10 66(4) 196(9) 60(4) 1(4) -8(3) -51(5) 
O10A 84(14) 119(17) 180.0(2) -88(17) -61(15) -4(14) 
N11 27.2(16) 24.4(15) 32.6(16) -7.8(13) -9.0(12) -2.3(13) 
O4 52.1(18) 48.9(17) 37.6(16) 2.5(13) -13.4(13) -29.1(15) 
O5 38.5(15) 31.7(14) 30.0(14) 1.2(11) -9.1(11) -6.0(12) 
O6 46.4(17) 40.8(16) 52.5(18) -9.2(14) -28.7(14) -10.4(13) 
N12 30.4(18) 33.4(18) 42.9(19) -7.4(15) -19.1(14) -1.3(15) 
O7 36.8(16) 31.4(15) 81(2) -4.3(15) -22.9(15) -7.0(13) 
O8 39.5(16) 31.9(15) 56.7(18) -7.1(13) -25.6(13) -2.8(13) 
O9 34.9(17) 55(2) 59(2) -3.0(16) -11.8(14) -1.4(15) 
Table 4 Bond Lengths for phw1109. 
Atom Atom Length/Å   Atom Atom Length/Å 
C1 C2 1.419(5)   C23 C24 1.408(5) 
C1 C6 1.392(5)   C24 N8 1.338(4) 
C1 N1 1.369(4)   C24 N9 1.372(4) 
C2 C3 1.370(5)   C25 C26 1.399(5) 
C3 C4 1.339(6)   C25 N9 1.385(4) 
C4 C5 1.434(6)   C25 N10 1.337(4) 





C6 N2 1.403(5)   C27 C28 1.385(5) 
C7 C8 1.440(4)   C28 C29 1.365(5) 
C7 C9 1.489(5)   C29 N10 1.357(4) 
C7 N2 1.343(5)   Co1 N3 1.882(3) 
C8 N1 1.342(4)   Co1 N5 1.941(3) 
C8 N3 1.307(4)   Co1 N7 1.941(3) 
C9 N4 1.347(5)   Co1 N8 1.948(3) 
C9 O3 1.203(4)   Co1 N10 1.953(3) 
C10 C11 1.365(5)   Co1 O1 1.883(2) 
C10 N5 1.356(4)   N1 O1 1.373(3) 
C11 C12 1.384(5)   N2 O2 1.292(4) 
C12 C13 1.362(5)   C30 C31 1.516(11) 
C13 C14 1.395(5)   C30 O10 1.437(11) 
C14 N5 1.337(4)   C30A C31A 1.481(19) 
C14 N6 1.379(4)   C30A O10A 1.446(17) 
C15 C16 1.399(5)   C31 C32 1.481(10) 
C15 N6 1.363(4)   C31A C32A 1.500(18) 
C15 N7 1.344(4)   C32 C33 1.469(10) 
C16 C17 1.365(5)   C32A C33A 1.425(17) 
C17 C18 1.389(6)   N11 O4 1.237(4) 
C18 C19 1.373(5)   N11 O5 1.252(4) 
C19 N7 1.352(4)   N11 O6 1.242(4) 
C20 C21 1.373(5)   N12 O7 1.240(4) 
C20 N8 1.359(4)   N12 O8 1.266(4) 
C21 C22 1.390(5)   N12 O9 1.224(4) 
C22 C23 1.363(5)         
Table 5 Bond Angles for phw1109. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 





N1 C1 C2 121.0(3)   N3 Co1 N8 174.75(12) 
N1 C1 C6 118.0(3)   N3 Co1 N10 89.71(12) 
C3 C2 C1 117.8(4)   N3 Co1 O1 84.32(11) 
C4 C3 C2 122.3(4)   N5 Co1 N7 90.59(11) 
C3 C4 C5 121.1(4)   N5 Co1 N8 93.36(11) 
C6 C5 C4 118.0(4)   N5 Co1 N10 175.43(11) 
C1 C6 N2 119.7(3)   N7 Co1 N8 92.19(11) 
C5 C6 C1 119.8(3)   N7 Co1 N10 92.93(11) 
C5 C6 N2 120.4(3)   N8 Co1 N10 89.41(11) 
C8 C7 C9 119.5(3)   O1 Co1 N5 89.08(11) 
N2 C7 C8 118.6(3)   O1 Co1 N7 177.33(11) 
N2 C7 C9 121.9(3)   O1 Co1 N8 90.47(10) 
N1 C8 C7 118.9(3)   O1 Co1 N10 87.26(11) 
N3 C8 C7 126.2(3)   C1 N1 O1 119.2(3) 
N3 C8 N1 115.0(3)   C8 N1 C1 123.4(3) 
N4 C9 C7 117.6(4)   C8 N1 O1 117.4(2) 
O3 C9 C7 118.9(3)   C7 N2 C6 121.4(3) 
O3 C9 N4 123.4(4)   O2 N2 C6 115.0(3) 
N5 C10 C11 123.0(3)   O2 N2 C7 123.6(3) 
C10 C11 C12 119.0(3)   C8 N3 Co1 113.6(2) 
C13 C12 C11 119.1(3)   C10 N5 Co1 120.4(2) 
C12 C13 C14 119.1(3)   C14 N5 C10 117.4(3) 
N5 C14 C13 122.4(3)   C14 N5 Co1 121.5(2) 
N5 C14 N6 119.4(3)   C15 N6 C14 126.5(3) 
N6 C14 C13 118.2(3)   C15 N7 C19 118.6(3) 
N6 C15 C16 118.4(3)   C15 N7 Co1 120.4(2) 
N7 C15 C16 121.2(3)   C19 N7 Co1 120.7(2) 
N7 C15 N6 120.3(3)   C20 N8 Co1 119.6(2) 





C16 C17 C18 119.8(3)   C24 N8 Co1 122.1(2) 
C19 C18 C17 118.3(3)   C24 N9 C25 126.6(3) 
N7 C19 C18 122.7(3)   C25 N10 C29 118.2(3) 
N8 C20 C21 122.9(3)   C25 N10 Co1 121.0(2) 
C20 C21 C22 118.8(3)   C29 N10 Co1 119.5(2) 
C23 C22 C21 119.1(3)   N1 O1 Co1 109.54(17) 
C22 C23 C24 119.5(3)   O10 C30 C31 108.2(9) 
N8 C24 C23 121.5(3)   O10A C30A C31A 115(2) 
N8 C24 N9 120.2(3)   C32 C31 C30 119.5(8) 
N9 C24 C23 118.3(3)   C30A C31A C32A 118(3) 
N9 C25 C26 118.0(3)   C33 C32 C31 110.2(8) 
N10 C25 C26 121.4(3)   C33A C32A C31A 92(2) 
N10 C25 N9 120.6(3)   O4 N11 O5 119.9(3) 
C27 C26 C25 119.2(3)   O4 N11 O6 120.5(3) 
C26 C27 C28 119.7(3)   O6 N11 O5 119.7(3) 
C29 C28 C27 118.1(3)   O7 N12 O8 120.1(3) 
N10 C29 C28 123.4(3)   O9 N12 O7 120.2(3) 
N3 Co1 N5 87.21(12)   O9 N12 O8 119.7(3) 
Table 6 Torsion Angles for phw1109. 
A B C D Angle/˚ 
C1 C2 C3 C4 -2.8(6) 
C1 C6 N2 C7 -0.6(5) 
C1 C6 N2 O2 179.0(3) 
C1 N1 O1 Co1 177.4(2) 
C2 C1 C6 C5 -0.2(5) 
C2 C1 C6 N2 -179.9(3) 
C2 C1 N1 C8 179.5(3) 
C2 C1 N1 O1 -2.1(4) 





C3 C4 C5 C6 -2.4(6) 
C4 C5 C6 C1 0.8(5) 
C4 C5 C6 N2 -179.6(3) 
C5 C6 N2 C7 179.8(3) 
C5 C6 N2 O2 -0.6(5) 
C6 C1 C2 C3 1.2(5) 
C6 C1 N1 C8 0.0(5) 
C6 C1 N1 O1 178.4(3) 
C7 C8 N1 C1 1.2(5) 
C7 C8 N1 O1 -177.3(3) 
C7 C8 N3 Co1 -179.8(3) 
C8 C7 C9 N4 -178.7(3) 
C8 C7 C9 O3 0.5(5) 
C8 C7 N2 C6 1.7(5) 
C8 C7 N2 O2 -177.8(3) 
C8 N1 O1 Co1 -4.1(3) 
C9 C7 C8 N1 177.4(3) 
C9 C7 C8 N3 -2.4(5) 
C9 C7 N2 C6 -177.7(3) 
C9 C7 N2 O2 2.8(5) 
C10 C11 C12 C13 -0.2(5) 
C11 C10 N5 C14 -1.1(5) 
C11 C10 N5 Co1 169.4(3) 
C11 C12 C13 C14 -0.8(5) 
C12 C13 C14 N5 0.8(5) 
C12 C13 C14 N6 -178.9(3) 
C13 C14 N5 C10 0.1(5) 
C13 C14 N5 Co1 -170.3(3) 





C15 C16 C17 C18 1.8(5) 
C16 C15 N6 C14 147.9(3) 
C16 C15 N7 C19 -5.8(5) 
C16 C15 N7 Co1 167.6(3) 
C16 C17 C18 C19 -3.2(6) 
C17 C18 C19 N7 0.2(5) 
C18 C19 N7 C15 4.3(5) 
C18 C19 N7 Co1 -169.1(3) 
C20 C21 C22 C23 -2.6(5) 
C21 C20 N8 C24 3.1(5) 
C21 C20 N8 Co1 -171.3(3) 
C21 C22 C23 C24 0.2(5) 
C22 C23 C24 N8 4.2(5) 
C22 C23 C24 N9 -175.0(3) 
C23 C24 N8 C20 -5.7(5) 
C23 C24 N8 Co1 168.6(2) 
C23 C24 N9 C25 151.4(3) 
C25 C26 C27 C28 -1.3(5) 
C26 C25 N9 C24 -154.1(3) 
C26 C25 N10 C29 2.8(4) 
C26 C25 N10 Co1 -163.6(2) 
C26 C27 C28 C29 1.8(5) 
C27 C28 C29 N10 0.1(5) 
C28 C29 N10 C25 -2.4(5) 
C28 C29 N10 Co1 164.3(3) 
N1 C1 C2 C3 -178.3(3) 
N1 C1 C6 C5 179.3(3) 
N1 C1 C6 N2 -0.3(5) 





N2 C7 C8 N1 -2.0(4) 
N2 C7 C8 N3 178.2(3) 
N2 C7 C9 N4 0.7(5) 
N2 C7 C9 O3 180.0(3) 
N3 C8 N1 C1 -179.0(3) 
N3 C8 N1 O1 2.6(4) 
N3 Co1 N5 C10 -113.4(3) 
N3 Co1 N5 C14 56.7(3) 
N3 Co1 N7 C15 -49.3(3) 
N3 Co1 N7 C19 123.9(3) 
N3 Co1 N10 C25 135.0(2) 
N3 Co1 N10 C29 -31.2(2) 
N3 Co1 O1 N1 3.25(19) 
N5 C10 C11 C12 1.1(5) 
N5 C14 N6 C15 33.6(5) 
N5 Co1 N3 C8 87.3(2) 
N5 Co1 N7 C15 37.9(3) 
N5 Co1 N7 C19 -148.9(3) 
N5 Co1 N8 C20 35.3(3) 
N5 Co1 N8 C24 -138.9(2) 
N5 Co1 O1 N1 -84.04(19) 
N6 C14 N5 C10 179.8(3) 
N6 C14 N5 Co1 9.4(4) 
N6 C15 C16 C17 -176.6(3) 
N6 C15 N7 C19 173.6(3) 
N6 C15 N7 Co1 -13.0(4) 
N7 C15 C16 C17 2.9(5) 
N7 C15 N6 C14 -31.5(5) 





N7 Co1 N5 C10 153.6(3) 
N7 Co1 N5 C14 -36.3(3) 
N7 Co1 N8 C20 -55.5(3) 
N7 Co1 N8 C24 130.4(2) 
N7 Co1 N10 C25 -132.0(2) 
N7 Co1 N10 C29 61.8(2) 
N8 C20 C21 C22 1.0(5) 
N8 C24 N9 C25 -27.8(5) 
N8 Co1 N5 C10 61.4(3) 
N8 Co1 N5 C14 -128.5(2) 
N8 Co1 N7 C15 131.3(3) 
N8 Co1 N7 C19 -55.5(3) 
N8 Co1 N10 C25 -39.8(2) 
N8 Co1 N10 C29 153.9(2) 
N8 Co1 O1 N1 -177.39(19) 
N9 C24 N8 C20 173.4(3) 
N9 C24 N8 Co1 -12.3(4) 
N9 C25 C26 C27 177.8(3) 
N9 C25 N10 C29 -176.0(3) 
N9 C25 N10 Co1 17.6(4) 
N10 C25 C26 C27 -1.0(5) 
N10 C25 N9 C24 24.8(5) 
N10 Co1 N3 C8 -89.4(2) 
N10 Co1 N7 C15 -139.2(2) 
N10 Co1 N7 C19 34.0(3) 
N10 Co1 N8 C20 -148.4(2) 
N10 Co1 N8 C24 37.4(3) 
N10 Co1 O1 N1 93.23(19) 





O1 Co1 N5 C10 -29.1(2) 
O1 Co1 N5 C14 141.1(2) 
O1 Co1 N8 C20 124.4(2) 
O1 Co1 N8 C24 -49.8(2) 
O1 Co1 N10 C25 50.7(2) 
O1 Co1 N10 C29 -115.6(2) 
C30 C31 C32 C33 174.7(9) 
C30A C31A C32A C33A -139(2) 
O10 C30 C31 C32 73.1(12) 
O10A C30A C31A C32A 95(3) 
Table 7 Hydrogen Atom Coordinates (Å×10
4





) for phw1109.  
Atom x y z U(eq) 
H2 6983 1465 2078 39 
H3 9084 630 1580 48 
H4 9369 -895 982 51 
H5 7524 -1582 664 47 
H10 4870 3495 1048 31 
H11 5423 4243 -654 37 
H12 3835 4441 -1658 40 
H13 1739 3865 -909 33 
H16 -1642 3172 1510 37 
H17 -2846 3271 3097 43 
H18 -1710 3224 4382 43 
H19 588 2927 4069 34 
H20 2196 4720 2072 30 
H21 2840 6179 2485 36 
H22 4249 5832 3657 36 





H26 4023 571 5724 33 
H27 2724 -883 6101 36 
H28 1214 -865 5075 35 
H29 1135 560 3673 31 
H3A 2000.0(4) 1010.0(3) 1890.0(3) 23(12) 
H4A 3690.0(5) -2050.0(4) 610.0(3) 49 
H4B 2200.0(5) -1830.0(4) 760.0(4) 54(17) 
H6 505 2695 565 32 
H9 4825 2139 4500 27 
H30C 412 1413 6173 102 
H30D -265 1839 7166 102 
H30A 195 1983 7284 102 
H30B -1076 2756 6966 102 
H31C 2100 2052 6565 98 
H31D 1704 2967 5633 98 
H31A 1325 3094 5630 98 
H31B 1171 3438 6664 98 
H32C 712 4118 6659 125 
H32D 966 3186 7637 125 
H32A -881 4388 5599 125 
H32B -54 4977 6137 125 
H33D 2956 4205 6085 134 
H33E 3271 3194 6986 134 
H33F 2604 4342 7217 134 
H33A 1686 3945 4911 134 
H33B 1452 5242 4795 134 
H33C 636 4668 4265 134 
H10B -1502 2642 6105 165 







[RSC Journal Format]  
Experimental  
Single crystals of C33H35CoN12O10 [phw1109] were recrystallised from [solvents] 
mounted in inert oil and transferred to the cold gas stream of the diffractometer.  
Crystal structure determination of [phw1109]  
Crystal Data. C33H35CoN12O10, M =818.66, triclinic, a = 10.371(2) Å, b = 
12.715(3) Å, c = 14.053(3) Å, α = 74.64(2)°, β = 76.945(18)°, γ = 81.408(19)°, U = 
1732.9(6) Å
3
, T = 110.0, space group P-1 (no. 2), Z = 2, μ(Mo Kα) = 0.574, 11512 
reflections measured, 7448 unique (Rint = 0.0280) which were used in all 
calculations. The final wR(F2) was 0.1558 (all data).  
This report has been created with Olex2, compiled on 2011.02.15 svn.r1672. Please let us know if there are any errors or if you would 












Crystallographic data for [Co(tpz)(dpHa)2](BF4)2  
  Table 1.  Crystal data and structure refinement for phw1008m. 
Identification code  phw1008m 
Empirical formula  C27 H25 B2 Co F8 N10 O3 
Formula weight  770.12 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 10.8037(13) Å = 82.644(2)°. 





 c = 13.1991(16) Å  = 66.186(2)°. 
Volume 1555.5(3) Å3 
Z 2 
Density (calculated) 1.644 Mg/m3 
Absorption coefficient 0.650 mm-1 
F(000) 780 
Crystal size 0.29 x 0.24 x 0.22 mm3 
Theta range for data collection 1.65 to 28.33°. 
Index ranges -14<=h<=14, -17<=k<=17, -17<=l<=17 
Reflections collected 21600 
Independent reflections 7719 [R(int) = 0.0258] 
Completeness to theta = 28.33° 99.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.870 and 0.773 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7719 / 12 / 525 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0372, wR2 = 0.0895 
R indices (all data) R1 = 0.0436, wR2 = 0.0938 






 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for phw1008m.  U(eq) is defined as one third of  the trace of the orthogonalized U ij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 11447(2) 5698(1) 6049(1) 17(1) 
C(2) 14098(2) 4146(1) 5998(1) 20(1) 
C(3) 15457(2) 3333(2) 5945(2) 26(1) 
C(4) 15835(2) 3141(2) 6860(2) 28(1) 
C(5) 14864(2) 3750(2) 7832(2) 27(1) 
C(6) 13533(2) 4567(2) 7891(2) 23(1) 
C(7) 13139(2) 4770(1) 6959(1) 19(1) 
C(8) 7079(2) 8035(2) 9621(1) 20(1) 
C(9) 6582(2) 8307(2) 10703(1) 24(1) 
C(10) 7495(2) 8464(2) 11139(1) 26(1) 
C(11) 8823(2) 8417(2) 10466(1) 23(1) 
C(12) 9240(2) 8197(1) 9351(1) 18(1) 
C(13) 10861(2) 8498(1) 7572(1) 18(1) 
C(14) 11874(2) 9006(2) 7111(2) 23(1) 
C(15) 12155(2) 9317(2) 6046(2) 25(1) 
C(16) 11443(2) 9119(2) 5438(1) 22(1) 
C(17) 10504(2) 8589(1) 5924(1) 19(1) 
C(18) 7118(2) 9396(1) 7219(1) 18(1) 
C(19) 6057(2) 10143(2) 6844(1) 20(1) 
C(20) 5381(2) 9710(2) 6380(1) 21(1) 
C(21) 5761(2) 8550(2) 6350(1) 20(1) 
C(22) 6828(2) 7827(1) 6780(1) 17(1) 
C(23) 7588(2) 5912(1) 7557(1) 20(1) 
C(24) 7233(2) 4945(2) 7777(2) 27(1) 
C(25) 7623(2) 4208(2) 8559(2) 30(1) 
C(26) 8351(2) 4444(2) 9128(2) 27(1) 
C(27) 8700(2) 5387(2) 8858(1) 23(1) 
Co(1) 9211(1) 7227(1) 7521(1) 15(1) 
N(1) 11846(1) 5555(1) 6937(1) 18(1) 
N(2) 13651(2) 4367(1) 5089(1) 19(1) 
N(3) 10160(2) 6444(1) 6147(1) 17(1) 
N(4) 12386(1) 5105(1) 5094(1) 19(1) 
N(5) 10229(1) 8254(1) 6977(1) 17(1) 
N(6) 10513(2) 8263(1) 8663(1) 21(1) 





N(8) 7539(1) 8238(1) 7163(1) 16(1) 
N(9) 7127(2) 6672(1) 6803(1) 19(1) 
N(10) 8347(2) 6110(1) 8062(1) 18(1) 
O(1) 10872(1) 6199(1) 7844(1) 19(1) 
O(2) 14519(1) 3832(1) 4205(1) 25(1) 
B(1) 8631(2) 7464(2) 3636(2) 27(1) 
F(1) 9129(2) 6325(1) 3401(2) 70(1) 
F(2) 8960(2) 7643(2) 4506(1) 52(1) 
F(3) 7144(1) 7921(1) 3888(1) 44(1) 
F(4) 9261(2) 8005(1) 2739(1) 38(1) 
O(3) 1373(2) 8875(2) 2603(2) 45(1) 
B(2A) 3426(10) 8345(8) 9766(7) 33(1) 
F(5A) 4427(3) 7244(3) 9829(3) 59(1) 
F(6A) 2120(4) 8241(4) 9954(3) 44(1) 
F(7A) 3248(3) 9040(3) 10580(2) 60(1) 
F(8A) 4084(11) 8676(7) 8808(6) 78(3) 
B(2B) 3440(20) 8056(17) 9527(16) 49(4) 
F(5B) 3644(8) 7093(6) 9044(8) 123(3) 
F(6B) 1974(7) 8772(6) 9803(6) 46(2) 
F(7B) 3783(7) 7896(7) 10454(5) 76(3) 













 Table 3.   Bond lengths [Å] and angles [°] for  phw1008m. 
_____________________________________________________  
C(1)-N(3)  1.300(2) 
C(1)-N(1)  1.356(2) 





C(2)-C(3)  1.398(2) 
C(2)-C(7)  1.401(2) 
C(2)-N(2)  1.405(2) 
C(3)-C(4)  1.372(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.407(3) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.376(2) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.403(2) 
C(6)-H(6)  0.9500 
C(7)-N(1)  1.360(2) 
C(8)-N(7)  1.361(2) 
C(8)-C(9)  1.368(2) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.394(2) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.370(2) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.404(2) 
C(11)-H(11)  0.9500 
C(12)-N(7)  1.345(2) 
C(12)-N(6)  1.378(2) 
C(13)-N(5)  1.343(2) 
C(13)-N(6)  1.377(2) 
C(13)-C(14)  1.408(2) 
C(14)-C(15)  1.369(3) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.397(3) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.370(2) 
C(16)-H(16)  0.9500 
C(17)-N(5)  1.362(2) 
C(17)-H(17)  0.9500 
C(18)-N(8)  1.365(2) 
C(18)-C(19)  1.369(2) 
C(18)-H(18)  0.9500 
C(19)-C(20)  1.396(2) 
C(19)-H(19)  0.9500 





C(20)-H(20)  0.9500 
C(21)-C(22)  1.407(2) 
C(21)-H(21)  0.9500 
C(22)-N(8)  1.341(2) 
C(22)-N(9)  1.377(2) 
C(23)-N(10)  1.336(2) 
C(23)-N(9)  1.379(2) 
C(23)-C(24)  1.404(2) 
C(24)-C(25)  1.370(3) 
C(24)-H(24)  0.9500 
C(25)-C(26)  1.396(3) 
C(25)-H(25)  0.9500 
C(26)-C(27)  1.373(3) 
C(26)-H(26)  0.9500 
C(27)-N(10)  1.364(2) 
C(27)-H(27)  0.9500 
Co(1)-O(1)  1.9059(12) 
Co(1)-N(3)  1.9077(14) 
Co(1)-N(8)  1.9314(14) 
Co(1)-N(7)  1.9361(14) 
Co(1)-N(10)  1.9385(14) 
Co(1)-N(5)  1.9494(14) 
N(1)-O(1)  1.3650(17) 
N(2)-O(2)  1.2668(18) 
N(2)-N(4)  1.309(2) 
N(3)-H(3A)  0.83(2) 
N(6)-H(6A)  0.78(2) 
N(9)-H(9A)  0.80(2) 
B(1)-F(1)  1.367(3) 
B(1)-F(2)  1.386(3) 
B(1)-F(4)  1.391(2) 
B(1)-F(3)  1.393(2) 
O(3)-H(3B)  0.87(3) 
O(3)-H(3C)  0.82(3) 
B(2A)-F(8A)  1.320(12) 
B(2A)-F(7A)  1.392(7) 
B(2A)-F(6A)  1.400(9) 
B(2A)-F(5A)  1.401(10) 
B(2B)-F(5B)  1.359(17) 





B(2B)-F(6B)  1.40(2) 































































































































































Symmetry transformations used to generate equivalent atoms:  
  
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for phw1008m.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 19(1)  17(1) 18(1)  0(1) -5(1)  -10(1) 
C(2) 19(1)  18(1) 27(1)  -1(1) -9(1)  -9(1) 
C(3) 20(1)  19(1) 39(1)  -4(1) -10(1)  -7(1) 
C(4) 22(1)  19(1) 46(1)  4(1) -18(1)  -8(1) 





C(6) 23(1)  26(1) 24(1)  4(1) -11(1)  -12(1) 
C(7) 18(1)  17(1) 24(1)  2(1) -9(1)  -8(1) 
C(8) 18(1)  22(1) 20(1)  -1(1) -6(1)  -9(1) 
C(9) 20(1)  29(1) 20(1)  -1(1) -3(1)  -11(1) 
C(10) 26(1)  35(1) 17(1)  -4(1) -6(1)  -10(1) 
C(11) 23(1)  30(1) 20(1)  -3(1) -9(1)  -10(1) 
C(12) 18(1)  18(1) 19(1)  0(1) -7(1)  -6(1) 
C(13) 16(1)  19(1) 19(1)  -2(1) -6(1)  -6(1) 
C(14) 18(1)  28(1) 28(1)  -1(1) -8(1)  -12(1) 
C(15) 17(1)  25(1) 31(1)  3(1) -5(1)  -10(1) 
C(16) 18(1)  23(1) 22(1)  3(1) -5(1)  -6(1) 
C(17) 17(1)  19(1) 18(1)  0(1) -7(1)  -5(1) 
C(18) 17(1)  19(1) 17(1)  -2(1) -4(1)  -8(1) 
C(19) 19(1)  17(1) 20(1)  -1(1) -3(1)  -6(1) 
C(20) 17(1)  23(1) 20(1)  2(1) -6(1)  -6(1) 
C(21) 19(1)  26(1) 18(1)  -1(1) -7(1)  -9(1) 
C(22) 16(1)  21(1) 14(1)  -2(1) -3(1)  -8(1) 
C(23) 19(1)  19(1) 19(1)  -2(1) -4(1)  -8(1) 
C(24) 31(1)  26(1) 30(1)  1(1) -12(1)  -17(1) 
C(25) 36(1)  23(1) 35(1)  4(1) -11(1)  -17(1) 
C(26) 32(1)  22(1) 25(1)  5(1) -9(1)  -10(1) 
C(27) 26(1)  24(1) 19(1)  1(1) -8(1)  -10(1) 
Co(1) 15(1)  17(1) 14(1)  -1(1) -5(1)  -7(1) 
N(1) 17(1)  18(1) 17(1)  -1(1) -6(1)  -6(1) 
N(2) 17(1)  18(1) 23(1)  -4(1) -5(1)  -8(1) 
N(3) 19(1)  19(1) 15(1)  -1(1) -7(1)  -7(1) 
N(4) 17(1)  20(1) 20(1)  -3(1) -5(1)  -7(1) 
N(5) 15(1)  18(1) 17(1)  -1(1) -5(1)  -6(1) 
N(6) 19(1)  29(1) 19(1)  -2(1) -9(1)  -12(1) 
N(7) 17(1)  19(1) 16(1)  -1(1) -5(1)  -8(1) 
N(8) 15(1)  18(1) 15(1)  -1(1) -4(1)  -7(1) 
N(9) 21(1)  19(1) 22(1)  -2(1) -10(1)  -10(1) 
N(10) 20(1)  18(1) 18(1)  0(1) -6(1)  -8(1) 
O(1) 18(1)  22(1) 15(1)  -3(1) -6(1)  -5(1) 
O(2) 19(1)  28(1) 25(1)  -12(1) -3(1)  -8(1) 
B(1) 30(1)  24(1) 23(1)  2(1) -6(1)  -7(1) 
F(1) 58(1)  26(1) 96(1)  -5(1) 11(1)  -17(1) 
F(2) 44(1)  93(1) 26(1)  12(1) -20(1)  -28(1) 
F(3) 30(1)  61(1) 35(1)  -4(1) -14(1)  -8(1) 





O(3) 33(1)  39(1) 70(1)  -11(1) -23(1)  -12(1) 
B(2A) 30(2)  49(4) 33(3)  19(3) -19(2)  -27(3) 
F(5A) 42(2)  56(2) 82(2)  29(2) -32(2)  -22(1) 
F(6A) 35(2)  74(3) 38(1)  8(2) -21(1)  -30(2) 
F(7A) 73(2)  101(3) 37(1)  6(1) -21(1)  -62(2) 
F(8A) 77(4)  107(5) 50(3)  37(2) -14(2)  -53(4) 
B(2B) 47(6)  66(11) 55(9)  19(7) -29(6)  -38(7) 
F(5B) 113(6)  64(4) 190(9)  -35(5) -68(6)  -8(4) 
F(6B) 28(2)  64(4) 48(3)  -14(3) -15(2)  -14(3) 
F(7B) 63(4)  122(7) 74(4)  70(4) -53(3)  -60(4) 
F(8B) 65(5)  25(2) 18(3)  7(2) -7(3)  -19(2) 
______________________________________________________________________________  
 
 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for phw1008m. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(3) 16107 2922 5288 31 
H(4) 16756 2593 6837 33 
H(5) 15134 3594 8463 32 
H(6) 12895 4984 8548 28 
H(8) 6464 7911 9328 24 
H(9) 5633 8387 11148 28 
H(10) 7199 8602 11897 31 
H(11) 9452 8533 10749 28 
H(14) 12354 9131 7533 28 
H(15) 12831 9665 5722 30 
H(16) 11607 9348 4703 27 
H(17) 10025 8449 5510 22 
H(18) 7578 9695 7530 21 
H(19) 5785 10945 6898 24 
H(20) 4669 10212 6089 25 
H(21) 5310 8238 6043 24 
H(24) 6727 4803 7387 32 
H(25) 7402 3545 8713 36 
H(26) 8601 3959 9692 32 
H(27) 9206 5542 9239 27 





H(6A) 10970(20) 8365(18) 8950(18) 24(5) 
H(9A) 6690(20) 6480(19) 6535(18) 24(5) 
H(3B) 1800(30) 8880(30) 1910(30) 54 





































































































































































 Table 7.  Hydrogen bonds for phw1008m  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(3)-H(3A)...F(2) 0.83(2) 2.11(2) 2.8802(19) 153(2) 
 N(6)-H(6A)...F(6B)#1 0.78(2) 2.05(2) 2.822(7) 174(2) 
 N(6)-H(6A)...F(6A)#1 0.78(2) 2.07(2) 2.828(4) 164(2) 
 N(9)-H(9A)...O(2)#2 0.80(2) 2.06(2) 2.8639(19) 174(2) 
 O(3)-H(3B)...F(7A)#3 0.87(3) 1.94(3) 2.753(3) 156(3) 
 O(3)-H(3B)...F(7B)#3 0.87(3) 2.30(3) 3.057(8) 145(3) 






Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z    #2 -x+2,-y+1,-z+1    #3 x,y,z-1    #4 x-1,y,z       
 
 
 
 
 
 
 
 
